Front of Book
1 Editors
2 PREFACE
Table of Contents
Antimicrobial Agents
3 Preparations and Recommended Dosing Regimens for
Antimicrobial Agents
4 Prefered Antimicrobial Agents for Specific Pathogens
5 Antimicrobial Dosing Regimens in Renal Failure
6 Use of Antimicrobial Agents in Hepatic Disease
7 Adverse Reactions to Antimicrobial Agents
8 Drug Interactions
Preventive Treatment
9 Adult Immunization Schedule
10 Prophylactic Antibiotics in Surgery
11 Antimicrobial Prophylaxis in Ambulatory Patients
12 Prevention of Bacterial Endocardits
13 Prevention of Diseases Associated with Travel
Nonbacterial Infections
14 Treatment of Fungal Infections
15 Treatment of Mycobacterial Infections
16 Drugs for Treatment of Parasitic Infections
17 Treatment of Viral Infections
Specific Infections
18 Sepsis and Sepsis Syndrome
19 Compromised Host
20 Toxic Shock Syndrome: Case Definition of Cdc
(MMWR 29:229, 1980)
21 Group A Streptococcal Infections
22 Anaerobic Infections
23 Fever of Unknown Origin
24 Treatment of Lyme Disease and Potential Exposures
25 Infections of Epidermis, Dermis, and Subcutaneous
Tissue
26 Deep Serious Soft Tissue Infections
27 Bone and Joint Infections
28 Ocular and Periocular Infections
29 Infections of Central Nervous System
30 Upper Respiratory Tract Infections
31 Pulmonary Infections
32 Endocarditis
33 Viral Hepatitis
34 Intra-Abdominal Sepsis: Antibiotic Selection
35 Helicobacter pylori: Treatment of Peptic Ulcer
Disease
36 Infectious Diarrhea
37 Foodborne Outbreaks
38 Urinary Tract Infections
39 Sexually transmitted diseases
40 Duration of Antibiotic Treatment
41 Trade Names of Antimicrobial Agents
Back of Book
INDEX
42 A
43 B
44 C
45 D
46 E
47 F
48 G
49 H
50 I
51 J
52 K
53 L
54 M
55 N
56 O
57 P
58 Q
59 R
60 S
61 T
62 U
63 V
64 W
65 X
66 Y
67 Z
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Front of Book > Editors
Editor
John G. Bartlett M.D.
Professor of Medicine; Chief
Division of Infectious Diseases, Johns Hopkins University School of
Medicine, Baltimore, Maryland
Secondary Editors
Jim Merritt
Acquisitions Editor
Raymond E. Reter
Developmental Editor
Jennifer Jett
Purchasing Manager
Clinical and Healthcare
Typesetter: Peirce Graphic Services, LLC
Printer: Transcontinental
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Front of Book > PREFACE
PREFACE
The 2004 Pocket Book of Infectious Disease Therapy is intended for
physicians and other care providers who manage adult patients with
infectious diseases. These include internists, generalists, surgeons,
obstetricians, gynecologists, medical sub-specialists, and surgical
subspecialists.
This book has the same lofty goals as the first eleven editions: to provide
standards of care for the management of infectious disease with particular
emphasis on antimicrobial agents, their selection, dosing regimens, costs,
and side effects. As with prior editions, there is extensive use of
recommendations from various authoritative sources such as the Centers
for Disease Control and Prevention (CDC) and the Medical Letter on Drugs
and Therapeutics and from official statements of learned societies such as
the American College of Physicians/American Society of Internal Medicine
(ACP/ASIM), the American Heart Association (AHA), the American Thoracic
Society (ATS), the Infectious Diseases Society of America (IDSA), and the
Surgical Infection Society (SIS).
The 2004 edition has extensive additions, deletions, and revisions. Tabular
material has been updated to account for recently approved antibiotics and
new recommendations for management. This edition includes topical issues
such as severe acute respiratory syndrome (SARS), West Nile Virus,
hepatitis C virus (HCV), and bioterrorism. It also contains the new
guidelines for intraabdominal sepsis, IV catheter-associated sepsis, fever
of unknown origin, fever in the neutropenic cancer patient, and HCV
management. Antimicrobials introduced since the tenth edition that are
now included are peginterform, valganciclovir, adefovir, caspofungin,
voriconazole, cefditoren, ertapenem, and nitazoxanide.
The HIV/AIDS section has been deleted because of space constraints and
the availability of an alternative resource: Medical Management of HIV
Infection by this author.
The reader is encouraged to notify the author (1830 Monument Street,
Room 437, Baltimore, MD 21205, 410-955-7634) if there are errors,
differences of opinion, or suggested additions.
The reader is also encouraged to visit the Johns Hopkins website for
updated information. For material related to HIV/AIDS:
http://www.hopkins-aids.edu; for maaterial related to general infectious
diseases: http://www.hopkins-id.edu. Use for management guidance
http://www.hopkins-abxguide.org, which is also availaable with hand-held
devices.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Preparations and Recommended Dosing Regimens for Antimicrobial Agents
Preparations and Recommended Dosing Regimens for
Antimicrobial Agents
(Adapted from Drug Information 03, American Hospital Formulary Service, 2003; Physicians' Desk
Reference, 57th Edition, 2003; and Drug Information for the Health Care Professional, USP DI, 23rd Edition,
2003)
Usual adult
Agent (generic) Pregnancy regimen and
category* Trade names Dosage form AWP**
Acyclovir Zovirax 5% ointment; 2 & 15 g Topical q3h
Category C*** tubes
200 mg cap
2 g @ $35.28
400 & 800 mg tabs
200 mg po; ×
200 mg/5 mL susp
3–5/d
500 & 1000 mg vials
200 mg @
(IV)
$1.12
400 mg po bid
800 mg po ×
5/d
800 mg @
$4.21
200–800 mg
po × 3–5/d
15–30
mg/kg/d IV
over 1 hr q8h
1 g @ $35.00
Adofovir Hepsera 10 mg tab 10 mg po qd ×
Category C 48–92 wks
10 mg @
$17.60
Albendazole Albenza 200 mg tabs 400 mg po bid
Category C
200 mg @
$1.49
Amantadine Symmetrel 100 mg cap 200 mg qd or 100
Category C Symadine 50 mg/5 mL soln mg bid (treatment
or prophylaxis);
100 mg/d age > 65
yr
100 mg @
$0.62
Amikacin Amikin 0.1, 0.5 & 15 mg/kg/d IV ×
Category D 1 g vials 1/d or q8–12h
500 mg @
$119.60
Aminosalicylic Paser granules 4 g packet 150 mg/kg/d po
acid* q6–12h
Amoxicillin Amoxil, Trimox, 250 & 500 mg caps 250–500 mg po tid
Category B Wymox 125 & 250 mg/5 mL susp
250 mg @
$0.25
500 mg @
$0.43
Amoxicillin + clavulanate Augmentin 125/31 & 250/62 mg/5 250–500 mg po tid
Category B mL susp (amoxicillin)
125/31 & 250/62 mg
chewable tab
875/15 mg @
250–250/125 & 500/125
$5.84
mg tab
500/125 mg
875/125 mg tab
@ $4.22
875/125 mg
po bid
Amphotericin B Fungizone 50 mg vial 0.3–1 mg/kg/d IV
Category B over 4–6 hr
50 mg @
$10.94
Amphotericin B Abelcet (ABLC) 100 mg vials 5 mg/kg/d IV
100 mg @
$230.00
lipid complex
Category B
Amphotec 50 & 100 mg vials 3–4 mg/kg/d IV
(ABCD)
100 mg @
$160.00
Amphotericin BM AmBisome 50 mg vials 3–5 mg/kg/d IV
liposomal Usually 5 mg/kg/d
Category B
50 mg @
$196.25
Ampicillin Omnipen 250 & 500 mg caps 250–500 mg po qid
Category B Totacillin 125, 250 & 500 mg/5 mL
250 mg @
susp
$0.23
500 mg @
$0.40
Ampicillin sodium Omnipen-N 0.125, 0.25, 0.5, 1, 2 & 1–2 g IV q4–6h
Category B Polycillin-N 10 g vials (up to 8 g/d)
Totacillin-N
2 g @ $4.69
Ampicillin + sulbactam Unasyn 1:0.5 & 2:1.0 g vials 1–2 g IV q6h
Category B (amp:sulbactam) (ampicillin)
2:1 g @
$15.85
Atovaquone Mepron 750 mg/5 mL susp 750 mg po bid
Category C w/food
210 mL (21
day supply) @
$738.64
Atovaquone + proguanil Malarone 100 250 mg atovaquone × Malaria
treatment—4
tabs/d × 3 days
(single daily dose)
250/100 mg
@ $4.70
62.5 mg atovaquone + Malaria
25 mg proguanil tabs prevention—1 tab/
(pediatrics) day
Take with food
mg proguanil Category C
tabs
Azithromycin Zithromax 250 & 600 mg tab 500 mg po first
Category B Z Pak with 6 250 mg day, then 250 mg
tabs q24h × 4 or 500
mg po qd
250 mg @
$7.83
600 mg @
$15.66
500 mg vial 500 mg IV qd
500 mg @
$27.83
Aztreonam Azactam 0.5, 1 & 2 g vials 0.5–2.0 g q 6–8 h
Category B
1 g @ $23.35
Bacitracin* Baci-IM 50,000 unit vial 10,000–25,000
Baciguent 500 units/g ointment 15, units IM q6h;
30, 120 & 454 g 25,000 units po
q6h (C. difficile
colitis)
50,000 units
@ $10.00
Butoconazole Femstat 2% vaginal cream, 3 1 dose hs × 3
single doses
5 g @ $34.62
Capreomycin Capastat 1 g vial 1 g/day IM or IV
Category D
1 g @ $26.60
Carbenicillin indanyl sodium Geocillin 382 mg tab (with 118 382–764 mg po
Category B mg indanyl sodium) q6h
382 mg @
$2.37
Caspofungin Cancidas 50 & 70 mg vials 70 mg IV (initial
Category C dose) 50 mg/d IV
(daily dose)
50 mg @
$283.71
Cefaclor Ceclor 250 & 500 mg caps 250–500 mg po tid
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Prefered Antimicrobial Agents for Specific Pathogens
Prefered Antimicrobial Agents for Specific Pathogens
Organism Usual disease Preferred agent(s) Alternatives (in random order)
Acinetobacter baumanii Sepsis (esp line sepsis) Imipenem/meropenem; Fluoroquinolone (6); ceftazidime;
(CID 2003;37:214;AAC Pneumonia-ventilator amikacin; ampicillin-sulbactam; tetracycline (4); antipseudomonad
2003;47:1681) Burn wound sepsis cefepime; fluoroquinolone (6) ± penicillin (2); aztreonam;
amikacin or ceftazidime colistin/polymyxin Note: Some
sensitive only to polymyxin
Actinobacillus Actinomycosis Penicillin; amoxicillin Clindamycin; tetracycline (4);
actinomycetemcomitans erythromycin; cephalosporins (5);
Endocarditis Penicillin + aminoglycoside (1) Cephalosporin (5) + aminoglycoside
(1)
Actinomyces israelii (also Actinomycosis Penicillin G; amoxicillin Clindamycin; tetracycline (4);
A. naeslundii, A. macrolide (8)
odontolyticus, and
Arachnia proprionica)
Aeromonas hydrophila (CID Diarrhea (see p 271) Fluoroquinolone (6); Tetracycline (4); gentamicin
sulfa-trimethoprim × 3d
Bacteremia Cephalosporin (3rd gen) Sulfa-trimethoprim;
Fluoroquinolone (6) imipenem/meropenem;
cephalosporin (3rd generation) (5)
2001;32:331)
Cellulitis/myositis/osteomyelitis Fluoroquinolone (6)
Sulfa-trimethoprim
Afipia felix (see Bartonella henselae)
Alcaligenes xylosoxidans Meningitis, septicemia Imipenem/meropenem Ceftazidime; sulfa-trimethoprim;
(AAC 1996;40:772) Antipseudomonad penicillin (2) doxycycline; ticarcillin-clavulanic
acid
Areanobacterium Pharyngitis, chronic ulcers Penicillin; macrolides (2) Clindamycin; doxycycline
haemolyticum (Clin Micro
Rev 1997;10:125)
Babesia microti (NEJM Babesiosis Atovaquone (750 mg po q12h) +
2000;343:1454;AAC azithromycin (500 mg × 1, then
2002;46:1163) 250 mg/d × 7)
Quinine (650 mg po tid × 7 d)
plus clindamycin (600 mg po qid
× 7 d)
Bacillus anthracis (JAMA Inhalation anthrax Ciprofloxacin IV or doxycycline In vitro sensitivity of strain for
2002;287:2236) IV plus 1–2 other agents: bio-terrorism will dictate
vancomycin, clindamycin, recommendations
rifampin, penicillin, imipenem, Other fluoroquinolones are probably
clarithromycin, chloramphenicol; comparable to ciprofloxacin
then oral ciprofloxacin (500 mg Steroids: Role is unclear; some
bid) or oral doxycycline (100 mg treat 100 days
bid) to complete 60 days Duration based on presumed
inhalation exposure
Cutaneous anthrax Ciprofloxacin 500 mg bid or
doxycycline 100 mg bid × 60
days
Prophylaxis Ciprofloxacin 500 mg bid or
doxycycline 100 mg bid × 60
days
Bacillus cereus Food poisoning Not treated
Endophthalmitis Intravitreal clindamycin 450 Gg Imipenem; fluoroquinolones (6)
and/or gentamicin 200–400 Gg
Bacillus species (Medicine Septicemia (comp host) Vancomycin Imipenem/meropenem;
1987;66:218) Endocarditis fluoroquinolones (6); clindamycin
Bacteroides bivius Female genital tract infections Metronidazole; clindamycin; Chloramphenicol; antipseudomonad
(Prevotella bivia) cefoxitin; cefotetan; penicillin (2);
beta-lactam-BLT (7) imipenem/meropenem
“B. fragilis group” (B. Abscesses Metronidazole; Clindamycin; antipseudomonad
distasonis, B. fragillis, B. Bacteremia beta-lactamase-BLT (7); penicillin (2); cefoxitin;
ovatus, B. Intra-abdominal sepsis imipenem/meropenem/ertapenem moxifloxacin; gatifloxacin
thetaio-tamicron, B.
vulgatus) (CID
2002;35:S126)
“B. melaninogenicus Oral-dental, pulmonary, and Metronidazole; clindamycin; Imipenem/meropenem cefoxitin
group” (Prevotella female genital tract infections beta-lactam-BLI (7)
melaninogenicus, P.
intermedius)
Bartonella bacilliformis Bartonellosis (Oroya fever) Chloramphenicol 2 g/d × 7 d Doxycycline; ampicillin
Bartonella henselae (PIDJ Cat-scratch disease Azithromycin Ciprofloxacin, sulfa-trimethoprim;
1998;17:447) gentamicin; rifampin
Bartonella henselae and B. Bacillary angiomatosis Erythromycin 500 mg po qid × Doxycycline 100 mg po q12h
Trench fever 2–4 mo
quintana (NEJM
1997;337:1876)
Peliosis hepatis, osteomyelitis, Erythromycin plus rifampin IV Doxycycline × rifampin IV
endocarditis
Bordetella pertussis Pertussis Erythromycin 2g/d × 14 days Sulfa-trimethoprim; clarithromycin;
azithromycin
Borrelia burgdorferi (see p Lyme disease, erythema Doxycycline 200 mg/d × 10 d Penicillin G po or IV; cefuroxime
216) migrans (Ann Intern Med 2003;138:697) axetil; cefotaxime
Amoxicillin
Lyme disease-late Ceftriaxone Penicillin G IV
Prophylaxis Doxycycline 200 mg × 1 within 72 hrs (NEJM 2001;345:79)
Borrelia recurrentis (Ann Louse-borne relapsing fever Tetracycline (0.5 g × 1) Erythromycin (0.5 g × 1)
Intern Med 1985;102:397)
Tick borne relapsing fever Doxycycline (200 mg/d × 5–10 Erythromycin (0.5 g qid × 5–10 d)
d)
Brucella (Ann Intern Med Brucellosis Doxycycline (200 mg/d) × 6 wks Doxycycline (200 mg/d) + rifampin
1992;117:25; CID + streptomycin (1 g/d IM) or (600–900 mg/d) × 6 wks;
1992;15:582) gentamicin × 3 wks sulfa-trimethoprim + gentamicin
Brucella meningitis, Doxycycline + rifampin + sulfa-trimethoprim × months
endocarditis
Burkholderia cepacia Septicemia Sulfa-trimethoprim, minocycline, Ceftazidime; meropenem;
(Pseudomonas cepacia) Pneumonia meropenem fluoroquinolone (6)
(AAC 1999;43:213)
Burkholderia pseudomallei Meliodosis Ceftazidime (120 mg/kg/d up to Sulfa-trim
(Pseudomonas Septicemia 6 g/d by continuous infusion chloramp
pseudomallei) (CID (AAC 39:2356, 1995) ± TMP-SMX imipenem
1999;29:381) (40 mg/kg/d trimethoprim) (CID TMP-SMX resistance in Thailand
2001;33:29)
Localized TMP-SMX; amoxicillin-clavulanate Tetracycline; chloramphenicol;
sulfisoxazole
Calymmatobacterium Granuloma inguinale Doxycycline 200 mg/d L 21 days Ciprofloxacin 750 mg bid L 21
granulomatis (MMWR Donovanosis TMP-SMX 1 DS/d × L 21 days days; erythromycin 500 mg bid × L
2002;51 RR-6) 21 days; fluoroquinolones (6)
Campylobacter fetus Septicemia, vascular infections, Imipenem Gentamicin; chloramphenicol;
meningitis fluoroquinolone (6)
Campylobacter jejuni (CID Diarrhea (see p 271) Erythromycin 500 mg bid × 5 d Tetracycline (4); furazolidine;
2001;32:331) fluoroquinolone (6)
Capnocytophaga canimorus Dog and cat bites Amoxicillin; clindamgcin Doxycycline;
(CDC group DF-2) (AAC amoxicillin-clavulanate; macrolides
1988;32:78) (8)
Bacteremia (asplenia) Clindamycin; penicillin Cephalosporins (3rd generation)
(5); imipenem/meropenem;
fluoroquinolones (6);
beta-lactam-BLI (7)
Capnocytophaga ochracea Periodontal disease Clindamycin; amoxicillin-clavulanic acid; erythromycin; doxycycline
(CDC group DF-1) (JID
1985;151:140)
Bactermia in neutropenic host Clindamycin; Beta-lactam-BLI (7);
imipenem/meropenem/ertapenem fluoroquinolone (6)
Cardiobacterium sp. Endocarditis Penicillin ± aminoglycoside Cephalosporin (5) ± aminoglycoside
(1)
Cat-scratch disease, (see Bartonella henselae)
Chlamydia pneumoniae Pneumonia (see p 255) Doxycycline or macrolide × Fluoroquinolone (6) × 10–14 d
10–14 d
Telithromycin × 7–10 d
Chlamydia psittaci Psittacosis (see p 255) Doxycycline Chloramphenicol
Chlamydia trachomatis Urethritis, cervicitis, PID, Doxycycline (200 mg/d × 7 d); Erythromycin (500 mg qid × 7d);
(see pp 293–294) (MMWR epididymitis, urethral azithromycin (1 g po × 1) ofloxacillin (300 mg bid × 7d)
2002;51:RR-6) syndrome
Lymphogranuloma venereum Doxycycline 200 mg/d × 21 d Erythromycin 500 mg qid × 21 d
Trachoma Azithromycin 20 mg/kg × 1 (CID Doxycycline 200 mg/d × 14 d
1997;24:363)
Inclusion conjunctivitis Doxycycline 200 mg/d × 7 d Erythromycin; azithromycin
Citrobacter diversus Urinary tract infections, Cephalosporin (2nd, 3rd gen) Fluoroquinolone (6);
pneumonia (5); cefepime; imipenem/meropenem; aztreonam
sulfa-trimethoprim
Citrobacter freundii Urinary tract infection, wound Imipenem/meropenem; Cefepime; antipseudomonad
infection, septicemia, fluoroquinolone (6); TMP-SMX; penicillins; aztreonam
pneumonia aminoglycoside
Clostridium difficile (NEJM Antibiotic-associated colitis and Metronidazole 250 mg po qid × Vancomycin 125 mg po qid × 10 d
2002; 346:334) diarrhea (see p 271) 10 d or vancomycin 500 mg by
nasogartic or rectal tube (patients
unable to take po drugs)
Clostridium sp. Gas gangrene Penicillin G (all systemic Chloramphenicol; metronidazole;
Sepsis clostridial infections) + ampicillin; clindamycin;
Clindamycin (JID 1987;155:220) imipenem/meropenem
Tetanus Metronidazole (Lancet Penicillin; cephalosporins;
1989;2:1216) + tetanus toxoid + imipenem; macrolides; tetracycline
tetanus
Immune globulin (500 IU IV)
Botulism Penicillin + A/B or E equine antitoxin (10 mL IV) (available from the CDC
at 404-639-3670)
Corynebacterium Diphtheria Erythromycin (250–500 mg qid) Clindamycin; tetracycline (4)
diphtheriae or penicillin (IM or po) × 14 d +
antitoxin (20,000–40,000 units
IM for pharyngeal disease O 48
hrs; 80,000–120,000 units IV/IM
for severe disease) (available
from CDC at 404-639-3670)
Corynebacterium jeikeium Septicemia Vancomycin Penicillin G + gentamicin;
(CDC group JK) daptomycin; fluoroquinolone (6);
macrolide (8)
Corynebacterium Erythrasma Erythromycin
minutissimum
Corynebacterium ulcerans Pharyngitis Erythromycin
Coxiella burnetii (MMWR Q fever Doxycycline (200 mg/d × 2–3 Chloramphenicol; erythromycin;
2002;51:924) wks) fluoroquinolone (6)
Q fever endocarditis Doxycycline (100 mg bid + Doxycycline × rifampin or
hydroxychloroquine 200 mg tid × fluoroquinolone (6) × 2 yrs.
18 mo–4 yr) (Arch Intern Med
1999;159:167)
Dysgonic fermenter type-2 See Capnocytophaga canimoris
(DF-2)
Ehrlichia chaffeensis E. Ehrlichiosis–human monocyte Doxycycline (100 mg bid po or Rifampin; fluoroquinolones (AAC
phagocytophia (Emerg ehrlichiosis (EMH) and human IV × 7–14 days) 1997;41:76)
Infect Dis 1996;2:18; AAC granulocyte ehrlichiosis (HGE)
1997;41:76)
Eikenella corrodens (AAC Oral infections, bite wounds Ampicillin; amoxicillin Tetracycline (4);
1988;32:1143) Penicillin G amoxicillin-clavulanic acid;
ampicillin-sulbactam; cephalosporin
(2nd & 3rd gen) (5);
fluoroquinolone (6); TMP-SMX
Enterobacter aerogenes, E. Sepsis, pneumonia, wound Imipenem/meropenem; cefepime; aminoglycoside (1); fluoroquinolone
cloacae (JAMA infections (6); ciprofloxacin; antipseudomonad penicillin (2)
2003;298:885)
Urinary tract infection Sulfa-trimethoprim Antipseudomonad penicillin (2);
Cephalosporin (3rd generation) aminoglycoside; fluoroquinolone
(5) (6); imipenem
Enterococcus (E. faecalis Urinary tract infection Ampicillin/amoxicillin Penicillin + aminoglycoside (1);
and E. faecium) Nitrofurantoin; fosfonomycin vancomycin; fluoroquinolone (6)
Wound infections, Ampicillin ± aminoglycoside (1) Vancomycin; daptomycin; linezolid;
intra-abdominal sepsis, penicillin ± aminoglycoside (1);
bacteremia imipenem (E. faecalis)
Endocarditis Penicillin G/ampicillin + Vancomycin + gentamicin or
gentamicin or streptomycin streptomycin
Enterococcus faecium Urinary tract infection Nitrofurantoin; fosfonomycin
Bacteremia and other systemic Linezolid; daptomycin
infections Some strains sensitive to chloramphenicol, tetracycline, or
fluoroquinolones; clinical results are variable (CID 1995;20:1137)
Nitrofurantoin (UTI)
(vancomycin-resistant)
Endocarditis Daptomycin
Erysipelothrix Localized cutaneous Amoxicillin; fluoroquinolone (6) Clindamycin; imipenem
rhusiopathiae (AAC (erysipeloid)
1990;34:2038)
Endocarditis/disseminated Penicillin 12–20 mil units/d × Cephalosporins—1st generation (5);
4–6 wks fluoroquinolone
E. coli (JAMA Septicemia, intra-abdominal Cephalosporin (3rd gen) (5) Imipenem/meropenem/ertapenem;
2003;289:885) sepsis, wound infection Ampicillin (if sensitive) fluoroquinolone (6); cefepime;
Sulfa-trimethoprim (if sensitive) cephalosporin (1st or 2nd gen) (5);
aztreonam; antipseudomonad
penicillin (2); beta-lactam-BLI (7)
aztreonam
Urinary tract infection TMP-SMX (if sensitive); Cephalosporin (5);
fluoroquinolone imipenem/meropenem
Diarrhea ETEC (travelers' Ciprofloxacin (500 mg bid × 3d); TMP-SMX (DS bid × 3d) (CID
diarrhea) (see p 272) 2001;32:331)
Francisella tularensis (CID Tularemia Streptomycin (1 g 1M bid × 10 Tetracycline (4); chloramphenicol;
1994;19:42) days); gentamicin (5 mg/kg/d × ciprofloxacin × L 14 days
10 days)
Fusobacterium Oral/dental/pulmonary Penicillin G; metronidazole; Cefoxitin/cefotetan;
infection, liver abscess, female clindamycin; imipenem/meropenem/ertapenem
genital tract amoxicillin-clavulanate
Gardnerella vaginalis Bacterial vaginosis Metronidazole (500 mg bid × 7 Metronidazole (2 g po × 1);
(MMWR 2002;51:RR-6) d); clindamycin 2% 5 g topical clindamycin (300 mg po bid × 7 d)
(see p 303) qd × 7; metronidazole gel 0.75%
5 g bid × 5 d
Haemophilus aphrophilus Sepsis, endocarditis Penicillin G + aminoglycoside (1) Cephalosporin (3rd gen) (5) +
aminoglycoside (1)
H. ducreyi (MMWR Chancroid (see p 296) Ceftriaxone (250 mg IM × 1)
2002;51:RR-1) Erythromycin (500 mg qid × 7 d)
Azithromycin (1 g po × 1)
H. influenzae (AAC Meningitis (see p 237) Cefotaxime; ceftriaxone Fluoroquinolones; cefuroxime (not
1997;41:292) Epiglottis, pneumonia (see p meningitis); beta-lactamase-BLT
253); arthritis; cellulitis
Otitis, sinusitis, exacerbations Sulfa-trimethoprim; azithromycin Tetracycline (4);
of exacerbations of chronic Cephalosporin (2nd or 3rd gen); beta-lactamase-BLT (7);
bronchitis clarithromycin fluoroquinolone (6)
Pneumonia, acute sinusitis, Telithromycin; azithromycin; Fluoroquinolone;
acute bacterial exacerbations cephalosporin (2nd + 3rd gen); beta-lactamase-BLT
of chronic bronchitis clarithromycin
Hafnia alvei (See Enterobacter)
Helicobacter pylori (Med Peptic ulcer disease Omeprazole (20 g) + amoxicillin Omeprazole or ranitidine +
Lett 1997;39:1 Ann Intern (1 g bid) + clarithromycin (500 clarithromycin
Med 1997;157:87 BMJ mg bid) × 14 d Omeprazole or lansoprazole +
2001;232:1047; NEJM Bismuth subsalicylate (2 tabs clarithromycin + metronidazole
2002;347:1175) (see p bid) + tetracycline (500 mg qid)
270) + metronidazole (500 mg tid) +
omeprazole (20 mg bid) × 14 d
Omeprazole + amoxicillin (1 g
bid), + clarithromycin (500 mg
bid) × 1 wk
Kingella sp. Endocarditis Penicillin + aminoglycoside Cephalosporin (5) + aminoglycoside
(1)
Septic arthritis Penicillin; cephalosporin TMP-SMX; doxycycline; macrolides
(8); fluoroquinolone (6)
Klebsiella pneumoniae K. Septicemia, nosocomial Cephalosporin (3rd gen) (5) Aminoglycoside (1);
oxytoca pneumonia, intra-abdominal Imipenem/meropenem; sulfa-trimethoprim
(JAMA2003;289:885) sepsis, urinary tract infection beta-lactam-BLI (7); aztreonam;
cefepime; fluoroquinolone (6)
Legionella sp (J Resp Dis Legionnaires' disease Gatifloxacin, moxifloxacin, or Erythromycin; doxycycline;
2002;23:229) (see p 255) levofloxacin × 10–14 d clarithromycin; sulfa-trimethoprim
Azithromycin × 7–10 d
Leptospira spp (CID Leptospirosis Mild disease Doxycycline 200 mg/d
1995;21:1) Amoxcillin 500 mg qid
Serious disease Penicillin G 1.5 mil units q6h
Ampicillin 0.5–1 g IV q6h
Leuconostoc (AAC Bacteremia Penicillin/ampicillin Erythromycin; aminoglycosides (1);
1990;34:543) Wound infection clindamycin
Listeria monocytogenes Meningitis (see p 237) Ampicillin or penicillin ± Sulfa-trimethoprim
(JCM 2003;41:483) Septicemia gentamicin
Moraxella catarrhalis Otitis, sinusitis, pneumonitis Sulfa-trimethoprim; doxycycline; Doxycycline; fluoroquinolone (6)
(Branhamella catarrhalis) cephalosporin (2nd or 3rd gen)
(AAC 1996;40:2884) (5); amoxicillin-clavulanate
macrolides (8)
Acute bacterial exacerbations Telithromycin; azithromycin; Doxycycline; fluoroquinolone
of chronic bronchitis cephalosporin (2nd + 3rd gen);
clarithromycin
Morganella morganii Bacteremia, pneumonia, Fluoroquinolone (6); Sulfa-trimethoprim; aztreonam;
urinary tract infection, wound imipenem/meropenem; antipseudomonad penicillin (2);
infection cephalosporin (3rd gen) (5); aminoglycoside (1);
cefepime beta-lactam-BLI
Mycobacterium abscessus Cutaneous pulmonary Amikacin + cefoxitin or Clarithromycin ± clofazimine
imipenem
M. avium-intracellulare Pulmonary infection Clarithromycin or azithromycin, Azithromycin; ethionamide;
(see p 170) Ethambutol, ± rifampin or amikacin; cycloserine;
ciprofloxacin (6) ciprofloxacin/ofloxacin/levofloxacin;
streptomycin
Disseminated infection (AIDS) Clarithromycin + ethambutol ± Ethionamide; cycloserine;
rifabutin or ciprofloxacin (6) rifampin/rifabutin; amikacin
M. chelonae (see p 171) Skin and soft tissue Tobramycin + cefoxitin or Clofazimine or clarithromycin, then
imipenem sulfonamide, rifampin, doxycycline,
or erythromycin
M. fortuitum (see p 170) Soft tissue and wound Amikacin + cefoxitin or Sulfonamide
infections imipenem × 2–4 wk, then
Pulmonary clarithromycin, ciprofloxacin, or
doxycycline
M. genavense (AIDS) (see Disseminated disease Clarithromycin + other agents INH; ethambutol; rifampin;
p 171) ciprofloxacin; pyrazinamide
M. haemophilum (AIDS) Disseminated disease (skin, Rifampin or rifabutin + amikacin Cycloserine
(see p 171) bone, gut, nodes) Pulmonary + ciprofloxacin
M. kansasii (see p 170) Pulmonary infection INH + rifampin + ethambutol Clarithromycin; ciprofloxacin;
rifabutin; ethionamide;
streptomycin; amikacin;
cycloserine; sulfa-trimethoprim
M. leprae Paucibacillary Rifampin 600 mg/mo Rifampin
(supervised) plus dapsone 100 100 mg/d
mg/d
Multibacillary Rifampin 600 mg/mo Rifampin 600 mg/d plus dapsone
(supervised) + dapsone 100 100 mg/d ± clofazimine 50 mg/d L
mg/d + clofazimine 100 mg/mo 24 mo
(supervised) or 50 mg/d
M. marinum (see p 171) Soft tissue infections Rifampin + ethambutol Clarithromycin
Sulfa-trimethoprim
Minocycline or doxycycline
M. tuberculosis (see pp Tuberculosis INH + rifampin + pyrazinamide + Capreomycin, kanamycin or
162) ethambutol or streptomycin amikacin; ciprofloxacin, ofloxacin
or moxifloxacin
Ethionamide; PAS; nitroimidazoles
Cycloserine; aerosolized
aminoglyco-sides
M. ulcerans (see p 171) Pulmonary Rifampin + ethambutol
Amikacin + sulfa-trimethoprim
Mycoplasma hominis (CID Genital tract infections Doxycycline 200 mg/d × 7 d
1996;23:671)
Mycoplasma pneumoniae Pneumonia (see p 255) Macrolide (8); doxycycline × Fluoroquinolones (6) × 10–14 d
10–14 d; telithromycin × 7–10 d
Neisseria gonorrhoeae (see Genital tract infections Ceftriaxone (125 mg IM × 1); Spectinomycin (2 g IM × 1);
ciprofloxacin (500 mg × 1); azithromycin (2 g po × 1); cefoxitin
ofloxacillin (400 mg × 1) (each 2 g IM probenecid 1 g po
with doxycycline or
azithromycin)
Disseminated gonococcal Ceftriaxone 1 g IV or IM/d until Cefotaxime 1 g IV q8h
infection asymptomatic 24–48 hr, then
oral Rx to complete 1 wk
pp 288–289) (MMWR
2002;51:RR-6)
N. meningitidis (see p 237) Meningitis (see p 237), Penicillin G (up to 24 mil units/d Ampicillin; cefotaxime; ceftriaxone;
bacteremia, pericarditis, IV) × 10–14 d chloramphenicol;
pneumonia sulfa-trimethoprim
Prophylaxis Ciprofloxacin (500 mg × 1) Rifampin (600 mg bid × 2 d)
Ceftriaxone (250 mg IM × 1)
Nocardia asteroides (Clin Nocardiosis: pulmonary Sulfonamide (usually sulfadiazine Minocycline ± sulfonamide
Microbiol Rev 1994;7:357) infection, abscesses—skin, or sulfisoxazole) (3–6 g/d) Amikacin ± imipenem, ceftriaxone,
lung, brain Sulfa-trimethoprim (5–10 cefuroxime, amoxicillin-clavulanate,
mg/kg/d trimethoprim po or IV or sulfa-trimethoprim
up to 15 mg/kg/d) Imipenem + cefotaxime or
sulfa-trimethoprim
Pasteurella multocida (AAC Animal bite wound Penicillin G; ampicillin; Tetracycline (4); fluoroquinolones;
1988; 32:213) amoxicillin Cephalosporins (2nd and 3rd gen)
(5)
Amoxicillin-clavulanic acid;
macrolides
Septicemia, septic Penicillin G Cephalosporins (3rd gen) (5);
arthritis/osteomyelitis beta-lactam-BLI (7);
imipenem/meropenem
Peptostreptococcus Oral/dental/pulmonary Penicillin G; ampicillin; Cephalosporin (1st gen) (5);
infection; intra-abdominal amoxicillin; clindamycin chloramphenicol; macrolides (8);
sepsis; gynecologic infection moxifloxacin, gatifloxacin;
vancomycin;
Imipenem/meropenem/ertapenem
Plesiomonas shigelloides Diarrhea (usually not treated) Sulfa-trimethoprim (IDS bid × 3 d)
(see p 273) Fluoroquinolone (6) × 3 d
(CID 2001;51:331)
Extra-intestinal infection Cephalosporin (3rd gen) (3) Aztreonam; sulfa-trimethoprim;
Aminoglycoside (1) imipenem/meropenem;
fluoroquinolone (6)
Propionibacterium acnes Acne Tetracycline (4) Clindamycin (topical); clindamycin
Proteus mirabilis (JCM Septicemia, urinary tract Ampicillin Aminoglycosides (1);
2002;40:1549) infection, intra-abdominal Cephalosporins (1st, 2nd, 3rd sulfa-trimethoprim; tetracycline
sepsis, wound infection generation) (5) Antipseudomonad penicillin (2);
aztreonam; fluoroquinolone (6);
beta-lactam-beta-lactamase
inhibitor (7)
Proteus vulgaris Septicemia Cephalosporin (3rd gen) (5) Aminoglycoside (1); TMP-SMX;
Urinary tract infection Imipenem; beta-lactam-BLT (7) antipseudomonad penicillin (2);
cefepime; aztreonam;
fluoroquinolone (6)
Providencia Septicemia Cephalosporin (3rd gen) (5) Aminoglycoside (1); aztreonam;
Urinary tract infection Imipenem; amikacin antipseudomonad penicillin (2);
cefepime; ticarcillin-clavulanate;
TMP-SMX; fluoroquinolone (6)
Pseudomonas aeruginosa Septicemia, pneumonia Aminoglycoside (tobramycin) Ciprofloxacin (6);
(JAMA 2003;289:885) Intra-abdominal sepsis and/or antipseudomonad piperacillin-tazobactam,
penicillin (2); ceftazidime; ticarcillin-clavulanate
cefepime; imipenem/meropenem;
aztreonam
Urinary tract infections Aminoglycoside (1); Imipenem/meropenem;
ciprofloxacin; antipseudomonad ceftazidime; cefepime;
penicillin (2) cefoperazone; aztreonam
P. cepacia(see Burkholderia cepecia)
Rhodococcus equi (CID Localized + immunocompetent 2 oral agents: rifampin, erythromycin, or ciprofloxacin
2002;34:1379)
Disseminated, severe, or 2 parenteral agents: vancomycin, imipenem/meropenem/ertapenem,
immunosuppressed ciprofloxacin, aminoglycoside, rifampin, or erythromycin
Rickettsia spp (MMWR Rocky Mountain spotted fever, Doxycycline (100 mg po or IV Chloramphenicol (2 g/d × 7 d)
2000;49:888) Q fever, tick-bite fever, murine bid × 7 days) fluoroquinolone (6)
typhus, scrub typhus, typhus,
trench fever
Rochalimaea quintana and R. henselae (See Bartonella henselae and B. quintana)
Salmonella typhi (AAC Typhoid fever (see p 273) Ceftriaxone 1–2 g/d × 10–14 d Ampicillin/amoxicillin (preferred if
1999;43:1441; CID Ciprofloxacin 500 mg bid × 10 d sensitive); chloramphenicol (4 g
2001;32:331) If severely ill: Steroids (RID IV/d); sulfa-trimethoprim (1 DS
1991;13:85) bid)
Carriers (see p 274) (Lancet Ciprofloxacin (× 4–6 wks)
1987;2:162) Amoxicillin (× 6 wks)
TMP-SMX (× 6 wks)
Salmonella sp. (other) Gastroenteritis (See indications Ciprofloxacin (500 mg bid × 5–7 Olfloxacin and norfloxacin
(CID 2001;32:331) p 274) d)
Ceftriaxone (100 mg/kg/d × 5–7
d)
TMP-SMX (1 DS bid × 5–7 d)
Bacteremia Ceftriaxone or quinolone (IV × 7–14 d)
Endovascular infection Ceftriaxone, ampicillin, or ciprofloxacin (IV × 6 wks ± surgery)
Carrier As for S. typhi (above)
Serratia marcescens Septicemia, urinary tract Cephalosporin (3rd gen) (5) ± Aztreonam; pip/tazobactam;
infection, pneumonia gentamicin; Ticar/sulbactam
imipenem/meropenem;
fluoroquinolone (6);
antipseudomonad penicillin (2) +
amikacin
Shigella spp (CID Colitis (see p 274) Sulfa-trimethoprim (1 DS bid × 3 Ofloxacillin; nalidixic acid;
2001;32:331) d) azithromycin
Ciprofloxacin 500 mg bid × 3 d)
Spirillum minus Rat-bite fever Penicillin G (IV × 5–7 d) then Tetracycline (4); streptomycin
amoxicillin × 7 days Possibly effective: clindamiycin;
erythromycin; ceftriaxone
Staphylococcus aureus Septicemia, pneumonia, Penicillinase-resistant penicillin Cephalosporins (1st gen) (5);
Methicillin-sensitive cellulitis, wound infection (3) cefepime; vancomycin;
sulfa-trimethoprim; macrolide (8);
beta-lactam-BLT (7);
fluoroquinolone (6) (increasing
resistance); clindamycin
Acute sinusitis Telithromycin; amoxicillin; Sulfa-trimethoprim; macrolide;
cephalosporin (2nd + 3rd gen) clindamycin
Methicillin-resistant As above Vancomycin Daptomycin (except pneumonia);
linezolid
Community-acquired MRSA are
often sensitive to clindamycin,
fluoroquinolones, TMP-SMX
Vancomycin-intermediate As above Vancomycin plus oxacillin, Quinupristin-dalfopristin
sensitive S. aureus (NEJM nafcillin, cefazolin, or cefotaxime
1999;340:493) (NEJM 1999;340:517); linezolid;
daptomycin (except pneumonia)
Vancomycin-resistant S. As above Linezolid; daptomycin (except Quinupristin-dalfopristin; some
aureus(NEJM pneumonia) strains sensitive to tetracycline,
2003;348:1342; MMWR TMP-SMX, chloramphenicol
2002;51:565)
S. saprophyticus Urinary tract infections Sulfa-trimethoprim Cephalosporins (5); tetracycline (4)
Ampicillin/amoxicillin
Fluoroquinolone (6)
Methicillin-resistant Septicemia Vancomycin ± gentamicin or Daptomycin; linezolid; (possibly
Infected prosthetic devices rifampin effective—chloramphenicol,
rifampin, tetracycline)
Stenotrophomonas Septicemia, pneumonia, UTI Sulfa-trimethoprim Ceftazidime; fluoroquinolone
maltophilia (Xanthomonas (6);minocycline
maltophilia) Ticarcillin-clavulanate
Streptobacillus Rat-bite fever Penicillin G IV × 5–7 d, then Tetracycline (4); erythromycin;
moniliformis Haverhill fever amoxicillin × 7 d clindamycin; streptomycin
Streptococcus, groups B, Pharyngitis Penicillin G or V (if Cephalosporin (1st gen),
C, G; S. bovis, S. milleri, Soft tissue infection penicillin-resistant S. cefuroxime, cefotaxime,
S. viridans, anaerobic Pneumonia (see p 253) pneumoniae— see below) ceftriaxone;
streptococci Abscesses Erythromycin, clarithromycin,
(Peptostreptococcus) and azithromycin
Vancomycin; clindamycin
penicillin-sensitive Endocarditis Penicillin G ± streptomycin or Cephalosporin: Parenteral—see
strains S. pneumoniae (S. gentamicin above vancomycin
pyogenes—see pp 241,
245) (CID 2002;35:113)
S. iniae Bacteremia, cellulitis Penicillin, clindamycin Beta-lactams
S. pneumoniae (see p 253) Meningitis (see p 237) Vancomycin + cefotaxime or Cefotaxime; ceftriaxone (activity
Ocular infections ceftriaxone variable)
S. pneumoniae Pneumonia (see p 253) Penicillin G; amoxicillin; Telithromycin;† macrolides (8);
Penicillin-sensitive (mic O cefotaxime or ceftriaxone cephalosporins—cefpodoxime,
1.0 Gg/mL) ceftibutin, cefprozil;
fluoroquinolone (6); clindamycin;
doxycycline; pip-tazobactam;
amoxicillin ± clavulanate
Meningitis Penicillin; ceftriaxone; Vancomycin; chloramphenicol
cefotaxime
Penicillin-intermediate Pneumonia As for penicillin-sensitive strains Most active
sensitive (MIC 2 Gg/mL) (see above) OR telithromycin† beta-lactams—amoxicillin;
cefotaxime; ceftriaxone; ceftibutin;
cefpodoxime
Other options—fluoroquinolone;
clindamycin; beta-lactam-BLI's
(7)—but not ticarcillin
Meningitis Vancomycin
Penicillin-resistant (mic Pneumonia Telithromycin;† fluoroquinolone Quinupristin-dalfopristin;
L 4.0 Gg/mL) (6); vancomycin; linezolid daptomycin
S. pyogenes Pharyngitis (CID 2002;35:113) Penicillin V 500 mg bid × 10 d Erythromycin 250 mg po tid × 10 d
Soft tissue Benzathine penicillin 1.2 mil
Toxic shock syndrome units IM × 1
Penicillin; amoxicillin
Clindamycin + penicillin
Treponema pallidum Syphilis (see pp 289–292) Penicillin G Tetracycline (4); ceftriaxone
Tropheryma whippelii Whipple's disease Induction: ceftriaxone (2 g IV/d) or penicillin (1.2 mil units/d) + strep
(Lancet 2003;361:231) (1 g/d) × 2 wks
Maintenance: TMP-SMX (1 DS/d) or doxycycline/minocycline (200 mg/d
× 1 yr)
Ureaplasma urealyticum Genital tract infection Doxycycline (200 mg/d × 7 d) Macrolides (8)
Vibrio cholerae (Lancet Cholera (see p 274) Doxycycline (300 mg × 1); Fluoroquinolone-single dose
2003;361:231) tetracycline (500 mg qid × 3 d)
Vibrio parahaemolyticus Diarrhea (usually not treated) Tetracycline (4)
(CID 2001;32:331) (see p 275) Fluoroquinolone (6)
Vibrio vulnificus (CID Septicemia Tetracycline (4) Cefotaxime/Ceftriaxone
2003;37:272) Wound infection Chloramphenicol
Gastroenteritis Aminoglycoside
Xanthomonas maltophilia (see Stenotrophomonas maltophila)
Yersinia enterocolitica (CID Enterocolitis and mesenteric Sulfa-trimethoprim; gentamicin; Cephalosporin (3rd gen) (5)
2001;32:331) adenitis (usually not treated) fluoroquinolone (6); doxycycline
Septicemia Aminoglycoside (gentamicin) Chloramphenicol; ciprofloxacin;
sulfa-trimethoprim
Yersinia pestis (JAMA Plague treatment Streptomycin; gentamicin Chloramphenicol; tetracycline (4);
2000;283:2281) ciprofloxacin
Prevention Doxycycline Chloramphenicol
Ciprofloxacin
Yersinia Mesenteric adenitis (usually not Aminoglycoside (1) Sulfa-trimethoprim; tetracycline (4)
pseudo-tuberculosis treated) Ampicillin
Septicemia
1 . Aminoglycosides: gentamicin, tobramycin, amikacin, netilimicin. Netilmicin is no longer available in the U.S.
2 . Antipseudomonad penicillin: ticarcillin, piperacillin.
3 . Penicillinase-resistant penicillins: nafcillin, oxacillin, methicillin, cloxacillin, dicloxacillin.
4 . Tetracycline: Tetracycline, doxycycline, minocycline.
5 . Cephalosporins and miscellaneous beta-lactams
1st generation: Cefadroxil*, cefazolin, cephalexin,* cephapirin, cephradine*
2nd generation: Cefaclor,* cefaclor ER, cefamandole, ceforanide, cefotetan, cefoxitin, cefuroxime,* cefprozil,* loracarbef*
3rd generation: Cefotaxime, ceftizoxime, ceftazidime, cefoperazone, ceftriaxone, moxalactam, cefixime,* cefpodoxime,* cefdinir,*
cefditoren,* ceftibuten*
4th generation: Cefepime
Cephamycins: Cefoxitin, cefotetan
Monobactam: Aztreonam
Carbapenem: Imipenem, meropenem, ertapenem
Carbacephem: Loracarbef*
6 . Fluoroquinolones: Norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, levofloxacin, trovafloxacin, gatifloxacin, gemifloxacin, and
moxifloxacin. Systemic infections are usually treated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, or moxifloxacin; all may be
used for urinary tract infections. With regard to spectrum:P. aeruginosa—ciprofloxacin and trovafloxacin;Mycobacterium—ciprofloxacin,
levofloxacin, gatifloxacin, moxifloxacin, or ofloxacin;C. trachomatis—ofloxacin; S. pneumoniae—levofloxacin, gatifloxacin, or moxifloxacin;
anaerobes—gatifloxacin and moxifloxacin are most active; ciprofloxacin and levofloxacin are least active; side-effects: trovafloxacin has a
FDA-mandated black box warning about hepatotoxicity and revised indications in 1999 that restrict use to infections for which alternative
antibiotics are unavailable.
7 . Beta-lactam-beta-lactamase inhibitor. Amoxicillin + clavulanate (Augmentin), ticarcillin + clavulanate (Timentin), ampicillin + sulbactam
(Unasyn), and piperacillin + tazobactam (Zosyn).
8 .Macrolides: Erythromycin, clarithromycin, azithromycin, dirithromycin.
* Oral cephalosporins; cefuroxime has both oral and parenteral formulations.
† Telithromycin is also active agent against multi-drug resistant Streptococcus pneumoniae.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Antimicrobial Dosing Regimens in Renal Failure
Antimicrobial Dosing Regimens in Renal Failure
A. GENERAL PRINCIPLES
1. Initial dose is not modified in renal failure.
2. Initial dose is not modified in renal failure.
3. Adjustments in subsequent doses for renally excreted drugs may be accomplished by a) giving the usual maintenance dose at extended intervals, usually
three half-lives (extended interval method); b) giving reduced doses at the usual intervals (dose reduction method); or c) a combination of each.
Female: Above value × 0.85
Pitfalls and notations with calculations follow.
a. Elderly patient: Serum creatinine may be deceptively low (with danger of overdosing) because of reduced muscle mass.
b. Pregnancy, ascites, and other causes of volume expansion: GFR may be increased (with danger of underdosing) in third trimester of pregnancy
and patients with normal renal function who receive massive parenteral fluids.
c. Obese patients: Use lean body weight.
d. Renal failure: Formulas assume stable renal function; for patients with anuria or oliguria assume creatine clearance (CCr) of 5–8 mL/min.
B. AMINOGLYCOSIDE DOSING
1. GUIDELINES OF THE JOHNS HOPKINS HOSPITAL CLINICAL PHARMACOLOGY DEPARTMENT
Subsequent doses (before level
measurements)
Loading dose, regardless of Therapeutic levels (1 hr after start of
Agent
renal function b,c infusion over 20–30 min)
CCr > 70 CCr < 70 mL/mind
mL/min
Gentamicina 2 mg/kg 1.7–2 mg/kg/8 0.03 × CCr = 5–10 Cg/mL
h mg/kg/8 h
Tobramycina 2 mg/kg 1.7–2 mg/kg/8 0.03 × CCr = 5–10 Cg/mL
h mg/kg/8 h
Amikacina 8 mg/kg 7.5–8 mg/kg/8 0.12 × CCr = 20–40 Cg/mL
h mg/kg/8 h
a Doses for gentamicin and tobramycin should be written in multiples of 5 mg; doses of amikacin and kanamycin should be written in multiples of 25
mg.
b Seriously ill patients with sepsis often need higher loading doses to achieve rapid therapeutic levels despite third spacing, e.g., 3 mg/kg for
gentamicin and tobramycin.
c Obese patients: use calculated lean body weight plus 40% of excess fat.
d Patients who are oliguric or anuric: use CCr of 5–8 mL/min.
2. MAYO CLINIC GUIDELINES (Mayo Clin Proc 47:519, 1999)
a. Initial dose: Gentamicin, tobramycin, netilmicin: 1.5–2 mg/kg; amikacin: 7.5–15 mg/kg. This is based on ideal body weight (IBW) calculated for males:
50 kg × 2.3 kg (height in inches–60 inches), and for female patients: 45 kg × 2.3 kg (height in inches–60 inches). For obese patients (>30% above
ideal body
P.40
weight) calculate dosing weight is IBW × 0.4 (actual weight in kg -IBW).
b. Maintenance dose: Cockcroft-Gault equation.
3. MONITORING: Measure peak levels at 1 hr after start of 20- to 30-min infusion. Goal with q8h dosing is 5–10 Cg/mL for gentamicin and tobramycin or
20–40 Cg/mL for amikacin; peak levels when using low doses of gentamicin or tobramycin for synergy vs staph, strep or enterococcus is 3 Cg/mL. Monitor
for nephrotoxicity with serum creatinine qd or qod. Monitor for ototoxicity when feasible in patients treated >3 days with periodic Romberg's sign
and with reading an eye chart after rapid head movements.
ONCE DAILY AMINOGLYCOSIDES
Rationale: see Infect Dis Clin Pract 5:12, 1996; AAC 39:650, 1995; Eur J Clin Microbiol Infect Dis 14:1029, 1995; Ann Intern Med 124:717, 1996
Clinical trials: 24 published trials (Eur J Clin Microbiol Infect Dis 14:1029, 1995): Showed comparable results with once daily versus multiple daily doses
for therapeutic response and toxicity.
Contraindication: Patients receiving aminoglycosides for synergy with beta-lactam agents for streptococcal endocarditis or enterococcal infections should
receive standard thrice daily dosing regimens.
Monitoring: Some authorities suggest monitoring predose levels (18 hr) after second dose, which should show gentamicin or tobramycin levels 0.6–2.0
Cg/mL and amikacin levels 2.5–5.0 Cg/mL; higher levels should lead to dose reduction. All patients receiving aminoglycosides should be monitored for
nephrotoxicity and ototoxicity (see above).
Regimen
1. Standard dose
Gentamicin and tobramycin: 5–6 mg/kg/d (some use 4–7 mg/kg/d)
Amikacin and streptomycin: 15–20 mg/kg/d
2. Dose adjustment based on trough levels
Gentamicin and tobramycin:I0.5 Cg/mL
Amikacin:<5 Cg/mL
3. Dose adjustment based on renal function (Mayo Clin Proc 1999;47:519.)
Dose (mg/kg) q24h
Creatinine clearance (mL/min) Gentamicin tobramycin Amikacin
>80 5.0 15.0
60–79 4.0 12.0
50 3.5 7.5
40 2.5 4.0
<30 Conventional dosing
P.41
C. DRUG THERAPY DOSING GUIDELINES
(Adapted in part from Drug Information for the Health Care Professional, USP DI, 23rd Edition, 2003; Physicians' Desk Reference, 57th Edition, 2003)
Maintenance regimen renal failure
Major
Half-life (hr)* Usual regimen GFR GFR GFR
excretory
Route
50–80
Drug Normal Anuria Oral Parenteral mL/min 10–50 mL/min <10 mL/min
Acyclovir Renal 2–2.5 20 200 mg — Usual Usual 200 mg q12h
3–5×/d — Usual Usual 200 mg q12h
400 mg — Usual 800 mg q8h 800 mg q12h
bid 5–10 mg/kg Usual 5–12 mg/kg 2.5–6 mg/kg
800 mg q8h q12–24h q24h
5×/d
—
Adofovir Renal 1.6 IC-16 (cid:1) 10 mg — Usual 10 mg q48–72h 10 mg q wk
q24h
Albendazole Hepatic 8 8 400–800 — Usual Usual Usual
mg bid
Amantadine Renal 15–20 170 100 mg — 100–150 mg 100–200 mg 100–200 mg q
bid q day 2–3 ×/wk wk
Amdinocillin Renal 1 3.3 — 10 Usual 10 mg/kg q6h 10 mg/kg q8h
mg/kg/q4–6h
Amikacin Renal 2 30 — 7.5 mg/kg <<<<<<< See pp 39–40 >>>>>>>
Amoxicillin Renal 1 15–20 250–500 — 0.25–0.5 g 0.25–0.5 g 0.25–0.5 g
mg q8h q12h q12–24h q12–24h
Amoxicillin clavulanic Renal 1 8–16 250–500 — Usual 0.25–0.5 g q12h 0.25–0.5 g
acid mg q8h q24–36h
Amphotericin B Nonrenal 15 days 15 days — 0.3–1.4 Usual Usual Usual
mg/kg/d
Amphotericin B lipid Nonrenal 7 days 1 day — 5 mg/kg/d Usual Usual Usual
complex (ABLC) (ABCD) (ABCD)
3–4 mg/kg/d
(ABLC)
Amphotericin B Nonrenal 4–6 days 4–6 — 3–5 mg/kg/d Usual Usual Usual
liposomal days
Ampicillin Renal 1 8–12 0.25–0.5 —1–3 g q4–6h Usual usual Usual
g q6h Usual 1–2 g IV q8h 1–2 g IV q 12h
Ampicillin-sulbactam Renal 1 8–12 — 1–2 g q6h 1–2 g IV q8h 1–2 g IV q8h 1–2 g IVq12h
Atovaquone Gut 70 70 750 mg — Usual Usual Unknown
bid susp
Atovaquone Urinary 70 ? 1–4 — Usual Usual Unknown
+proguanil tabs/day
Azithromycin Hepatic 68 68 250 mg/d 500 mg/d Usual No data—“use caution”
Aztreonam Renal 1.7–2 6–9 — 1–2 g q6h 1–2 g 1–2 g q12–18h 1–2 g
q8–12h q24hq12–18h
Bacampicillin Renal 1 8–12 0.4–0.8 g — Usual Usual Usual
q12h
Capreomycin Renal 4–6 50–100 1 g q day — Usual 7.5 mg/kg 1–2 7.5 mg/kg
2×/wk days 2×/wk
Carbenicillin Renal 1 13–16 0.5–1 g — Usual 0.5–1 g q8h Avoid
q6h
Caspofungin Metabolized 9–11 9–11 — 70 mg d 1 50 Usual Usual Usual
mg qd
Cefaclor Renal 0.75 2.8 0.25–0.5 — Usual Usual Usual
g q8h
Cefadroxil Renal 1.4 20–25 0.5–1 g — Usual 0.5 g q12–24h 0.5 g q36h
q12–24h
Cefamandole Renal 0.5–2.1 10 — 0.5–2 g 0.5–2 g q6h 1–2 g q8h 0.5–0.75 g q12h
q4–8h
Cefazolin Renal 1.8 18–36 — 0.5–2 g q8h 0.5–1.5 g 0.5–1 g q8–12h 0.25–0.75 g
q8h q18–24h
Cefdinir Renal 1.7 ? 300 mg Usual 300 mg qd 300 mg qod
bid
Cefditoren Renal 1.4 4–5 200–400 — Usual 200 mg 200 mg q24h
mg bid q12–24h
Renal 2 13 — 0.5–2 g q12h 0.5–2g q24h 0.5–1 g q24h 250–500 mg
Cefepime
q24h
Cefixime Renal (50%) 3–4 12 200 mg — Usual 300 mg/d 200 mg/d
q12h
Cefmetazole Renal 1.2 — — 2 g q6–12h 1–2 g q12h 1–2 g q18–24h 1–2 g q48h
Cefonicid Renal 4–5 50–60 — 0.5–2 g q24h 8–25 mg/kg 4–8 mg/kg q24h 4 mg/kg q3–5d
q24h
Cefoperazone Gut 1.9–2.5 2–2.5 — 1–2 g q6–12h Usual Usual Usual
Ceforanide Renal 3 20–40 — 0.5–1 g q12h Usual 0.5–1 g q24h 0.5–1 g
q48–72h
Cefotaxime Renal 1.1 3 — 1–2 g q4–8h Usual 1–2 g q6–12h 1–2 g q12h
Cefotetan Renal 3–4 12–30 — 1–2 g q12h Usual 1–2 g q24h 1–2 g q48h
Cefoxitin Renal 0.7 13–22 — 1–2 g q6–8h 1–2 g 1–2 g q12–24h 0.5–1 g
q8–12h q12–48h
Cefpodoxime Renal 2.4 — 200–400 — Usual q24h 200–400 3× 200–400 mg
mg q12h weekly weekly
Cefprozil Renal 1.3 5–6 0.25–0.5 — Usual 0.25–0.5 g q24h 0.25 g q12–24h
g q12h
Ceftazidime Renal 0.9–1.7 15–25 — 1–2 g q8–12h Usual 1 g q12–24h 0.5 g q24–48h
Ceftibutin Renal 2.4 ? 400 mg/d — Usual 200 mg/d 100 mg/d
Ceftizoxime Renal 1.4–1.8 25–35 — 1–3 g q6–8h 0.5–1.5 g 0.25–1 g q12h 0.25–0.5 g q24h
q8h
Renal and 6–9 12–15 — 1–2 g q24h Usual Usual Usual
Ceftriaxone
biliary
Cefuroxime Renal 1.3–1.7 20 — 0.75–1.5 g Usual 0.75–1.5 g 0.75 g q24h
q8h q8–12h
Cefuroxime axetil Renal 1.2 20 250 mg — Usual Usual 250 mg q24h
q12h
Cephalexin Renal 0.9 5–30 0.25–1 g — Usual 0.25–1 g 0.25–1 g
q6h q8–12h q24–48h
Cephalothin Renal 0.5–0.9 3–8 — 0.5–2 g Usual 1.0–1.5 g q6h 0.5 g q8h
q4–8h
Cephapirin Renal 0.6–0.9 2.4 — 0.5–2 g 0.5–2 g q6h 0.5–2 g q8h 0.5–2 g q12h
q4–6h
Cephradine Renal 0.7–2 8–15 0.25–1 g — Usual 0.5 g q6h 0.25 g q12h
q6h 0.5–2 g 0.5–1 g q6h 0.5–1 g q6–24h 0.5–1 g
— q4–6h q24–72h
Chloramphenicol Hepatic 2.5 3–7 0.25–0.75 0.25–1 g q6h Usual Usual Usual
g q6h
Chloroquine Renal and 48–120 ? 300–600 — Usual Usual 150–300 mg po
metabolized mg po qd qd
Cidofovir Renal 17–65 (cid:1) — 5 mg/kg q 2 Usual Contraindicated
wk
Cinoxacin Renal 1.5 8.5 0.25–0.5 — 0.25 g q8h 0.25 g q12h 0.25 g q24h
g q12h
Ciprofloxacin Renal and 4 5–10 0.25–0.75 — Usual 0.25–0.5 g q12h 0.25–0.5 g q18h
hepatic slight g q12h 400 mg q12h Usual 0.4 g q18h 0.4 g q24h
metabolism —
Clarithromycin Hepatic and 4 250–500 — Usual Usual 250–500 mg
renal mg q12h q24h
metabolism
Clindamycin Hepatic 2–2.5 2–3.5 150–300 300–900 mg Usual Usual Usual
mg q6h q6–8h
Cloxacillin Renal 0.5 0.8 0.5–1 g — Usual Usual Usual
q6h
Colistin Renal 3–8 10–20 — 1.5 mg/kg 2.5–3.8 1.5–2.5 mg/kg 0.6 mg/kg q24h
q6–12h mg/kg/d q24–36h
Cyclacillin Renal 0.6 — 0.5–1 g — Usual Usual 0.5–1 g q12h
q6h
Cycloserine Renal 8–12 ? 250–500 — Usual 250–500 mg qd 250 mg qd
mg bid
Dapsone Hepatic 30 Slight 50–100 — Usual Usual No data
metabolism mg/d
Daptomycin Renal 9.4 30 — 4 mg/kg/d Usual 4 mg/kg q48h CrCl>30 mL/min
Dicloxacillin Renal 0.5–0.9 1–1.6 0.25–0.5 — Usual Usual Usual
g q6h
Dirithromycin Bile 30–44 30–44 500 mg/d — Usual Usual Usual
Doxycycline Renal and gut 14–25 15–36 100 mg 100 mg bid Usual Usual Usual
bid
Enoxacin Renal and 3–6 — 200–400 — Usual 1/2 usual dose 1/2 usual dose
hepatic mg bid
Ertapenem Renal and 4 ? — 1 g q24h Usual 500 mg qd 500 mg qd
hepatic
Erythromycin Hepatic 1.2–1.6 4–6 0.25–0.5 1 g q6h Usual Usual Usual
metabolism g q6h
Ethambutol Renal 3–4 8 15–25 — 15 mg/kg 15 mg/kg 15 mg/kg q48h
mg/kg q24h q24–36h
q24h
Ethionamide Metabolized 4 9 0.5–1 — Usual Usual 5 mg/kg q48h
g/d, 1–3
doses
Famciclovir Renal 2.3 13 125 mg — Usual 125 mg q24h 125 mg q48h
q12h 500 — Usual 500 mg q 250 mg q48h
mg q8h 12–24h
Fluconazole Renal 20–50 100 100–200 100–400 Usual 50% usual dose 25–50 mg/d
mg/d mg/d
Flucytosine Renal 3–6 70 37 mg/kg — Usual 37 mg/kg Adjust to keep 2
q6h hr level at
q12–24h 50–100 Cg/mL
Foscarnet induction Renal 3 8 — 60 mg/kg q8h 40–50 mg/kg 20–30 mg/kg Contra-
q8h q8h indicated (CrCl
<20 mL/min)
maintenance 90 mg/kg qd 60–70 mg/kg 50–70 mg/kg qd Contra-indicated
qd (CrCl <20
mL/min)
120 mg/kg/d 80–90 mg/kg 60–80 mg/kg qd Contra-indicated
qd (CrCl <20
mL/min)
Ganciclovir-induction Renal 2.5–3.6 10 — 5 mg/kg bid 2.5 mg/kg 2.5 mg/kg qd 1.25 mg/kg
doses 5 mg/kg/d bid 1.2 mg/kg/d 3×/wk
(maintenance—1/2 2.5 mg/kg/d 0.6
dose) mg/kg/3×/wk
Ganciclovir—oral GI 3–7 10 1000 mg — 500 mg tid 500 mg/d 500 mg 3×/wk
tid
Gatifloxacin Renal 8 400 mg 400 mg qd Usual 400 mg 400 mg qod
qd q24–48h
Gemifloxacin Renal 5–9 (cid:1) 320 mg — Usual 160 mg qd 160 mg qd
qd
Gentamicin Renal 2 48 — 1.7 mg/kg <<<<<<< See pp 39–40 >>>>>>>
q8h
Grepafloxacin Metabolized 15 15 400–600 — Usual Usual Usual
mg qd
Griseofulvin microsize Hepatic 24 24 0.5–1 g — Usual Usual Usual
ultramicrosize metabolism 24 24 qd — Usual Usual Usual
Same 0.33–0.66
g qd
Imipenem- cilastatin Renal 0.8–1 3.5 — 0.5–1 g q6h 0.5 g q6–8h 0.5 g q8–12h 0.25–0.5 mg
q12h
Interferon alpha Nonrenal 2–3 Same ? — 3 mil units Usual Usual Usual(?)
q3d (HCV)
30–35 mil
units/wk(HCV)
Isoniazid Hepatic 0.5–4 2–10 300 mg 300 mg q24h Usual Usual Slow
q24h acety-lators
1/2dose
Itraconazole Hepatic 20–60 20–60 200–400 200 mg/d Usual Usual Usual
mg/d
Ivermectin Metabolized 16 16 12–18 mg — Usual Usual Usual
× 1
Kanamycin Renal 2–3 27–30 — 7.5 mg/kg <<<<<<< See pp 39–40 >>>>>>>
q12h
Ketoconazole Hepatic 1–4 1–4 200–400 — Usual Usual Usual
metabolism mg
q12–24h
Lamivudine Renal 5–7 (cid:1) 100 mg — Usual 100 mg × 1 25–50 mg q24h
IC-12 q24h 50 mg q24h
(HBV)
Levofloxacin Renal 6.3 35 500 mg 500 mg q24h Usual 250 mg q24h 250 mg q48h
q24h
Linezolid Nonrenal 5–7 5–7 600 mg 600 mg bid Usual Usual Usual
bid
Lomefloxacin Renal 8 45 400 mg — Usual 400 mg; then Unknown
q24h 200 mg qd
Loracarbef Renal 1 32 200–400 — Usual 200–400 mg 200–400 mg 5d
mg q12h q24h
Mefloquine Hepatic 2–4 wk 2–4 wk 1250 mg — Usual Usual Usual
× 1
250 mg q
wk
Meropenem Renal 1 (cid:1) — 1 g q8h Usual 500 mg q12h 500 mg q24h
Methenamine Renal 3–6 ? 1 g q12h — Usual Avoid
hippurate Renal 3–6 ? 1 g q6h — Usual Avoid
mandelate
Methicillin Renal(hepatic) 0.5 4 — 1–2 g q4–6h 1–2 g q6h 1–2 g q8h 1–2 g q12h
Metronidazole Hepatic 6–14 8–15 0.25–0.75 0.5 g q6h Usual Usual Usual
g tid
Mezlocillin Renal 1 1.5 — 3–4 g q4–6h Usual 3 g q8h 2 g q8h
Miconazole Hepatic 0.5–1 0.5–1 — 0.4–1.2 g q8h Usual Usual Usual
Minocycline Hepatic and 11–26 17–30 100 mg 100 mg q12h Usual Usual Usual or slight
metabolized q12h decrease
Moxifloxacin Metabolized 12 12 400 mg 400 mg qd Usual Usual Usual
qd
Nafcillin Hepatic 0.5 1.2 0.5–1 g 0.5–2 g Usual Usual Usual
metabolism q6h q4–6h
Nalidixic acid Renal and 1.5 21 1 g q6h — Usual Usual Avoid
hepatic
metabolism
Netilmicin Renal 2.5 35 — 2.0 mg/kg <<<<<<< See pp 39–40 >>>>>>>
q8h
Nitazoxanide Metabolized 1–1.6 1–1.6 500 mg — Usual Usual Usual
q6–12h
Nitrofurantoin Renal 0.3 1 50–100 — Usual Avoid Avoid
mg q6–8h
Norfloxacin Renal and 3.5 8 400 mg — Usual 400 mg qd 400 mg qd
hepatic bid
metabolism
Nystatin Not absorbed — — 0.4–1 mil — Usual Usual Usual
units 3–5
× /d
Ofloxacin Renal 6 40 200–400 — Usual 200–400 mg qd 100–200 mg qd
mg bid 200–400 mg Usual 200–400 mg 100–200 mg
— q12h q24h q24h
Oseltamivir Renal 6–10 hr (cid:1) 75 mg bid — Usual 75 mg qd Avoid
Oxacillin Renal 0.5 1 0.5–1 g 1–3 g q6h Usual Usual Usual
q6h
Peginterferon Renal-30% 40 Slight (cid:1) — 180 mcg/kg Usual Half dose(?) Half dose(?)
SC q wk
(Roche)
1.5 mcg/kg
SC q wk
(Schering)
Penicillin G, Renal 0.5 7–10 — 1–4 mil units Usual Usual 1/2 usual dose
crystalline Renal 24 — — q4–6h Usual Usual Usual
benzathine Renal 10–15 — 0.4–0.8 0.6–1.2 mil Usual Usual Usual
Penicillin V Renal days 7–10 mil units units IM q12h Usual Usual
0.5–1.0 q6h 0.6–1.2 mil
units IM
—
Pentamidine Non-renal 6 6–8 — 4 mg/kg q24h Usual 4 mg/kg 4 mg/kg q48h
q24–36h
Piperacillin Renal 1 3 — 3–4 g q4–6h Usual 3 g q8h 3 g q12h
Piperacillin + Renal 1 3 — 3/0.375 g q6h Usual 2/0.25 g q6h 2/0.25 g q8h
tazobactam
Polymyxin B Renal 6 48 — 7500–12,500 7500–12,500 5625–12,500 3750–6250
units/kg/d units/kg/d units/kg/d q12h units/kg/d q12h
q12h q12h
Praziquantel Hepatic 0.8–1.5 ? 10–25 — Usual Usual Usual
metabolism mg/kg tid
Pyrazinamide Metabolized 10–16 ? 15–35 — Usual Usual 12–20 mg/kg/d
mg/kg/d
Pyrimethamine Hepatic 1.5–5days ? 25–75 — Usual Usual Usual
metabolism mg/d
Quinacrine Renal 5 days — 100–200 — Usual ? ?
mg q6–8h
Quinine Hepatic 4–5 4–5 650 mg 7.5–10 mg/kg Usual Usual Usual
metabolism tid q8h
Quinupristin/delforistin Hepatic 1.5 1.5 — 7.5 mg/kg Usual Usual Usual
metabolism q8–12h
Ribavirin Hepatic 0.5–2 Same 0.8–1.2 — Usual Usual Half dose
IC 40 g/d
Rifampin Hepatic Early 2–5 2–5 600 mg/d 600 mg/d Usual Usual Usual
Late 2
Rifapentine Hepatic 16–19h — 600 mg — Usual Usual Usual
2×/wk
Rimantadine Hepatic 24–30 48–60 100 mg — Usual Usual 100 mg/d
bid
Spectinomycin Renal 1–3 ? — 2 g/d IM Usual Usual Usual
Streptomycin Renal 2–5 100–110 — 500 mg q12h 15 mg/kg 15 mg/kg 7.5 mg/kg
q24–72h q72–96h q72–96h
Sulfadiazine Renal 8–17 22–34 0.5–1.5 g — Usual 0.5–1.5 g 0.5–1.5
q4–6h q8–12h gq12–24h
Sulfisoxazole Renal 3–7 6–12 1–2 g q6h — Usual 1 g q8–12h 1 g q12–24h
Teicoplanin Renal 6 41 — 6–12 mg/kg/d Usual 1/2 usual dose 1/3 usual dose
Telithromycin Hepatic 9.8 hr (cid:1) sl 800 mg — Usual Usual No data
qd No dose
recommendation
when
GFR<30mL/min
Tetracycline Renal 8 50–100 0.25–0.5 Usual Use doxycycline
g q6h
Ticarcillin Renal 1–1.5 16 — 3 g q4h Usual 2–3 g q6–8h 2 g q12h
Ticarcillin + clavulanic Renal 1–1.5 16 — 3 g q4–6h Usual 2–3 g q6–8h 2 g q12h
acid
Tobramycin Renal 2.5 56 — 1.7 mg/kg <<<<<<<See pp 39–40 >>>>>>>
q8h
Trimethoprim Renal 8–15 T:24 100 mg — Usual 100 mg q24h Avoid
q12h
Trimethoprim- Renal T:8–15 T:24 2–4 — Usual Half dose Avoid
sulfamethoxazole S:7–12 S:22–50 tabs/d or 3–5 mg/kg Usual 3–5 mg/kg Avoid
1–2 DS/d q6–12h q12–24h
Trovafloxacin Renal and 10 10 100–200 200–300 mg Usual Usual Usual
metabolism mg qd qd
Valacyclovir Renal 2.5–3.3 14 1000 mg — Usual 1 g q 12–24 hr 500 mg qd
tid — Usual 500 mg q 12–24 500 mg qd
500 mg h
bid
Valganciclovir Renal 4 20 900 mg — Usual 1/2 dose 450 mg qod 3
IC-18 bid × 3 wks
wks 450 mg biw
900 mg
qd
Vancomycin Renal 6–8 200–250 0.125–0.5 — Usual Usual 0.125 g po q6h
g q6h 15 mg/kg 1 g q24h 1 g q3–10d 1 g q5–10d
— q12h
Voriconazole Hepatic — — 200 mg 6 mg/kg q12h Usual po-usual po-usual
q12h ×2, then 4 IV-not IV-not
mg/kg q12h recommended recommended
Zanamivir Renal 3 18 10 mg bid — Usual No data No data
inhaled
* Half life in serum
IC = intracellular half life.
P.42
P.43
P.44
P.45
P.46
P.47
P.48
P.49
P.50
P.51
P.52
P.53
D. ANTIMICROBIAL DOSING REGIMENS DURING DIALYSIS
(Adapted from Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York:1995:506–519; American Hospital Formulary Service
1995:37–587)
Drug Hemodialysis Peritoneal dialysis
Acyclovir 2.5–5.0 mg/kg/d + extra dose postdialysis 2.5 mg/kg/d
Adofovir 10 mg q7d —
Amdinocillin No extra dose —
Amikacin 2.5–3.75 mg/kg postdialysis Loading dose predialysis 9–20 mg/L dialysate*
Amoxicillin 0.25 g postdialysis Usual regimen
Amoxicillin + clavulanic acid 0.50 g (amoxicillin) + 0.125 (CA) halfway through dialysis Usual regimen
and another dose at end
Amphotericin B Usual regimen Usual regimen
Amphotericin lipid forms Usual regimen Usual regimen
Ampicillin Usual dose postdialysis Usual regimen
Ampicillin + sulbactam 2 g ampicillin postdialysis Usual regimen
Atovaquone Unknown Unknown
Azithromycin Usual regimen Usual regimen
Aztreonam 1/8 initial dose (60–250 mg) postdialysis Usual loading dose, then 1/4 usual dose at usual
intervals
Carbenicillin 0.75–2.0 g postdialysis 2 g 6–12h
Caspofungin Usual regimen Usual regimen
Cefaclor Repeat dose postdialysis Usual regimen
Cefadroxil 0.5–1.0 g postdialysis 0.5 g/d
Cefamandole Repeat dose postdialysis 0.5–1.0 g q12h
Cefazolin 0.25–0.5 g postdialysis 0.5 g q12h
Cefdinir 300 mg plus 300 mg postdialysis —
Cefditoren — —
Cefepime Standard dose postdialysis Standard dose q48h
Cefixime 300 mg/d 200 mg/d
Cefonicid No extra dose Usual regimen
Cefoperazone Schedule dose postdialysis Usual regimen
Cefotaxime 0.5–2.0 g daily plus supplemental dose postdialysis 1–2 g/d
Cefotetan 1/4 usual dose q24h on non-dialysis days and 1/2 dose on 1 g/d
dialysis days
Cefoxitin 1–2 g postdialysis 1 g/d
Cefpodoxime 200–400 mg 3×/wk
Cefprozil 250–500 mg postdialysis 0.25 g q12–24h
Ceftazidime 1 g loading 0.5–1.0 g loading, then 0.5 g/d or 250 mg in
1 g postdialysis each 2 L dialysate
Ceftibutin 400 mg cap postdialysis —
Ceftizoxime Scheduled dose postdialysis 1 g/d
Ceftriaxone No extra dose Usual regimen
Cefuroxime Repeat dose postdialysis 15 mg/kg post-dialysis or 750 mg/d
Cephalexin 0.25–1.0 g postdialysis 250 mg po tid
Cephalothin Supplemental dose postdialysis Option to add I6 mg/dL to dialysate
Chloramphenicol Schedule dose postdialysis Usual regimen
Ciprofloxacin 250–500 mg q24h postdialysis 250–500 mg/d
Clindamycin Usual regimen Usual regimen
Clofazimine Usual regimen Usual regimen
Cloxacillin Usual regimen Usual regimen
Daptomycin 4 mg/kg q48h 4 mg/kg q48h
Dicloxacillin Usual regimen Usual regimen
Doxycycline Usual regimen Usual regimen
Ertapenem 500 mg qd —
150 mg supplement postdialysis
Erythromycin Usual regimen Usual regimen
Ethambutol 15 mg/kg/d postdialysis 15 mg/kg/d
Famciclovir 250 mg (zoster) or 125 mg (genital herpes) postdialysis —
Fluconazole 100 mg postdialysis 1/2 usual dose
Flucytosine 37.5 mg/kg postdialysis 0.5–1.0 g/d
Ganciclovir—IV 1.25 mg/kg q24h given postdialysis on dialysis days ?
Ganciclovir—po 500 mg postdialysis 3×/wk —
Gentamicin 1.0–1.7 mg/kg postdialysis Loading dose predialysis, 2–4 mg/L dialysate*
Imipenem + cilastatin Supplemental dose postdialysis and q12–24h thereafter 500 mg/d
Interferon Usual Usual
Isoniazid 5 mg/kg postdialysis Daily dose postdialysis or 1/2 usual dose
Itraconazole Usual regimen Usual regimen
Kanamycin 4–5 mg/kg postdialysis 3.75 mg/kg/d
Ketoconazole Usual regimen Usual regimen
Lamivudine 25–50 mg/d dose postdialysis 25–50 mg/d
Levofloxacin 500 mg, then 250 mg q48h 500 mg, then 250 mg q48h
Linezolid Usual dose Usual dose
Metronidazole Usual regimen Usual regimen
Mezlocillin 2–3 g postdialysis then 3–4 g q12h 3 g q12h
Minocycline Usual dose (some suggest reduced dose) Usual dose (some suggest reduced dose)
Moxalactam 1–2 g postdialysis 1–2 g/d
Moxifloxacin Usual dose Usual dose
Nafcillin Usual regimen Usual regimen
Netilmicin 2 mg/kg postdialysis Loading dose predialysis 3–5 mg/L dialysate*
Ofloxacin 200 mg, then 100 mg q24h ?
Oxacillin Usual regimen Usual regimen
Peginterferon — —
Penicillin G 500,000 units postdialysis —
Penicillin V 0.25 g postdialysis —
Pentamidine Usual regimen Usual regimen
Piperacillin 1 g postdialysis, then 2 g q8h 3–6 g/d
Piperacillin—tazobactam 2/0.25 g q8h + additional dose postdialysis 3–6 g/d
Pyrazinamide Usual dose postdialysis Avoid
Quinupristin—dalfopristin Usual regimen Usual regimen
Ribavirin Usual dose —
Rifampin Usual regimen Usual regimen
Rifapentine Usual dose Usual dose
Saquinavir 1200 mg tid 1200 mg tid
Streptomycin 0.5 g postdialysis
Tetracycline 500 mg postdialysis Use doxycycline
Ticarcillin 3 g postdialysis, then 2 g q12h 3 g q12h
Ticarcillin + clavulanic acid 3 g (ticarcillin) postdialysis, then 2 g q12h 3 g (ticarcillin) q12h
Tobramycin 1 mg/kg postdialysis Loading dose predialysis, 2–4 mg/L dialysate*
Trimethoprimsulfa 4–5 mg/kg (as trimethoprim) postdialysis 0.16/0.8 g q48h
Trovafloxacin Usual regimen Usual regimen
Valacyclovir 1 g po postdialysis No supplemental doses
Valganciclovir Not recommended —
Vancomycin 1 g/wk 0.5–1.0 g/wk
Vidarabine Scheduled dose postdialysis
Voriconazole IV-not recommended po-standard dose IV-not recommended po-standard dose
* Aminoglycosides given for prolonged periods to patients receiving continuous peritoneal dialysis have been associated with high rates of ototoxicity.
Monitor level after loading dose, and follow for symptoms of ototoxicity with periodic Romberg's sign and reading after rapid head movement.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Use of Antimicrobial Agents in Hepatic Disease
Use of Antimicrobial Agents in Hepatic Disease
Many antimicrobial agents are metabolized by the liver and/or excreted via the biliary tract.
Nevertheless, few require dose modifications in hepatic disease; with few exceptions, doses are usually
modified only if there is concurrent renal failure and/or the liver disease is either acute or is associated
with severe hepatic failure as indicated by ascites or jaundice. The following recommendations are
st
adapted from Drug Information for the Health Care Professional, USP DI, 21 Edition, 2001.
Agent: Recommended Dose Modification
Aztreonam: Some recommend a dose reduction of 20–25%.
Caspofungin: Usual maintenance dose of 50 mg/d is reduced to 35 mg/d with moderate hepatic
disease; no data for severe hepatic disease.
Cefoperazone: Maximum dose is 4 g/d; if higher, monitor levels; with coexisting renal impairment
maximum dose is 1–2 g/d.
Ceftriaxone: Maximum daily dose of 2 g with severe hepatic and renal impairment.
Chloramphenicol: Use with caution with renal and/or hepatic failure; monitor serum levels to
achieve levels of 5–20 :g/mL.
Clindamycin: Dose reduction recommended only for severe hepatic failure.
Daptomycin: No dose adjustment.
Fluoroquinolones: Use standard dose except with trovafloxacin (see below).
Isoniazid: Use with caution and monitor hepatic function for mild-moderate hepatic disease; acute
liver disease or history of INH-associated hepatic injury is contraindication to INH.
Itraconazole: Two-fold increase in half-life with cirrhosis; give with caution.
Linezolid: No dose adjustment.
Metronidazole: Modify dose for severe hepatic failure, although specific guidelines are not
provided; peak serum levels with 500 mg doses are 10–20 :g/mL.
Mezlocillin: Reduce dose by 50% or double the dosing interval.
Nafcillin: Metabolized by liver and largely eliminated in bile; nevertheless, dose modifications are
suggested only for combined hepatic and renal failure.
Penicillin G.: Dose reduction for hepatic failure only when accompanied by renal failure.
Ribavirin: AUC is unchanged wih severe hepatic failure.
Rifampin: Induces hepatic enzymes responsible for inactivating methadone, cortico steroids, oral
anti-diabetic agents, digitalis, quinidine, cyclosporine, oral anticoagulants, estrogens, oral
contraceptives, and chloramphenicol. Concurrent use of these drugs with rifampin and use in
patients with prior liver disease require careful review.
Rimantadine: Severe hepatitis disease use 100 mg/d (half dose).
Telithromycin: No dose adjustment.
Ticarcillin: For patients with hepatic dysfunction and creatinine clearance <10 mL/min, give 2 g/d
IV in one or two doses.
Ticarcillin/clavulanate: For patients with hepatic dysfunction and creatinine clearance <10 mL/min
give usual loading dose (3.1 g) followed by 2 g once daily.
Trovafloxacin: For hepatic failure, adjust by indicated dose—indicated dose 300 mg/d IV, use 200
mg/d; indicated dose 200 mg/d IV or po, use 100 mg/d; indicated dose 100 mg/d, use 100 mg/d.
Voriconazole: Mild to moderate hepatic insufficiency—6 mg/kg IV q12h × 2, then 2 mg/kg IV q12h.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Adverse Reactions to Antimicrobial Agents
Adverse Reactions to Antimicrobial Agents
A. Adverse Reactions by Class
Adapted from Medical Letter Handbook of Antimicrobial Therapy, Revised Edition 2000:5–200
Drug Frequent Occasional Rare
Acyclovir (Zovirax) Irritation at infusion site Rash—nausea and vomiting; diarrhea; renal toxicity CNS (especially with high
(especially with rapid IV infusion, prior renal disease, dose in renal
and nephro-toxic drugs); dizziness; abnormal liver failure)—agitation,
function tests; itching; headache encephalopathy, lethargy,
Topical—local reaction tremor, transient
hemiparesis, disorientation,
seizures, hallucina-tions,
anemia, hypotension,
neutropenia
Adofovir Asthenia, GI intolerance (nausea, vomiting, diarrhea, Nephrotoxicity; lactic
abdominal pain), headache, pruritis, rash acidosis
Albendazole Diarrhea, abdominal pain Leukopenia, alopecia,
increased transaminase
levels
Amantadine (Symmetrel) Insomnia, lethargy, GI intolerance especially nausea (5–10%), rash, CNS—lethargy, tremor,
dizziness, inability to depression, confusion, livedo reticularis confusion, obtundation,
concentrate (10–15% of delirium, psychosis, visual
adults receiving 200 hallucinations, paranoia,
mg/d) mania, seizures (primarily in
elderly renal failure and/or
seizure disorder), heart
failure, eczematoid
derma-titis, photosensitivity,
oculogyric episodes,
orthostatic hypotension,
peripheral edema, bone
marrow suppression, sudden
loss of vision, urinary
retention
Aminoglycosides Tobramycin Renal failure—related to Vestibular and auditory damage: related to dose and Fever, rash, blurred vision,
Gentamicin Amikacin Netilmicin dose, duration, hepatic duration, only risk is advanced age (AAC neuromuscular blockage
Kanamycin function, prior renal 1987;31:1383)—note dizziness, vertigo, roaring, especially with myasthenia
function, concurrent tinnitis, high tone hearing loss; ototoxicity is or Parkinson's—may be
nephrotoxic drugs, irreversible reversible with calcium salts,
hydration status, paresthesias, hypotension,
hypotention, increased allergic reactions—usually
trough levels, and caused by sulfites in some
advanced age (Am J Med preparations
1987;83:1091) (monitor
creatinine 3–7×/wk and
output). Nephrotoxicity
is usually reversible
Aminosalicylic acid (PAS) GI intolerance Liver damage; allergic reactions, thyroid enlargement, Acidosis, vasculitis,
hepatotoxicity hypoglycemia (diabetes),
hypokalemia,
encephalopathy, decreased
prothrombin activity,
myalgias, renal damage,
gastric hemorrhage
Amoxicillin + clavulanic acid Similar to amoxicillin—see penicillins
Amphotericin B (Fungizone) Fever (maximal at 1 hr) Hypomagnesemia, nausea, vomiting, metallic taste, Hypotension, rash, pruritus,
and chills (at 2 headache blurred vision, peripheral
hr)—prevent/reduce neuropathy, convulsions,
with hydrocortisone, hemorrhagic gastroenteritis,
ibuprofen, ASA, arrhythmias, diabetes
acetaminophen, insipidus, hearing loss,
meperidine pulmonary edema,
Renal tubular anaphylaxis, acute hepatic
acidosis—dose failure, eosinophilia,
dependent and usually leukopenia,
reversible in absence of thrombocytopenia, delirium
prior renal damage and (especially with intrathecal
dose <3 g, reduce with use)
hydration and sodium
supplementations
Hypokalemia
Anemia (treat severe
anemia with
erythropoietin)
Phlebitis and pain at
injection site (add 1,000
units heparin to
infusions)
Amphotericin B lipid complex Chills and fever during GI intolerance, electrolyte abnormalities Hypotension, anaphylaxis
and liposomal (Amphotec infusion;
Abelcet AmBisome) infusion-related side
effects and
nephrotoxicity are
significantly less
compared with
amphotericin
B(Amphotec > Abelcet >
AmBisome) (CID
2000;31:1155)
Dose-related
nephrotoxicity
(substantially less than
with amphotericin B;
Abelcet > Amphotec >
AmBisome)
Ampicillin + sulbactam Similar to those for ampicillin alone—see penicillins
(Unasyn)
Atovaquone (Mepron) Rash—20%; rash Nausea, vomiting, mild diarrhea; headache in Fever, elevated
requiring comparative trial for PCP—9% required discontinuation aminotransferases (generally
discontinuation—4%; GI because of side effects vs 24% with sulfatrimetho-prim; mild), abdominal pain
intolerance—20%; 7% vs 21% with IV pentamidine
diarrhea—20%
Atovaquone + proguanil Abdominal pain—20%, Dizziness—5%, increased transaminases
(Malarone) nausea—12%,
vomiting—20%,
headache—10%,
diarrhea—8%
Azithromycin (Zithromax) GI intolerance (4%), diarrhea, nausea, abdominal pain, Reversible hearing loss
vaginitis (more common with 500 mg
× 30–90 days); erythema
multiforme; increased
transaminase; C. difficile
colitis
Aztreonam (Azactam) Eosinophilia Phlebitis at infusion site, rash, diarrhea, nausea, Thrombocytopenia, colitis,
eosinophilia, abnormal liver function tests hypotension, unusual taste,
seizures, chills
Bacitracin Nephrotoxicity Rash, blood dyscrasia
(proteinuria, oliguria,
azotemia), pain with IM
use
Bithionol (Bitin) Photosensitivity, Leukopenia, toxic hepatitis
vomiting; diarrhea,
abdominal pain,
urticaria
Capreomycin Renal damage (tubular Ototoxicity (vestibular > auditory—should assess Allergic reactions,
necrosis especially in vestibular function before and during treatment); leukopenia, leukocytosis,
patients with prior renal electrolyte abnormalities; pain, induration, sterile neuromuscular blockage
damage): Increased abscesses at injection sites (large IV doses—reversed
creatinine, proteinuria, with neostigmine),
cylindruria—monitor UA hypersensitivity reactions,
and creatinine weekly hepatitis?
Caspofungin Nausea, vomiting Histamine-mediated adverse
drug reaction with rash, face
swelling, pruritis; fever;
increased alkaline
phosphotase; hypokalemia;
proteinuria
Ceftibutin — GI intolerance—4%, headache, diarrhea, rash pruritis; C. difficile-associated
2% in clinical trial discontinued drug due to ADR diarrhea, colitis
Cephalosporins Phlebitis at infusion Allergic reactions (anaphylaxis rare), diarrhea and C. Hemolytic anemia,
sites; diarrhea difficile colitis, hypoprothrombinemia (cefamandole, interstitial nephritis
(especially cefoperazone cefoperazone, moxalactam), platelet dysfunction (cephalothin), hepatic
and cefixime); pain at (moxalactam), eosinophilia, positive Coombs' test dysfunction, convulsions
IM injection sites (less Serum sickness (especially prolonged parenteral use of (high dose with renal
with cefazolin) cefaclor), cholelithiasis (ceftriaxone) failure), neutropenia,
thrombocytopenia,
confusion, disorientation,
hallucinations
Chloramphenicol (Chloromycetin) GI intolerance (oral), marrow suppression (dose related) Fatal aplastic anemia
(1:40,000), fever, allergic
reactions, peripheral
neuropathy, optic neuritis,
C. difficile colitis
Chloroquine (Aralen) Visual disturbances (related to dose and duration of CNS—headache, confusion,
treatment with O100 g as used for rheumatoid dizziness, extraocular
arthritis), GI intolerance, pruritus, weight loss, alopecia muscle palsies, psychosis,
peripheral neuropathy,
cardiac toxicity, hemolysis
(G6PD deficiency), marrow
suppression, exacerbate
psoriasis, eczema and other
rashes, photophobia,
myalgias, hematemesis
Cidofovir Nephropathy—dose GI intolerance, neutropenia, metabolic acidosis Uveitis, ocular hypotony
dependent: Reduce with
IV hydration and
probenecid; monitor
creatinine and
urinalysis. Report renal
failure to Gilead:
800-GILEAD-5 or the
FDA: 800-FDA-1088.
Probenecid: Chills,
fever, headache, rash,
nausea in 30–50%
Ciprofloxacin (Cipro) See quinolones
Clarithromycin (Biaxin) GI intolerance (4%), diarrhea Headache, transaminase
elevation, C. difficile colitis,
reversible dose-related
hearing loss
Clindamycin (Cleocin) Diarrhea (frequency of Rash, C. difficile colitis, GI intolerance (oral) Blood dyscrasias, hepatic
C. difficile toxin is 5% damage, neutropenia,
for all clindamycin neuromuscular blockade,
recipients and 15–25% eosinophilia, fever, metallic
for those with taste, phlebitis at IV infusion
clindamycin-associated sites, esophageal ulceration
diarrhea)
Colistimethate (Coly-Mycin) See polymyxins
Cycloserine (Seromycin) CNS—anxiety, Liver damage, malabsorption, peripheral neuropathy, Coma, seizures
confusion, depression, folate deficiency, anemia (contraindicated in
somnolence, epileptics), hypersensitivity
disorientation, reactions, heart failure,
headache, arrhythmias
hallucinations, tremor,
hyper-reflexia,
increased CSF protein,
and pressure (dose
related and reversible)
(contraindicated in
active alcoholics;
twitching and seizures
prevented with large
doses of
pyridoxine—100 mg tid)
Dapsone Rash, fever, nausea, Blood dyscrasias (methemogloblinemia and Hypoalbuminemia, epidermal
anorexia, sulfahemoglobinemia ± G6PD deficiency)—warn patient necrolysis, optic atrophy,
neutropenia—sufficiently to observe for cyanosis and dark urine; nephrotic agranulocytosis, peripheral
severe to require syndrome; blurred vision; photosensitivity, tinnitis; neuropathy, aplastic anemia,
discontinuation in insomnia; irritability; headache (transient) “sulfone syndrome” (fever,
30–40% of HIV infected exfoliative dermatitis,
patients jaundice, adenopathy,
methemo-globinemia, and
anemia—treat with steroids),
renal papillary necrosis
Daptomycin (Cubicin) Dose related elevated CPK with or without symptoms or Elevated transaminases;
myopathy (reversible) neuropathy
Diethylcarbamazine citrate Severe allergic or febrile Encephalopathy
(Hetrazan) reactions in patient with
microfilaria in blood or
skin, GI intolerance
Diloxanide (Furamide) Flatulence, diarrhea, nausea Dizziness, diplopia,
headache, urticaria
Dirithromycin GI intolerance, — —
abdominal pain, nausea
Eflornithine (DFMO, Ornidyl) Anemia, leukopenia Diarrhea, thrombocytopenia, seizures Hearing loss
Emetine Arrhythmias, precordial Diarrhea, vomiting; neuropathy, heart failure; headache, dyspnea
pain, muscle weakness,
phlebitis
Ertapenem Nausea, vomiting, diarrhea; increased ALT; seizures in 0.5%
Erythromycins GI intolerance (related Diarrhea, stomatitis, cholestatic hepatitis (especially Allergic reactions, C. difficile
to oral doses); phlebitis estolate-reversible), generalized rash colitis, hemolytic anemia,
(IV) reversible ototoxicity
(especially high dose and
renal failure), QT
prolongation with drug
induced torsades de pointes
especially in women (JAMA
280:1774, 1998),
hypothermia, aggravation of
myasthenia gravis
Ethambutol (Myambutol) Optic neuritis (decreased acuity, reduced color Hypersensitivity reactions,
discrimination, constricted fields, scotomata—dose peripheral neuropathy,
related and infrequent with 15 mg/kg), GI intolerance, thrombocytopenia, toxic
confusion, precipitation of acute gout epidermal necrolysis,
lichenoid skin rash
Ethionamide (Trecator) GI intolerance (CNS Allergic reactions, peripheral neuropathy (prevented Optic neuritis, gouty
effect) with pyridoxine), reversible liver damage (9%) with arthritis, hypothyroidism,
jaundice (1–3%)—monitor transaminase q2–4 wk, impotence, poor diabetic
gynecomastia, menstrual irregularity control, rash, hypotension
Famciclovir (Famvir) Headache, nausea, fatigue
Fluconazole (Diflucan) GI intolerance (bloating, Transaminase elevations to O 8 × normal (1%), Hepatic necrosis,
nausea, vomiting, pain, headache, rash, diarrhea, prolonged prothrombin time Stevens-Johnson syndrome,
anorexia, weight loss) with warfarin thrombocytopenia,
dose related: 8–11% anaphylaxis, possible
with 400 mg/d, 30% seizures
with >400 mg/d.
Reversible alopecia in
10–20% receiving O400
mg/d × 3 mo (Ann
Intern Med 123:354,
1995)
Flucytosine (Ancobon) Note: GI intolerance—nausea, Marrow suppression with leukopenia or Hallucinations, eosinophilia,
Levels should be <100 Ug/mL vomiting, diarrhea thrombocytopenia (dose related, especially with renal blood dyscrasias with
failure, serum concentration >100 Ug/mL, or concurrent agranulocytosis and
amphotericin); confusion; rash; hepatitis (dose related); pancytopenia, fatal
enterocolitis headache; photosensitivity reaction hepatitis, anaphylaxis,
anemia
Fluoroquinolones—see quinolones
Foscarnet (Foscavir) Renal failure (usually Mineral and electrolyte changes—reduced calcium, Marrow suppression,
reversible; 30% get magnesium, phosphorus, ionized calcium, arrhythmias, nephrogenic
creatinine >2 mg/dL; potassium—monitor serum electrolytes 1–2 ×/wk and diabetes insipidus,
monitor serum monitor for symptoms of paresthesias; seizures (10%); hypertension
creatinine 1–3 ×/wk and fever; GI intolerance; anemia; genital ulceration;
discontinue if creatinine neuropathy
>2.9 mg/dL)
Fosfomycin — Diarrhea (10%), headache, vaginitis, nausea Angioedema, aplastic
anemia, cholestatic jaundice,
hepatic necrosis, toxic
megacolon
Furazolidone (Furoxone) GI intolerance Allergic reactions, pulmonary infiltrates, headache, Hemolytic anemia (G6PD
fever deficiency), hypotension,
polyneuropathy,
hypoglycemia,
agranulocytosis, disulfiram
reaction with alcohol
Ganciclovir—IV (Cytovene) Neutropenia (ANC Anemia; fever; rash; CNS—headache, seizures, CNS—psychosis, delirium,
<500/mm3 in 15–20%, confusion; changes in mental status; abnormal liver confusion, agitation;
usually early in function tests (2–3%) neuropathy; impaired
treatment and responds reproductive function (?);
within 3–7 days to drug hematuria; renal failure;
holiday or to nausea; vomiting; GI
G-CSF/GM-CSF); bleeding or perforation;
thrombocytopenia myocardiopathy;
(platelet count hypotension; ataxia; coma;
<20,000/mm3 in 10%, somnolence; alopecia;
reversible). Monitor CBC pruritis, urticaria
2–3×/wk and
discontinue with ANC
<500–750/mm3 or
platelet count
<25,000/mm3
Griseofulvin (Fulvicin) Headache (often Photosensitivity GI disturbances, allergic
resolves with continued reactions, paresthesias,
treatment) exacerbation of lupus or
leprosy, liver damage,
lymphadenopathy, blood
dyscrasias, thrush, transient
hearing loss, fatigue,
dizziness, insomnia,
psychosis
Halofantrine (Halfan) Diarrhea, abdominal pain
Imipenem + cilastatin (Primaxin) Phlebitis at infusion sites, allergic reactions, nausea, Myoclonus, C. difficile colitis,
vomiting and diarrhea, eosinophilia, hepatotoxicity bone marrow suppression,
(transient), drug fever, transient hypotension during renal toxicity
infusion, seizures (increased rates with high doses,
renal failure, elderly patient, prior seizure disorder)
Interferon alfa (Roferon A, Flu-like illness (80% Marrow suppression—leukopenia, anemia ± Edema, arrhythmias,
Intron) with >5 mil units/d); thrombocytopenia (3–70%, dose related, usually cardiomyopathy, renal
fever; fatigue; transient and well tolerated); neuropsychiatric failure, hearing loss,
anorexia; headache; effects—psychosis, confusion, somnolence, anxiety; pulmonary infiltrates. Some
myalgias hepatitis—dose related in up to 40% receiving high patients with hepatitis B
Depression doses; alopecia (8%); rash; activation of lupus; have increased risk of
GI intolerance with proteinuria decompensation with
nausea, vomiting, and decreasing albumin levels,
pain or diarrhea prolonged prothrombin time,
(20–65%) and increased ALT; delirium,
Toxic effects start obtundation
within 6 hr and last
2–12 hr; pretreat with
NSAIDs
Iodoquinol Rash, acne, GI intolerance—nausea, diarrhea, cramps Optic atrophy, vision loss,
peripheral neuropathy (with
use for months), iodine
sensitivity
Isoniazid (INH) Hepatitis—age related Allergic reactions; fever; peripheral neuropathy CNS—optic neuritis,
<20 yr—nil; 35–6%; (reduced with pyridoxine) especially with alcoholism, psychosis, agitation,
45–11%; 55–18%. Rate diabetes, pregnancy, malnutrition, glossitis depression, hallucination,
of symptomatic paranoia, convulsions; toxic
hepatitis+ transaminase encephalopathy; twitching;
levels O 5× ULN among coma; blood dyscrasias;
patients taking INH hyperglycemia; lupus-like
prophylaxis by current syndrome; keratitis;
guidelines is only 0.1% pellagra-like rash; B-6 and
(Ann Intern Med folate deficiency; chronic
281:1014, 1999). liver injury
Patient should be
warned of symptoms,
and drug should be
discontinued if
transaminase levels are
O 3–5 × normal limit
Itraconazole (Sporanox) Headache; GI intolerance—nausea (10%), vomiting, Hepatitis (1/1000), toxic
rash (8%), high dose (600 mg/day)—hypokalemia, epidural necrolysis,
adrenal insufficiency, impotence, gynecomastia, leg hypertension
edema
Ivermectin (Stromectol) Mazzotti reaction in
onchocerciasis with
hypotension, fever, pruritus,
bone and joint pain
IVIG Hypotension, flushing, fever, chills, headache Renal failure, hemolysis,
aseptic meningitis,
hyponatremia, anaphylaxis
Ketoconazole (Nizoral) GI intolerance (dose Endocrine—decreased steroid and tes-tosterone Abrupt and fulminant
related; take with food synthesis with impotence, gynecomastia, oligospermia, hepatitis (1:15,000), rare
or at hs to improve reduced libido; menstrual abnormalities (prolonged use cases of fetal hepatic
tolerance) and dose related, usually O600 mg/d); headache; necrosis, anaphylaxis,
Temporary increase in somnolence; dizziness; asthenia; pruritus; rash; lethargy, arthralgias, fever,
transaminase levels abdominal pain; photophobia marrow suppression,
(2–5%) hypothyroidism (genetically
determined), hallucinations,
thrombocytopenia
Linezolid Neutropenia, thrombocytopenia, anemia—monitor CBC Fever, thrush, rash,
weekly (see dizziness
MedWatch—http://www.fda.gov/medwatch/feedback.htm
); diarrhea, nausea, headache
Mebendazole (Vermox) Diarrhea, abdominal pain Leukopenia, agranulocytosis,
hypospermia
Mefloquine (Lariam) Vertigo, Psychosis and panic attacks, seizures; disorientation Prolonged cardiac
light-headedness, (dose related—rare at doses used for prophylaxis); GI conduction, hypotension,
nausea, nightmares, intolerance; dizziness seizures, coma
headache, visual
disturbances (dose
related), decreased fine
motor function
Melarsoprol (Mel B) Heart damage, Peripheral neuropathy Shock
hypertension, colic,
encephalopathy,
vomiting
Meropenem Diarrhea (5%), nausea, headache, rash Anaphylaxis, seizures
(especially with CNS
disorders or renal failure),
thrombocytopenia,
pseudomembranous colitis
Methenamine (Mandelamine) GI intolerance, dysuria (reduced dose or acidification) Allergic reactions, edema,
tinnitus, muscle cramps
Metronidazole (Flagyl) GI intolerance, metallic Peripheral neuropathy (prolonged use—reversible), Seizures, ataxic
taste, headache phlebitis at injection sites, disulfiram-like reaction with encephalitis, C. difficile
alcohol, insomnia, stomatitis colitis, leukopenia, dysuria,
pancreatitis, allergic
reactions, mutagenic in
Ames test (significance is ?),
depression, uncontrolled
crying, hallucinations,
agitation, C. difficile colitis
Miconazole (Monistat) Phlebitis at injection sites; chills; pruritus; rash; Marrow suppression—anemia
dizziness; blurred vision; hyperlipidemia; nausea; and thrombocytopenia, renal
vomiting; hyponatremia; hyperlipidemia; irritation with damage, anaphylaxis,
topical use hypotension,
thrombo-cytosis, psychosis,
cardiac arrhythmias or
cardiac arrest with initial
dose
Nalidixic acid (NegGram) See quinolones
Niclosamide (Niclocide) Nausea, abdominal pain
Nifurtimox (Lampit) GI intolerance, loss of Seizures, fever, pulmonary
memory, sleep infiltrates
disorders, paresthesias,
weakness, polyneuritis
Nitazoxanide Abdominal pain (give with food), headache Hypotension
Nitrofurantoin (Macrodantin) GI intolerance Hypersensitivity reactions, pulmonary infiltrates (acute, Peripheral neuropathy,
subacute, or chronic ± fever, eosinophilia, rash, or hepatitis, hemolytic anemia
lupus-like reaction) (G6PD deficiency), lactic
acidosis, parotitis,
pancreatitis, pulmonary
fibrosis, cholestatic
jaundice, trigeminal
neuralgia
Nitrofurazone Local irritation Allergic reactions, contact
dermatitis, renal failure with
wound dressing in severe
burn patients
Nystatin (Mycostatin) GI intolerance Allergic reactions
Ofloxacin (Floxin) See quinolones
Ornidazole Dizziness, headache, GI intolerance Reversible peripheral
neuropathy
Oseltamivir Nausea, vomiting Dizziness, headache, fatigue, insomnia
(nausea usually resolves
in 1–2 days and reduced
with food)
Oxamniquine (Vansil) Headache, fever, dizziness, somnolence, GI intolerance, Seizures, neuropsychiatric
hepatitis, insomnia, EEG changes, ECG changes, orange disturbances
discoloration of urine
Paromomycin (Humatin) GI intolerance Ototoxicity and
nephrotoxicity (especially
with GI absorption plus renal
failure)
Peginterferon See interferon. Side effect profile is identical.
Penicillins Hypersensitivity GI intolerance (oral agents), fever, Coombs' test Anaphylaxis; leukopenia;
reactions, rash positive, phlebitis at infusion sites and sterile abscesses thrombocytopenia; C.
(especially ampicillin at IM sites, Jarisch-Herxheimer reaction (syphilis or difficile colitis (especially
and amoxicillin), other spirochetal infections) ampicillin); hepatic damage;
diarrhea (especially renal damage;
ampicillin) CNS—seizures, twitching
(high doses in patients with
renal failure); hyperkalemia
(penicillin G infusion);
abnormal platelet
aggregation with bleeding
diathesis (carbenicillin,
ticarcillin, piperacillin,
nafcillin); thrombocytopenia
(methicillin, mezlocillin);
sodium overload (ticarcillin,
nafcillin); GI bleeding
(dicloxacillin)
Pentamidine (Pentam Nephrotoxicity—in 25%, Hypotension (administer IV over 60 min); hypoglycemia Hepatotoxicity, leukopenia,
NebuPent) usually reversible with (5–10%, usually occurs after day 5 of treatment thrombocytopenia,
discontinuation (IV including past treatment, may last days or weeks, treat pancreatitis, toxic epidermal
Pentam) with IV glucose); diabetes mellitus, may be insulin necrolysis, fever
Aerosol dependent; cardiotoxicity; delirium; rash (including
administration—cough Stevens-Johnson syndrome); marrow suppression
(30%), pretreat with (common in AIDS patients); GI intolerance with nausea,
albuterol, 2 puffs vomiting, abdominal pain, anorexia, and/or bad taste
Aerosol administration—asthma reaction (2–5%)
Polymyxins (Aerosporin) Pain and phlebitis at Allergic reactions,
injection sites, neuromuscular
neurotoxicity (ataxia, blockade—sometimes
paresthesias), reversed with IV CaCl (not
nephrotoxicity, neostigmine)
dizziness, drowsiness,
facial flushing
Praziquantel (Biltricide) Malaise, headache, Sedation, abdominal pain, fever, sweating, fatigue Pruritis, rash
dizziness
Primaquine Hemolytic anemia (G6PD deficiency); warn patient to Headache, pruritus,
observe for dark urine and cyanosis, or screen for G6PD neutropenia, CNS symptoms,
deficiency; GI intolerance hypertension, arrhythmias,
disturbed visual
accommodation
Pyrazinamide Non-gouty Hepatitis (dose related, frequency not increased when Rash, fever, porphyria,
polyarthralgia, given with INH or rifampin, rarely serious), GI photosensitivity
asymptomatic intolerance, gout (treated with allopurinol and
hyperuricemia probenecid)
Pyrimethamine (Daraprim) Folic acid deficiency with megaloblastic anemia and CNS—ataxia, tremors,
pancytopenia (dose related and reversed with headache, malaise, seizures
leucovorin), allergic reactions, GI intolerance (nausea, (dose related), fatigue
anorexia, vomiting)
Quinacrine (Atabrine) Dizziness, headache, Yellow staining of skin, psychosis, blood dyscrasias, Hepatic necrosis, seizures,
vomiting, diarrhea rash, insomnia exfoliative dermatitis, ocular
effects like chloroquine
Quinine GI intolerance, cinchonism (tinnitus, headache, visual Arrhythmias, hypotension
disturbances), hemolytic anemia (G6PD deficiency) with rapid IV infusion,
hypoglycemia, hepatitis,
thrombocytopenia
Quinolones Animal studies show GI intolerance; CNS—headache, malaise, insomnia, Papilledema; nystagmus;
Ciprofloxacin arthropathies in restlessness, dizziness; allergic reactions; diarrhea; visual disturbances;
Enoxacin weight-bearing joints of photosensitivity (especially lomefloxacin and naladixic diarrhea; C. difficile colitis;
Gatifloxacin immature animals; acid); increased hepatic enzymes; tendon rupture marrow suppression;
Gemifloxacin significance in humans (especially Achilles—over 100 cases reported); photosensitivity;
Levofloxacin is unknown prolonged QT interval (rare, but important, especially anaphylaxis; serum
Lomefloxacin Contraindicated during when combined with other drugs that can cause this) sickness; seizures; toxic
Moxifloxacin pregnancy and in psychosis; CNS
Nalidixic acid persons <18 yr stimulation—tremors,
Norfloxacin Gemifloxacin—high rate restlessness, insomnia,
Ofloxacin of apparently delirium, psychosis,
Trovafloxacin inconsequential rash confusion, hallucinations;
especially with persons encephalopathy with coma;
< 40 years, women and interstitial nephritis;
courses > 7 days prolonged bleeding time;
vasculitis
Hepatotoxicity—trovafloxacin
implicated in 14 cases of
liver failure resulting in liver
transplantation or death,
which led to revised
indications that generally
limit the drug to hospital use
for patients with infections
that cannot be managed with
alternative antibiotics
Quinupristin—dalfopristin Arthralgias and myalgias Phlebitis at IV infusion sites, rash, nausea, headache, Colitis
Hyperbilirubinemia transaminase increase
Ribavirin + interferon (see Hemolytic anemia in wk Cough, dyspnea, fatigue, headache, insomnia, GI intolerance
interferon) 1–4; dose related
Rifabutin (Mycobutin) Orange discoloration of Hepatitis, GI intolerance, allergic reactions Dose-related polyarthralgias,
urine, tears (contact thrombotic thrombocytopenic
lens), sweat (see drug purpura, hemolysis,
interactions) myositis, confusion, seizures
Uveitis with eye pain,
photophobia, redness,
and blurred
vision—usually high
doses (600 mg/d or
concurrent use of
fluconazole or
clarithromycin); usually
responsive to topical
corticosteroids plus
mydriatics (NEJM
330:438, 1994)
Major concern is drug
interactions because
rifabutin accelerates
cytochrome p-450 (see
drug interactions)
Rifampin (Rifadin) Orange discoloration of Hepatitis—usually cholestatic changes during first month Thrombocytopenia,
urine, tears (contact (frequency not increased when given with INH); leukopenia, hemolytic
lens), sweat jaundice (usually reversible with dose reduction and/or anemia, eosinophilia, renal
Major concerns are drug continued use); GI intolerance; hypersensitivity damage, proximal myopathy,
interactions because reactions; accelerated metabolism of steroids so hyperuricemia, anaphylaxis,
rifampin accelerates increase steroid requirement in adrenal insufficiency; renal damage, acute organic
cytochrome P-450 may require alternative to oral contraceptives; brain syndrome, C. difficile
contraindicated for concurrent use with protease colitis
inhibitors (see drug interactions); flu-like syndrome
with intermittent use characterized by dyspnea,
wheezing
Rimantadine (Flumadine) GI intolerance (3–8%); CNS—light headed-ness, Seizures (primarily in
insomnia, reduced concentration, nervousness (4–8%, patients with seizure
about half the rate with amantadine) disorder)
Sodium stibogluconate Muscle pain, joint Weakness, colic, hepatic damage, bradycardia, Diarrhea, rash, pruritus,
(Pentostam) stiffness, nausea, leukopenia hemolytic anemia, cardiac
T-wave flattening, damage, renal damage,
increased hepatic shock, sudden death
enzymes
Spectinomycin (Trobicin) Pain at injection site, urticaria, fever, insomnia, Anaphylaxis, fever, anemia,
dizziness, nausea, headache renal failure and abnormal
liver function test (multiple
doses)
Sulfonamides Allergic reactions—rash, Periarteritis nodosum, lupus, Stevens-Johnson Myocarditis, psychosis,
pruritus, fever (appears syndrome, serum sickness; crystalluria with renal confusion, euphoria,
to be dose related, damage, urolithiasis and oliguria (prevent with disorientation, neuropathy,
usually within 7–10 days increasing urine pH, hydration, and use of dizziness, depression,
of initial dose), cross sulfonamide-sulfonamide combinations); GI intolerance; hemolytic anemia (G6PD
reactions noted between thiazide diuretics and oral hypoglycemics deficiency), marrow
sulfonamides including photosensitivity; hepatitis suppression, agranulocytosis
thiazide diuretics and
oral hypoglycemics
Suramin GI intolerance, pruritis, Peripheral neuropathy, renal damage, blood dyscrasias, optic atrophy
photophobia,
hyperesthesia
Telithromycin GI intolerance—nausea, vomiting, diarrhea; dysgeusia; Elevated transaminases, C.
headache; dizziness difficile colitis; blurred
vision; exacerbation of
myasthenia gravis; potential
to prolong QTc interval
(similar to clarithromycin)
Terbinafine GI intolerance—diarrhea, dyspepsia, abdominal pain; Anaphylaxis, neutropenia
rash; taste perversion; hepatitis; pruritis
Tetracyclines GI intolerance (dose Hepatotoxicity (dose related, esp pregnant women); Malabsorption, allergic
Demeclocycline related); stains and esophageal ulcerations; diarrhea; candidiasis (thrush reactions, visual
Minocycline deforms teeth in and vaginitis); photosensitivity (esp demeclocycline and disturbances, aggravation of
Tetracycline children up to 8 yr; doxy- cycline); phlebitis with IV treatment and pain with myasthenia (reversed with
vertigo (minocycline); IM injection Ca++), hemolytic anemia, C.
negative nitrogen difficile colitis, increased
balance and increased intra-cranial pressure,
azotemia with renal hemolytic anemia,
failure (except papilledema
doxycycline; vaginitis)
Thiabendazole (Mintezol) Nausea, vomiting, Rash, hallucinations, olfactory disturbances, leukopenia Stevens-Johnson syndrome,
vertigo shock, tinnitis, cholestasis,
seizures, angioneurotic
edema
Ticarcillin + clavulanic acid Similar to those for See penicillins
(Timentin) ticarcillin alone
Trifluridine (Viroptic) Burning at application site Palpebral edema,
hypersensitivity reactions,
epithelial keratopathy
Trimethoprim GI intolerance (dose Marrow suppression—megaloblastic anemia, Pancytopenia; erythema
related), rash, pruritis neutropenia, thrombocytopenia (hematologic toxicity multiforme, Stevens-Johnson
increased with folate depletion and high doses—treat syndrome, TEN
with leucovorin, 3–15 mg/d × 3 days); reversible
hyperkalemia (dose related); photosensitivity
Trimethoprim-sulfamethoxazole Fever, leukopenia, rash, Candida vaginitis, thrush (AIDS patients); anemia; Ataxia, apathy, ankle clonus,
(see sulfonamides and and/or GI intolerance in thrombocytopenia, renal failure; hemolytic anemia with erythema multiforme,
trimethoprim) (Bactrim, 25–50% of HIV-infected G6PD deficiency; hepatitis including cholestatic jaundice Stevens-Johnson syndrome,
Septra) persons; dose related C. difficile-associated colitis,
and most tolerate pancreatitis, hepatic
readministration of necrosis
lower dose after 2 wk
discontinuation;
reactions noted above
for sulfonamides and
trimethoprim
Trimetrexate Marrow suppression with Hepatotoxicity with increased trans-aminase levels Seizures— ? relation,
neutropenia and (3%), rash (3%); GI toxicity (1%), stomatitis, anaphylaxis
thrombocytopenia. Must nephrotoxicity
give with folinic acid
(leucovorin) 20–40
mg/m2 q6h). Must
monitor CBC, renal
function, and liver
function, tests O2 times
a week
Tryparsamide Nausea, vomiting Impaired vision, optic atrophy, fever, allergic reactions, rash, tinnitus
Valacyclovir (Valtrex) GI intolerance—nausea,
vomiting, diarrhea,
headache, constipation
Valganciclovir (Valtrex) Neutropenia; anemia; Thrombocytopenia; confusion; headache; fever; abnormal LFTs, rash
contraindicated with
ANC × 500 Hgb × 8 g/dL
GI intolerance
Vancomycin (Vancocin) Phlebitis at injection “Red-man syndrome” (flushing over chest and face) ± Anaphylaxis, ototoxicity and
sites hypotension and pruritis (infusion >60 min; may be nephrotoxicity (dose
reversed or prevented with anti-histamine); fever; related), peripheral
eosinophilia; allergic reactions with rash neuropathy, marrow
suppression
Voricmazole (Valtrex) Visual distrubances in Increased LFTs D/C for hepatotoxicity in 4–8%; hallucination in 4%; rash in 6%
20% (blurring, color
distortion, etc)—usually
treat through; D/C in ×
1%
Zanamivir Bronchospasm or reduced expiratory flow rate especially Dizziness
in patients with asthma or chronic lung disease; should
have rapidly acting broncho-dilator available in
susceptible patients
P.59
P.60
P.61
P.62
P.63
P.64
P.65
P.66
P.67
P.68
P.69
P.70
P.71
P.72
P.73
P.74
P.75
B. Penicillin Allergy— Guidelines based primarily on recommendations of the Joint Council of Allergy, Asthma and Immunology (J Allergy Clin Immunol
1998;101:S465–S528.) and the CDC recommendations for penicillin skin testing (MMWR 2002; 51: RR-6.)
1. Classification of Penicillin Hypersensitivity Reactions(JAMA 2001;285:2498.)
Type Mechanism Clinical expression
I IgE Urticaria, angioedema, anaphylaxis,* laryngeal edema, asthma frequency—0.02%,
mortality—10%
II Cytotoxic Ab of IgG class Hemolytic anemia
III Immune complexes IgG and Serum sickness
IgM Ab
IV Cell-mediated Contact dermatitis
Idiopathic Unknown Maculopapular rash (common), interstitial nephritis, drug fever, eosinophilia, exfoliative
dermatitis, Stevens-Johnson syndrome
* Anaphylaxis is defined as an immediate systemic reaction due to IgE. Anaphylactoid reactions mimic anaphylaxis but are not caused by IgE.
2. Cross Reactions Among Beta-lactam Agents (J Allergy Clin Immunol 1998; 101:S465.)
Allergy to one penicillin indicates allergy to all.
Allergy to penicillins may indicate allergy to cephalosporins and carbapenems (imipenem, meropenem, etc.); it is generally considered safe to
give cephalo sporins to patients with non–IgE-mediated reactions to penicillins such as maculopapular rashes. The risk of an allergic reaction to a
cephalosporin in a patient with penicillin allergy is >10%; it is greater with first generation cephalosporins than second or third generation
agents. Penicillin skin testing is a valid method to test safety of cephalosporins in penicillin-allergic patients.
There are rare cross reactions with aztreonam.
Ampicillin and amoxicillin cause morbilliform rashes in 5–13% of patients; these do not constitute a reaction meriting skin testing unless the
reaction is urticarial or anaphylactic.
Serum sickness to cefaclor is caused by a hereditary defect in metabolism and does not indicate risk with other beta-lactams (Immunol Allergy
Clin N. Am 1998; 189:745.).
3. Skin Testing
This is considered a safe, rapid, and effective method to exclude an IgE-mediated response with O 97% assurance (MMWR 1993;42(RR-14):45.).
a. The indication is a patient who has a history of an allergic reaction to penicillin or a cephalosporin and who needs penicillin. Morbilliform
rashes to amoxi cillin or ampicillin do not count as a positive history. The test may be used for the penicillin allergic patient who requires a
cephalosporin as well.
b. Patients with a history of severe reactions during the past year should be tested in a monitored setting in which treatment for anaphylaxis
is possible. Antigens should be diluted 100-fold.
c. Patients with a history of penicillin allergy and a negative skin test should receive penicillin 250 mg po and be observed for 1 hr before
treatment with therapeutic doses.
Those with a positive skin test should be desensitized.
P.76
d. Penicillin allergy skin testing: Patient should not have taken anti histamines in the previous 48 hr.
1. Reagents (Ann Allergy Asthma Immunol 1999;83:665.; MMWR 2002;51: RR-6.)
Major determinants:
Benzylpenicilloyl-polylysine (Pre-Pen, Kremers-Urban, Milwaukee, WI) as conjugated of benzylpenicillin with poly-L-lysine in concen
tration of 6 × 10-5 mEq penicilloyl moieties.
Benzyl penicilloyl (10-2 or 6000 units/mL).
Minor determinants:
Freshly diluted aqueous penicillin G.
Positive control (histamine 1 mg/mL).
Negative control (buffered saline solution).
Dilute the antigens 100-fold for preliminary testing if there has been an immediate generalized reaction within the past year.
2. Procedure
Epicutaneous (scratch or prick) test: apply one drop of material to volar forearm and pierce epidermis with a 26-gauge needle without
drawing blood; observe for 20 min. A wheal of O4 mm is a positive test. If there is no wheal O4 mm or systemic reaction, proceed to
intradermal test. With a positive scratch test, the subsequent intradermal test should be performed with the corresponding reagent
diluted 102–104 fold.
Intradermal test: Inject 0.02 mL intradermally raising a 2- to 3-mm wheal using a 27-gauge short-bevelled needle; observe for 20 min.
A wheal of 2 mm larger than original wheal is positive.
3. Interpretation
For test to be interpretable, negative (saline) control must elicit no reaction, and positive (histamine) control must elicit a positive reaction.
Positive test: A wheal >2 mm in mean diameter to any penicillin reagent; erythema must be present. A positive history and a positive
skin test gives a 50% chance of an immediate reaction if penicillin is given (J Allergy Clin Immunol 1998;101:S465.)
Negative test: Wheals at site of penicillin reagents are equivalent to negative control. A negative test to major and minor determinants
gives a 97–99% probability of no immediate reaction if penicillin is given (J Allergy Clin Immunol 1998;101:S465.)
Indeterminate: All other results.
Epicutaneous test Histamine Diluent Conclusion
Neg Pos Neg Do epidermal test; wheal 2 mm larger than original wheal at 15–20 min is positive
Neg Neg Neg False negative. No conclusion.
Pos Pos Neg Avoid penicillin or desensitize
From Ann Intern Med 1987;107:204; JAMA 1993;270:2456
e. Experience with test (JAMA 1993;270:2456.)
Test results in 4977 patients with indication for penicillin therapy
Results by history of penicillin reaction
Positive history 55*/776 (7.1%)
Negative history 73/4201 (1.7%)
Total 128/4977 (2.6%)
* History of urticaria—34/274 (12.4%), rash—7/166 (4%), other or uncertain—5/284 (1.7%)
P.77
Reaction pattern with 128 positives
Positive—major determinants 96 (75%)
Positive—minor determinants 13 (10%)
Positive—both 19 (15%)
Results with penicillin given to 596 patients with positive history and negative skin test
Anaphylaxis 2/596 (0.3%)
Urticaria 15/596 (2.5%)
Rash/pruritis 13/596 (2.1%)
f. Experience with cephalosporins
Literature review of 15,987 patients who received first or second generation cephalosporins showed reactions in 8.1% with a history of
penicillin reaction versus 1.9% without this history (Arch Intern Med 1992;152:930.).
A review of 9388 patients with a history of penicillin allergy showed 2 cases of anaphylaxis (0.02%) with cephalosporin treatment.
The rate of cephalosporin reactions with a positive penicillin skin test is 6/135 (4.4%) compared to 2/351 (0.6%) in those with a negative
skin test (NEJM 2001;345:804.).
Patients with an allergic reaction to a cephalosporin should not receive the same agent again, but other cephalosporins with different side
chains may not cause cross reactions. Animal studies suggest side-chain specific antibodies may dominate the immune response to cephalo
sporins (Biochem 1971;123:183.; Ann Intern Med 1987;107:204.).
4. Testing without Minor Determinant
If the full battery of skin test reagents is unavailable (minor determinant is difficult to obtain), testing should be performed with major determinant
(Pre-Pen, Taylor Pharmaceutical Co, Decatur, IL) and penicillin G (benzylpenicillin G 6000 units/mL). This testing detects 90–97% of allergic patients;
because lack of minor determinants misses 3–10% of allergic patients, caution is necessary. Patients at high risk of anaphylaxis (history of
penicillin-induced anaphylaxis, urticaria, asthma etc should be tested with a 100-fold dilution of test reagents before testing full strength. A 10-fold
dilution is suggested for other types of immediate, generalized reactions within the past year. Test methods are described above using the
epicutaneous (scratch) test followed by the intradermal test.
5. Penicillin Desensitization (MMWR 2002;51:RR-6.)
a. Penicillin desensitization should be performed in a hospital because IgE-mediated reactions can occur, although they are rare.
Desensitization may be done po or IV, although oral administration is often considered safer, simpler, and easier. Desensitization requires about 4
hr, after which the first dose is given.
b. Parenteral desensitization: Give 1 unit penicillin IV, and then double the dose at 15-min intervals or increase the dose 10-fold at 20- to 30-min
intervals.
c. Oral desensitization protocol (NEJM 1985;312:1229.):
Amountb
Dosea Penicillin V suspension (units/mL) mL units Cumulative dose (units)
1 1000 0.1 100 100
2 1000 0.2 200 300
3 1000 0.4 400 700
4 1000 0.8 800 1500
5 1000 1.6 1600 3100
6 1000 3.2 3200 6300
7 1000 6.4 6400 12,700
8 10,000 1.2 12,000 24,700
9 10,000 2.4 24,000 48,700
10 10,000 4.8 48,000 96,700
11 80,000 1.0 80,000 176,700
12 80,000 2.0 160,000 336,700
13 80,000 4.0 320,000 656,700
14 80,000 8.0 640,000 1,296,700
Observation period: 30 min before parenteral administration of penicillin.
a Interval between doses, 15 min; elapsed time, 3 hr and 45 min; cumulative dose, 1.3 mil units.
b Specific amount of drug was diluted in approximately 30 mL of water and then given po.
P.78
6. Management of Allergic Reactions
Medical facilities should have a protocol for dealing with allergic reactions, especially anaphylaxis. Supplies include oxygen, aqueous epinephrine,
injectable antihistamine, IV steroids, airway intubation suppliers, and IV access supplies.
Epinephrine: IgE-mediated reactions
Antihistamines: Accelerated and late urticaria, maculopapular rashes
Glucocorticoids: Severe urticaria, prolonged systemic anaphylaxis, serum sick-ness, contact dermatitis, exfoliative and bullous skin reactions,
interstitial nephritis, pulmonary and hepatic reactions
7. Anaphylactic Shock
Epinephrine dose
Initial treatment
SC (preferred) or IM: Repeat every 20–30 min prn up to 3× 0.3–0.5 mL (1:1000)
Severe shock or inadequate 3–5 mL at 5- to 10-min intervals
response to IM or SC: (1:10,000)
IV administration
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Antimicrobial Agents > Drug Interactions
Drug Interactions
(Adapted from Medical Letter Handbook of Adverse Drug Interactions, 2000 and Drug Information for
the Health Care Professional, USP DI, 21st Edition, 2001)
Drug Effect of interaction
Acyclovir
Narcotics Increased meperidine level
Probenecid Possible increased acyclovir level
Adofovir
Ibuprofen Adofovir AUC increases 23%
Amantadine
Anticholinergics Hallucination, confusion, nightmares
Thiazide diuretics Increased amantadine toxicity with
hydrochlorothiazide-triamterene combination
Trimethoprim–sulfamethoxazole Amantadine toxicity with delirium
Aminoglycosides
Amphotericin Increased nephrotoxicity
Bumetanide Ototoxicity
Cephalosporins Increased nephrotoxicity
Cisplatin* Increased nephrotoxicity—avoid
Cyclosporine* Increased nephrotoxicity—avoid
Enflurane* Increased nephrotoxicity—avoid
Ethacrynic acid* Increased ototoxicity—avoid
Furosemide* Increased oto- and nephrotoxicity—avoid
Gallium Increased nephrotoxicity
MgSO Increased neuromuscular blockage
4
Malathion Possible respiratory depression
Methotrexate Possible decreased methotrexate activity with oral
aminoglycosides
Neuromuscular blocking agents Increased neuromuscular blockade
Vancomycin Increased nephrotoxicity and possible increased
ototoxicity
Aminosalicylic acid (PAS)
Anticoagulants, oral Increased hypoprothrombinemia
Digitalis Decreased digoxin level
Probenecid Increased PAS toxicity
Rifampin Decreased rifampin effectiveness (give as separate
doses by 8–12 hr)
Amphotericin B
Aminoglycosides Increased nephrotoxicity
Capreomycin Increased nephrotoxicity
Cisplatin Increased nephrotoxicity
Corticosteroids Increased hypokalemia
Cyclosporine* Increased nephrotoxicity (JID 29:106, 1994)—avoid
Digitalis Increased cardiotoxicity due to
+
hypokalemia—monitor K
Diuretics Increased hypokalemia
Leukocyte transfusions Acute pulmonary toxicity
Methoxyflurane Increased nephrotoxicity
Pentamidine Increased nephrotoxicity
Skeletal muscle relaxants Increased effect of relaxants
Vancomycin Increased nephrotoxicity
Atovaquone
AZT Increased AZT levels (Clin Pharmacol Ther 59:14,
1996)
Food (fat) Increased absorption (should be taken with meals)
Metoclopramide Decreased atovaquone levels
Rifampin and rifabutin Decreased atovaquone levels
Sulfa-trimethoprim Slight decrease in TMP-SMX levels
Tetracycline* Decreased atovaquone levels (40%)—avoid
Azithromycin
Antacids with Mg ++ or Al ++ Area under curve does not change peak level
Coumadin Increased prothrombin time
Food Tablets: No effect
Oral suspension: Absorption increases, but area
under curve is unchanged
Theophylline Increased theophylline levels (Pharmacotherapy
17:827, 1997)
Capreomycin
Aminoglycosides* Increased oto- and nephrotoxicity—avoid
Theophylline Increased theophylline effect and toxicity
Caspofungin
Cyclosporine* Increases levels of caspofungin 35%—avoid or
monitor LFTs
Dexamethasone May decrease caspofungin levels
Efavireniz May decrease caspofungin levels
Nelfinavir May decrease caspofungin levels
Nevirapine May decrease caspofungin levels
Phenytoin May decrease caspofungin levels
Rifampin May decrease caspofungin levels
Tacrolimus May decrease caspofungin levels
Cephalosporins
Alcohol Disulfiram-like reaction for those with
tetrazole-thiomethyl side chain: Cefamandole,
cefoperazone, cefotetan
Aminoglycosides Possibly increased nephrotoxicity
Antacids with Al ++ or Mg ++ or H 2 Reduced absorption of cefdinir and cefditoren, take
blockers J 2 hr apart
Contraceptives Decreased contraceptive effect; mechanism
unknown—two case reports (Br J Clin Pharmacol
25:527, 1988)
Cyclosporine Increased cyclosporine levels with ceftriaxone
(Nephron 59:681, 1991)
Ethacrynic acid Increased nephrotoxicity
Food Most oral agents are unaffected; oral cefuroxime
absorption promoted
Furosemide Increased nephrotoxicity
Probenecid Increased concentrations of most cephalosporins
Chloramphenicol
Anticoagulants, oral Increased hypoprothrombinemia
Chlorpropamide Increased chlorpropamide activity
Dicumarol Increased dicumarol activity
Phenobarbital Decreased concentrations of chloramphenicol
Phenytoin Increased phenytoin activity
Rifampin Decreased chloramphenicol levels (NEJM 312:788,
1985)
Tolbutamide Increased tolbutamide activity
Cidofovir
Nephrotoxic drugs* Promotes nephrotoxicity—must avoid concurrent
use of aminoglycosides, amphotericin B, foscarnet,
IV pentamidine, and nonsteroidal anti-inflammatory
agents—avoid all
Probenecid Reduces nephrotoxicity of cidofovir and must be
given before cidofovir infusion. Probenecid
increases levels of acetaminophen, acyclovir,
aminosalicylic acid, barbiturates, beta-lactam
antibiotics, benzodiazepines, bumetanide,
clofibrate, methotrexate, furosemide, and
theophylline
Ciprofloxacin (see fluoroquinolones)
Clarithromycin
Carbamazepine* Increased carbamazepine levels and possible
reduction in clarithromycin effect (Ann
Pharmacother 28:1197, 1994)—avoid
Cisapride* Ventricular arrhythmias—avoid
Disopyramide* Increased disopyramide levels with cardiac
arrhythmia (Lancet 349:326, 1997)—avoid
Pimozide Increased pimozide levels with cardiac toxicity (Clin
Pharmacol Ther 59:189, 1996)
Rifabutin Increased rifabutin levels with uveitis (Genitourin
Med 72:419, 1996)
Seldane* Ventricular arrhythmias—avoid
Theophylline Elevated theophylline levels
Clindamycin
Antiperistaltic agents Increased risk and severity of C. difficile colitis
(Lomotil, loperamide)
Cycloserine
Alcohol Increased alcohol effect or convulsions; warn
patients
Ethionamide Increased CNS toxicity
Isoniazid CNS toxicity, dizziness, drowsiness
Phenytoin Increased phenytoin effect (toxicity)
Dapsone
Coumadin Increased prothrombin time
ddl Decreased levels of dapsone
Primaquine Increased hemolysis with G6PD deficiency
Probenecid Increased dapsone levels
Pyrimethamine Increased marrow toxicity (monitor CBC)
Rifampin Decreased levels of dapsone
Saquinavir Increased levels of dapsone
Trimethoprim Increased levels of both drugs
Daptomycin
HMG-CoA reductase inhibitors Caution with concurrent use since both may cause
(statins) myopathy—recommend temporary discontinuation
of statins
Ertapenem
Dextrose Incompatible—do not infuse in dextrose
Probenecid Increased ertapenem AUC 25%
Erythromycins (inhibit cytochrome P-450)
Anticoagulants, oral Increased hypoprothrombinemia
Carbamazepine Increased carbamazepine toxicity
Cisapride (Propulsid)* Ventricular arrhythmias—avoid
Corticosteroids Increased methylprednisolone levels
Cyclosporine Increased cyclosporine toxicity (nephrotoxicity)
Digoxin Increased digitalis levels
Disopyramide* Increased disopyramide levels—avoid
Ergot alkaloids Increased ergot levels
Felodipine Increased felodipine levels (Clin Pharmacol Ther
60:25, 1996)
Phenytoin Possible decreased phenytoin levels
Quinidine Increased quinidine levels with cardiac toxicity
(Pharma-cotherapy 117:626, 1997)
Seldane* Ventricular arrhythmias—avoid
Tacrolimus Increased tacrolimus levels (Lancet 344:825, 1994)
Theophylline Increased theophylline levels (Pharmacotherapy
17:827, 1997)
Triazolam Increased triazolam toxicity
Valproate Increased valproate levels (Ann Intern Med
116:877, 1992)
Ethionamide
Cycloserine Increased CNS toxicity
Isoniazid Increased CNS toxicity
Famciclovir
Cimetidine Increased penciclovir levels
Digoxin Increased digoxin levels
Probenecid Increased penciclovir levels
Theophylline Increased penciclovir levels
Fluconazole (inhibits cytochrome P-450)
Alprazolam Increased sedation
Atovaquone Increased atovaquone levels
Benzodiazepines Increased benzodiazepine levels
Caffeine Possible caffeine toxicity
Cisapride (Propulsid)* Ventricular arrhythmias—avoid
Clarithromycin Increased clarithromycin levels
Contraceptive Decreased contraceptive effect—three cases
reported
Coumadin Increased prothrombin time
Cyclosporine Increased cyclosporine nephrotoxicity
Midazolam Increased sedation
Nortriptyline Increased sedation, cardiac arrythmias
Phenytoin Increased phenytoin levels
Rifabutin* Increased rifabutin levels with possible
uveitis—avoid
Rifampin Reduced fluconazole absorption
Saquinavir Increased saquinavir levels
Seldane* Ventricular arrhythmias—avoid
Sulfonylureas Increased levels with hypoglycemia
Tacrolimus Increased nephrotoxicity
Theophylline Increased levels of theophylline
Triazolam Increased sedation
Zidovudine Increased levels of zidovudine (JID 169:1103,
1994)
Fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin, levofloxacin, trovafloxacin, gatifloxacin,
moxifloxacin, gemifloxacin, lomefloxacin)
Antacids Decreased fluoroquinolone absorption with Mg ++ ,
++ ++
Ca , or Al containing antacids or sucralfate;
give antacid > 2 hr after fluoroquinolone
Anticoagulants, oral Increased hypoprothrombinemia
Caffeine Increased caffeine effect; significance?; not noted
with ofloxacin, sparfloxacin, levofloxacin
Cyclosporine Possible increased nephrotoxicity
Diazepam Increased diazepam levels with ciprofloxacin (Eur J
Clin Pharmacol 44:365, 1993)
Food Decreased absorption of norfloxacin and
ciprofloxacin: Take 1–2 hr before or after meal
Food (dairy products) Decreased absorption
Foscarnet Possible seizures with ciprofloxacin (Ann
Pharmacother 28:869, 1994)
Iron Decreased fluoroquinolone absorption—give
quinolone >2 hr before or > 6 hr after iron
Nonsteroidal anti-inflammatory Possible seizures and increased epileptogenic
agents potential of theophylline, opiates, tricyclics, and
neuroleptics
Pentoxifyline Headaches with ciprofloxacin
Phenytoin Possible decrease in phenytoin level
Probenecid Increased fluoroquinolone levels
Theophylline Increased theophylline toxicity—especially
ciprofloxacin and enoxacin; not noted with
ofloxacin, levofloxacin, or sparfloxacin
Zinc Decreased fluoroquinoline absorption
Foscarnet
Aminoglycosides Increased renal toxicity
Amphotericin B Increased renal toxicity
Pentamidine Increased hypocalcemia
Ganciclovir
AZT (Retrovir) Increased leukopenia: Must monitor CBC and
discon-tinue or give G-CSF
Imipenem Increased frequency of seizures (?)
Myelosuppressing drugs: Increased leukopenia
TMP-SMX, AZT, azathio-prine,
pyrimethamine, flucytosine, interferon,
doxorubicin, vinblastine, vincristine
Probenecid Increased ganciclovir levels
Griseofulvin
Alcohol Possibly potentiates effect of alcohol
Anticoagulant, oral Decreased anticoagulant effect
Aspirin Decreased aspirin effect
Contraceptive Decreased contraceptive effect
Cyclosporine Possible decreased cyclosporine effect
Food Fat increases absorption
Phenobarbital Decreased griseofulvin levels
Theophylline Decreased theophylline effect
Imipenem
Ganciclovir* Increased frequency of seizures
Probenecid Increased imipenem levels
Isoniazid
Alcohol Increased hepatitis; decreased INH effect in some
Antacids Decreased INH with AI ++ containing antacids
Anticoagulants, oral Possible increased hypoprothrombinemia
Benzodiazepines Increased effects of benzodiazepines
Carbamazepine* Increased toxicity of both drugs (NEJM 307:1325,
1982) avoid
Cycloserine Increased CNS toxicity, dizziness, drowsiness
Diazepam Increased diazepam levels—reduce diazepam dose
Disulfiram* Psychotic episodes, ataxia (Am J Psychol 125:1725,
1969)—avoid
Enflurane* Possible nephrotoxicity—avoid
Ethionamide Increased CNS toxicity
Food Decreased absorption INH
Itraconazole Decreased itraconazole levels
Ketoconazole* Decreased ketoconazole levels—avoid
Phenytoin Increased phenytoin toxicity
Rifampin, rifabutin Possible increased hepatic toxicity
Theophylline Increased theophylline levels
Tyramine (foods and fluids rich in Palpitations, sweating, urticaria, headache,
tyramine) vomiting, and hypertension with consumption of
cheese, wine, some fish (rare reaction to
monoamine-rich foods) (Lancet 2:671, 1985)
Vincristine Increased neurotoxicity
Itraconazole (inhibits cytochrome P-450)
Alprazolam* Increased sedation—avoid
Antacids Decreased itraconazole absorption
Astemizole* Ventricular arrhythmias—avoid
Carbamazepine (Tegretol) Decreased itraconazole levels
Cisapride* Ventricular arrhythmias—avoid
Contraceptives Decreased contraceptive effect
Coumadin Increased hypoprothrombinemia
Cyclosporine Increased cyclosporine levels with nephrotoxicity
ddl Reduced itraconazole absorption
Digoxin Increased digoxin levels
Felodipine Increased felodipine with edema
Food Increased itraconazole absorption: Give with meal
H antagonists*, antacids*, Decreased itraconazole absorption—avoid
2
omeprazole*
Hypoglycemics, oral Severe hypoglycemia
INH Decreased itraconazole levels
Loratadine Increased loratadine levels with cardiac arrhythmia
Lovastatin Large increase in lovastatin levels with possible
rhabdomyolysis (NEJM 333:664, 1995)
Midazolam* Increased midazolam levels—avoid
Nifedipine Increased nifedipine with edema
Phenobarbital Decreased itraconazole levels
Phenytoin Decreased itraconazole levels
Protease inhibitors Increased level of saquinavir and indinavir
Rifampin, rifabutin Decreased itraconazole levels (CID 18:266, 1994)
Seldane (terfenadine)* Ventricular arrhythmias—avoid
Tacrolimus Increased tacrolimus levels—monitor levels
Triazolam* Increased triazolam effect—avoid
Sucralfate Decreased itraconazole absorption
Sulfonylureas Increased sulfonylurea with hypoglycemia
Ketoconazole (inhibits cytochrome P-450)
Alcohol Possible disulfiram-like reaction
Alprazolam Increased alprazolam with increased sedation
Anticoagulants, oral Increased hypoprothrombinemia
Astemizole* Increased astemizole levels—avoid
Chlordiazepoxide Increased chlordiazepoxide toxicity
Cisapride (Propulsid)* Ventricular arrhythmias—avoid
Contraceptives Decreased contraceptive effect
Corticosteroids Increased methylprednisolone levels
Cyclosporine Increased cyclosporine levels
ddI Decreased ketoconazole level—give J2 hr apart
Food Decreased absorption: take 1–2 hr before or after
meal
H antagonists, antacids, omeprazole Decreased ketoconazole effect; use sucralfate or
2
antacids given 2 hr before
Hypoglycemics, oral Severe hypoglycemia
Indinavir Increase indinavir levels 70%
Isoniazid* Decreased ketoconazole levels (NEJM 311:1681,
1984)—avoid
Loratadine (Claritin) Increased loratadine levels
Midazolam* Increased midazolam levels—avoid
Phenobarbital Reduced ketoconazole levels
Phenytoin Altered metabolism of both drugs; increased
phenytoin levels and decreased ketoconazole levels
Rifampin*, rifabutin* Decreased levels of both drugs—avoid
Ritonavir Increased ritonavir levels
Saquinavir Increased saquinavir levels by 150% (often desired)
Seldane (terfenadine)* Ventricular arrhythmias—avoid
Sucralfate Possible decreased ketoconazole effect
Tacrolimus Possible tacrolimus toxicity
Theophylline Increased theophylline levels
Triazolam* Increased triazolam toxicity—avoid
Linezolid
Phenylpropanolamine Risk of hypertension
Pseudoephedrine Risk of hypertension
Tyramine > 100 mg/d Risk of hypertension
Mebendazole
Phenytoin and carbamazepine Decreased mebendazole concentrations; clinically
significant only for extraintestinal helminthic
infections
Mefloquine
Beta-adenergic blockers* Increased risk of cardiac toxicity including cardiac
arrest—avoid
Chloroquine Increased risk of seizures
Halofantrine* QT prolongation—avoid
Quinidine* Increased risk of cardiac toxicity including cardiac
arrest—avoid
Quinine* Increased risk of cardiac toxicity including cardiac
arrest—avoid
Meropenem
probenecid* Increases meropenem levels 40%—avoid
Metronidazole
Alcohol Disulfiram-like reaction (flushing, headache, nausea
± vomiting, and chest/abdominal pain)
Anticoagulants, oral Increased hypoprothrombinemia
Barbiturates Decreased metronidazole effect with phenobarbital
Cimetidine* Possible increased metronidazole toxicity—avoid
Corticosteroids Decreased metronidazole levels
Disulfiram* Organic brain syndrome (NEJM 280:1482,
1969)—avoid
Fluorouracil Transient neutropenia
Food Food often reduces gastric irritation
Lithium Lithium toxicity—monitor lithium levels (JAMA
257:3365, 1987)
Phenobarbital Decreased metronidazole levels—double
metronidazole dose if phenobarbital is essential
(NEJM 305:529, 1983)
Miconazole
Aminoglycosides Possible decreased tobramycin levels
Anticoagulant, oral Increased hypoprothrombinemia
Hypoglycemics Severe hypoglycemia with sulfonylurea
Phenytoin Increased phenytoin toxicity
Nalidixic acid
Anticoagulants, oral Increased hypoprothrombinemia
Nitrofurantoin
Antacids Possible decreased nitrofurantoin effect; give 6 hr
apart
Food Increases absorption
Probenecid Decreased nitrofurantoin effect (for UTIs)
Nitazoxanide None known
Oseltamivir
probenecid Increases levels of oseltamivir
Penicillins
Allopurinol Increased frequency of rash with ampicillin
Anticoagulants, oral Decreased anticoagulant effect with nafcillin and
dicloxacillin
Cephalosporins Increased cefotaxime toxicity with mezlocillin +
renal failure
Contraceptives Possible decreased contraceptive effect with
ampicillin or oxacillin
Cyclosporine Decreased cyclosporine effect with nafcillin and
increased cyclosporine toxicity with ticarcillin
Food Decreased absorption of oral ampicillin, cloxacillin,
oxacillin, dicloxacillin, and penicillin G
Lithium Hypernatremia with ticarcillin
Methotrexate Possible increased methotrexate toxicity
Probenecid Increased concentrations of penicillins
Pentamidine
Aminoglycosides Increased nephrotoxicity
Amphotericin B Increased nephrotoxicity
Capreomycin Increased nephrotoxicity
Foscarnet Increased nephrotoxicity
Piperazine
chlorpromazine Possibly induces seizures
Polymyxin or colistimethate
Aminoglycoside Increased nephrotoxicity; increased neuromuscular
blockade
Neuromuscular blocking agents Increased neuromuscular blockade
Vancomycin Increased nephrotoxicity
Pyrazinamide
allopurinol* Failure to decrease hyperuricemia—avoid
Pyrimethamine
Antacids Possible decreased pyrimethamine absorption
Dapsone* Agranulocytosis reported
Kaolin Possible decreased pyrimethamine absorption
Phenothiazines Possible chlorpromazine toxicity
Quinolones (see fluoroquinolones)
Quinupristin-dalfopristin (inhibits cytochrome P-450 3A4) (Synercid)
Cyclosporine Increased cyclosporine levels—63% (monitor
cyclosporine levels)
Midazolam Increased midazolam levels—33%
Nifedipine Increased nifedipine levels
Terfenadine Increased terfenadine levels—44%
(other drugs metabolized by cytochrome P-450 3A4: Astemizole, diazepam, verapamil,
diltiazem, lovastatin, cisapride, protease inhibitors, carbamazepine quinidine)
Ribavirin
ddI* Increased intracellular ddI with risk of pancreatitis,
neuropathty, or lactic acidosis—avoid
AZT, 3TC, ABC Possible in vitro antagonism; significance not known
Rifabutin: Presumed to be identical to rifampin except for clarithromycin and fluconazole, both
of which increase rifabutin levels and increase risk of uveitis. Effect on cytochrome P-450 is
somewhat less than rifampin. Rifabutin should not be given concurrently with saquinavir; dose
with indinavir should be reduced by 50%
Rifampin (induces cytochrome P-450)
Aminosalicylic acid (PAS) Decreased effectiveness of rifampin; give in
separate doses by 8–12 hr
Amprenavir Reduced amprenavir levels
Anticoagulants Decreased hypoprothrombinemia
Atovaquone Decreased atovaquone levels
Barbiturates Decreased barbiturate levels
Beta-adrenergic blockers Decreased beta-blocker levels
Chloramphenicol Decreased chloramphenicol levels
Clofazimine Reduced rifampin levels
Clofibrate Decreased clofibrate levels
Contraceptives Decreased contraceptive levels (JAMA 227:608,
1974)
Corticosteroids Decreased corticosteroid levels (Arch Intern Med
154:1521, 1994); if used together—increase
corti-costeroid dose
Cyclosporine* Decreased cyclosporine levels
Dapsone Decreased dapsone effect (not significant with
treatment of leprosy)
Delavirdine Reduced delavirdine levels
Diazepam Decreased diazepam levels
Digitalis Decreased digitalis levels
Disopyramide* Decreased disopyramide levels
Doxycycline Decreased doxycycline levels
Efavirenz Efavirenz can be used with rifampin in standard
doses for both drugs
Estrogens Decreased estrogen effect—use alternative method
of birth control
Fluconazole Decreased fluconazole levels
Food Decreased absorption
Haloperidol Decreased haloperidol levels
Hypoglycemics Decreased hypoglycemic effect of sulfonylurea
Isoniazid Increased hepatotoxicity
Ketoconazole* Decreased effect of ketoconazole and
rifampin—avoid
Methadone Methadone withdrawal symptoms
Mexiletine Decreased antiarrhythmic levels
Nevirapine* Combination not recommended
Nifedipine Decreased antihypertensive effect
Nisoldipine Decreased nisoldipine antihypersensitive effect
Phenytoin Decreased phenytoin levels
Progestins Decreased norethindrone levels
Protease inhibitors Ritonavir and ritonavir + saquinavir can be used
with standard doses; other protease inhibitors
should be avoided
Quinidine Decreased quinidine levels
Theophyllines Decreased theophylline levels
Triazolam Decreased triazolam levels (Br J Clin Pharmacol
42:249, 1997)
Trimethoprim Decreased trimethoprim levels
Trimetrexate Decreased trimetrexate levels
Verapamil Decreased verapamil levels
Sulfonamides
Anticoagulants, oral Increased hypoprothrombinemia
Barbiturates Increased thiopental levels
Digoxin Decreased digoxin levels with sulfasalazine
Food Decreased absorption
Hypoglycemics Increased hypoglycemic effect of sulfonylurea
Methotrexate Possible increased methotrexate toxicity
Monoamine oxidase inhibitors Possible increased phenelzine toxicity with
sulfisoxazole
Phenytoin Increased phenytoin levels except with sulfisoxazole
Telithromycin
Cisapride Prolonged QTc interval—Avoid
Digoxin Increased digoxin levels
Itraconazole Increased telithromycin levels
Ketoconazole Increased telithromycin levels
Metoprolol Increased AUC of metoprolol
Midazolam Increased midazolam levels, monitor and adjust
dose if necessary
Pimozide Prolonged QTc interval—Avoid
Rifampin Decreased AUC of telithromycin
Simvastatin Increased simvastatin levels with risk of myopathy
Sotalol Decreased AUC of sotalol
Theophylline Increased GI intolerance
Tetracyclines
Alcohol Decreased doxycycline effect in alcoholics
Antacids* Decreased tetracycline effect with antacids
++ ++ ++
containing Ca , Al , Mg , and NaHCO (give 3
3
hr apart)
Anticoagulants, oral Increased hypoprothrombinemia
Antidepressants, tricyclic* Localized hemosiderosis with amitriptyline
Antidiarrheal agents Agents containing kaolin and pectin or bismuth
subsalicylate decrease tetracycline effect
Barbiturates* Decreased doxycycline effect (Br Med J 2:470,
1974)—avoid
Bismuth subsalicylate, Pepto-Bismol Decreased tetracycline effect
Carbamazepine (Tegretol)* Decreased doxycycline effect—avoid
Contraceptives, oral* Decreased contraceptive effect—avoid
Digoxin Increased digoxin level (10% of population)
Food (dairy products) Decreased absorption (except doxycycline)
Iron, oral Decreased tetracycline effect (except with
doxycycline) and decreased iron effect; give 3 hr
before
Laxatives Agents containing Mg ++ decrease tetracycline effect
Lithium Increased lithium toxicity—monitor levels (J Clin
Psychopharmacol 17:59, 1997)
Methotrexate Possible increased methotrexate toxicity
Methoxyflurane anesthesia, Possibly lethal nephrotoxicity
Penthrane
Milk* Decreased absorption of tetracycline. Does not
apply to doxycycline or minocycline
Molindone Decreased tetracycline levels
Phenformin* Decreased doxycycline levels—avoid
Phenytoin Decreased doxycycline levels
Rifampin Possible decreased doxycycline levels
Theophylline Possible increased theophylline toxicity
Zinc* Decreased tetracycline levels—avoid
Thiabendazole
Theophyllines Increased theophylline toxicity
Trimethoprim
Amantadine Increased levels of both drugs
Azathioprine Leukopenia
Contraceptives Decreased contraceptive effect—two case reports
(Br J Clin Pharmacol 25:527, 1988)
Cyclosporine* Increased nephrotoxicity—avoid
Dapsone Increased levels of both drugs; increased
methemoglobinemia
Digoxin Possible increased digitalis levels
Phenytoin Increased phenytoin levels
Rifampin Decreased trimethroprim levels
Thiazide diuretics Possible increased hyponatremia with concomitant
use of amiloride with thiazide diuretics
Trimethoprim-sulfamethoxazole See trimethoprim
Amantadine Amantadine toxicity with delirium (Am J Med Sci
298:410, 1992)
Anticoagulants, oral Increased hypoprothrombinemia
Atovaquone Slight decrease in TMP-SMX levels
Contraceptives Decreased contraceptive effect—five case reports
(Br J Clin Pharmacol 25:527, 1988)
Mercaptopurine* Decreased mercaptopurine activity—avoid
Methotrexate* Megaloblastic anemia
Paromomycin Increased nephrotoxicity
Phenytoin Increased phenytoin toxicity
Procainamide Increased procainamide levels
Tricyclic antidepressants Recurrence of depression
Possible imipramine toxicity
Desipramine toxicity
Trimetrexate
Acetaminophen Increased trimetrexate levels
AZT Increased bone marrow suppression
Cimetidine Increased trimetrexate levels
Erythromycin Increased trimetrexate levels
Fluconazole Increased trimetrexate levels
Ketoconazole Increased trimetrexate levels
Rifampin, rifabutin Decreased trimetrexate levels
Valacyclovir
Cimetidine Increased acyclovir levels
Probenecid Increased acyclovir levels
Valganciclovir
Myelosuppressive drugs Increased risk of anemia, neutropenia, and
thrombo-cytopenia
Probenecid Increased ganciclovir levels
Vancomycin
Aminoglycosides Increased nephrotoxicity and possible increased
ototoxicity
Amphotericin B Increased nephrotoxicity
Cisplatin Increased nephrotoxicity
Digoxin Possible decreased digoxin effect
Neuromuscular blocking agents Increased succinylcholine and vecuronium effect
Paromomycin Increased nephrotoxicity
Polymyxin Increased nephrotoxicity
Voriconazole (Drugs that induce cytochrome P-450 enzymatic activity reduce voriconazole
activity; drugs that inhibit cytochrome P-450 increase toxicity. Voriconazole inhibits cytochrome
P-450 enzymes)
Astemizole* Risk ventricular arrhythmia—avoid
Barbiturates Increase barbiturate levels—avoid long acting
barbiturates
Benzodiazepines Anticipated prolonged sedative effect—avoid
midazolam, triazolam, and alprazolam
Calcium channel blockers May increase calcium channel blocker level—monitor
for toxicity
Cisapride* Risk ventricular arrhythmias—avoid
Cyclosporine Risk nephrotoxicity—use half cyclosporine dose and
monitor levels
Ergot Risk ergotism
Pimozide* Risk ventricular arrhythmias—avoid
Quinidine* Risk ventricular arrhythmias—avoid
Rifampin* Reduce voriconazole levels—avoid
Rifabutin* Reduce voriconazole levels—avoid
Sirolimus Risk sirolimus toxicity—avoid
Statins Anticipated increase in statin levels—consider lower
statin dose
Tacrolimus Increase tacrolimus levels—reduce dose to 1/3 and
monitor
Warfarin Increase prothrombin time 2×—monitor
prothrombin time
* Concurrent use should be avoided if possible.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Preventive Treatment > Adult Immunization Schedule
Adult Immunization Schedule
A. ADULT IMMUNIZATION SCHEDULE
MMWR 2002;51;RR-2:1–36.
Vaccine 19–49 yrs 50–64 yrs >65 yrs
Tetanus, diphtheria Booster dose every 10 yrs
Influenza Medical, occupational, or household contact Annual dose
indication
Pneumovax Medical indication 1 dose or revaccination at 5 yrs
Measles, rubella, Mumps 1 dose if hx unreliable
Varicella 2 doses (0 and 4–8 wks) if susceptible
Hepatitis A 2 doses (0, 6–12 mo) for indications
Hepatitis B 3 doses (0, 4, and 6 mo) for indications
Note: The only true contraindications to vaccinations are a history of severe allergic reaction after a prior dose or a vaccine
constituent. Severely immunocompromised persons should not receive live virus vaccines. (MMWR 2002;51 RR-2:8)
Common mistakes which are not contraindications
1. Mild illness ± fever
2. Local reaction ± fever with prior vaccination
3. Current antimicrobial therapy
4. Convalescent phase of illness
5. Fever <40.5°C
B. VACCINES AVAILABLE IN UNITED STATES
MMWR 2002;51(RR-2).
Vaccine Type and indications (adults) Route and usual regimena
BCG (bacillus of Live bacteria. Percutaneous or 0.2–0.3 mL
Calmette-Guérin) No longer advocated
Cholera Inactivated bacteria. 0.5 mL SC × 2 >1 wk apart or
Not recommended by WHO, but sometimes required for intradermal 0.2 mL × 2
international travel
DT (diphtheria, tetanus) Toxoids. Booster dose recommended q10yr 0.5 mL SC
DTP (diphtheria, tetanus, Toxoids and inactivated bacteria; Td or DT preferred for adults 0.5 mL IM
pertussis eIPV Enhanced inactivated viruses of all three serotypes. 0.5 mL SC × 1
(inactivated polio-virus Travel to epidemic areas and immunocompromised patient or
vaccine) household contact
Note: Polio is eradicated in Western hemisphere
Haemophilus influenzae Polysaccharide conjugated to protein. 0.5 mL IM × 1
B conjugate (HbCV) Adult at risk—splenectomy
HB (hepatitis B) Inactive viral antigen (surface antigen). 1.0 mL IM × 3 at 0, 1, and 6
Increased risk: Public safety workers exposed to blood; health mo
care workers; injection drug users; gay men; household/ sex
contacts with HBsAg pos; recent STD; renal disease; multiple sex
partners
Hepatitis A Inactivated virus with 1440 ELISA units/mL 1 mL IM (deltoid mm) +
Travel to or work in endemic areas; gay men; injection drug booster dose at 6–12 mo
users; chronic liver disease; HCV infection; persons with
occupational risk (lab workers who handle HAV)
Hepatitis A and B Bivalent vaccine with 720 ELISA units HAV Ag (Havrix) and 20 1 mL IM at 0, 1, and 6 mo
(Twinrix) mcg HBsAg (Energix-B).
Indications for HAV and HBV vaccine including travelers who can
receive two doses before travel
Influenza Inactivated virus or viral components. High risk, age >65, chronic 0.5 mL IM × 1 annually
disease; health care workers; pregnant women who will be in
second or third trimester during flu season
Japanese B encephalitis Inactivated JE virus. Travel >1 mo in epidemic area 1 mL SC at days 0, 7, and 30
Measles Live virus. Unvaccinated adults born after 1956 without measles; 0.5 mL SC × 1 with second >1
unless pos serology or documented vaccination—highest priority mo after first
are women of childbearing potential, health care workers,
international. travelers
Meningococcal vaccine Bacterial polysaccharides of serotypes A/C/Y/W-135. Outbreaks of 0.5 mL SC × 1
N. meningitidis serotype C disease; offer to college freshman in
dormatories. Travel to epidemic area
MMR (M, measles; M, Live viruses. Usual form for persons susceptible to two of these 0.5 mL SC × 1 or 2 with >1
mumps; r, rubella) viruses mo after first
No link to autism found by IOM (BMJ 2001;322:1083)
Mumps Live virus. Unvaccinated adults born after 1956 without mumps 0.5 mL SC × 1
OPV (oral poliovirus Live viruses of all three sero-types. All-IPV schedule po × 1
vaccine) recommended in U.S. at 2, 4, 6–18 mos, 4–6 y per CDC-2000
Pertussis Inactivated whole bacteria IM—Distributed by Biologic
Products Program, Michigan
Department of Public Health
(phone: 517-335-8120)

Live attenuated strain (Ty21a). Travelers to epidemic area po × 4 qod, boosters at 5-yr
intervals
Typhim Vi capsular polysaccharide vaccine. Travelers to epidemic 0.5 mL IM × 1
areas
Varicella Live attenuated virus Adults: 0.5 mL SC × 2
Susceptible adults (negative history of chickenpox ± negative separated by 4–8 wk
serology) and risk category: Health care workers, household
contacts of immunosuppressed patient, persons living or working
in high-risk area (schools, day care centers), nonpregnant women
of childbearing age, or international travelers
Yellow fever (17 D strain) Live virus. Travel to epidemic areas 0.5 mL SC × 1
a Assumes childhood immunizations have been completed
b Dt, tetanus and diphtheria toxoids for use in children aged <7 yr. Td, tetanus and diphtheria toxoids for use in persons aged 07
yr. Td contains the same amount of tetanus toxoid as DPT or DT but a reduced dose of diphtheria toxoid.
P.94
P.95
P.96
P.97
C. RECOMMENDATIONS BY RISK CATEGORY
Adapted from Guide for Adult Immunization, American College of Physicians, 3rd Edition, Philadelphia 1994:1–218; MMWR 2002;51(RR-2).
Category/vaccine Comments
AGE
18–24 yr
Tda (0.5 mL IM) Booster every 10 yr at mid-decades (age 25, 35, 45, etc) or single dose at midlife (age 50) for
those who completed primary series
Measlesb Post-high school institutions should require two doses of live measles vaccine (separated by 1 mo);
(MMR, 0.5 mL SC × 1 first dose preferably given before entry
or 2)
Rubellac Especially susceptible females; pregnancy now or within 3 mo postvaccination is contraindication
(MMR, 0.5 mL SC × 1) to vaccination
Influenza Advocated for young adults at increased risk of exposure (military recruits, students in dorms, etc)
Meningococcus Military—new recruits
0.5 mL SC × 1 Offer to college students—especially freshmen who live in close quarters (JAMA 2001;286:720; CID
2002;35:1376)
25–64 yr
Tda Booster every 10 yr
Influenza Optional
Mumpsc As above
Measlesb Persons born after 1957—need positive serology or proof of vaccination
(MMR, 0.5 mL SC × 1)
Rubellac (MMR, 0.5 mL Principally females O45 yr of childbearing potential; pregnancy now or within 3 mo after
SC × 1) vaccination is contraindication to vaccination
> 65 yr
Tda Booster every 10 yr
Influenza (0.5 mL IM) Annually, usually in October–November
Pneumococcal (23 Single dose; efficacy for elderly established for preventing invasive pneumococcal infection
valent, 0.5 mL IM or SC) (bacteremia and meningitis, but not for preventing pneumonia (NEJM 2003;348:1737; NEJM
2003;348:1747)
PREGNANCY All pregnant women should be screened for hepatitis B surface antigen (HBsAg) and rubella
antibody
Live virus vaccinesd should be avoided unless specifically indicated. It is preferable to delay
vaccines and toxoids until 2nd or 3rd trimester. Immune globulins are safe; most vaccines are a
theoretical risk only
Tda (0.5 mL IM) If not previously vaccinated—dose at 0, 4 wk (preferably second and third trimesters) and 6–12
mo; protection to infant is conferred by placental transfer of maternal antibody
Measles Risk for premature labor and spontaneous abortion; exposed pregnant women who are susceptibleb
should receive immune globulin within 6 days and then MMR post-delivery at least 3 mo after
immune globulin (MMR is contraindicated during pregnancy)
Mumps No sequelae noted; immune globulin is of no value, and MMR is contraindicated
Rubella Rubella during first 16 wk carries great risk, e.g., 15–20% rate of neonatal death and 20–50%
incidence of congenital rubella syndrome; history of rubella is unreliable indicator of immunity.
Women exposed during first 20 wk should have rubella serology and if not immune should be
offered abortion. Inadvertent vaccine administration to 300 pregnant women showed no
vaccine-associated malformations
Hepatitis A Immune globulin preferably within 1 wk of exposure
Hepatitis B All pregnant women should have prenatal screening for HBsAg; newborn infants of HBsAg carriers
should receive HBIG and HBV vaccine; pregnant women who are HBsAg negative and at high risk
should receive HBV vaccine
Inactivated polio vaccine Advised if exposure is imminent in women who completed the primary series more than 10 yr ago.
(0.5 mL po) Unimmunized women should receive two doses separated by 1–2 mo; unimmunized women at high
risk who need immediate protection should receive oral live polio vaccine
Influenza
Pneumococcal vaccine Not routinely recommended, but can be given if there are other indications
Varicella (VZIG, 125 Varicella-zoster immune globulin (VZIG) may prevent or modify maternal infection
units/10 kg IM; maximum
625 units)
FAMILY MEMBER Recommendations apply to household contacts
EXPOSURE
H. influenzae type B H. influenzae meningitis: Rifampin prophylaxis for all household contacts in households with
another child <4 yr; contraindicated in pregnant women
Hepatitis A Immune globulin within 2 wk of exposure
Hepatitis B HBV vaccine (three doses) plus HBV immune globulin for those with intimate contact and no
serologic evidence of prior infection
Influenza A and B With exposure to influenza A unimmunized high-risk family members should receive prophylactic
amantadine, rimantadine, or oseltamivir (×14 days) and vaccine; prevention of influenza B
requires oseltamavir or zanamivir
Meningococcal infection Rifampin, ciprofloxacin, or ceftriaxone for close contacts of meningococcal meningitis
Varicella-zoster No treatment unless immunocompromised or pregnant: consider VZIG
RESIDENTS OF NURSING HOMES
Influenza (0.5 mL IM) Annually for staff and residents; vaccination rates of 80% required to prevent outbreaks; for
influenza A outbreaks consider prophylaxis with amantadine or rimantadine
Pneumococcal (23 Single dose, efficacy not clearly established in this population
valent, 0.5 mL IM)
Tda (0.5 mL IM) Booster dose at mid-decades
RESIDENTS OF INSTITUTIONS FOR MENTALLY RETARDED
Hepatitis B Screen all new admissions and long-term residents: HBV vaccine for susceptible residents
(seroprevalence rates are 30–80%)
PRISON INMATES
Hepatitis B As above
HOMELESS
Tda Most will need primary series or booster
Measles, rubella, mumps MMR 0.5 mL SC (young adults)
Influenza Annual
Pneumococcal vaccine Give × 1
(0.5 mL IM)
HEALTH CARE WORKERS
Hepatitis B (1.0 mL IM × Personnel in contact with blood or blood products; serologic screening with vaccination only of
3) seronegatives is optional; serologic studies show 5% are non-responders (negative for anti-HBs)
even with repeat vaccinations
Influenza (0.5 mL IM) Annual usually in October–November
Rubella (MMR, 0.5 mL Personnel who might transmit rubella to pregnant patients or other health care workers should
SC) have documented immunity or vaccination
Mumps (MMR, 0.5 mL Personnel with no documented history of mumps or vaccine should be vaccinated
SC)
Measles (MMR, 0.5 mL Personnel who do not have immunityb should be vaccinated; those vaccinated in or after 1957
SC) should receive an additional dose, and those who are unvaccinated should receive two doses
separated by at least 1 mo; during outbreak in medical setting vaccinate (or revaccinate) all health
care workers with direct patient contact
Polio Persons with incomplete primary series should receive inactivated polio vaccine
Varicella Personnel with negative history of chickenpox and/or negative serology (5–10% of adults have
negative serology)
IMMIGRANTS AND REFUGEES
Tda Immunize if not previously done
Rubella, measles, mumps Most have been vaccinated or had these conditions, athough MMR is advocated except for pregnant
(MMR 0.5 mL SC) women
Polio Adults will usually be immune
Hepatitis B Screen for HBsAg and vaccinate susceptible family members and sexual partners of carriers;
screening is especially important for pregnant women
HOMOSEXUAL MEN
Hepatitis B Prevaccination serologic screening advocated because 30–80% have serologic evidence of HBV
Hepatitis A markers
IV DRUG ABUSERS
Hepatitis B As above; seroprevalence rates of HBV markers are 50–80%
Hepatitis A
IMMUNODEFICIENCY
HIV infection
Measles Vaccine is contraindicated. Postexposure prophylaxis with immune globulin for AIDS patients with
CD4 count <200/mm3: Immune globulin—0.5 mL/kg IM (15 mL maximum)
Pneumococcal vaccine Recommended for patients with CD4 count > 200/mm3. Revaccination at 5 yr
(0.5 mL SC)
Influenza (0.5 mL IM) Annual
Hepatitis A All with HCV co-infection (if seronegative)
Hepatitis B All who have negative screening anti-HBc
Asplenia
Pneumococcal vaccine Recommended, preferably given 2 wk before elective splenectomy; revaccinate those who received
(0.5 mL IM) the 14 valent vaccine and those vaccinated >6 yr previously
Meningococcal vaccine Indicated
(0.5 mL SC)
H. influenzae B Consider
conjugate (0.5 mL IM)
Renal failure
Hepatitis B (1.0 mL IM × For patients whose renal disease is likely to result in dialysis or transplantation; double dose and
3) periodic boosters advocated
Pneumococcal vaccine Give × 1
(0.5 mL SC)
Influenza (0.5 mL IM) Annual
Bone marrow transplant At 12 mo post-transplant: Revaccinate with inactivated vaccines including Td, hepatitis B, eIVP, H.
recipients influenza type B, Pneumovax, and influenza; at R 24 mo—MMR if not immunosuppressed and no
graft-vs-host disease (see Vaccine Adults, CDC 3:1).
Alcoholics
Pneumococcal vaccine Give × 1
(0.5 mL SC)
DIABETES AND OTHER HIGH-RISK DISEASES
Influenza (0.5 mL IM) Annually from October to December
Pneumococcal vaccine Give × 1
(0.5 mL SC)
TRAVELa For travelers to developed countries (Canada, Europe, Japan, Australia, New Zealand) the risk of
(recommendations of Med developing vaccine-preventable disease is no greater than for those traveling in the U.S.
Lett 1999;41:39; CDC Each country has its own vaccine requirements
Health Information for Smallpox vaccination is no longer required and should not be given
International Travel
1999–2000)
Yellow fever (0.5 mL SC) Recommended and usually required for endemic area: Tropical South America and most of Africa
(see MMWR 1990; between 15° North and 15° South. Give 10 days before travel; booster every 10 yr
39(RR6)) Available only at sites designated by local or state health departments
Some African countries require certification of vaccination by all incoming travelers; some
countries in Africa, South America, or Asia require certification of vaccination by travelers traveling
from or through endemic areas
Contraindications: Age <4 mo and hypersensitivity to eggs. Relative contraindications are
pregnancy, age 4–9 months and immunosuppression (HIV, leukemia, lymphoma, generalized
malignancy, cancer chemotherapy, chronic steroid use)
ACIP reported 7 cases of multiple organ failure in recipients of 17D derived yellow fever vaccine;
all became ill within 2–5 days of vaccination and six died (MMWR 2001;50:643)
(http://www.cdc.gov/ncidod/dvbid/yellowfever/index.htm ).
Cholera Not recommended because risk is low and vaccine has limited effectiveness (Lancet 1990;1:270)
Typhoid fever Recommended for travel to rural areas of countries where typhoid fever is endemic or any area of
an outbreak, primarily travelers outside the usual tourist routes in Latin America, Asia, and Africa
Live oral vaccine—Vivotif (1 cap every other day × 4 starting at least 2 wk before travel)—is
preferred over the parenteral killed bacterial vaccine because of comparable efficacy, longer
protection, and better tolerance (Lancet 1990;336:891); available from Berna Prod
(800-533-5899). New polysaccharide vaccine (Typhim Vi, Connaught 800-822-2463) is also
effective and requires only one IM dose (J Infect Dis 1992;25:63; MMWR 1994;43(RR-14); Clin
Infect Dis 1995;4:186)
Hepatitis A Susceptibility may be determined with tests for IgG antibody that are widely available (Lancet
1988;1:1447)
Vaccine (Havrix, SmithKline Beecham; VAQTA, Merck) is recommended for travel outside U.S.,
Canada, Western Europe, Japan, Australia, or New Zealand. Protective. Consult CDC advisory
(NEJM 1992;327:453; JAMA 1994;271:1328; Ann Intern Med 1996;124:35)
Protective levels of antibody are usually achieved 2–4 wk after a single dose. A booster is
recommended at 6–12 mo, but a single dose is considered adequate protection if given at least 2–4
wk before travel. Twinrix requires two doses separated by 1 month prior to travel, otherwise the
monovalent vaccine is preferred. Alternative is immune globulin (0.02 mL/kg IM) available from
800-843-7477. This has established efficacy and is sometimes required for patients who need
immediate protection
Hepatitis B (1 mL IM × HBV vaccine if travel to endemic areas, and there is risk of need for medical or dental care, travel
3) >6 mo, sexual contact with local persons is likely, or if contact with blood is likely. Major risk
areas are China, Korea, all of Africa, Middle East, Southern and Pacific Islands, Amazon region of
South America, Haiti, Dominican Republic, and Southeast Asia (Med Letter 2001;43:67). (All of
these are high risk areas for HAV as well)
Accelerated schedule is dosing at 0, 1, and 2 mo with a fourth dose at 12 mo
Twinrix is available for patients at risk for HAV and HBV
Rabies Consider human diploid cell rabies vaccine (HDCV), rabies vaccine absorbed (RVA), or purified
chick embryo cell vaccine (PCEC) for travelers with occupational risk and those with extended
travel to endemic area
Japanese encephalitis Vaccine recommended endemic areas with stays of >1 mo in rural rice-growing areas with
(JE-Vax, 1 mL SC × 3 in extensive exposure to mosquitoes. Potential problem countries include Bangladesh, Cambodia,
2–4 wk) Indonesia, Laos, Malasia, Myanmar (Burma), Pakistan, China, Korea, Taiwan, Thailand, Singapore,
eastern Russia, Vietnam, India, Nepal, Sri Lanka, and the Philippines (NEJM 1988;319:641)
JE Vax is Formalin-inactivated, purified, mouse-brain-derived vaccine that causes urticaria,
angioedema, or other serious reactions in 0.5% of recipients (MMWR 1993;42(RR-1):12)
Attack rate is low: <10 cases in U.S. travelers over 1985–95
Influenza Indicated for persons at risk traveling to Southern Hemisphere April–September or at any time of
year for travelers to tropics or travelers in large tourist groups including cruise ships
Need vaccination R 2 wk before travel
Measles (MMR 0.5 mL SC Susceptible personsb should receive a single dose before travel
× 1)
Meningococcal vaccine Recommended for travel to areas of epidemics, most frequently sub-Saharan Africa
with serogroups A, C, Y, (December–June)
and W 135 (0.5 mL SC × 1) Saudi Arabia requires certificate of vaccination for pilgrims to Mecca or Medina
Vaccine is single dose and provides protection for 3 yr
Polio Travelers to developing countries outside the Western Hemishere should receive a primary series
and inactivated polio vaccine if not previously immunized
If protection is needed within 4 wk, single dose elPV or trivalent (live) OPV recommended.
Previously immunized travelers should receive one booster of OPV or elPV
a Diphtheria and tetanus toxoids adsorbed (for adult use). Primary series is 0.5 mL IM at 0, 4 wk and 6–12 mo; booster doses at
10-yr intervals are single doses of 0.5 mL IM. Adults who have not received at least three doses of Td should complete primary
series. Persons with unknown histories should receive series.
b Persons are considered immune to measles if there is documentation of receipt of two doses of live measles vaccine after first
birthday, prior physician diagnosis of measles, laboratory evidence of measles immunity, or birth before 1957.
c Persons are considered immune to mumps if they have a record of adequate vaccination, documented physician diagnosed
disease, or laboratory evidence of immunity. Persons are considered immune to rubella if they have a record of vaccination after
their first birthday or laboratory evidence of immunity. (A physician diagnosis of rubella is considered nonspecific.)
d Live virus vaccines: measles, rubella, yellow fever, oral polio vaccine.
P.98
P.99
P.100
P.101
P.102
P.103
P.104
D. SPECIFIC VACCINES
1. INFLUENZA VACCINE
Recommendations of Advisory Committee on Immunization (MMWR 2003;52:RR-8.).
Preparations: Inactivated egg-grown viruses that may be split (chemically treated to reduce febrile reactions in children) or
whole. The 2003–04 trivalent vaccine contains A/Moscow/10/99 (H3H2), A/New Caledonia/20/90 (H1N1) and B/Hong
Kong/330/2001. Product information available from Connaught 800-822-2463 and, Parke Davis 800-543-2111.
Flu mist: This is the first nasally administered vaccine in the U.S. It consists of live viruses including two strains of influenza A
and one strain of influenza B. This was FDA approved in June 2003 for use in persons
P.105
5–49 years; a single dose is advocated for persons 9–49 years, persons >50, those with medical conditions that constitute
indications for the vaccine, and persons with immunosuppression should use standard influenza vaccine since FluMist is a live
virus vaccine and has not been tested in high risk populations. The cost is $46/dose.
Administration (older than 12 yr): Whole or split virus vaccine, 0.5 mL × 1 IM in the deltoid muscle, preferably mid-October
to mid-November. Recommendations for the 2003–04 season are for preferential immunization of high risk persons in October to
assure an adequate supply for this group. This includes: Age >50 years, children 6–23 mo., persons 2–49 years with medical
indications, healthcare workers and household contacts of high risk persons. The needle should be R1 inch. Protection begins 2
wk post-vaccination and may last 6 mo, but antibody titers may fall below protective levels within 4 mo in elderly patients.
Effectiveness: At least 70–90% effective in preventing influenza in healthy persons (MMWR 1993;42(RR-5):1., Drugs
1997;54:841.) when there is a good match between the vaccine antigens and the prevalent strain(s) of influenza. This has been
achieved in 12 of the last 13 seasons. In elderly nursing home residents, the vaccine is 30–40% effective in preventing influenza
and up to 80% effective in preventing influenza-related mortality (JAMA 1985;251:1136.). Population-based studies show
influenza vaccinations of persons >65 years are associated with a 20–30% reduction in hospitalization for heart disease and
pneumonia and a 50% reduction in all-cause mortality (NEJM 2003;348:1322.).
Target Group for Influenza Vaccine
Note: This list defines the two categories that should have the highest priority for initial vaccination in the event that supplies are
limited.
Groups at increased risk for influenza-related complications
1. Persons > 50 yrs
2. Residents of nursing homes and other chronic care facilities housing persons of any age with chronic medical conditions
3. Persons with chronic disorders of the pulmonary or cardiovascular system, including those with asthma
4. Adults and children who required regular medical follow-up or hospitalization during the prior year due to chronic metabolic
diseases (diabetes), renal dysfunction, hemoglobinopathies, or immunosuppression (including HIV infection)
5. Children and teenagers who are receiving long-term aspirin therapy (risk of Reye's syndrome)
6. Women who will be in the second or third trimester of pregnancy during influenza season
7. Elderly and other high-risk persons embarking on international travel: Tropics—all year; Southern Hemisphere—April–September
P.106
Groups that can transmit influenza to high-risk patients
1. Physicians, nurses, and other personnel who have contact with high-risk patients
2. Employees of nursing homes and chronic care facilities who have contact with patients or residents
3. Employees of assisted living and other residences for persons at high risk
4. Providers of home care to high-risk persons
5. Household family members of high-risk persons
Contraindications
1. Severe allergy to eggs
2. Persons with acute febrile illness (delay until symptoms abate); persons with minor illnesses such as URIs may be vaccinated
3. Pregnancy: There has been no significant excess in the influenza-associated mortality among pregnant women since the 1957–58
pandemic (Am J Obstet Gynecol 1959;78:1172.). Influenza vaccine is not routinely recommended, but pregnancy is not viewed
as a contraindication in women with other high-risk conditions. A study of more than 2000 pregnant women who received
influenza vaccine showed no adverse fetal effects (Int J Epidemiol 1973;2:229.). Some experts prefer to vaccinate in the second
trimester to avoid a coincidental association with spontaneous abortions unless the first trimester corresponds to the influenza
season
Adverse Reactions for Influenza Vaccine
1. Soreness at the vaccination site for up to 2 days in about one-third
2. Fever, malaise, etc—infrequent and most common in those not previously exposed to influenza antigens, e.g., young children.
Reactions begin 6–12 hr postvaccination and persist 1–2 days
3. Allergic reactions—rare and include hives, angioedema, asthma, anaphylaxis; usually allergy to egg protein
4. Guillain-Barré syndrome: 1976–77 influenza vaccine was associated with a statistically significant risk of Guillain-Barré
syndrome. A review of the influenza vaccine for 1992–93 and 1993–94 showed the odds ratio for Guillain-Barré with vaccination
was 1.8; this represents a risk of 1–2 cases/1 million persons vaccinated (MMWR 1998;47(RR–6).; NEJM 1998;339:1797.)
2. MEASLES PREVENTION
Revised recommendations of the Advisory Committee on Immunization Practices (MMWR 1991;40(RR-12):20–21.)
Category Recommendations
Routine childhood schedule Two dosesa: first at 12 mo (high-risk area) or 15 mo (most areas); second dose at 4–6 yr
Adults Single dose unless documentation of at least one dose of live measles vaccine R1 yrb or other
evidence of immunityc
Colleges and other Two dosesa unless documentation of receipt of two dosesb live measles vaccine at R1 yr or
educational institutions other evidence of immunityc
Medical personnel Two dosesa for all persons who do not have proof of two dosesb live measles vaccine at R1 yr
beginning employment or other evidence of immunityc
Outbreaks in institutions or Two dosesa for all persons born after 1956 who do not have proof of two dosesb live measles
medical facilities vaccine at R1yr or other evidence of immunityc
Exposures Vaccine preferred if given <72 hr after exposure. Alternative is immune globulin (0.25 mL/kg
IM, maximum 15 mL), acceptable if given within 6 days. Live measles vaccine should be given
3 mo after IG
a Usually MMR (0.5 mL SC). Two doses in adults should include second dose R1 mo after first
b Single dose of live measles vaccine given at age R1 yr should provide long-lasting immunity in 95%. In some settings a 5%
rate of susceptibility provides enough non-immune persons to sustain an epidemic. Persons vaccinated with killed measles
vaccine (1963–67) are considered unvaccinated.
c Born before 1957, physician-diagnosed measles or laboratory evidence of immunity (measles-specific antibody). Serologic
studies in health care workers showed 9% of persons born before 1957 were not immune, and 29% of health care workers
who acquired measles (1985–89) were born before 1957. Therefore, vaccine should be offered to those born before 1957 if
there is reason to consider them susceptible.
P.107
3. RABIES PREVENTION
Recommendation of Advisory Committee on Immunization Practice (MMWR 1999; 48:(RR–1.))
Experience: From 1980 to 1997 there were a total of 36 cases of human rabies in the U.S.—12 from dogs outside the U.S. and
21 from bats. Rabies in wildlife (primarily racoons, skunks, and bats) account for gt;85% of animal rabies in the U.S. The major
animal source in Asia, Africa, and Latin America is dogs. Rabies is now rare in domestic animals in the U.S., although gt;80% of
exposures that qualify for post-exposure rabies prevention treatment are dog and cat contacts (JAMA 2000;284:1001.).
Greatest risk is bats including bat exposure with no clear bite; these account for all five rabies cases acquired in the
U.S. from 1998–2000 (MMWR 2000;49:1111.). A review of 26 cases of bat variant rabies indicated that only two were
associated with known bat bites (CID 2002;35:738.). The revised recommendations are for rabies prophylaxis for a
bat bite, but also for situations where there is a reasonable possibility that a bite has occurred (MMWR 2002;51:828.).
Rabies biologics
1. Vaccines: Neutralizing antibodies are produced in 7–10 days and persist R2 yr
Vaccine Name Source
Human diploid cell vaccine (HDCV) Pasteur Merieux Connaught
IM Imovax Rabies 800-822-2463
Intradermal Imovax Rabies ID
Rabies vaccine absorbed (RVA) IM Rabies Vaccine Adsorbed (RVA) Bio Port Corp
517-327-1500
Purified chick embryo cell vaccine (PCEC) IM Rab Avert Chiron Corp
Rabipur 800-244-7668
P.108
2. Rabies immune globulin (RIG): Provides rapid passive immunity with a half-life of 21 days
Rabies immune globulin product Source
Imogam Rabies-HT Pasteur-Merieux Connaught
800-822-2463
BayRab Bayer Corp
800-288-8370
Cost: AWP cost for five doses of any of the three vaccines is $735–$760; for rabies immune globulin the cost is about $700 for a
70-kg patient.
RABIES POSTEXPOSURE PROPHYLAXIS—UNITED STATES, 1999
Note: In reality, the major risk for rabies is from a dog bite that takes place in the developing world or a bat exposure (with or
without a bite) in the U.S. These recommendations do not account for the latter experience.
Evaluation and
Animal type disposition of animal Postexposure prophylaxis recommendations
Dogs and cats Healthy and available Should not begin prophylaxis unless animal develops
for 10 days' symptoms of rabiesa
observation
Rabid or suspected Immediate vaccination
rabid Consult public health officials
Unknown (escaped)
Skunks, raccoons, bats, foxes, and Regarded as rabid Consider immediate vaccination
most other carnivores unless animal proven
negative by laboratory
testb
Livestock, small rodents and Consider individually Consult public health officials. (Bites of squirrels,
lagomorphs (rabbits and hares), hamsters, guinea pigs, gerbils, chipmunks, rats, mice,
large rodents (wood-chucks and other small rodents, rabbits, chucks and beavers), and
beavers), and other mammals hares almost never require antirabies treatment
a During the 10-day holding period, begin postexposure prophylaxis at the first sign of rabies in the dog, cat, or ferret that
has bitten someone. If animal exhibits clinical signs of rabies, it should be euthanized immediately and tested.
b Animal should be euthanized and tested as soon as possible. Holding for observation is not recommended. Discontinue
vaccine if immunofluorescence test results of animal are negative.
P.109
RABIES POSTEXPOSURE PROPHYLAXIS SCHEDULE
MMWR 1998;47:4.
Vaccination Treatment Regimena
status
Not previously Local wound Postexposure treatment should begin with immediate thorough cleansing of all woun
vaccinated cleaning with soap and water. If available, a virucidal agent such as a povidone-iodine solution
should be used to irrigate the wounds (J Am Acad Dermatol 1995;33:1019)
RIG 20 IU/kg body weight. If anatomically feasible, full dose should be infiltrated around
wound and the rest should be given IM at a site distant from vaccine administration. RIG
and vaccine should not be administered in the same syringe. Because RIG may partially
suppress active production of antibody, no more than recommended dose should be given
Vaccine HDCV, RVA—1.0 mL or PCEC IM (deltoid area),b one each on days 0, 3, 7, 14, and 28
Previously Local wound All post-exposure treatment should begin with immediate thorough cleansing of all wounds
vaccinatedc cleaning with soap and water. If available, a virucidal agent such as a povidone-iodine solution
should be used to irrigate the wounds.
RIG RIG should not be administered
Vaccine HDCV, RVA, or PCEC 1.0 mL IM (deltoid area); one each on days 0 and 3
a Regimens are applicable for all age groups, including children.
b Deltoid area is the only acceptable site of vaccination for adults and older children. For younger children, the outer aspect
of the thigh may be used. Vaccine should never be administered in gluteal area.
c Any person with a history of pre-exposure vaccination with HDCV, RVA, or PCEC; prior post-exposure prophylaxis with
HDCV, RVA, or PCEC; or previous vaccination with any other type of rabies vaccine and a documented history of antibody
response in the prior vaccination.
4. TETANUS-DIPHTHERIA VACCINE
Recommendations of Advisory Committee on Immunization Practices (MMWR 1991;40(RR-10).
Vaccine: Inactivated toxoid vaccine tetanus and diphtheria toxoids adsorbed (Td) are preferred to tetanus toxoid because most
adults who need tetanus toxoid are susceptible to diphtheria (Mayo Clin Proc 1999;74:381.). The primary series is 0.5 mL IM
doses at 0 time, 1–2 mo, and 6–12 mo. Doses should not be repeated if the schedule is delayed. Booster doses are recommended
at 10-yr intervals.
Cost: Td adsorbed, 0.5 mL—$9.75.
Susceptibility: Antigenic response is good but is reduced in elderly
P.110
patients. Current estimates are that 27% of U.S. persons >70 yr are unprotected against diphtheria and tetanus (NEJM
1995;332:761.)
Adverse reactions: Pain and tenderness at injection site; systemic reactions are rare. The frequency of local reactions
increases with increases in the number of doses given.
Contraindications: Anaphylactic reaction or neurologic reaction to prior Td dosing. Persons with a history of an Arthrus reaction
or fever > 39.4°C should not receive Td more than once every 10 yr. Persons who report reactions to a “tetanus shot” before
1938 probably received equine antitoxin and can receive the current vaccine tetanus prophylaxis.
TETANUS PROPHYLAXIS
MMWR 1991;40(RR-12):1–94.
History of tetanus toxoid Clean, minor wounds Otherb
Tda TIGa Tda TIGa
Unknown or <3 doses Yes No Yes Yes
R3 dosesc No unless >10 yr since last dose No No, unless >5 yr since last dose No
a Td. tetanus toxoid; TIG. tetanus immune globulin.
b Wounds contaminated with dirt, stool, soil, saliva, etc; puncture wounds; avulsions; from missiles, crushing, burns and
frostbite.
c If only three doses of toxoid, a fourth should be given.
5. PNEUMOCOCCAL VACCINE
Advisory Committee on Immunization Practices, CDC (MMWR 1997;46(RR-8)..
Vaccine: 23 valent polysaccharide vaccine for the S. pneumoniae contains antigens responsible for 87% of bacteremic
pneumococcal disease in the U.S. The 23 types (Danish nomenclature) follow: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F,
14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Six serotype (6B, 9V, 14, 19A, 19F, 23F) account for most antibiotic
resistance and are included in the vaccine. Most adults show a 2 × rise in type-specific antibody at 2–3 wk after vaccination.
Efficacy: Seven systematic reviews of Pneumovax between 1994 and 2002 show no decrease in mortality or in rates of
pneumococcal pneumonia in high risk patients (elderly or immunosuppressed) who are the target of current vaccine policies (see
below) (BMJ 2002;325:292.). A more recent report shows efficacy in reducing invasive pneumococcal disease (primarily
pneumococcal bacteremia), but not pneumonia or pneumococcal pneumonia (NEJM 2003;348:1747.)
Preparation and cost: Pneumovax (Merck Human Health) — $7.66/ dose.
Recommendations for adults:
1. Immunocompetent adults at increased risk of pneumococcal disease or its complications because of chronic illness (e.g.,
cardiovascular disease, pulmonary disease, diabetes, alcoholism, cirrhosis, or cerebrospinal fluid
P.111
leaks) or who are R65 yr old. Current recommendations are to review risks for pneumococcal disease at the 50th birthday
because 30–40% have medical conditions that merit vaccine.
2. Immunocompromised adults at increased risk of pneumococcal disease or its complications (e.g., splenic dysfunction or
anatomic asplenia, lymphoma, Hodgkin's disease, multiple myeloma, chronic renal failure, nephrosis organ transplant
recipients, HIV infection, and other conditions associated with immunosuppression).
3. Persons in special environments or social settings with identified risk of pneumococcal disease (Native Americans, homeless,
etc).
4. Patients with HIV infection should be given vaccine early during disease for adequate antibody response.
Note: 1) Vaccine should be given at least 2 wk before elective splenectomy; 2) vaccine should be given as long as possible
before planned immunosuppressive treatment; 3) hospital discharge is a convenient time for vaccination because two-thirds of
patients with serious pneumococcal infections have been hospitalized within the prior 5 yr; 4) may be given simultaneously with
influenza vaccine (separate injection sites).
Adverse reactions:
1. Pain and erythema at injection site: 50%.
2. Fever, myalgia, severe local reaction: <1%.
3. Anaphylactoid reactions: 5/million; severe reactions: Estimated frequency of anaphylactoid reactions is 5/million. A
meta-analysis of 7531 pneumococcal vaccine recipients in nine trials showed no patients had severe fever or anaphylactic
reactions. There have been no cases of Guillain-Barré syndrome. Arthrus reactions are more common with revaccination at
<4 yr.
4. Frequency of severe reactions is increased with revaccination <13 mo after primary vaccination; severe reactions are no
more frequent when revaccination occurs >4 yr after primary vaccination.
Revaccination: This is recommended at 5 yr for adults who are immunosuppressed or have asplenia and those who were <65 yr
when first vaccinated. Frequency of local reactions is 3.3× higher with revaccination (JAMA 1999;281:243.).
Pneumococcal conjugate vaccine (Prevnar): 7 valent conjugate vaccine with antigens for serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F. These account for 80% of invasive pneumococcal disease in children < 6 yr in the U.S. Use is currently restricted to
pediatrics.
6. VARICELLA VACCINE
Recommendations of Advisory Committee on Immunization Practice (MMWR 1996;45(RR-11).; MMWR 1999;48(RR-6).)
P.112
Morbidity in adults: Approximately 5–8% of adults are susceptible; about 75% of adults with a negative history for chickenpox
have antibody indicating prior exposure (JAMA 1991;266:2724.). Chickenpox is more severe in young adults; risks are greatest
in pregnant and immunocompromised hosts (Ann Intern Med 1980;93:414.). About 15% of adults develop herpes zoster. The
rate of zoster in vaccine recipients was 2.6/100,000 person-yr in vaccine recipients compared with 68/100,000 persons-yr in a
general population of persons age <20 yr, but these numbers are not necessarily comparable (MMWR 1999;48(RR-6).)
Vaccine: VARIVAX—live attenuated virus vaccine
Note: Vaccine must be stored frozen at < - 15°C to maintain potency. Once reconstituted it must be used within 30 min
Dose: Adult—0.5 mL SC × 2 separated by 4–8 wk
Cost: $65.40/dose
Efficacy: Seroconversion rate in adults is 78% with one dose; 99% with two doses. Protection at 7–10 yr is 70–90% against
infection and 95% against severe disease. Impact in rates of zoster is unknown. It is speculated that reactivation of the vaccine
strain causes mild disease and boosted immunity (Nature Med 2000;6:451.). There are recent reports of vaccine failure that
are expected to occur more frequently as the period of time from vaccination increases (NEJM 2002;347:1909.). A
concern is the possible confusion with smallpox (NEJM 2002;347:1962.)
Indications: Susceptible adults in rank order are in the following categories (Ann Intern Med 1996;124:35.).
1. Health care workers
2. Susceptible household contacts of immunosuppressed persons
3. Persons living or working in areas where transmission of VZV is likely—teachers of young children, day care employees,
staff members in institutional settings
4. Young adults in closed or semiclosed populations—military personnel, college students, inmates and staff of prisons and
jails
5. Nonpregnant women of childbearing potential
6. International travelers
7. Adolescents or adults living in households with children
Cost effective analysis: Serologic testing in adults and vaccinating seronegatives would be cost effective only for those 20–29
yr. Assumptions were cost of vaccination—$78, cost of serology—$20, cost for outpatient treatment of chickenpox—$80 plus
acyclovir at $124 (Am J Med 2000;108:723.)
Contraindictions:
1. Pregnancy or this possibility within 1 mo
P.113
2. Immunosuppressed patients
3. Miscellaneous: Active tuberculosis; persons who have received blood products within 6 mo (passive immunity precludes
antibody response); persons with anaphylactic reactions to gelatin or neomycin
Adverse reactions:
Fever >100°F: 10%
Local reaction at injection site: 30% in 0–2 days
Varicella-like rash at injection site: In 6–20 days reported in 37/100,000 vaccine doses; 3% in clinical trials
Generalized varicella rash: 10% in 7–21 days; this usually consists of <10 lesions fasting R3 days and may be source of
VZV transmission to susceptible contacts
Transmission: Transmission of the vaccine strain is a theoretical risk but is documented in only three cases out of 15 million
vaccine doses distributed; all three were mild (MMWR 1999;48(RR-6).).
Post-exposure prophylaxis: Should be given within 3 days of exposure. Comparative cost and efficacy with other postexposure
strategies follow:
Strategy Time from exposure Cost Efficacy
Vaccine 3 days $40 70–90%
Acyclovir 40–80 mg/kg 7–9 days $120 80–85%
ZIG 625 units IM 4 days $400 90%
7. HEPATITIS A VACCINE
Recommendations of Advisory Council on Immunization Practices (MMWR 1996;45(RR-15):1–30.; Ann Intern Med 1996;124:35.;
NEJM 1997;336:196.; Med Letter 2001;43:67.)
Vaccine: HAVRIX-killed, formalin-inactivated (SmithKline Beecham) and VAQTA (Merck & Co); Twinrix (Glaxo SmithKline) (HBV
+ HAV vaccines)
Dose (adult): 1440 ELISA units (Havrix) (1 mL) IM × 1 or 2 (separated by R6 mo); 50 units/1.0 mL (VAQT). Twinrix—720 units
HAV vaccine and 20 mcg HBV vaccine/1.0 mL to be given at 0, 1 and 6 mo
Cost: $59.45—1440 units Havrix; $62.94—50 units VAQTA; $92.00/dose—Havrix and HBV vaccine (Twinrix)
Adverse reactions: Local reactions in 20–50%, fever in 4% and rare severe reactions: Anaphylaxis, Guillain-Barré syndrome
and other neurologic syndromes
Efficacy: 80% seroconvert in 15 days; >96% at 30 days, with booster dose—100% respond. Duration of immunity expected to
be at least 10 years
Indications: Travelers to countries with endemic HAV (Note: Unnecessary in northern and western Europe, New Zealand,
Australia, Canada, and Japan. Also note that immune globulin is a less expensive
P.114
alternative for short term protection); gay men; injection drug users; persons with clotting disorders; persons >30 yr with
chronic liver disease (including persons with chronic HCV infection); lab workers handling HAV; persons working with nonhuman
primates. Twinrix is recommended for adults with indications. Indications for both vaccines, especially travelers
Consideration: Day care workers, food handlers, staff of institutions for institutionally disabled
Hepatitis A: Immune globulin: Available from Michigan Department of Public Health (517-335-8120). May be given with HAV at
separate injection sites.
8. HEPATITIS B VACCINE
MMWR 1987;36:353–366.; MMWR 1987;37:342–351.; MMWR 1991;40(RR-13).; Guide for Adult Immunization, American College of
Physicians 3rd Edition, 1994:74–83.; NEJM 1997; 336:196.; Mayo Clin Proc 1997;74:377.; MMWR 1999;48:33.; MMWR
2001;50(RR-1).
Vaccine preparations
1. Recombivax HB (Merck & Co): Recombinant vaccine produced by Saccharomyces cerevisiae (baker's yeast) and available
since July 1986; 10 or 40 Zg HBsAg/m; usual adult dose is three 1-mL doses (10 Zg) at 0, 1, and 6 mo; three 1-mL doses
(40 Zg) for dialysis patients
2. Engerix-B (Glaxo SmithKline): Recombinant vaccine available since 1989; 20 Zg HBsAg/mL; usual adult dose regimen is
three 1-mL doses (20 Zg) at 0, 1, and 6 mo; alternative schedule is four 1-mL doses (20 Zg) at 0, 1, 2, and 12 mo (for
more rapid induction of immunity)
3. Twinrix (Glaxo SmithKline): bivalent vaccine with Havrix (HAV vaccine,
P.115
720 ELISA units/ml) + Energix-B (20 Zg HBsAg/ml); usual adult regimen is 3 1 mL doses at 0, 1, and 6 mo.
Cost: Recombivax HB @ $57/dose (10 Zg); Engerix-B @ $55/dose (20 Zg); Twinrix @ $92/dose for HAV and HBV)
Adverse reactions: Injection site reactions in up to 20%. Systemic reactions are uncommon; anaphylaxis is rare, but
epinephrine should be available for immediate use. Fever is reported in 1–6% of HBV vaccine recipients. Hypersensitivity to
yeast and to thimerosal are contraindications to HBV vaccine. HBV vaccine appears to play no role in the etiology or relapses of
multiple sclerosis (NEJM 2001;344:319.; NEJM 2001;344:327.)
Pre-exposure vaccination:
1. Regimen. Three IM doses (deltoid) at 0 time, 1 mo, and 6 mo; 0, 2 and 4 mo; or 0, 1, and 4 mo. There must be R4 wk
between dose #1 and #2,R8 wk between dose #2 and #3, and >4 mo between #1 and #3. If series is delayed, start where
you left off. Usual adult dose is 1 mL (20 Zg Engerix B or 10 Zg Recombivax HB); hemodialysis patients and possibly other
immunocompromised patients should receive 2–4 × the usual adult dose (usually 40 Zg doses of either recombinant vaccine
preparation). HBV deposited into fat rather than muscle results in lower seroconversion rates, so needle length is important.
Needles for all men and for women 60–90 kg should be 2.5 cm, for women >90 kg should be 3.8 cm, and for women <60 kg
should be 1.6 cm (JAMA 1997;277:1709.).
2. Response rate. >95% of young, healthy adults develop adequate antibody response (>10 mIU/mL). Non-response is greater
with age over 40 yr, with certain HLA haplotypes, smoking history, obesity, HIV infection, hemodialysis, and accelerated
schedule (JAMA 1993;270:2935.); response rates are 50–70% in persons with HIV infection; 60–70% with renal failure;
70–80% in diabetics; and 60–70% with chronic liver disease. Age-related response rates show >95% seroconversion rates
in 20-yr-olds, 86% in 40-yr-olds, and 47% in persons >60 yr (Am J Prev Med 1998;15:73.). A meta-analysis of 24 studies
with 11,037 vaccine recipients showed a continuous risk of non-response above 30 years. (CID 2002;35:1368.). This review
also showed that a booster dose substantially improved the response rate. If the schedule is interrupted it may be resumed
with good results providing the second and third doses are separated by R2 mo.
3. Post-vaccination serologic testing. Recommended for some persons whose subsequent clinical management depends on this
knowledge (e.g., health care workers, dialysis patients, infants born to HBsAg-positive mothers) and for vaccine recipients
who have decreased response rates: Age >30 yr, renal failure, HIV infection, diabetes, and chronic liver failure. When done,
test at 1–6 mo after last dose. Studies in Taiwan show serologic titer decrease of about 10% per year, but efficacy persists
(JID 2003;187:134.).
4. Revaccination. Revaccination based on measurements of serologic response is controversial. One point-of-view is that
persons at risk, including health care workers, should have periodic antibody
P.116
measurements with boosters if levels are below 10mlU/mL (Arch Intern Med 1999;159:1481.). The contrary view from the
ACIP is that antibody levels do not measure immunologic memory and that immunologic protection lasts more than 12 yr
regardless of antibody levels (Clin Microbiol Rev 1999;12:351.; Arch Intern Med 2000;160:3170.). If done, revaccination of
nonresponders will produce response in 15–25% with one additional dose and in 30–50% with three doses (Ann Intern Med
1982;97:362.). 13–60% of responders lose detectable antibody within 9 yr. New ACIP recommendations include routine
postvaccination serologic testing for healthcare workers, patients with HIV infection and hemodialysis patients. Response is
defined as HBsAb levels of >10 mIU/mL (MMWR 2001;50:RR-1.) Testing is done at R1 month after the 3rd dose.
5. Prevaccination serologic testing. Testing groups at highest risk is usually cost-effective if the prevalence of HBV markers is
>20% (see table below). Routine testing usually consists of one antibody test: Either anti-HBc or anti-HBs. Anti-HBc fails to
detect persons immune from prior vaccination and anti-HBs (only) will falsely identify HBsAg as susceptible. Average
wholesale price of three-dose vaccine regimen is $165–$213; usual cost of serologic testing for anti-HBs or anti-HBc is
$12–$20.
Prevalence of Hepatitis B Serologic Markers
Population group HBsAg (%) Any marker (%)
Immigrants/refugees from areas of high HBV endemicity 13 70–85
Alaska/Pacific Islands natives 5–15 40–70
Clients in institutions for the developmentally disabled 10–20 35–80
Users of illicit parenteral drugs 7 60–80
Sexually active homosexual men 6 35–80
Household contacts of HBV carriers 3–6 30–60
Patients of hemodialysis units 3–10 20–80
Health-care workers—frequent blood contact 1–2 15–30
Prisoners (male) 1–8 10–80
Staff of institutions for developmentally disabled 1 10–25
Heterosexuals with multiple partners 0.5 5–20
Health-care workers—no or infrequent blood contact 0.3 3–10
General population (NHANES II)
Blacks 0.9 14
Whites 0.2 3
6. Side effects. Pain at injection site (3–29%) and fever >37.7°C (1–6%). Note: These side effects are no more frequent than
in placebo recipients in controlled studies. Experience in more than 4 million adults shows rare cases of Guillain-Barré
syndrome with plasma-derived vaccine and no serious side effects with recombinant vaccines. Adverse reactions should be
reported to 800-822-7967.
7. Vaccine efficacy. 80–95% for preventing HBV infection in gay men and virtually 100% if protective antibody response (R10
mIU/mL) is achieved.
P.117
Candidates for pre-exposure vaccination:
All infants and children by the age of 18 yr
Persons with occupational risk
Now defined by the Occupational Safety and Health Administration, these include health care workers and many public
service workers. For persons in health care fields, vaccination should be completed during training before students
encounter blood
Persons with lifestyle risk
Heterosexual persons with multiple partners (more than one partner in the preceding 6 mo) or any sexually transmitted
disease, homosexual and bisexual men, injecting drug users
Special patient groups
Hemophiliac persons
Hemodialysis patients
Environmental risk factors
Household and sexual contacts of HBV carriers, clients and staff of institutions for the developmentally disabled, prison
inmates, immigrants and refugees from areas where HBV is highly endemic, international travelers to HBV endemic areas
who are health care workers, who will reside there more than 6 mo, or who anticipate sexual contact with local persons
Pregnant women (MMWR 1991;40(RR-13)).: Risk of HBV transmission from HBsAg-positive pregnant woman to infant is
10–85% depending on HBeAg status. Perinatal infection has a 90% risk of chronic HBV infection and 25% mortality due to liver
disease—cirrhosis or hepatocellular carcinoma. Children who do not acquire HBV perinatally are at increased risk for
person-to-person spread during the first 5 yr. Over 90% of these infections can be prevented using active and passive
immunizations. Recommendations follow.
1. All pregnant women should be tested for HBsAg during an early prenatal visit
2. Infants born to HBsAg-positive mothers should receive HBIG (0.5 mL) IM × 1 (preferably within 12 hr of delivery) and HB
vaccine (0.5 mL) IM × 3 (5 Zg Recombivax or 10 Zg Engerix-B) at 0 time (concurrent with HBIG) at 1–2 mo, and at 6 mo.
Test infants for HBsAg and antiHBs at 12–15 mo
3. Infants of HBsAg-negative mothers and children <11 yr should receive routine vaccination with three doses of Recombivax
(2.5 Zg) or Engerix-B (10 Zg)
Postexposure vaccination: (MMWR 1991;40(RR-13).):
Acute exposure to blood: Occupational exposure
Definition of exposure is percutaneous (needlestick, laceration, or bite) or permucosal (ocular or mucous membrane)
exposure to blood. Recommendations depend on HBsAg status of source and vaccination/vaccine response of exposed
person.
Note: HBIG, when indicated, should be given as soon as possible, and value beyond 7 days post-exposure is unclear.
P.118
RECOMMENDATIONS FOR POSTEXPOSURE PROPHYLAXIS FOR PERCUTANEOUS OR PERMUCOSAL EXPOSURE TO
HEPATITIS B, UNITED STATES
Treatment when source is
Hepatitis B
Hepatitis B surface antigen surface antigen
Exposed person positive negative Source not tested or unknown
Unvaccinated HBIG; × 1a and initiate HB' Initiate HB Initiate HB vaccineb
vaccine** vaccineb
Previously vaccinated Test exposed for anti-HBs' No treatment No treatment
known responder 1. If adequate,c no
treatment
2. If inadequate, HB
vaccine booster dose
Known nonresponder HBIG × 2 or HBIG × 1 plus 1 No treatment If known high-risk source, may
HB vaccine dose treat as if source were HBsAg
positive
Response unknown Test exposed for anti-HBs No treatment Test exposed for anti-HBs
1. If inadequate,c HBIG × 1 1. If inadequate, HB vaccine
+ HB vaccine booster booster dose
dose 2. If adequate, no treatment
2. If adequate, no
treatment
HBIG, hepatitis B immunoglobulin.
a HBIG dose 0.06 mL/kg IM.
b For HB vaccine dose, see p 114.
c Adequate antiHBs is 10 SRU by radioimmunoassay or positive by enzyme immunoassay (MMWR 1993;42:707).
d Antibody to hepatitis B surface antigen.
POST-EXPOSURE IMMUNOPROPHYLAXIS WITH OTHER TYPES OF EXPOSURES
(MMWR 40(RR-13):9, 1991)
Type of exposure Immunoprophylaxis Comments
Perinatal HBIG + vaccination HBIG + vaccine within 12 hr of birth
(HBsAg-positive
mother)
Sexual HBIG (0.06 mL/kg IM) ± HBIG efficacy 75%; all susceptible partners should
contact—acute HBV vaccination receive HBIG and start vaccination within 14 days of last
exposure; testing susceptibility with anti-HBc
recommended if it does not delay prophylaxis >14 days.
Vaccination is optimal if exposed person is not in a
high-risk category and sex partner is HBsAg negative at
3 mo
Sexual Vaccinationa
contact—chronic
carrier (HBsAg × 6
mo)
Household None unless there is sexual With known exposure; HBIG plus vaccination
contact—acute HBV contact or blood exposure
(sharing toothbrushes,
razors, etc)
Household Vaccinationa
contact—chronic
carrier (HBsAg × 6
mo)
a 1 mL IM × 3 at 0, 1, and 6 mo.
P.119
9. SMALLPOX VACCINATION
Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program: Supplemental Recommendations of the Advisory
Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC) [CDC
MMWR 2003;52:RR-7.]:
Vaccination Method: The bifurcated needle is inserted into the vaccine vial to obtain a small droplet of vaccine which is
delivered with 2–3 punctures (primary vaccination) or 15 punctures (revaccination) with sufficient force to allow a trace of blood
after 15–20 seconds.
Normal Response: Most of the local reaction and significant complications occur at 5–15 days after vaccination, which
corresponds with the time of viral replication and the immune response. Adverse events are much less frequent with
revaccination and are most common in older perons who have not been vaccinated for decades or those with cellular immune
deficiencies. With primary vaccination, the maximal inflammation and induration occurs at 6–8 days with a pustule, ulcer, or
scab. Revaccination in a highly immune person may cause a lesion similar to that seen with a positive Tine test, and full
resolution may occur at day three with nothing evident at 6–8 days. This may reflect good immunity or poor technique; it is
called “equivocal response” and requires revaccination.
Contact vaccinia: Vaccinia virus can be recovered from the vaccination site from the time of the papule (2–5 days after
vaccination) until the scab separates (14–21 days after vaccination); maximal shedding is at 4–14 days after vaccination and
might be of shorter duration with revaccination.
Nosocomial transmission of vaccina: This has rarely been described and the majority of cases involve direct person-to-person
transmission; the 2003 experience with 24,000 healthcare workers who received smallpox vaccination and continued to provide
patient care showed no nosocomial transmission.
Contraindications: The vaccine is contraindicated in potential recipients with the following conditions or household contacts
with these conditions: (1) history of eczema or atopic dermatitis; (2) other acute, chronic, or exfoliative skin conditions
including burns, impetigo, varicella-
P.120
zoster, HSV, severe acne or psoriasis; (3) immunosuppression (HIV, leukemia, lymphoma, generalized malignancy, solid organ
transplantation, cellular or humoral immunodeficiencies or therapy with alkylating agents, antimetabolites, radiation, or high
dose steroids); (4) pregnancy; and (5) persons with coronary artery disease. The vaccine is contraindicated for potential
recipients (but not household contacts) who are breast-feeding, are less than one year of age (not recommended for persons
under 18 years), and those who are allergic to a vaccine component.
Pregnancy: The risk is small but fetal vaccinia is serious. During 1932–72, there were 20 affected pregnancies; 18 in vaccine
recipients and 2 with contact vaccinia. Of the 20 pregnancies, 7 occurred during the first trimester and 13 occurred in the second
trimester; only one of the 20 pregnancies was maintained to term and three survived. The vaccine is contraindicated in women
who are pregnant or plan pregnancy within four weeks. A urine pregnancy test should be available on the day scheduled for
vaccination. Inadvertent vaccination during pregnancy or pregnancy within four weeks should not be used as reason to terminate
pregnancy.
HIV infection: There has been one reported case of disseminated vaccinia in a patient with AIDS. There were also 732 recruits
vaccinated between 1981 and 1985 who subsequently had positive serology in 1985–88 without known consequences. This gives
a frequency of serious adverse events in this population of 0.14%. The 2003 military experience included inadvertent vaccination
of 10 HIV-infected recruits with CD4 counts >300/mm3; all had “takes” and none had complications. Vaccination is not
recommended with HIV infection; mandatory HIV testing is not recommended, but the test should be available.
Major Adverse Events: (See Ann Intern Med 2003;138:488.)
1. Encephalitis: Develops at 5–15 days after primary vaccination. The mortality rate is about 25%, residual sequelae are noted
in 25%, the virus is rarely detected in brain or CSF, natural history is completed in two weeks, it is not progressive and is
managed with supportive care only. This is more common in children under one year of age and accounts for the delay in
vaccination to the second year of life per a policy in the mid 1960s.
2. Progressive vaccinia: In the 1960s, this was most common in persons with leukemia or agammaglobulinemia. At present,
the greatest concerns are for people with HIV, organ transplants, cancer chemotherapy, and other iatrogenic
immunosuppressive disorders. The complication is characterized by continued viral replication with continuous enlargement
and metastasis. Treatment is with VIG and possibly cidofovir.
3. Eczema vaccinatum: The condition is characterized by widespread vaccinal lesions in patients with eczema or history of
eczema. This complication in the 1960s was more common with contact vaccinia than a complication in vaccine recipients
due to exclusion of these patients for immunization. Treatment is with VIG, which reduces the
P.121
mortality rate from 10% to about 1% with supportive care similiar to that given to burn victims.
4. Accidental implantation: This occurs when patients touch the vaccination site and then touch another anatomical site. The
greatest concern is ocular involvement; about 6% with vaccinia in the eye develop vaccinal keratitis. VIG is controversial
because of animal studies that suggest an antigen-antibody cause.
5. Fetal vaccinia: This complication is exceedingly rare. Pregnant women exposed to smallpox should be vaccinated because
smallpox is associated with a mortality rate in pregnant women of up to 90% and fetal wastage nearly 100%.
6. Cardiac: Myocarditis at 1–3 weeks postvaccination. Most common with primary vaccination in white men in 20's; all military
recruits with this complication in 2003 recovered without sequelae. Ischemic cardiac events (14 cases) and dilated
cardiomyopathy (4 cases) were noted in the 2003 experience with about 500,000 vaccinations but were probably unrelated.
Treatment of Adverse Events: Clinical trials with VIG or any other antiviral agent have not been done with humans. Cidofovir
may be used because of its in vitro activity against vaccinia.
EXPERIENCE WITH SMALLPOX VACCINATION IN 2003
The following table summarizes the adverse events encountered with vaccination of 450,293 military recruits in 2003 (JAMA
2003;289:3278.)
Reactions n = 450,293 Rate/million Historic Rate/million
Mild/temporary
Generalized vaccinia 36 80 45–212
Erythema multiforme 1 — —
Inadvertent self inoculation 48 107 606
Contact vaccinia 21 47 8–27
Moderate-serious
Encephalitis 1 2.2 2.6–8.7
Progressive vaccinia 0 0 1.5
Eczema vaccination 0 0 38
Myocarditis 37 82 100*
* Based on Finnish military recruit study. Acta Med Scand 1983;213:65.
10. MENINGOCOCCAL VACCINE (see p 133)
P.122
E. IMMUNE GLOBULINS
RECOMMENDED TREATMENT
Adapted from Guide for Adult Immunization, American College of Physicians, 3rd Edition, Philadelphia, 1994:86.; and MMWR
1994;43(RR-1)., pp 5, 17
Infection Indication Preparation Recommendation

Clinical tetanus TIG* 3000–6000 units (therapy)
Vaccinia Severe reaction to vaccinia VIG* CDC 404-639-3670
vaccination
Varicella-zoster Immunosuppressed or newborn VZIG* 125 units/10 kg IM up to 625 units
contact Available from state health departments
* Human antibodies.
P.123
F. RECOMMENDATIONS FOR USE OF VACCINES IN IMMUNOCOMPROMISED HOST
Recommendation of the Advisory Committee on Immunization Practices of the CDC (MMWR 1993;42(RR-4).; Clin Micro Rev 1998;11:1.)
Organ
transplantation,
chronic Renal failure,
HIVa immuno-suppressive alcoholism,
response therapy, severely alcoholic
Routine (not HIV with CD4 immuno- cirrhosis, and
Vaccine immuno-compromised)a infection/AIDS <200 compromisedb Asplenia diabetes
Td Recommended Recommended Reduced Recommended Recommended Recommended
MMR(MR/M/R)c Use if indicated Contraindicated Poor Contraindicated Use if Use if
indicated indicated
Hepatitis B Use if indicated Recommendedd Reduced Use if indicated Use if Use if
indicated indicated c
Hib Not recommended Not indicated Reduced Recommended Recommended Use if
indicated
Pneumococcal Recommended if R65 yr Recommended Poor Recommended Recommended Recommended
old with CD4 >
200
Meningococcal Use if indicated Use if indicated No data Use if indicated Recommended Use if
indicated
Influenza Recommended if R 65 yr Recommended Poor Recommended Recommended Recommended
old
Varicella Use if indicated Contraindicated No data Contraindicated Use if Use if
indicated indicated
a Non-routine vaccines:
Contraindicated vaccines for organ transplant recipients, chronic medication induced immunosuppression (alkalylating agents,
radiation, chronic prednisone, anti-metabolites), severe immunosuppression (congenital immunodeficiency, AIDS, leukemia, lymphoma,
aplastic anemia or generalized malignancy): BCG, OPV, smallpox, typhoid TY21a, and yellow fever.
Use if indicated in above population: elPV, cholera, plague, typhoid, inactivated rabies, anthrax
Patients with renal failure, alcoholism; cirrhosis or asplenia may receive the following vaccines if indicated: BCG, OPV, smallpox,
typhoid TY21a, yellow fever, cholera, plague, rabies, anthrax
b Severe immunosuppression can be the result of congenital immunodeficiency, HIV infection, leukemia, lymphoma, generalized
malignancy, or therapy with alkylating agents, antimetabolites, radiation, or large doses of corticosteroids.
c See discussion of MMR.
d Patients with renal failure on dialysis or HIV infection should have their anti-HBs response tested after vaccination, and those found
not to respond should be revaccinated with three doses.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Preventive Treatment > Prophylactic Antibiotics in Surgery
Prophylactic Antibiotics in Surgery
Prophylaxis is recommended for procedures associated with high risk of infection, procedures involving
implantation of prosthetic material, and some procedures when infections are especially serious.
Cefazolin is usually preferred owing to the long half-life and established efficacy. Routine use of
vancomycin is discouraged due to promotion of vancomycin-resistant enterococcus (Infect Control Hosp
Epidemiol 1995;16:105.). A single dose given preoperatively 30 min before the skin incision is usually
adequate; a second dose is often given if the procedure is long or is associated with large blood losses
or if the drug has a short half-life. Postoperative doses are usually unnecessary (Med Lett
2001;43:93.).
Antimicrobial Agents in Surgery
Adapted from Med Lett 2001;43:93.; NEJM 1986;315:1129–1138.; Rev Infect Dis Suppl 1991;10,
13:S779.; Mayo Clin Proc 1992;67:288.; Clin Proc 1992;67:288.; CID 1992;15:S 313.; Arch Surg
1993;128:79.; and Antibiotic Guidelines, Johns Hopkins Hospital 2003
Type of surgery Preferred Alternative Comment
regimen*
CARDIOTHORACIC
Cardiovascular, Cefazolin Vancomycin 1 g IV Likely pathogens: S.
coronary bypass, 1–2 g IV. pre-op infused over 60 epidermidis, S. aureus,
valve surgery pre-op ± min** ± second dose Corynebacterium,
q4h when removed from Gram-negative bacilli.
intraop*, or by-pass Single doses appear to be as
Cefuroxime effective as multiple
1.5 g IV dosesprovided high serum
pre-op ± concentrations are maintained
q6h intraop throughout the procedure (Eur
J Clin Microbiol Infect Dis
1994;13:1033). Main benefit is
reduced rates of wound
infections
Some recommend a second
dose at time of removal from
bypass
Pacemaker Cefazolin Vancomycin 1 g IV Likely pathogens: As above
insertion, 1–2 g IV pre-op infused over 60 Meta-analysis of 7 controlled
defibrillator pre-op* min** studies showed prophylaxis
implant reduced infections associated
with pacemaker implantation
(Circulation 1998;97:1796)
Peripheral Cefazolin Vancomycin 1 g pre-op Likely pathogens: S. aureus, S.
vascular surgery, 1–2 g IV infused over 60 min** epidermidis, Gram-negative
abdominal aorta, pre-op bacilli, clostridia.
and legs or any Prophylaxis recommended for
procedure procedures on abdominal aorta
involving a and procedures on leg that
prosthesis include groin incision or
including amputation for ischemia and
coronary stents any vascular procedure
and grafts for involving a prosthesis (Scand J
hemodialysis Infect Dis 1998;30:547)
Many use prophylaxis with any
vascular prosthetic material
Prophylaxis is not indicated for
carotid endarterectomy
Carotid or None
brachial artery
Thoracic Cefazolin Vancomycin 1 g IV Efficacy of prophylaxis
surgery: 1–2 g IV pre-op infused over 60 antibiotics for lung surgery is
Lobectomy, pre-op or min** or not established [RID 1991;13
pneumonectomy Cerfuroxime Clindamycin 600 mg IV (Suppl 10):S869]. Some
1.5 g IV pre-op studies show decreased rates of
pre-op wound infection but no
reduction in pneumonia or
empyema
One report showed efficacy of
cephalosporin prophylaxis after
chest tube insertion for chest
trauma (Am Surg 1998;64:617)
GASTROINTESTINAL
Esophageal Cefazolin Cefoxitin 1–2 g IV Likely pathogens:
dilatation or 1–2 g IV pre-op Gram-negative bacilli,
sclerotherapy pre-op Clindamycin 600 mg IV Gram-positive cocci, anaerobes
pre-op Antibiotic prophylaxis common
practice, but proof of efficacy is
lacking
Gastric surgery Cefazolin Clindamycin 600 mg IV Likely pathogens: Enteric
(high risk only) 1–2 g IV + gentamicin 1.7 Gram-negative bacilli,
pre-op mg/kg Gram-positive cocci.
Prophylaxis advocated for high
risk that is usually due to
reduced gastric acidity or
motility—obstruction,
treatment with H -blocker or
2
proton pump inhibitor,
hemorrhage, gastric cancer,
and gastric bypass. Morbid
obesity is also a high risk.
Prophylaxis is usually given for
percutaneous gastrostomy but
efficacy not established
(Gastroenterol 2000;95:3133)
Prophylactic antibiotics are not
indicated for uncomplicated
duodenal ulcer surgery (Ann
Intern Med 1987;107:824)
Biliary tract Cefazolin Gentamicin 1.7 mg/kg Likely pathogens: Enteric
(high risk only) 1–2 g IV pre-op × 1 or q8h × 3 Gram-negative bacilli,
ERCP: See pre-op enterococci, clostridia.
comment Traditionally advocated only for
high risk—acute cholecystitis,
obstructive jaundice,
nonfunctioning gallbladder,
common duct stones, or age
>70 yr. Meta-analysis of 42
studies showed benefit to
high-risk and low-risk patients
(Br J Surg 1990;77:283).
ERCP—one study showed
benefit of 1–3 pipericillin doses
in patients with cholestasis
(CID 1995;20:1236)
Laparoscopic cholecystectomy:
Prophylactic antibiotics are not
indicated (Arch Surg 1999;
65:226; Arch Surg
1999;134:611)
Colorectal Neomycin 1 Cefoxitin 1–2 g IV or Likely pathogens: Enteric
g po and cefotetan 1 g IV or Gram-negative bacilli,
erythromycin Metronidazole 0.5 g IV anaerobes. Most U.S. surgeons
1 g po at 1 plus cefazolin 1–2 g IV use both an oral and a
PM, 2 PM, or metronidazole 0.5 g parenteral prep plus bowel
and 11 PM IV plus gentamicin 1.7 cleansing (Dis Colon Rectum
the day mg/kg IV 1990;33:154). Some advocate
before three subsequent doses of
surgery parenteral agents at 8-hr
(19,18, and intervals. Oral prep with
11 hr metron idazole + neomycin or
pre-op) ± kanamycin is probably as
cefoxitin 2 g effective as erythromycin +
IV or neomycin [RID 1991;13(Suppl
cefotetan 2 10):815)
g IV
Penetrating Cefoxitin Ticarcillin-clavulanate Likely pathogens: Enteric
trauma abdomen 1–2 g IV or Gram-negative bacilli
immediately, piperacillin-tazobactam anaerobes.
then q6h or or combination of an Patients with intestinal
cefotetan aminoglycoside + perforation should receive
1–2 g IV metronidazole these agents for 2–5 days.
q12h or Most studies use suboptimal
clindamycin doses of aminoglycosides [RID
900 mg IV + 1991 13(Suppl 10):S847]. If
gentamicin laparotomy shows no bowel
1.7 mg/kg injury, one dose is adequate
immediately,
then q8h
Appendectomy Cefoxitin Metronidazole 1 g IV Likely pathogens: Enteric
1–2 g IV or clindamycin 600 mg Gram-negative bacilli,
pre-op or IV ± gentamicin 1.7 anaerobes.
cefotetan mg/kg For perforated or gangrenous
1–2 g IV appendix continue regimen for
3–5 days. For nonperforated
appendix 1–4 doses are
adequate [RID 1991; 13(Suppl
10):S813]
Laparotomy, None
lysis of
adhesions,
splenectomy, etc
without GI tract
surgery
GYNECOLOGY AND OBSTETRICS
Vaginal and Cefazolin Doxycycline 200 mg IV Likely pathogens: Enteric
abdominal 1–2 g IV pre-op or clindamycin Gram-negative bacilli
hysterectomy pre-op or 600–900 mg IV pre-op anaerobes, group B
Cefotetan or metronidazole 500 streptococci, enterococcus.
1–2 g IV mg IV pre-op Efficacy of prophylaxis is
pre-op established for vaginal and
or abdominal hysterectomy (Infect
Cefoxitin 1 g Dis Obstet Gynecol
IV pre-op 2000;8:230) Single dose
appears to be as effective as
multiple doses.
Recommendation for radical
hysterectomy is cefazolin 1–2 g
pre-op [RID 1991;(Suppl
10):S821; CID 1995;20:677]
Cesarean Cefazolin 1 g Cefoxitin 2 g IV or Likely pathogens as above.
section (high risk IV after cefotetan 2 g IV or Prophylaxis advocated primarily
only) clamping clindamycin 900 mg IV for emergency procedures in
cord or metronidazole 0.5 g high risk—active labor
IV after clamping cord premature rupture of
membranes, but low-risk
patients may also benefit [RID
1991;13 (Suppl 10):S821;
Drugs 1991;41:19]
Antibiotics should be given
after cord is clamped
Abortion (first First Metronidazole 500 mg Likely pathogens as above.
trimester, high trimester: po × 3 doses in Efficacy shown for first and
risk only) Doxycycline perioperative period second trimester abortions
100 mg po (Drugs 1991;41:19) and
before and high-risk patients—prior PID,
200 mg po gonorrhea, or multiple sex
30 min after partners.
or aqueous For patients with N.
penicillin G 2 gonorrhoeae or C. trachomatis,
mil units IV treat STD with minimum delay
Second in abortion (Am J Obstet
trimester: Gynecol 1984;150:689)
Cefazolin 1 g A meta-analysis showed benefit
IV with prophylaxis for all
therapeutic abortions (Obstet
Gynecol 1996;87:884)
Dilation and Cefazolin 1 g Complicated procedures only
curretage IV pre-op
(see
comment)
Cystocele or None
rectocele repair
Tubal ligation None
HEAD AND NECK
Tonsillectomy None Controlled studies are limited
± adenoidectomy
Rhinoplasty None
Major surgery Clindamycin Cefazolin 1–2 g IV Likely pathogens: S. aureus,
with entry via 600–900 mg pre-op* streptococci, oral anaerobes.
oral cavity or IV ± Cefuroxime 1.5 g IV Efficacy established but
pharynx gentamicin pre-op* preferred agent is unclear
1.7 mg/kg IV (Head Neck 1997;19:188; Ear,
pre-op* Nose Throat J 1997;76:790)
Controlled study showed
cefazolin dose of 2 g superior
to 0.5 g (Ann Surg
1988;207:108). Meta-analysis
showed single dose of
clindamycin alone was most
effective (Plast Reconstr Surg
1991;87:429).
Another study showed
ampicillin-sulbactam (Unasyn)
more effective than clindamycin
(Arch Otolaryngol Head Neck
Surg 1992;118:1159)
ORTHOPEDIC SURGERY
Joint Cefazolin Vancomycin 1 g IV Likely pathogens: S. aureus, S.
replacement 1–2 g IV pre-op infused over 60 epidermidis.
pre-op* min** Efficacy of prophylaxis is
established (Lancet 1996;
347:1133; RID 1991;10:S42)
Cefazolin dose should be 2 g
for knee replacement with
tourniquet (Orthop Rev
1989;18:694).
Antibiotic-impregnated cement
may be effective (Int Orthop
1987;11:241)
Open reduction Cefazolin Vancomycin 1 g IV Likely pathogens: S. aureus; S.
of 1–2 g IV 1 g pre-op infused over 60 epidermidis
fracture/internal q8h × 1–3 min** repeat q12h × Efficacy established for
fixation days (closed 1–3 days (closed hip compound or open fractures
hip fracture) fractures) or 10 days treated with screws, plates, or
or 10 days (open hip fracture) wires and surgical repair of
(open hip closed fractures (Lancet 1996;
fracture) 347:1133; Pharmacother
1991;11:157)
Antibiotics are not indicated for
arthroscopic surgery
(Orthopedics 1997;20:133)
Compound Cefazolin Vancomycin 1 g IV Start treatment immediately
fracture 1–2 g IV q8h q12h** or clindamycin and continue 5–10 days
× 5–10 days 900 mg IV q8h
or nafcillin
1–2 g q4h
Amputation of Cefazolin Clindamycin 600 mg IV Likely pathogens: S. aureus,
leg 1–2 g IV or + gentamicin 1.7 enteric Gram-negative bacilli,
cefoxitin 1–2 mg/kg IV or Clostridia
g or Vancomycin 1 g IV Efficacy of prophylaxis is
cefotetan pre-op infused over 60 established (J Bone Joint Surg
1–2 g IV min** 1985;67:800)
pre-op*
NEUROSURGERY
Cerebrospinal Cefazolin Clindamycin 600 mg IV Likely pathogens: S. aureus, S.
fluid shunt 1–2 g IV pre-op ± second dose epidermidis.
pre-op ± at 4 hr Efficacy of antimicrobials
second dose supported with meta-analysis
at 4 hr. (CID 1993;17:98); agents used
most were
trimethoprim-sulfamethoxazole,
cloxacillin, and cephalosporins
for P48 hr. Some studies fail to
show efficacy (Lancet
1994;344:1547)
Craniotomy Cefazolin Vancomycin 1 g IV Likely pathogens: S. aureus, S.
1–2 g pre-op over 60 min pre-op** epidermidis
Efficacy established (J
Neurosurg 1990;13:383;
Neurosurgery 1994;35:484),
advocated even for low-risk
procedures except where
infection rates are <0.1%
(Neurosurg 1989;24:401).
Preferred drugs do not cross
blood-brain barrier well
presumably because most are
soft tissue infections
(Neurosurg Clin North Am
1992;3:355)
Spinal surgery None Rates of infection are too low
for demonstrable benefit with
lumbar discectomy; infection
rates are higher and use of
antibiotics more common with
fusion, insertion of foreign
material, or prolonged
procedures, but benefit is not
established (Spine
2000;25:2544)
OCULAR Gentamicin, tobramycin, cipro-floxacin, Likely pathogens: S. aureus, S.
olfloxacin or epidermidis, streptococcus,
neomycin-gramicidin-polymyxin B as enteric gram-negative bacilli,
eye drops over 2–24 hr Pseudomonas
Cefazolin 100 mg subconjunctivally Most use eye drops but some
give subconjunctival injection
of cefazolin, cefuroxime,
ceftazidime, vancomycin, or
ciprofloxacin (Mayo Clin Proc
1997;72:149)
Post-operative: 5%
povidone-iodine ophthalmic
soln may be more effective
than topical antibiotics (Am J
Ophthalmol 1995;119:701)
There is no consensus on best
antibiotics or route of
administration (Cornea
1999;18:383)
There is no evidence of efficacy
with procedures that do not
invade the globe
UROLOGY
Prostatectomy Likely pathogens: Enteric
Sterile urine Ciprofloxacin 500 mg po or 400 mg IV Gram-negative bacilli and
(high risk only) or gatifloxacin 400 mg po or IV enterococcus
Prophylaxis is not usually
recommended if pre-op urine is
sterile
Cefazolin sometimes advocated
for open prostatectomy (Urol
Clin North Am 1990;17:595)
Infected urine Continue agent active in vitro or give Sterilization of urine before
single pre-operative dose surgery is preferred
Radical Cefoxitin Clindamycin 600 mg IV pre-op
retropubic 1–2 g IV or
prostectomy or cefotetan
nephrectomy 1–2 g IV
pre-op
Prostatic None
biopsy
Dilation of None
urethra
MISCELLANEOUS
Inguinal hernia Cefazolin 1 g IV pre-op (see comment) One study showed benefit of
repair cefonicid, 1 g IV 30 min pre-op
(NEJM 1990;322:153); sequel
study showed diverse
antibiotics (primarily cefazolin)
in high-risk patients was
beneficial (JID 1992;166:556)
Prophylaxis is not generally
recommended (Med Lett
2001;43:91)
Mastectomy Cefazolin 1 g IV pre-op (see comment) One study showed benefit of
cefonicid for breast surgery
(NEJM 1990;322:153);
Greatest risks were radical
mastectomy and axillary node
dissection:
Most authorities do not
recommend prophylaxis (Med
Lett 2001;43:91)
Traumatic Cefazolin 1–2 g IV q8h Likely pathogens: S. aureus,
wound group A strep, clostridia
* Pre-op usually indicates administration with induction of anesthesia. Intra-op dose often given
with prolonged procedures. Optimal duration is usually unclear, but most studies show a single
dose is adequate. Use of more than a single pre-operative dose is arbitrary and usually
discouraged. When repeat dosing: cefazolin q4h, cefoxitin q4h, cefotetan q8h, clindamycin q8h,
vancomycin q12h. With cefazolin, obese patients should receive 2 g (Surgery 1989;106:750).
** Vancomycin preferred for hospitals with a high rate of wound infections caused by
methicillin-resistant S. aureus or S. epidermidis and for patients with allergy to penicillins or
cephalosporins. Hypotension is a common complication with rapid infusion and may occur even if
infused over 60 min. Treat with Benadryl and further slowing of infusion (J Thorac Cardiovasc
Surg 1992;104:1423). Hospitals should reduce all unnecessary vancomycin use due to concern
for possible promotion of vancomycin-resistant enterococci.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Preventive Treatment > Antimicrobial Prophylaxis in Ambulatory Patients
Antimicrobial Prophylaxis in Ambulatory Patients
(Mayo Clin Proc 2000;75:98.)
A. Prevention of recurrent attacks of rheumatic fever (Recommendation of AHA Committee on
Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council of Cardiovascular Disease in
the Young. JAMA 1992;268:2069.)
1. Indications
Rheumatic carditis: Long-term antibiotic prophylaxis well into adulthood and possibly
for life. This includes continued prophylaxis after valve surgery
Rheumatic fever without carditis: Continue until age of early 20s and 5 yr past last
rheumatic attack. Then reevaluate
2. Regimens
Preferred: Penicillin G benzathine 1.2 mil units IM every 4 wk
Alternatives: Penicillin V 250 mg po twice daily, sulfadiazine 1 g po once daily, or
erythromycin 250 mg po twice daily (allergy to penicillins and sulfonamides)
B. Meningococcal disease
Prevention and Control of Meningococcal Disease (MMWR 2000;29:RR-7.): This document
presents the CDC and the ACIP recommendations regarding control and prevention of
infections caused by N. meningitidis. The two issues of keen importance are recommendations
for meningococcal vaccine and the recommendations for post-exposure prophylaxis.
Recommendations for the use of meningococcal vaccine:
1. Control of meningococcal outbreaks involving serogroup C.
2. Consideration for college freshman, particularly those living in dormitories and resident
halls so that the student and parents can make “individualized, informed decisions”
(MMWR 2000;49:RR-7.) (see below).
3. Routine use in high-risk patients including those with deficiencies in the terminal
complement components, persons who are asplenic and those who are routinely exposed
to N. meningitidis for research or laboratory work
4. Travelers to the “meningitidis belt” in sub-Saharan Africa extending from Senegal to
Ethiopia. Updated information about risk to travelers is available at the CDC:
877-394-8747 and on the Internet at http://www.cdc.gov/travel/.
5. Efficacy is 90% for preventing meningococcal infection but does not appear to reduce
mortality in those who get infected despite vaccination (CID 2002;35:1376.)
Antimicrobial prophylaxis for contacts of patients with meningococcal disease: The
target population should include the following: household members, daycare center contacts,
and anyone exposed to the patient's oral secretions (kissing, mouth-to-mouth resuscitation,
or intubation). The drugs recommended for adults are:
P.134
rifampin (600 mg q12h × 4), ciprofloxacin (500 mg × 1), or ceftriaxone (250 mg IM × 1).
Recommendations for college students: The risk is small and the following
recommendations are made:
1. Students and parents should be informed about meningococcal disease and the benefits
of vaccination, but the ACIP does not recommend this as a routine vaccination strategy.
2. The risk for non-freshman students is about the same as for the general population.
3. The vaccine should be given to students at increased risk for meningococcal disease as
defined above.
4. This policy has been criticized as being vague and inconsistent (JAMA 2001;286:720.)
C. Pneumococcal infection in asplenic patients(Recommendations of American Academy of
Pediatrics Redbook, 22nd Edition, 1991, pp 52–53, 373–378; Sickle Cell Disease Guideline Panel,
AHCPR Pub 93-0562, 1993, pp 39–42)
1. Indications Anatomically and functionally asplenic patients (including those with sickle cell
disease), especially children and adolescents; indications in adult patients are unclear
2. Regimens Pneumococcal, meningococcal, and H. influenzae type B vaccines
Preferred For adults and children >5 yr, penicillin V 250 mg po bid, usually for 2–4 yr in
children
Alternatives Penicillin G benzathine 1.2 mil units IM q4wk
D. Persons with cochlear implants (MMWR 2002;51:931.). This recommendation is based on
reports of meningitis in 53 such patients including pneumococcal meningitis in 16 of the 23
patients with a microbial pathogen detected
E. Prevention of recurrent bacterial UTIs in women (See Fihn SD: NEJM 2003;349:3.)
1. Indications Young to middle-aged nonpregnant women with L2 recurrent infections within 6
mo or L3 recurrent infections in 12 mo
2. Options
Continuous prophylaxis: Indications are two or more symptomatic infections in one six
month period or three or more in twelve months. Controlled trials show single daily doses
of TMP-SMX, TMP, nitrofurantoin or a fluoroquinolone reduces recurrences by 95% (Int J
Antimicrob Agents 2001;17:259.). This is usually given on a trial basis for six months but
has been shown to be effective without resistance (Rev Infect Dis 1991;13:77.).
Postcoital prophylaxis may be used when there is a clear relationship with sex using a
single postcoital dose (Ann Intern Med 2001;135:9.)
P.135
Self-treatment: Most women can accurately diagnose recurrent cystitis and can be given
a three day supply of antibiotics. They should be instructed to get medical attention if the
symptoms persist for 48–72 hours.
3. Regimens
Cost Pregnancy
category
Prophylaxis (6 months)
TMP-SMX ½ SS tab qd or 3×/week $11–28 C
Trimethoprim 100 mg hs × 6 mo $103 C
Nitrofurantoin macrocrystals 50 or 100 mg hs × 6 $166 B
mo
Norfloxacin 200 mg hs $353 C
Postcoital prophylaxis
TMP-SMX ½ SS tab or whole tab $0.30 C
Nitrofurantoin 50 or 100 mg $1–2 B
Ciprofloxacin 250 mg × 1 $9 C
Levofloxacin 250 mg × 1 $7 C
Gatifloxacin 400 mg × 1 $7 C
Intermittent self-treatment
TMP-SMX 1 DS bid × 3 d $2 C
Trimethoprim 100 mg bid × 3 d $23 C
Norfloxacin 400 mg bid × 3 d $23 C
Ciprofloxacin 250 mg bid × 3 d $53 C
Levofloxacin 250 mg qd × 3 d $44 C
Gatifloxacin 400 mg qd × 3 d $21
or 400 mg × 1 $7 C
F. Pertussis prevention (Epidemiol Infect 1998;120:143.)
1. Indications
All household and other close contacts regardless of age and immunization status
2. Regimens
Preferred: Erythromycin 40–50 mg/kg/d (up to 2 g) in four doses × 14 days
Note: Erythromycin estolate may be more effective than the ethylsuccinate or stearate in
eliminating B. pertussis carriage
Alternative: Trimethoprim/sulfamethoxazole 8 mg/40 mg/kg/d
3. Prophylaxis vs infections in bone marrow and organ transplantation Position paper
from Eastern Cooperative Oncology Group (ECOG) (Ann Intern Med 1994;120:143.; NEJM
1998;338:141.)
1. P. carinii prophylaxis: Trimethoprim-sulfamethoxazole (2 DS 2–3× wk) starting after
3
engraftment when absolute neutrophil count is >1000/mm × 4–12 mo or if chronic graft
vs host disease and as long as immunosuppressive treatment given. If allergic to
TMP-SMX: Aerosolized pentamidine (300 mg monthly)
2. Fungal prophylaxis/treatment: Consider prophylaxis with fluconazole or low-dose
amphotericin B. Patients with fever plus
P.136
neutropenia × 3–5 days without response to broad-spectrum antibiotics should receive
amphotericin B (0.5–1.0 mg/kg/d)
3. CMV prophylaxis
a. Allogenic transplant, CMV seronegative donor, and CMV seronegative recipient plus
strict use of CMV negative blood products: No prophylaxis
b. Allogenic transplant with CMV seropositive donor or CMV seropositive recipient:
Ganciclovir 5 days/wk or valganciclovir for prophylaxis or for pre-emptive treatment
(antigenemia or CMV VL) (Bone Marrow Transpl 2000;26:763.; Oncology
2000;14:1701.)
c. Autologous transplant and seronegative recipient: Use CMV negative blood products
or leukocyte-filtered blood products. Valganciclovir prophylaxis (900 mg/d days
10–100) to prevent CMV disease approved for kidney and heart transplant D+R-
4. Cirrhosis with ascites: Prevention of spontaneous bacterial peritonitis
Trimethoprim—sulfamethoxazole 1 DS 5 days/wk (Ann Intern Med 1995;122:595.) or
norfloxacin 400 mg po qd (Hepatology 1990;12:716.) or ciprofloxacin 750 mg q wk
(Hepatology 1995;22:1174.)
5. Primary immune deficiency, such as X-linked agammaglobulinemia. IV gamma-globulin
200 mg/kg monthly
6. Preterm premature rupture of membranes. Intravenous ampicillin (2 g q6h) plus
erythromycin (250 mg IV q6h) × 48 hr followed by oral amoxicillin (250 mg q8h) plus
erythromycin (333 mg po q8h) × 5 days (JAMA 1997;278:990.)
7. Prevention of perinatal group B streptococcal (GBS) disease. CDC recommends
treatment of high-risk patients (MMWR 1996;45(RR-7):1.; MMWR 1998;47:665.)
Risk factors
Risk based on a) history of prior infant who had GBS disease; b) GBS bacteruria
during pregnancy, or c) delivery at <37 wk gestation (ruptured membranes at <37
wk without labor: Culture for GBS and treat positives or treat emperically until
culture is negative)
Vaginal and rectal culture for GBS at 35–37 wk gestation
Culture not done: Intrapartum fever >100.4°F or ruptured membranes L18 hr
Intrapartum prophylaxis IV penicillin G (5 mil units, then 2.5 mil units IV q4h until
delivery). Alternatives: Ampicillin 2 g IV, then 1 g IV q4h or clindamycin 900 mg IV q8h
until delivery or erythromycin 500 mg IV q6h until delivery
8. Varicella (Ann Intern Med 1999;130:922.)
PREVENTION OF VARICELLA IN ADULTS
Intervention Efficacy Cost Candidate/comments
VZIG 625 units IM 90% $400 Immunocompromised persons; pregnant
within 4 days women; efficacy shown in children
Acyclovir* 40–80 80–85% $120 Late presentation or vaccine
mg/kg po within contraindicated; 20% do not seroconvert
7–9 days
First vaccine dose 70–90% $40 Two dose regimen for any vaccine
within 3 days candidate; contraindicated for
immunosuppressed patients and pregnant
women
* Oral acyclovir has the benefit of demonstrated efficacy (Pediatrics 1993;92:219).
Valacyclovir or famciclovir make more sense.
P.137
G. High risk dog or cat bite Amoxicillin-clavulanate (Augmentin) 500 mg po tid× 3–5 days;
penicillin allergy—clindamycin 300 mg po qid or levofloxacin 500 mg po qd × 3–5 d
H. Tuberculosis (see p 168)
I. Malaria (see p 142)
J. Influenza (see pp 196–197)
K. Endocarditis (see p 138)
L. Traveler's diarrhea (see p 141)
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Preventive Treatment > Prevention of Bacterial Endocardits
Prevention of Bacterial Endocardits
Recommendations of the American Heart Association, Infectious Diseases Society of America, American
Dental Association, American Academy of Pediatrics, and American Society for Gastrointestinal
Endoscopy (JAMA 1997;277:1794.; CID 1997;25:1448.; Med Lett 2001;43:98.)
A. CARDIAC CONDITIONS
Cardiac conditions considered at risk (not all inclusive)
a. High Risk
Prosthetic cardiac valve, including bioprosthetic and homograph valves
Prior endocarditis
Complex cyanotic congenital heart disease
Surgically constructed systemic pulmonary shunts
b. Moderate Risk
Rheumatic and other acquired valvular dysfunction (even after valve surgery)
Hypertrophic cardiomyopathy (IHSS)
Mitral valve prolapse with valve regurgitation (patients with mitral valve prolapse
associated with thickening and/or redundancy of the valve may be at increased risk,
especially men age $ 45 yr)
Prophylaxis not recommended
Isolated secundum atrial septal defect
Surgical repair without residual >6 mo of secundum atrial defect, ventricular septal
defect, or patent ductus or arteriosus (without residual beyond 6 mo)
Prior coronary bypass surgery
Mitral valve defect without regurgitation (see above)
Physiologic or functional heart murmurs
Prior rheumatic fever without valve disease
Cardiac pacemakers and implanted defibrillators
Prior Kawasaki's disease without valve dysfunction
B. Procedures
Endocarditis prophylaxis recommended
Dental procedures: Extractions; periodontal procedures—surgery, scaling, root planing,
probing; dental implant, root canal, subgingival placement of antibiotic strips; initial
placement of orthodontic bands; intraligamentary local anesthetic injections, and tooth
cleaning if bleeding is anticipated
Note: Three major studies have challenged the benefit of prophylactic antibiotics before
dental procedures to prevent endoarditis (Arch Intern Med 1992;152:1869.; Lancet
1992;339:135.; and Ann Intern Med 1998;129:761.). Some authorities recommend
prophylaxis only with extractions and gingival surgery and only when the risk is a
prosthetic valve or previous endocarditis (Ann Intern Med 1998;129:829.).
Tonsillectomy and adenoidectomy
Surgical procedures that involve intestinal or respiratory mucosa
Bronchoscopy with a rigid bronchoscope
Sclerotherapy for esophageal varices*
Esophageal dilation*
P.139
Endoscopic retrograde cholangiography with biliary obstruction*
Surgical procedures that involve intestinal mucosa*
Gallbladder surgery*
Cystoscopy
Urethral dilation
Endocarditis prophylaxis not recommended**
Dental procedures: Restorative dentistry, local anesthesia, intracanal endodontic
treatment, placement of rubber dams, suture removal, placement of removable
prosthodontic or orthopedic appliances, fluoride treatments, impressions, orthodontic
appliance adjustment, shedding of primary teeth
Endotracheal intubation
Tympanostomy tube insertion
Bronchoscopy with flexible bronchoscopy with or without biopsy**
Transesophageal echocardiography
Endoscopy of GI tract with or without biopsy**
Cardiac catheterization including balloon angiopathy
Transesophageal echocardiography**
Implanted cardiac pacemakers, defibrillators, and coronary stents
Incision and drainage of prepped sites
Circumcision
Vaginal hysterectomy**
Vaginal delivery**
Cesarean section
Genitourinary surgery in uninfected tissue: urethral catheterization, uterine dilation and
curettage, therapeutic abortion, sterilization procedures, or insertion or removal of
intrauterine device
Recommended Regimens Based on recommendations of the American Heart Association (JAMA
1997;227:1794.; CID 1997;25:1454.; Med Letter 2001;43:98.)
C. Dental, oral and upper respiratory procedures
Standard
Amoxicillin: 2.0 g po 1 hr before procedure
Alternatives: Penicillin V, 2 g po 1 hr pre-procedure; then 1 g 6 hr after first dose
Amoxicillin or penicillin allergy
Clindamycin 600 mg po 1 hr pre-procedure or
Cephalexin or cefadroxil, 2 g po 1 hr pre-procedure or
Azithromycin or clarithromycin, 500 mg po 1 hr pre-procedure
Cannot take oral medications
Ampicillin 2.0 g IM or IV 30 min pre-procedure
Amoxicillin or penicillin allergy and unable to take oral medicines
Clindamycin 600 mg IV within 30 min pre-procedure or
Cefazolin 1 g IM or IV within 30 min pre-procedure
P.140
D. Genitourinary or gastrointestinal procedures
High risk*: Ampicillin, 2 g IM or IV plus gentamicin 1.5 mg/kg IM or IV × 30 min of start-ing
procedure; 6 hr later ampicillin 1 g IV or amoxicillin 1 g po
High risk plus penicillin allergy: Vancomycin 1 g IV over 1–2 hr plus gentamicin 1.5 mg// kg
IV or IM (J 120 mg) complete infusion within 30 min of starting procedure
Moderate risk: Amoxicillin, 2 g po 1 hr pre-procedure or ampicillin 2.0 g IM or IV within 30
min of starting procedure
Moderate risk plus penicillin allergy: Vancomycin 1 g IV over 1–2 hr; complete infusion within
30 min of starting the procedure
E. Miscellaneous issues (CID 1997;25:1454.)
Target organisms: Upper respiratory tract procedures—S. viridans; GI and GU procedures—E.
faecalis
Patients already receiving an antibiotic: Pick from a different class. Thus, if receiving a
beta-lactam, use clindamycin, clarithromycin, or axithromycin
Anticoagulated patients: Avoid IM injections of antibiotics
Procedures involving infected tissue: Treat cause of infection
Cardiac surgery candidates: Antibiotic prophylaxis advocated, usually a first generation
cephalosporin or vancomycin
Cardiac transplant recipients: Experience is very limited, but most treat as the moderate-risk
category
Endocarditis experience: Most cases of strep viridans endocarditis have not followed dental
procedures; most procedure related endocarditis occurs within 2 wk of the procedure
Effectiveness of prophylaxis: Efficacy of prophylaxis has never been shown (CID 1999;29:1.).
Nevertheless, most infectious disease-trained physi-cians follow these guidelines, mainly
because of the liability risk rather than the supporting science (CID 2002;34:1621.).
F. GProphylaxis for Dental, Gastrointestinal, or Genitourinary Procedures in Patients with
Prosthetic Joints
1. Analysis by Gillespie showed no evidence of benefit (Infect Dis Clin North Am 1990;4:465.).
2. Review in CID 1995;20:1420.: Patients with prosthetic joints do not require prophylaxis for
dental, gastrointestinal, or genitourinary procedures; possible exceptions are long procedures,
surgery in infected area (e.g., periodontal disease), and other procedures with a high risk of
bacteremia (Med Lett 1995;37:79.; J Bone Joint Surg 1996;78-A:1755.).
3. Updated statement of American Academy of Orthopedic Surgeons and American Dental
Association (J Am Dent Assoc 1997;128:1004.): Prophylaxis is not indicated for dental
patients with pins, plates, and screws, and it is not routinely indicated for most dental
patients with total joint replacements. However, it is advisable to consider prophylaxis in a
small number of patients who may be at potential increased risk of hematogenous total joint
infection.
Footnotes
*Prophylaxis is recommended for high-risk patients and is considered optional for medium-risk patients.
**Prophylaxis is optional for high-risk patients.
*High risk: Prosthetic valve, history of endocarditis or surgically constructed systemic shunts or
conduits or complex cyanotic congenital heart disease.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Preventive Treatment > Prevention of Diseases Associated with Travel
Prevention of Diseases Associated with Travel
A. International Travel Directory: CDC Travel Hotline and Fax Information Service
Travel advise 877-394-8747 24 hr/d voice mail
Traveler's Health FAX 888-232-3299 24 hr/d automated FAX service
service (patients and providers)
Travel information http://www.cdc.gov/ Select “Traveler's Health”
Malaria—Prevention and 770-488-7100
management
Travel—Emergency 770-488-7100 24 hr/d service
consultation
CDC Parasitic Diseases Drug 404-639-3670 Drugs for special use
Service
B. TRAVELER'S DIARRHEA (Adapted from Med Lett 2002;44:33.; NEJM 1993;328:1821.; CID
1993;16:616.; Infect Dis Clin North Am 1998;12:301.)
1. Risk
High-risk areas (incidence 20–50%): Developing countries of Latin America, Africa,
Middle East, and Asia
Intermediate risk: Southern Europe and some Caribbean islands
Low risk: Canada, Northern Europe, Australia, New Zealand, United States
2. Agents
E. coli (enterotoxigenic—most common, enteroinvasive, enteroadherent)
Shigella
Campylobacter jejuni
Aeromonas (especially Thailand)
Plesiomonas shigelloides
Salmonella sp
Non-cholera vibrios (coastal Asia)
Rotavirus (Mexico)
Norovirus (cruise ships)
Giardia (North America and Russia)
Cryptosporidium (Russia)
E. histolytica (Rare)
3. Prevention
Safe foods: Food served fresh and steaming hot; dry food (e.g., bread); hyperosmolar
food (e.g., jellies, acidic fruits); fruit that is self-peeled; alcoholic beverages; carbonated
beverages; water that is filtered and iodinized
Avoid: Salads, cold foods, sauces, cream-filled desserts, raw seafood, raw meat, soft
cheeses, tapwater, ice
4. Antimicrobial prophylaxis (CID 2000;31:1079.)
a. Candidates for prophylaxis Travelers with important underlying health problem (active
IBD, type I diabetes, elderly person with heart disease, AIDS) Trip will be ruined if
traveler has brief illness Traveler requests chemoprophylaxis and/or is unwilling to follow
dietary instructions (consider bismuth subsalicylate)
b. Recommended regimens for selected patients (see a)
Regimen Cost/d Comment
Bismuth subsalicylate $3.40 Less effective than antimicrobials; few side
2–262 mg tabs qid* effects*
Fluoroquinolones (once daily)
Norfloxacin 400 mg/d $3.80 Fluoroquinolones are most predictably
Ciprofloxacin 500 mg/d $4.51 effective drugs; concern is abuse, resistance,
Ofloxacin 300 mg/d $4.92 cost, and side effects
Levofloxacin 500 mg/d $8.52
* Pepto-Bismol turns tongue and stools black, sometimes causes tinnitis, may reduce
absorption of doxycycline (sometimes given for malaria prophylaxis), and should not
be taken with salicylates or anticoagulants and should not be taken >3 wk.
P.142
5. Treatment of traveler's diarrhea (CID 2000;31:1079.)a and CDC
(http://www.cdc.gov/travel accessed 8/1/03)
Clinical feature Treatment options
Mild (or moderate diarrhea: N3 No treatment or loperamide 4 mg, then 2 with
loose stools/8 hrs with no loose each loose stool up to 16 mg/d or bismuth
stools/d) Fever or blood subsalicylate 2–262 mg tabs qid
Severe: Diarrhea is severe (N 3 Loperamide × fluoroquinolone b
stools/8 hrs), associated with 1. Norfloxacin 400 mg po bid × 3 d
fever or bloody stools 2. Ciprofloxacin 500 mg po bid × 3 d
3. Levofloxacin 500 mg qd × 3 d
Pregnancy: Loperamide + azithromycin 1000 mg
× 1 or 500 mg qd × 3 d
a
The 3-day course of treatment appears superior to single dose treatment for
salmonellosis (AAC 1989;33:1101; JID 1992;165:1557) and for shigellosis due to S.
dysenteriae type 1 (Ann Intern Med 1992;117:727). A study of shigellosis in Thailand
failed to show loperamide is contraindicated when given with a quinolone (Ann Intern
Med 1985;102:582).
b
Rates of C. jejuni fluoroquinolone resistance are 20–25% in U.S., 60–80% in
Taiwan, Thailand, and Spain (Emerg Infect Dis 2001;7:24).
6. Oral rehydration: Potable fruit juice, caffeine-free soft drinks, salted crackers. Severe
symptoms: WHO Oral Rehydration Salts. Ingredients/L water: NaCl 3.5 g (3/4 tsp), trisodium
citrate 2.9 g (could use 1 tsp baking soda) and glucose 20 g, KCl 1.5 g (1 cup orange juice or
bananas). Packets of oral rehydration salts are available from Cera Products, Jessup, MD
(888-237-2598) and Jianas Bros, Kansas City, MO (816-421-2880)
7. Antibiotic resistance: Rate of resistance by Shigella, Salmonella, and E. coli is 50–90% for
tetracycline and 35–76% for TMP-SMX (Infect Dis Clin North Am 6:333, 1992). Quinolone
resistance is increasing. About 50% of campylobacter strains in Thailand are resistant to
ciprofloxacin (J Trav Med 1994;1:119.)
C. MALARIA PROPHYLAXIS (CDC Health Information for International Travel 1996–97, U.S.
Department of Health and Human Services, pp 128–139; Med Lett 2002;44:33.; MMWR
1997;46:55.)
CDC Malaria Hotline: Recommendations for prevention and case management—770-488-7788
(8 AM–4:30 PM EST) Emergency hotline for treatment guidance after hours—770-488-7100;
http://www.cdc.gov/
P.143
Risk areas: Most areas of Central and South America, Hispaniola, sub-Saharan Africa, the
Indian subcontinent, Southeast Asia, the Middle East, and Oceania. During 1998 there were
1,227 reported cases of malaria in the U.S. including 43% P. falciparum, 38% P. vivax, 3.5%
P. malariae, and 2.1% P. ovale (MMWR 2001;50:55–5.). Areas of acquisition included Africa
(60%), Asia (20%), Central America and Caribbean (19%). Of the 1,227 cases at least 73%
were U.S. citizens who did not receive malaria prophylaxis. There were 4 deaths attributed to
malaria for a mortality rate of 0.3%.
Drug resistance of P. falciparum to chloroquine (CRPF) is probable or confirmed in all
countries with P. falciparum except Central America west of the Panama Canal Zone, Haiti, the
Dominican Republic, Egypt, and most of the Middle East. Resistance to both Fansidar and
chloroquine is widespread in Thailand, Myanmar (formerly Burma), Cambodia, and the Amazon
basin of South America and has been reported in sub-Saharan Africa. Resistance to mefloquine
has been reported primarily in Thailand. There is no documented resistance to tetracycline.
Advice to travelers (Med Lett 2002;44:33.)
1. Personal protection:
a. Transmission is most common between dusk and dawn.
b. Precautions include remaining in well-screened areas and using mosquito nets,
clothing that covers most of the body, insect repellent containing DEET on exposed
areas, and pyrethroid containing insect spray for environs and clothing. Permethrin
may also be sprayed on clothing.
Drugs to Prevent Malaria in Areas of Chloroquine-resistant P. falciparum (adapted from
Med Lett 2000;42:9)
*
Countries with a Risk of Malaria (Reprinted from Med Lett 2002;44:33)
AFRICA
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Central African Republic
Chad
Comoros
Congo
Côte d'lvoire
Democratic Republic of the Congo (formerly Zaire)
Djiubouti
Equitorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
**Mauritius
Mayotte (French territorial collectivity)
Mozambique
Namibia
Niger
Nigeria
Rwanda
São Tomé and Principe
Senegal
Sierra Leone
Somalia
**South Africa
Sudan
Swaziland
Tanzania
Togo
Uganda
Zambia
Zimbabwe
AMERICAS
**Argentina
**Belize
**Bolivia
Brazil
**Colombia
**Costa Rica
**Dominican Republic
Ecuador
**El Salvador
French Guiana
**Guatemala
**Guyana
Haiti
**Honduras
**Mexico
Nicaragua
**Panama
**Paraguay
**Peru
**Suriname
**Venezuela
ASIA
Afghanistan
Armenia
**Azerbaijan
Bangladesh
**Bhutan
Cambodia
**China, People's Republic
Georgia
India
Indonesia
**Iran
Iraq
**Korea
Laos
Malaysia
**Myanmar
**Nepal
**Oman
Pakistan
**Philippines
**Saudi Arabia
Sri Lanka
**Syria
Tajikistan
**Thailand
Turkey
**Turkmenistan
**United Arab Emirates
**Viet Nam
Yemen
OCEANIA
Papua New Guinea
Solomon Islands
Vanuatu
*Only includes countries for which prophylaxis is recommended. For more information: The
Medical Letter's Advice for Travelers CD-ROM or CDC at 1-888-232-3228.
**No malaria in urban areas.
Distribution of Malaria and Chloroquine-resistant Plasmodium falciparum, 1997
Figure. No caption available
CDC Health Information for International Travel 1999-2000. Washington DC: Government Printing
Office, 2001:104
DRUGS USED IN PRESUMPTIVE TREATMENT OF MALARIA
Drug Adult dose
Pyrimethamine-sulfadoxine (Fansidar) 3 tabs po, single dose
Atovaquone + proguanil (Malarone) 4 tabs as single daily dose × 3
P.144
P.145
D. VACCINES (See pp 93–96 for complete listing)
1. Hepatitis A:
Prevalence of antibody: Age related <10% in preadolescent and 75% in elderly
Indication: Susceptibility (anti-HAV negative) and travel to area where HAV endemicity is
high or moderate
2. Hepatitis B:
Prevalence of antibody: Risk related general U.S. adult population 3% in caucasians, 14%
in African Americans, and 35–80% in gay men. See p 264–266.
P.146
Indication: Susceptibility (anti-HBcAg negative) and travel to area where HBV endemicity
is high or moderate plus: visits frequent, long stays, medical or dental care, or
unprotected sex with residents
Prevalence of HAV and HBV (Med Letter 2001;43:67.)
HAV HBV prevalence
prevalence
U.S., Canada, Australia, Japan, Low Low
northern and western Europe
Caribbean Moderate Moderate; high in Haiti and
Dominican Republic
Central America High
South America High High in Amazon River basin
Eastern and southern Europe and Moderate Moderate
Russia
Middle East High Moderate
Africa High Moderate–high
Asia (except Japan) High Moderate–high
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
>Table ofContents>NonbacterialInfections>TreatmentofFungalInfections
Treatment of Fungal Infections
Adapted from IDSA Recommendation 1999; CID 2000;30:652.; nonbacterial infections consultantsof the Medical Letter (1997;39:86), and other sources (CID 1998;26:1383.; AAC
1998;42:606.)
Fungus Form Preferred treatment Alternative agent(s), comment
Aspergillus Aspergilloma (fungus ball) Massive hemoptysis—surgical resection with perioperative
amphotericin; progressive invasive disease—amphotericin B IV,
total dose 30–40 mg/kg; intracavitary amphotericin B (Thorax
1993;48:928). Surgical resection: High rates of complications
(Ann Thorac Surg 1992;54:1159)
Bronchopulmonary Corticosteroids Short courses for exacerbations
Indolent, nonmeningeal Itraconazole*** 400 mg/d po Itraconazole*** is less effective with sinus or CNS involvement,
or disseminated disease (Arch Intern Med 1997;157:1857)
Sinusitis: Acute invasive Surgery Immunocompetent: Surgery alone often successful (RID
1990;12:1147)
Sinusitis: Allergic Surgical drainage (Medicine
1988;67:231)
CNS Surgery ± amphotericin B + 5-FC Case reports of success with amphotercin B lipid complex,
itraconazole, and voriconazole (CID 1995;21:1485)
Invasive pulmonary or extrapulmonary Voriconazole 6 mg/kg IV × 2 doses Caspofungin 70 mg IV, then 50 mg/d IV
day 1, then 4 mg/kg IV bid for D 7 Experimental: Voriconazole
days, then 200 mg po bid (see Surgery successful in some cases (J Clin Oncol 1997;15:139)
comment) (NEJM 2002;347:408) Alternatives: Amphotericin B 1.0–1.5 mg/kg/d IV or a lipid
formulation. Note: The IDSA guidelines rank amphotericin B as
preferred for invasive asper- gillosis, but a more recent clinical
trial of amphotericin B (1–1.5 mg/kg/d) versus voriconazole
showed voriconazole was significantly better in clinical outcome,
survival, and adverse events (NEJM 2002;347:408)
Itraconazole*** 600 mg/d po × 4 days, then 200 mg bid; failure
rate highest in extrapulmonary disease and relapse rate high in
immunosuppressed patients (Am J Med 1994;97:135; Arch
Intern Med 1997;157:1857)
Flucytosine (100 mg/kg/d po) or rifampin (600 mg/d po) or
azoles sometimes added, but efficacy is not established and
antagonism is seen in animal models
Blastomyces Severe pulmonary Amphotericin B when > 500 mg Total amphotericin B dose: 1.5–2.5 g or switch to itraconazole
0.7–1 mg/kg/d amphotericin B and stable
Mild to moderate pulmonary Itraconazole*** 200–400 mg/d po Alternative: Ketoconazole 400–800 mg/d, fluconazole 400–800
for D6 mo mg/d, amphotericin B 0.5–0.7 mg/kg IV*, total dose 20–40
mg/kg
Disseminated (immunocompetent Itraconazole*** 200–400 mg/d × Alternative: Ketoconazole 400–800 mg/d or fluconazole
without CNS involvement) D6 mo po or amphotericin B 0.7–1 400–800 mg/d Osteomyelitis: Treat D 1 yr
mg/kg/d Progression on azoles or seriously ill: Amphotericin B to total
dose 1.5–2.5 g
Disseminated (immunocompromised or Amphotericin B 0.7–1.0 mg/kg/d Some patients may be switched to fluconazole (800 mg/d) when
CNS involvement) for total dose 2 g clinically stable
Candida Localized-mucocutaneous Oral (thrush) Clotrimazole troche 10 mg troches Fluconazole is preferred by Medical Letter consultants
5×/days × 7–14 days Fluconazole (1997;39:86); AIDS: Continue any of above regimens
Onychomycosis Itraconazole 200 mg bid × 1 wk Alternative: Terbinafine is alternative, but experience is
repeated monthly × 3–4 mo inconsistent
(AAC 1998;42:1057; AAC 1987;31:1558)
Esophageal Fluconazole 100 mg po qd (up to Patients with AIDS may require continuous suppression with
400 mg/d) × 14–21 days 100–200 mg/d
Alternatives: Ketoconazole 200 mg po bid × 2–3 wk,
itraconazole***
200 mg po qd × 2–3 wk, or amphotericin B 0.3–0.7 mg/kg/d
Biliary Amphotericin B or fluconazole Must establish functional drainage
Local installation of antifungals is unnecessary
Peritonitis Amphotericin B or fluconazole; Catheter-associated: Must remove catheter. Catheter
Urinary usually 2–3 wk instillations of ampho-tericin B are painful and should be
Fluconazole 200 mg po qd × 7–14 avoided
days Non-catheter associated: Treat 2–3 wk
Asymptomatic candiduria rarely requires therapy
Main indications to treat: Possible disseminated candidiasis,
symptomatic UTI, neutropenia, renal transplant, or candidate for
urologic manipulation
Bladder installations of amphotericin B (50 mg/mL) via closed
triple lumen catheter × 5 days(rarely indicated because of high
frequency of relapse)
Alternative: Amphotericin B 0.7–1.0 mg/kg/d × 1–7 days or
flucytosine 25 mg/kg qid (must have normal renal function)
Bloodstream (septicemia) Fluconazole 400 mg/d po or IV Remove or change IV lines. Line sepsis: Remove line and treat
(see comment: voriconazole is the with fluconazole 400 mg/d IV (NEJM 1994;331:1325)
preferred azole for Voriconazole is active in vitro vs 99% of C. albicans, C.
fluconazole–resistant Candida) parapsilosis, C. tropicalis, and C. krusei (Antimicrob Ag
Amphotericin B IV D Chemother 2002;46:1647)
0.7–mg/kg/d*; total dose: 3–10 Amphotericin B is more predictably active versus non-albicans
mg/kg Candida sp, especially C. krusei
Caspofungin (see comment) Caspofungin 70 mg IV, then 50 mg/d IV appears equal to
amphotericin and is less toxic (NEJM 2002;347:2020)
Treat until negative blood cultures × 2 wk and resolution of
signs and symptoms
Disseminated or metastatic Amphotericin B 0.7–1.0 mg/kg/d*; Indications for flucytosine: Normal marrow and renal function
(deep organ infection) total dose 20–40 mg/kg IV or clinical deterioration with amphotericin B
Alternative: Fluconazole 400 mg/day po or IV (best results with
peritonitis, UTI, and hepatosplenic abscesses); may give up to
800 mg/d; caspofungin IV 70 mg, then 50 mg/d
Voriconazole 6 mg/kg IV ×2 on day 1, then 4 mg/kg IV bid
(especially for fluconazole-resistant strains
Hepatosplenic candidiasis Fluconazole 6 mg/kg/d Treat until there is resolution of lesions
(stable patient) Amphotericin preferred for acutely ill patients and those with

Pulmonary—severe or progressive Fluconazole 400–800 mg/d po Alternatives: ketoconazole 400–600 mg/d × 6–18 mo po
infiltrate Amphotericin B 0.5–0.7 mg/kg/d Itraconazole*** 400 mg/d × 6–18 mo po
IV*; total dose: 7–20 mg/kg IV
Diffuse pneumonia Amphotericin B 0.5–0.7 mg/kg/d Amphotericin several weeks followed by azole for D 1 yr
Evaluate for extrapulmonary disease; presume immunodeficiency
Nodule—asymptomatic No therapy If resected, no antifungal treatment is indicated unless
immunosuppressed
Cavity—asymptomatic Observation Consider resection if cavity persists D 1–2 yr, progresses in
size, or is near the pleura
Cavity—symptomatic Azole therapy or resection Fluconazole 400 mg/d, ketoconazole 400 mg/d, or
itraconazole*** 400 mg/d
Cavity—rupture into pleura Lobectomy or decortication + May give amphotericin B or azole 1 wk before surgery
amphotericin B or azole Chest tube drainage without surgery may be adequate
Cavity—chronic fibrocavitary Azole D 1 yr Azoles—above doses
Failure to respond—switch azoles, increase dose of fluconazole,
use amphotericin B or resect
Disseminated Itraconazole 200 mg bid Alternatives: Fluconazole 400–600 mg/d or ketoconazole 400
(nonmeningeal) mg/d × 6–18 mo or longer or amophotericin B
Itraconazole appears superior to fluconazole in response rates
and relapse rates (Ann Intern Med 2001;133:676)
May require surgical debridement
Patients with fulminant disease should receive amphotericin B;
indolent lesions may be treated with azoles. AIDS patients need
lifelong treatment with azoles
Meningitis Fluconazole 400–800 mg/d po Alternative: Fluconazole 800 mg/d + intrathecal amphotericin B
lifelong 0.01–1.5 mg 1–7 ×/wk, itraconazole 400–600 mg/d or
intrathecal amphotericin usually used for fluconazole failures
Hydrocephalitis requires a shunt for decompression and does not
indicate treatment failure
Cryptococcus Pulmonary—stable and Usually none Exclude extrapulmonary disease: Culture blood, urine, and CSF;
immunocompetent follow-up x-rays q 1–2 mo × 1 yr
Pulmonary (mild moderate) Fluconazole 200–400 mg/d × 6–12 Must do LP to exclude meningitis
mo Fluconazole usually preferred
Itraconazole 200–400 mg/d × 6–12
mo
Amphotericin B 0.5–1.0 mg/kg/d,
1–2 g
Pulmonary—progressive and/or Amphotericin B 0.5–1.0 mg/kg/d Alternative for pulmonary or extrapulmonary nonmeningeal
immuno-suppressed host IV*; total dose 1–2 g disease that is mild to moderate: Fluconazole 200–400 mg/d or
itraconazole 200–400 mg/d × 6–12 mo in immunocompetent
patients. AIDS patients—treatment is lifelong unless CD4 count
increases to > 200/mm3
Extrapulmonary non-meningeal, Fluconazole 200–400 mg/d × 3–12 Duration fluconazole: Asymptomatic 3–6 mo
non-HIV associated mo mild–moderate disease 6–12 mo
Alternative: Itraconazole 200–400 mg/d × 6–12 mo or
amphotericin B 0.4–0.7 mg/kg/d, total dose 1–2 g
Cryptococcemia (positive Crypt Ag Azole therapy Must do LP to exclude meningitis
assay) or positive urine cult Amphotericin B 0.7–1.0 mg/kg/d + Amphotericin B 0.7–1.0 mg/kg/d ± flucytosine 100 mg/kg/d ×
Meningitis—immunocompetent flucytosine 100 mg/kg/d × 2 wk, 6–10 wk
then fluconazole 400 mg/d × D
10wk
Meningitis—AIDS patients Amphotericin B 0.7–1 mg/kg/d + Alternative: Fluconazole 400–800 mg ± flucytosine 100–150
flucytosine 100 mg/kg/d × 14 days mg/kg/d × 6 wk then fluconazole 200 mg/d (considered safe for
then fluconazole 400 mg/id × 8 initial treatment only if mental status is normal)
wk, then 200 mg/d Maintenance treatment for life with fluconazole (200 mg/d)
required for all
AIDS patients unless CD4 count increases > 200
Fluconazole may be used in dose up to 800 mg/d (JID
1994;170:238)
Histoplasma Pulmonary—acute ± erythema Usually none Focal infiltrates: Consider itraconazole 200 mg/d × 6–12 wk in
nodosum patients
who fail to improve after 1 mo
Severe disease: Amphotericin B 0.7 mg/kg/d for total course of
up to 35 mg/kg × prednisone 60 mg/d × 12 wk posthospital
discharge—itraconazole 200–400 mg/d to complete 12 wk of
therapy
Pulmonary—chronic Amphotericin B, then Alternatives: Ketoconazole, 200–800 mg/d × 12–24 mo or
itraconazole*** po 200–400 mg/d amphotericin B 0.7 mg/kg/d IV*; total dose: 30–40 mg/kg;
× 12–24 mo amphotericin B is preferred for patients who are seriously ill,
(severe disease) immunosuppressed, or fail oral treatment
Itraconazole × 12–24 mo Treat until clinical symptoms and lab tests are negative
(mild–moderate disease) including ESR and histoplasma antigen assay, usually >12 mo
amphotericin B 0.5–0.6 mg/kg/d IV*; total dose: 30–40 mg/kg
Surgery for intractable hemoptysis despite medical treatment
Disseminated—immuno-competent, Amphotericin B until stable, then Alternatives: Amphotericin 0.7–1.0 mg/kg/d IV* or
without CNS involvement itraconazole*** 200–400 mg/d × ketoconazole 200–400 mg/d × 6–12 mo or fluconazole 200–400
6–18 mo mg/d × 6–18 mo
(severe disease) Treat until histoplasma antigen assays in blood and urine are >
Itraconazole 200–400 mg/d × 6–18 4 units, usually > 1 yr
mo Intraconazole is preferred for patients with mild or moderately
(mild–mod disease) severe disease and for patients who have responded to
amphotericin B (CID 1996;23:996; Am J Med 1992;93:489)
Disseminated—AIDS Amphotericin B 0.7–1.0 Patients with severe illness should receive amphotericin B; AIDS
mg/kg/d IV*; then itraconazole patients should receive lifelong maintenance with
400 mg/d itraconazole***, 200–400 mg po qd (Ann Intern Med
Itraconazole*** 600 mg/d × 3 1993;118:610; Am J Med 1995;98:336)
days, then 200 mg po bid × 12 wk Fluconazole (800 mg/d) is less effective, and ketoconazole
should not be used (Am J Med 1997;103:223; Medicine
1990;69:361)
Maintenance therapy: Itraconazole 200–400 mg/d for life or
amphotericin B, 50 mg/wk. Immune reconstitution may alter this
recommendation
Meningitis Amphotericin B 0.7–1 mg/kg/d to Relapse on amphotericin B: Intrathecal or intraventricular
complete 35 mg/kg then amphotericin B
fluconazole 800 mg/d for Itraconazole is more active in vitro but fails to penetrate CNS
additional 12 mo
Pericarditis Non-steroidal anti-inflammatory Usually no azole therapy except with corticosteroid treatment:
agents × 2–12 wk or Itraconazole 200–400 mg/d × 12 wk
corticosteriods × 1–2 wk if
hemodynamic compromise
Percutaneous or surgical
drainage for severe
hemo-dynamic compromise
Fibrosing mediastinitis Trial with itraconazole 200–400 Progressive obstruction vena cava, airways, heart, esophagus:
mg/d Surgical mortality is 20% (Medicine 1990;69:361)
Intravascular stents for vascular Corticosteroids are not helpful (Medicine 1988;67:295)
obstruction Itraconazole is advocated only if work-up fails to distinguish
granulomatous and fibrosing mediastinitis, ESR increased, or CF
titer > 1:32
Granulomatous Amphotericin B, then itraconazole Less severe cases can be treated with itraconazole alone × 6–12
mediastinitis 200–400 mg/d × 6–12 mo ± mo Use steroids for airway obstruction
prednisone 40–80 mg/d × 2 wk Surgery recommended if symptoms of obstruction persist despite
antifungal therapy
Ocular Laser photocoagulation Appears to be immune-mediated disease
Intraocular steroids
Retinal irradiation
Malassezia furfur Fungemia Amphotericin B 1 mg/kg/d May require removal of IV line
Paracoccidioides Pulmonary or mucocutaneous Itraconazole*** po 100 mg/d × 6 Alternatives: Amphotericin B 0.4–0.5 mg/kg/d IV*; total dose:
mo 30–35 mg/kg (preferred for severe disease); sulfonamides (such
as sulfadiazine, 4–6 g/d po × 6–12 mo) or ketoconazole
200–400 mg/d po × 6–12 mo
Phycomycetes Pulmonary and extra-pulmonary Amphotericin B IV 1.0–1.5 mg/kg/d Rhinocerebral: Surgical debridement required.
Absidia IV*; total dose: 30–40 mg/kg
Mucor
(Mucormycosis)
Rhizopus
Penicillium Disseminated disease Amphotericin B, then itraconazole Endemic in Thailand, China, Vietnam, Hong Kong, Indonesia
marneffei involving skin, marrow, nodes, lung, ±
liver
Pseudoallescheria Sinusitis, endophthalmitis Ketoconazole 400–800 mg/d po × Alternative: Miconazole 600 mg IV q8h
boydii 1–12 mo
Itraconazole*** 200 mg bid po ×
1–12 mo
Voriconazole 6 mg/kg bid × 1
day, then 4 mg/kg bid IV bid, then
200 mg po/d
Sporothrix Lymphocutaneous Itraconazole*** 100–200 Alternatives: Potassium iodide (1 g/mL) 5 drops tid increasing
mg/d po × 3–6 mo to 40–50 gtts tid × 3–6 mo
Itraconazole is preferred; fluconazole (400 mg/d × 6 mo) should
be used only with intolerance to itraconazole. SSKI has side
effects and is inconvenient but is less expensive
Local hyperthermia × 2–3 mo
Disseminated Amphotericin B 0.5 mg/kg/d IV* Alternative: Itraconazole 200 mg po bid
Amphotericin is preferred for CNS, severe disseminated disease,
and itraconazole failures
Pulmonary Amphotericin B until clinically Focal disease with cavity; cure rates with antifungal agents are
stable, then itraconazole*** 200 <50%; surgical resection often required
mg bid po
Meningeal Amphotericin B, 1–2 g Life-long maintenance with itraconazole 200 mg bid or
fluconazole D800 mg qd
Osteoarticular Itraconazole 200 mg bid × 12 mo Alternative: Amphotericin B, 1–2 g or fluconazole 800 mg/d ×
12 mo
Pregnancy Amphotericin B Exception is local hyperthermia for lymphadenitis
(Sporotrichosis)
AIDS Amphotericin B 1–2 g, then Itraconazole may be used for less serious disease and for
itraconazole life-long maintenance after treatment with amphotericin B
* Amphotericin B: Lipid formulations compared with amphotericin B appear to be equally effective, have the disadvantage of high cost (10- to 20-fold greater), and the
advantage of reduced nephrotoxicity and reduced frequency and severity of infusion-related adverse effects. See summary on p 159.
** Flucytosine levels should be 25–50 Og/mL; some advocate maximum daily dose of 100 mg/kg/d and reduced dose (50–75 mg/kg/d) if levels are unavailable. Follow
platelet count and WBC daily (CID 1993;16:1).
*** Itraconazole: Usual dose regimen is 200 mg tid (loading dose) × 3 days, then 200 mg bid for severe infections. Itraconazole SHOULD be given with food, and Coca-Cola
or other acid drink may be given to improve absorption. Bioavailability may be improved with liquid formulation which should be given on an empty stomach. Blood levels
should be monitored in any recipient of itraconazole given for a serious infection for a prolonged period, especially if there is concern about absorption or compliance.
Levels measured after 1 wk should be D 1 Og/mL; usual therapeutic levels are 1–10 Og/mL. Fluconazole has advantages of more predictable absorption, reduced drug
interactions, and good CNS penetration.
P.148
P.149
P.150
P.151
P.152
P.153
P.154
P.155
P.156
P.157
P.158
COMPARISON OF ANTIFUNGAL AGENTS
Antifungal agents Amphotericin Flucytosine Ketoconazole Fluconazole Itraconazole Caspofungin (Cancidas)
(Fungizone) (Ancobon) (Nizoral) (Diflucan) (Sporanox)
Oral bioavail-ability Nil >80% 75% >80% >70% Nil
Effect of gastric — — Reduced — Reduced —
achlorhydria absorption absorption
Serum half-life 15 days 3–6 hr 6–10 hr 24–30 hr 30–45 hr 9–11 hr
Half-life—anuria 15 days 70 hr 6–10 hr 100 hr 30–45 hr 9–11 hr
Urine level 3% 80% <2–4% 80% <1% 1%
(active agent)
CSF levels 3% 75% <10% 70–90% <1% ?
(% serum)
Usual dose/d 25–50 mg IV/day 1500–2500 mg po 200–400 mg 100–200 mg IV or 200–400 mg IV or 70 mg IV, then 50 mg/d IV
q6h po/day po/day po/day $360/50mg
Cost (average $11/50 mg Ampho $100/7 g po $4/200 mg po $13/200 mg po $8/200 mg po $360/50 mg
wholesale)/d $480–1200/3 g lipid $133/400 mg IV $177/250 mg IV
preps.
COMPARISON OF AMPHOTERICIN PREPARATIONS LIPID FORMULATIONS OF AMPHOTERICIN B: IDSA GUIDELINES
(CID 2000;30:653.; CID 2003;37:415.)
Potential advantages compared with conventional amphotericin B: Increased daily dose (up to 10-fold); high tissue concentration, especially in RE system (lungs, spleen,
liver), reduced infusion related reactions (especially AmBisome), substantial decrease in nephrotoxicity
Disadvantages compared with conventional amphotericin B: the lipid-based formulations are much more expensive: Amphotericin B: $11/d; AmBisome: $800–$1500/d;
Abelcet: $640/d; Amphotec: $480–640/d (average wholesale price, 2003)
Indications (See IDSA Guidelines, CID 2000;30:653.)
1. Patients receiving amphotericin B who develop renal dysfunction (creatinine>2.5 mg/mL), severe infusion related adverse events or disease progression despite>500 mg
total dose of amphotericin
2. Patients who require amphotericin therapy with baseline creatinine>2.5 mg/mL
3. Some immunocompromised patients with life-threatening mold disease (aspergillosis or zygomycosis)
Update: Some argue it is time to embrace the lipid preparations as the new standard since experience shows that these preparations are as active or more active than
amphotericin B desoxycholate, they are superior for some and are clearly less toxic (CID 2003;37:415.)
COMPARISON OF LIPID-BASED AMPHOTERICIN PREPARATIONS
(CID 2003;37:415.)
Preparation Amphotec (ABCD) Abelset (ABLC) AmBisome (LAmB)
FDA approval Invasive aspergillosis plus contraindication Invasive fungal infections plus Empiric RX in neutropenic patients
or failure with Ampho B contraindications or failure with Ampho B Cryptococcal meningitis with AIDS
Candida, Crypto, and As-pergillis infection plus failure
or contraindication with Ampho B
Dose—FDA 3–4 mg/kg/day 3 mg/kg/d—empiric therapy
approved 3–5 mg/kg systemic fungal disease
6 mg/kg cryptococcal meningitis
Efficacy*
Aspergillis 34% 46% 61%
Candidiasis 59% 75% 80%
Cryptococcosis 45% 67% 100%
Tissue penetration**
Liver 2× 2× 0.5–1×
Kidney 0.1× 0.2× 0.2×
Lung — 2× 0.2×
Brain 0.1 0.1 1.2×
Cmax 3.1 Og/mL 1.7 Og/mL 83 Og/mL
Usual AWP (/day) $400–500 $800–850 $950–1300
* Efficacy based on non-comparative clinical trials
** Tissue concentrations relative to amphotericin B
SPECTRUM OF ACTIVITY OF ANTIFUNGAL AGENTS
(Based on in vitro sensitivity tests and animal models)
Candida Candida Chromo-mycosis Phyco-myces
Asper-gillus Blasto-myces albicans krusei agents Crypto-coccus Coccidi-oides Histo-plasma Paracoccidi-oides (mucor-mycosis)
Amphotericin +* +* +* +* +* +* +* + +*
B
Flucytosine + + — +* + — — — —
Ketoconazole — + + — + + + + + —
Fluconazole — + +* — — +* +* + + —
Itraconazole + +* + — + + + +* +* —
Voriconazole + + + + + + + + ? —
Caspofungin + — + + — — — — — —
* Preferred agent(s) for most clinical infections.
COMPARISON OF AZOLES
Ketoconazole Itraconazole Fluconazole Voriconazole
Bioavailability 75% >70% >80% 95%
Half live (hrs) 8 30 28 8
CSF/plasma <10 <1 >80 >50
Urine levels <5 <1 80 <2
Side effects* Reduced libido Cardiomyopathy Alopecia Vision changes
Menstrual changes Hypokalemia
Drug Steroids, ritonavir saquinavir, Statins, pimozide, protease inhibitors, verapamil, INH, Theophyllin Statins, omeprazole,
interactions** carbamazepine, phenytoin, INH carbamazepine, phenoparbital phenytoin
* All may cause hepatitis, GI intolerance, and rash
** All have decreased AUC with rifampin and increased AUC with warfarin, sulfonaureas, phenytoin, midzolium, tirzolam, alprazolam, cyclosporin, and tacrolimus.
TREATMENT OF DERMATOPHYTIC FUNGAL INFECTIONS
Condition Agents Location Treatment
Tinea corporis T. rubrum Circular, erythema well Topical agents: Miconazole, clotrimazole, econazole, naftifine, ciclopirox, or terbinafine bid
(ringworm) T. mentagrophytes demarcated with scaly, or ketoconazole, oxiconazole, sul-conazole qd for D4 wk. If no response then griseofulvin ×
M. canis vesicular, or pustular border 2–4 wk (see below)
E. floccosum Non-hairy skin
Pruritic
Tinea cruris (Jock E. floccosum Erythema and scaly groin and Topical agents as above. Loose fitting clothes
itch) T. rubrum upper thighs Absorbent powder. Unresponsive cases: Griseofulvin × 2–4 wk
T. mentagrophytes Pruritic
Tinea pedis T. rubrum T. Foot, especially fissures Topical agents as above. Keep feet dry and cool
(athlete's foot) mentagrophytes between toes; scaly, Unresponsive cases: griseofulvin 4–8 wk
E. floccosum vesicles, pustules ± nail
involvement
Tinea unguium (nail T. rubrum Nails, usually distal and Oral griseofulvin or ketoconazole 6–24 mo (until new nail) or itraconazole 200 mg bid × 1
involvement) T. mentagrophytes lateral nail thick-ening with wk × 2 (fingernails) separated by 3 wk; 200 mg/d × 12 wk or 200 mg bid × 1 wk/mo × 3–4
Candida adjacent skin involved mo (toenails) (Med Lett 1996;38:5), terbinafine (Lamisil) 250 mg/d × 6 wk (fingernails) or
T. soudanense 12 wk (toenails) (Med Lett 38:76, 1996) or butenafine (Mentax) (1%) topical qd × 4 wk
(Med Lett 39:63, 1997)
Tinea capitis T. tonsurans Scaling and erythematous Griseofulvin × 4–8 wk + 2.5% selenium sulfide shampoo 2×/wk. Alternative to griseofulvin
(ringworm—scalp) T. mentagrophytes area of scalp with broken is ketoconazole
T. verrucosum hairs and localized alopecia
M. canis
Tinea versicolor Malassezia furfur Scaling oval macular and Topical 2.5% selenium sulfide applied as thin layer over entire body × 1–2 hr or overnight
patchy lesions on upper trunk for 1–2 wk, then monthly × 3; wash off. Alternatives: Topical clotrimazole, econazole,
and arms; dark or light, fail ketoconazole, naftifine, haloprogin, or oral ketoconazole
to tan
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Nonbacterial Infections > Treatment of Mycobacterial Infections
Treatment of Mycobacterial Infections
I. Tuberculosis
Guidelines of CDC, American Thoracic Society, and Infectious Diseases Society of America (Am J Respir Crit Care Med
2003;167:603.; MMWR 2003;52:RR-11.; NEJM 2001;345:189.)
A. Treatment
1. Four drug treatments preferred for initial empiric treatment: Isoniazid (INH), rifampin (Rif), pyrazinamide
(PZA), and ethambutol (EMB).
2. Directly observed therapy (DOT) is preferred for all patients. Priorities for DOT: Pulmonary TB with positive
smear, treatment failure, relapse, drug resistance, HIV co-infection, current or prior drug abuse, psychiatric
illness, memory impairment, or prior non-adherence.
3. Susceptibility tests should be performed on the initial isolate and on any isolate obtained at 3 mo
post-treatment (failure to convert).
4. Future therapy: Fluoroquinolones are the most promising new agents (BMJ 2002;325:1282.).
5. Monitoring: Some recommend routine baseline LFTs and periodic monitoring due to hepatotoxicity of INH, PZA,
and rifampin. Increases in ALT in up to 20%, but major liver disease in <1% (BMJ 2002;325:1282.)
6. Relapse: Probability of relapse is <5%; most occur within 6 months and involve drug sensitive strains.
7. Resistant strains: Give 4 active drugs, usually 3 oral and one parenteral aminoglycoside.
Regimen Options for Initial Treatmentof TB Among Adults
Drugs Phase 1 (8 weeks) Phase 2*: Regimen, doses, minimal duration
INH 8 weeks INH/RIF 7 d/wk, 126 doses or 5 d/wk, 90 doses,
RIF 7 d/wk, 56 doses, 8 wks 18 wks
RZA 5 d/wk, 40 doses, 8 wks INH/RIF 2×/wk, 36 doses, 18 wks
EMB INH/RPT, 1×/wk, 18 doses, 18 wks**
INH 2 wk/6 week INH/RIF 2×/wk, 36 doses, 18 wks
RIF 7 d/wk, 14 doses, 2 wks, then 2×/week, 12 INH/RPT 1×/wk, 18 doses, 18 wks**
RZA doses, 6wks
EMB
INH 8 weeks INH/RIF 3×/wk, 54 doses, 18 wks
RIF 3×/wk, 24 doses, 8 wks
RZA
EMB
INH 8 weeks INH/RIF 7 d/wk, 217 doses or 5 d/wk, 155
RIF 7 d/wk, 56 doses or 5 d/wk, 40 doses, 8 wks doses, 31 wks
EMB INH/RIF 2×/wk, 62 doses, 31 wks
INH = Isoniazide, RIF = Rifampin, RPT = rifapentine, PZA = Pyrazinamide, EMB = Ethambutol
* Patients with cavitation at baseline and positive cultures at 2 months should receive 31 week continuation
phase for total of 9 months.
** Not recommended for HIV infected patients.
Recommended First Line Drugs
(Am Rev Respir Crit Care 2003;167:603.)
Cost/mo
Twice/thrice daily
Agent Forms Daily dose weekly dose regimen Adverse reactions Comment
Isoniazid Tabs: 5 mg/kg po or 15 mg/kg $1.50 Elevated ALT Liver injury
(INH) 50 IM Max—900 mg 10–20% clinical increased with
mg, Max—300 mg, hepatitis* 0.6%, RIF and/or PZA,
100 po or IV peripheral EtOH, age
mg, neuropathy 0.2% Peripheral
300 neuropathy is
mg prevented with
Syrup: pyridoxine (50
50 mg/d)
mg/5 suggested for
mL diabetes, HIV,
Vials: uremia,
1g alcoholism,
(IM) malnutrition,
pregnancy, or
seizure
disorder
Rifampin Caps: 10 mg/kg 10 mg/kg $123 Orange Multiple drug
(RIF) 150 Max—600 mg Max—600 mg discoloration of interactions:
mg, po or IV secretions and accelerates
300 urine, purpura clearance of
mg (rare) methadone,
Vials: Hepatitis*, warfarin,
600 cholestatic corticosteroids,
mg Pruritis ± rash 6% estrogens,
(IV) Flu sx with 2×/wk ketoconazole,
cyclosporine,
phenytoin, oral
hypoglycemics,
protease
inhibitors
wt Daily 2×/wk 3×/wk
(kg)
Pyrazinamide Tabs: 40–55 1.0 2.0 g 1.5 $127 Hepatitis*—frequent Severe liver
(PZA) 500 56–75 g 3.0 g g with RIF + PZA injury in 6%
mg 76–90 1.5 4.0 g 2.5 Nongouty given PZA +
g g polyarthralgias RIF
2.0 3.0 Hyperuricemia Hyperuricemia
g g (gout rare) is usually
inconsequential
Ethambutol Tabs: 40–55 0.8 2.0 g 1.2 $168 Optic neuritis, Decreased
(EMB) 100 56–75 g 2.8 g g dose-related acuity or
mg, 76–90 1.2 4.0 g 2.0 red–green
400 g g discrim-ination;
mg 1.6 2.4 dose-related
g g
* All patients receiving INH, rifampin, and/or pyrazinamide should be instructed to report immediately any
symptoms of hepatitis: anorexia, nausea, vomiting, jaundice, malaise, fever >3 days, or abdominal tenderness.
Risk of hepatitis is greater with age >35 yr and daily alcohol use.
Second Line Antituberculous Drugs
Daily dose*
Agent Forms (maximum) Adverse reactions Monitoring/comments
Streptomycin Vials 15 mg/kg/d* Auditory, vestibular, Audiometry and vestibular tests at
1 g/d and renal toxicity baseline and periodically; renal
Age >50 yrs function tests
10 mg/kg/d
750 mg/d
Capreomycin Vials: 15 mg/kg IM Auditory, vestibular, Audiometry and vestibular tests at
(Capastat) 1 g (1 g) and renal toxicity baseline and periodically; renal
function; high frequency hearing
loss in 3–10%
Kanamycin Vials: 15 mg/kg IV Auditory, vestibular, Audiometry and vestibular tests at
(Kantrex) 75 and or IM 1 g (rare), and renal baseline and periodically;
500 mg toxicity
1 g
Amikacin Vials: 15 mg/kg IV Auditory, vestibular, Audiometry and vestibular tests at
(Amikin) 0.1, or IM and renal toxicity baseline and periodically; renal
0.5 function
and 1 g
Ethionamide Tabs: 500–750 mg GI intolerance, Hepatic enzymes monthly and D/C
(Trecator) 250 mg qd; 15–20 hepatotoxicity, if transaminase Q5 × upper limits
mg/kg/d photosensitivity, normal. GI intolerance—may need
arthralgias, to gradually increase dose and/or
impotence, metallic give hs and 30 min after antiemetic
taste
Gatifloxacin Caps: 400 mg/d Nil No monitoring for ADR
400 mg
Moxifloxacin Caps: 400 mg/d Nil No monitoring for ADR
400 mg
Levofloxacin Caps: 500 mg bid Nil No monitoring for ADR
500
and
750 mg
PAS Tabs: 4–6 g po bid; GI intolerance, Delayed release granules should be
500 150 mg/kg/d hepatotoxicity, sodium given with acidic food or drink
mg, 1 load, hypersensitivity
g
Cycloserine Caps: 500–750 mg Psychosis, rash, Assess mental status; some give
(Seromycin) 250 mg po bid; convulsions pyridoxine (50 mg/250 mg
10–15 cycloserine) to decrease psychiatric
mg/kg/d effects, seizures, and neuropathy
* Give IM or IV 5–7 days/wk × 2–4 months, then 2–3×/wk after culture conversion
P.163
P.164
B. Diagnostic Tests
1. AFB smear: Sensitivity of AFB stain with expectorated sputum, induced sputum and bronchoscopy aspirates are
similar at 40–60% in culture positive cases (Am J Respir Crit Care Med 2000;162:2238.). Specificity depends on
the prevalence of TB and MOTT, but may be as low as 50% (J Clin Micro 1998;36:1046.)
P.165
2. Nucleic acid amplification (NAA assays) (Am J Respir Crit Care Med 2001;164:2020.): Commercially available
as MTB (Gen Probe) and Amplicor (Roche) at $50–100/assay. Sensitivity of NAA assays is 80–84% including
virtually all smear-positive cases and about half of smear-negative/culture-positive cases. CDC
recommendations (MMWR 2000;49:593.):
AFB smear and NAA on the first sputum collected. If the smear is positive and the NAA is positive, TB is
diagnosed with near 100% certainty.
If the smear is positive and the NAA is negative, the sputum should be tested for inhibitors by spiking the
sample with lysed M. tuberculosis and repeat the assay. If inhibitors are not present, the patient is
assumed to have MOTT.
If the smear is negative and the NAA is positive, additional sputum samples are recommended. If positive,
the patient is presumed to have TB.
If both the smear and the NAA are negative, additional specimens should be tested by NAA and, if negative,
TB is assumed to be excluded.
3. AFB culture: Frequency of false positive results in a review of 14 studies with >100 patients show a mean of
3.1% false positives (CID 2000;31:1390.). The presumed mechanism is laboratory cross-contamination. The
major clue is a single positive culture, especially if not supported by clinical observations.
4. Broth-based cultures: When combined with DNA probes, broth-based cultures are capable of detecting M.
tuberculosis within two weeks with smear-positive cases and within three weeks with smear-negative cases (Am
J Clin Path 2000;113:770.; Diag Microbiol Infect Dis 2000;37:31.)
C. Monitoring Drug Therapy
1. Monitoring for adverse drug reactions (ADRs)
a. Most frequent reactions with standard 4 drug therapy are rash ± fever, hepatitis, and GI intolerance. The
main cause of hepatotoxicity appears to be PZA (Am J Resp Crit Care Med 2003;167:1472.). Ethambutol is
a rare cause of toxicity except for occasional cases of dose-related vision changes.
b. Recommendations
INH: Baseline and monthly LFTs if pre-existing liver disease, or development of abnormal LFTs that do
not require discontinuing INH Monthly inquiries about symptoms that suggest hepatitis
RIF: No monitoring for ADRs
PZA: LFTs as for INH; uric acid is usually elevated, but usually is not consequential and monitoring is
not recommended
EMB: Baseline visual acuity and Ishihara test of color discrimination. Inquire about vision changes at
each monthly visit and warn to contact clinic immediately if vision changes. Monthly tests of acuity
and color discrimination with doses >15–20 mg/kg for >2 months or with renal failure
2. Duration of therapy with drug-sensitive strains
Initial 8 week course: Identical for all patients
Continuation phase:
Cavitation or positive culture at 2 months
Cavitation Positive culture at 8 wks Duration continuation phase
+ - 4 mo.
- + 4 mo.
+ + 7 mo.
No cavitation, negative culture at 2 months, negative HIV and no extrapulmonary TB: RIF/INH or RPT/INH
× 4 mo.
HIV or extrapulmonary TB: INH/RIF (only)
P.166
Rationale: Risk for relapse with cavitation and/or positive sputum at 2 months using standard initial 4 drug
initial phase and INH/RIF 2×/week × 16 weeks USPH study 22 (Lancet 2002;360:528.).
Cavity Sputum positive at 2 mo Sputum negative at 2 mo
Yes 21% (n = 48) 5% (n = 150)
No 6% (n = 17) 2% (n = 181)
3. Treatment interruptions
Initial phase
Duration of interruption <14 days: Continue therapy, if not completed in 3 months—restart
Duration Q14 days: Restart
Continuation phase:
Q80 doses: No additional therapy
<80% doses
Duration of interruption <3 months: Continue, if not completed in 6 months—restart
Duration of interruption Q3 months: Restart 4 drug initial phase
4. Evaluation of response: Symptoms usually improve within 4 wk, and 85% of patients treated with
INH-rifampin containing regimen convert sputum culturees to negative by the end of 2 mo. Sputum smear and
culture should be performed at least monthly until conversion is documented. Weekly sputum smears with
quantitation are encouraged. Patients with positive sputum cultures after 2 mo of treatment need reevaluation,
drug susceptibility test, and directly observed treatment. If resistance noted, give at least two active drugs
under DOT. Patients with negative cultures T2 mo should have one additional smear and culture at completion
of treatment. Some recommend x-ray at 2–3 mo and at completion of treatment.
5. Relapse: Most relapses occur within 6 months and involve drug sensitive strains. Major risks are: (1) extent
and severity of the lung disease as indicated by cavitation and bilateral infiltrates, and (2) positive cultures at
two months (Lancet 2002;360:528.)
D. Special Considerations With Treatment
1. HIV Infection
Identical for general population except:
CD4 <100/mm3: Continuation phase should be daily or 3×/week
Once weekly rifapentine regimen should not be used.
Positive cultures at 2 months: Strongly consider 7 month continuation phase (total 9 mo.)
In absence of prior HIV therapy and CD4 <350/mm3: Delay antiretroviral drugs for 4–8 weeks.
RIF may be used with 2 NRTIs + EFV, RTV + SQV (Invirase or Fortovase) or AZT/3TC/ABC.
Rifabutin combined with other PIs and NNRTI requires a dose adjustment of both. See:
http://www.cdc.gov/nchstp/tb/ or http://www.medscape.com/updates/quickguide
When starting NNRTI or PI in patient receiving RIF, substitute rifabutin 2 weeks prior to NNRTI or PI to give
a 2 week washout period for RIF
Paradoxical reaction: Frequency in 7–36%; clinical features—high fever; increased adenopathy, CNS
lesions, pulmonary infiltrates and pleural effusions. Treatment is symptomatic; if severe, give prednisone 1
mg/kg and reduce dose at 1–2 weeks.
P.167
2. Extrapulmonary TB
Standard 4 drug initial phase followed by INH/RIF for 4–7 months except for CNS. TB which is treated 9–12
months.
Site Duration Steroids
Lymph nodes 6 months No
Bone or joint 6–9 months No
Pleural disease 6 months No
Pericarditis 6 months Recommended
CNS TB 9–12 months Recommended
Disseminated 6 months No
GU TB 6 months No
Peritoneal 6 months No
3. Culture negative suspected active TB
Low probability: No initial treatment
Culture negative at 2 mo and x-ray unchanged
RIF ± INH × 4 mo.
INH × 9 mo
RIF/PZA × 2 mo
High probability
INH/RIF/EMB/PZA × 2 mo
Culture negative at 2 mo. and x-ray improved: INH/RIF × 2 mo
Culture negative and x-ray unchanged: D/C therapy
4. Pregnancy and breast feeding
Regimen: INH/RIF/EMB × 9 mo or standard treatment wit INH/RIF/EMB/PZA × 2 mo, then INH/RIF × 4 mo. The
issue is the safety of PZA, which has no evidence of adverse effects in pregnancy, but inadequete experience to
assure safety.
Streptomycin: Only anti-TB drug with documented harm to human fetuses.
5. Renal insufficiency
Drug Dose with CrCl <30 cc/min
INH Standard
RIF Standard
RZA 25–35 mg/kg 3×/wk
EMB 15–25 mg/kg 3×/wk
Levofloxacin 750–1000 mg 3×/week
Cycloserine 250 mg qd or 500 mg 3×/wk
Ethionamide Standard
PAS Standard
Aminoglycosides 12–15 mg/kg 2–3×/wk
6. Hepatic disease
Regimen excluding INH: RIF/PZA/EMB × 6 months
Regimen excluding PZA: INH/RIF/EMB × 2 months, then INH/RIF × 7 months
Regimen for severe liver disease:
RIF/fluoroquinolone/cycloserine/aminoglycoside × 18 months or
Streptomycin/EMB, fluoroquinolone/another second line drug × 18–24 months
7. Drug-resistant TB
Drug Resistance Regimen
INH RIF/PZA/EMB ± fluoroquinolone 6 mo
INH/RIF Fluoroquinolone/PZA EMB aminoglycoside ± alternative agent ± 18–24 mo
RIF INH/PZA/EMB ± fluoroquinolone 9–12 mo
INH/RIF and EMB or Fluoroquinolone/aminoglycoside/2 alternative agents and PZA or EMP (if
PZA active)
P.168
II. Preventive Treatment for Tuberculosis Infection in the U.S.
ATS/CDC Statement Committee on Latent Tuberculosis Infection [MMWR 2000;49(RR-6).; Am J Resp Crit Care Med
2000;161:S221.; MMWR 2003;52:735.)
A. Testing (NEJM 2002;347:1860.)
1. Testing methods: The traditional method is the PPD skin test which has been used for more than 100 years. A
new test has been approved by the FDA which mesures the release of interferon-gamma in blood following
stimulation by PPD (JAMA 2001;286:1740.). At present, the usual test is the traditional PPD skin test with the
following characteristics:
Standard test: 5 tuberculin units given intracutaneously and read at 48–72 hours, although reading up to
one week is considered accurate (ARRD 1986;134:1043.).
BCG: In one study, only 8% of those given BCG vaccine at birth had a positive PPD skin test at 15 years
(ARRD 1992;145:621.). BCG is given in countries that have the highest incidence of tuberculosis making it
difficult to discount a positive PPD. The current recommendation is to ignore BCG vaccination when
interpreting PPD skin tests.
Sensitivity: 10–20% of persons with tuberculosis have negative skin tests (NEJM 1971;285:1506.; Chest
1980;77:32.).
Anergy testing: Most authorities no longer recommend it.
Boosting: The concern is that a negative test may boost the size of the reaction with a second test. The
recommendation is that persons who undergo annual PPD skin tests such as health care workers should
undergo two-step testing on initial evaluation with the second PPD given one week after a negative test.
2. Indications for PPD
Risk Example
Recent TB Recent close (>12 hours) contact with active case
exposure
Health care workers with TB cases
Risk of TB Prior residence in countries with high TB rates
infection
Homeless
Residents of long-term care facilities
Risk of HIV infection
activation of Recent TB infection: children <4 years, PPD conversion (>10 mm induration) in T2
latent years, injection drug use, silicosis, renal failure, diabetes, immunosuppressive
infection therapy, hematologic cancers, prior gastrectomy or jejunoileal bypass
Malnourished or recent weight loss > 10% ideal weight
P.169
B. Candidates for treatment of latent tuberculosis
Induration caterogy of PPD
Q5 HIV infection
mm Recent contacts of active TB
Fibrotic changes on x-ray consistent with TB
Immunosuppressed: Organ transplants and others with immuno-suppression including chronic
prednisone (equivalent to 15 mg/d forQ1 mo)
Q10 Recent immigrants (<5 yr) from high prevalence area
mm Injection drug users
Residents and employees of prisons, jails, nursing homes, long term care facilities for elderly,
hospitals, homeless shelters
Mycobacteria lab personnel
Patients with silicosis, diabetes, renal failure, leukemia, lymphoma, ca head or neck, weight
loss>10%, gastrectomy and jejuroleal by-pass
Q15 Persons with no risk factors (Note that targeted PPD skin testing should be done only in people
mm with defined risks. It is often unclear why these people are tested and treatment is optional)
C. Antimicrobial regimens (MMWR 2003;52:735.)
1. Recommended regimens
INH 300 mg/d × 9 mo
INH 300 mg/d × 6 mo (not for HIV co-infection or patients with fibrotic lesions on chest x-ray)
INH 900 mg 2 ×/wk (DOT) × 9 mo
INH 900 mg 2 ×/wk (DOT) × 6 mo (not for HIV co-infection or patients with fibrotic lesions on chest x-ray)
Rifampin 600 mg/d × 4 mo (contacts of patients with INH resistant, rifampin susceptible strains)
Note: The 2 month course of RIF + PZA is no longer recommended due to high rates of hepatotoxicity
(MMWR 2003;52:735.)
INH regimen
Efficacy: Studies of more than 70,000 participants show efficacy of about 60% in reducing active
tuberculosis (Bibl Tuberc 1970;26:28.). Most studies were done with one year of therapy; a study of
INH for six months showed 65% efficacy (Bull WHO 1982;60:555.).
Hepatitis: Increases in serum transaminase levels occur in 10–20%, but symptomatic hepatitis is
uncommon with about one case per 1,000 (JAMA 1992;281:1014.). The risk increases with alcohol
consumptoin and with increasing age, but age is no longer considered in the recommendations for
treatment.
Peripheral neuropathy: Allegedly occurs in up to 2% (Am Rev Tuberc 1954;70:504.) and may be
prevented with pyridoxine (Tubercle 1980;61:191.).
Current recommendations: INH for 6–9 months in the usual dose of 300 mg/day, monthly clinical
monitoring, baseline transaminase levels only in persons with risk factors for hepatitis, abstinence
from alcohol during the INH course and suspension of treatment if transaminase levels exceed the
upper limit of normal by five-fold. The alternative regimen is 900 mg twice weekly by directly observed
therapy.
Rifampin regimen
Efficacy: Thought to be equivalent to INH (ARRD 1992;145:36.).
P.170
Adverse reactions: Uncommon.
Drug interactions: Common and often important.
Current recommendations: 600 mg/day for four months with clinical monitoring at monthly intervals,
baseline transaminase measurements only for persons at risk for hepatitis, and concern for drug
interactions such as protease inhibitors, warfarin, contraceptive pills, and methadone.
D. Monitoring
Laboratory monitoring: INH
No lab tests at baseline unless the following:HIV infection, pregnancy, or<3 mo postpartum, history of liver
disease (HCV, HBV, alcoholic hepatitis, cirrhosis), persons who use EtOH daily
Baseline lab tests: AST, ALT, and bilirubin
Active hepatitis and end-stage liver disease are relative contraindications to INH and PZA
Follow-up lab tests: symptoms of hepatotoxicity—D/C INH if AST/ALT Q3×ULN + symptoms or AST/ALT>5 ×
ULN without symptoms
Clinical monitoring: Monitor for symptoms of hepatotoxicity at baseline and every mo for INH regimen.
III. Atypical Mycobacteria Treatment (Recommendations of American Thoracic Society: Am Rev Respir Dis 1997;156:S1.)
and M. Iseman (personnel communication 2003)
Agent Condition Treatment and comment
M. kansasii Pulmonary and RIF + EMB + INH ± AK 15–18 mo (AK for extensive disease)
extrapulmonary RIF + EMB × 9 mo
RIF + EMB + clarithromycin or azithromycin × 9 mo
RIF + EMB + AK × 9 mo
Contraindication or resistance to RIF: EMB + CIP + clarithromycin
M. avium Pulmonary and Clarithromycin or azithromycin + EMB + RIF ± AK × 18–24 mo
extrapulmonary Clarithromycin + EMB + CFZ ± AK × 18–24 mo
RIF + EMB + CFZ ± AK ± ciprofloxacin × 18–24 mo Use for macrolide
resistance or intolerance
Clarithromycin + EMB ± CFZ × 18–24 mo Use for elderly patients with
less extensive disease
Note: Can substitute azithromycin for clarithromycin if intolerant of
clarithromycin or to avoid interaction between clarithromycin and RIF
Note: Twice weekly therapy is probably as effective as daily
therapy—advantages include reduced cost and toxicity
M. fortuitum Cutaneous and In vitro tests required
bone Standard: Amikacin (10–15 mg/kg/d) + cefoxitin (12 g/d) or imipenem Q
2 wk, then oral regimen based on vitro activity—usually clarithromycin
(500 mg bid), doxycycline (100 mg bid), sulfamethoxazole (1 g tid) ±
ciprofloxacin (500 mg bid) × Q 4 mo (cutaneous) or Q 6 mo (bone)*
Surgery: Usually indicated for extensive disease and with foreign bodies
Pulmonary Most lung disease caused by rapid growers i.e. M. abscessus
M. fortuitum: Two oral agents based on in vitro activity × 6–12 mo
M. abscessus Cutaneous Standard: Amikacin + cefoxitin or imipenem as above, then oral agent if
any are active in vitro—usually clarithromycin ± clofazimine × Q4 mo
Pulmonary Standard: Amikacin + cefoxitin (as above) × 2–4 wk, then periodic
parenteral treatment or clarithromycin for suppressive therapy*
Surgery: May be curative for local disease (Am Rev Respir Dis
1993;148:1271)*
M. chelonae Cutaneous Standard: Tobramycin + cefoxitin (12 g/d) or imipenem × Q 2 wk, then
oral agents based on in vitro activity especially clarithromycin (500 mg
bid) monotherapy × 6 mo* (Am Intern Med 1993;119:482)
M. marinum Cutaneous Standard: Multiple regimens—clarithromycin (500 mg bid); doxycycline
(100 mg bid); TMP-SMX (DS bid); rifampin (600 mg bid) + ethambutol
(15 mg/kg/d)—all Q 3 mo*
Surgery: Infections in closed space of hand and refractory infections
M. Lymphadenitis Surgical excision; very resistant to drugs—INH, rifampin, streptomycin +
scrofulaceum cycloserine (rare in U.S.)
M. ulcerans Buruli ulcer Rifampin + amikacin (7.5 mg/kg IV bid) or ethambutol + TMP-SMX (1 DS
tid) × 4–6 wk; surgical excision
M. Skin, soft tissue, Sensitive to ciprofloxacin, cycloserine, kanamycin, rifabutin; experience
haemophilum osteomyelitis with treatment limited (Ann Intern Med 1994;120:118)
M. bovis Pulmonary As with M. tuberculosis but resistant to pyrazinamide
M. szulgae Pulmonary, Same as M. kansasii (Thorax 1987;42:838)
extrapulmonary
M. Pulmonary, Clarithromycin + ethambutol + rifabutin ± streptomycin × 18–24 mo
malmoense disseminated (Tubercle 1985;66:197; CID 1994;18:596)
M. xenopi Pulmonary Rifampin or rifabutin + clarithromycin ± streptomycin; surgery for
relapses (Am Rev Respir Dis 1981;123:104; Tubercle 1988;69:47)
M. simiae Pulmonary Clarithromycin, ethambutol, rifabutin + streptomycin (need in vitro
susceptibility tests)
M. smegmatis Soft tissue, bone, Ethambutol, amikacin, ciprofloxacin, sulfonamides, clofazimine,
etc imipenem, doxycycline
M. gordonae Pulmonary, Combinations of rifampin, ethambutol, streptomycin ± INH, clofazimine,
disseminated clarithromycin (AAC 1992;36:1987; Dermatology 1993;187:301)
M. genavense Disseminated Clarithromycin + other agents—INH, ethambutol, rifampin, ciprofloxacin,
pyrazinamide (AIDS 1993;7:1357)
* Efficacy is established.
P.171
P.172
A. Doses
Amikacin: 12–15 mg/kg/day IV or IM or 15–22 mg/kg tiw
Azithromycin: 250–500 mg/day or 500 mg tiw
Cefoxitin: 2 g IV q8–12h
Ciprofloxacin: 500–750 mg bid, 750 mg qd or 750 mg tiw
Clarithromycin: 500–750 mg/d, 500 mg bid or 750 mg tiw
Doxycycline: 100 mg bid
Ethambutol: 25 mg/kg/d × 2 mo, then 15 mg/kg or 25–30 mg/kg tiw
Imipenem: 1 g IV q12h
Isonazid: 300–600 mg/d or 600 mg tiw
Levofloxacin: 500–750 mg/day or 750 mg tiw
Linezolid: 600 mg IV or po bid
Rifabutin: 150–300 mg/d or 300 mg tiw
Rifampin: 600 mg qd or 600 mg tiw
Streptomycin regimens
Wt/age Initial 6–12 wks Maintenance
>50 kg <50 yr 1 g 5×/wk 1 g 3×/wk
<50 kg <70 yr 500 mg 5×/wk 750 mg 2×/wk
>70 yr 750 mg 2×/wk 750 mg 2×/wk
B. Classification of atypical mycobacteria (adapted from Am Rev Respir Crit Care Dis 1997;156:59.)
M. kansasii U.S., Pigmented
Europe coal
mining
M. abscessus Mostly U.S. Nonpigmented
Rapid growth
M. xenopi Europe Pigmented
canada slow growth
Lymphadenitis M. avium Worldwide Nonpigmented M. fortuitum, M. chelonae, M.
ab-scessus, M. kansasii, M.
haemophilum
M. Worldwide Pigmented
scrofulaceum
M. U.K. Scand Slow growth
malmoense
Skin M. marium Worldwide Growth at 28–30°C M. aviam, M. kansasii, M.
nonchromo-genicum, M.
M. ulcerans Australia Pigmented
SE Asia, Slow growth
Africa
Disseminated M. avium Worlwide AIDS patients—80% M. xenopi, M. abscessus, M.
pigmented malmoense, M. simiae, M.
genovense, M. marium, M.
fortuitum, M. canspicum
M. kansasii U.S. Photochromogen
M. chelonae U.S. Nonpigmented
M. U.S. Nonpigmented
haemophilum Australia Needs hemin, low
temperature, and
CO2
Runyon classification
M. marium 7–14 Optimal growth at 32°C. Rare
contam-inant. Skin and soft tissue
M. simiae 7–14 Rare human pathogen. Lung
M. asiaticum 7–14 Rarely pathogenic
Scotochromogens (slow II M. 10–28 Nearly disappeared from U.S.
scrofula-ceum Lymphadenitis
M. szulgae 12–28 Infrequent human pathogen. Lung
M. gordonae 10–28 Rarely pathogenic. Environmental
contaminant
M. flavescens 7–10 Rarely pathogenic. Environmental
contaminant
Nonphotochromogens III M. avium 10–21 M. avium and M. intracellulare
sometimes referred to as M. avium
(slow growing)
M. malmoense 18–84 Infrequent human pathogen. Lung.
Optimal growth at 20–32°C. Skin
and soft tissue in
immunosuppressed
M. haemophilum
M. terrae 10–21 Rarely pathogenic. Environmental
complex contaminant
M. gastri 10–21 Rarely pathogenic. Environmental
contaminant
M. flavescens Rarely pathogenic
M. triviale 10–21 Environmental contaminant
Rapid growers IV M. fortuitum 3–7 Environmental contaminant. Ulcers
M. chelonae 3–7 Environmental contaminant. Ulcers
M. smegmatis 3–7 Rarely pathogenic
M. phlei 3–7 Rarely pathogenic
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Nonbacterial Infections > Drugs for Treatment of Parasitic Infections
Drugs for Treatment of Parasitic Infections
th
Reproduced with permission from Medical Letter Handbook of Antimicrobial Therapy 16 Edition
2002;120–143.)
Infection Drug Adult dosage
Acanthamoeba keratitis
Drug of choice: See footnote 1
AMEBIASIS (Entamoeba histolytica)
asymptomatic
Drug of choice: lodoquinol 650 mg tid × 20 d
or Paromomycin 25–35 mg/kg/d in 3 doses
× 7 d
Alternative: Diloxanide furoate 2 500 mg tid × 10 d
3
mild to moderate intestinal disease
Drug of choice: 4 Metronidazole 500–750 mg tid × 7–10 d
or Tinidazole 5 2 g/d divided tid × 3 d
3
severe intestinal and extraintestinal disease
Drug of choice: Metronidazole 750 mg tid × 7–10 d
or Tinidazole 5 800 mg tid × 5 d
AMEBIC MENINGOENCEPHALITIS, PRIMARY
Naegleria
Drug of choice: Amphotericin B 6,7 1 mg/kg/d IV, uncertain
duration
Acanthamoeba
Drug of choice: See footnote 8
Balamuthia mandrillaris
Drug of choice: See footnote 9
Sappinia diploidea
Drug of choice: See footnote 10
ANCYLOSTOMA caninum (Eosinophilic enterocolitis)
Drug of choice: Albendazole 7 400 mg once
or Mebendazole 100 mg bid × 3 d
or Pyrantel pamoate7 11 mg/kg (max. 1 g) × 3 d
or Endoscopic removal
Ancylostoma duodenale, see HOOKWORM
ANGIOSTRONGYLIASIS
Angiostrongylus cantonensis
Drug of choice: See footnote 11
Angiostrongylus costaricensis
Drug of choice: See footnote 12
ANISAKIASIS(Anisakis)
Treatment of choice: Surgical or endoscopic removal
ASCARIASIS (Ascaris lumbricoides, roundworm)
Drug of choice: Albendazole 7 400 mg once
or Mebendazole 100 mg bid × 3 d or 500
mg once
or Pyrantel pamoate 7 11 mg/kg once (max. 1 g)
BABESIOSIS (Babesia microti)
Drugs of choice: 13 Clindamycin 7 1.2 g bid IV or 600 mg tid
po × 7–10 d
plus quinine 650 mg tid po × 7 d
or Atovaquone7 750 mg bid × 7–10 d
plus azithromycin 7 600 mg po daily × 7–10 d
Balamuthia mandrillaris, see AMEBIC MENINGOENCEPHALITIS, PRIMARY
BALANTIDIASIS (Balantidium coli)
Drug of choice: Tetracycline 7,14 500 mg qid × 10 d
Alternatives: Metronidazole 7 750 mg tid × 5 d
Iodoquinol 7 650 mg tid × 20 d
BAYLISASCARIASIS (Baylisascaris procyonis)
Drug of choice: See footnote 15
BLASTOCYSTIS hominis infection
Drug of choice: See footnote 16
CAPILLARIASIS (Capillaria philippinensis)
Drug of choice: Mebendazole 7 200 mg bid × 20 d
Alternative: Albendazole 7 400 mg daily × 10 d
Chagas' disease, see TRYPANOSOMIASIS
Clonorchis sinensis, see FLUKE infection
CRYPTOSPORIDIOSIS (Cryptosporidium)
Drug of choice: See footnote 17
CUTANEOUS LARVA MIGRANS (creeping eruption, dog and cat hookworm)
Drug of choice: 18 Albendazole 7 400 mg daily × 3 d
or Ivermectin 7 200 Gg/kg daily × 1–2 d
P.175
P.176
P.177
P.178
P.179
P.180
P.181
P.182
P.183
P.184
P.185
P.186
P.187
P.188
P.189
MANUFACTURERS OF SOME ANTIPARASITIC DRUGS
ALBENDAZOLE—Albenza (GlaxoSmithKline)
§ARTEMETHER—Artenam (Arenco, Belgium)
§ARTESUNATE—(Guilin No. 1 Factory, People's Republic of China)
ATOVAQUONE—Mepron (GlaxoSmithKline)
ATOVAQUONE/PROGUANIL—Malarone (GlaxoSmithKline)
BACITRACIN—many manufacturers
§BACITRACIN-ZINC—(Apothekernes Laboratorium A.S., Oslo, Norway)
§BENZNIDAZOLE—Rochagan (Roche, Brazil)
†BITHIONOL—Bitin (Tanabe, Japan)
CHLOROQUINE HCI and CHLOROQUINE PHOSPHATE—Aralen (Sanofi), others
CROTAMITON—Eurax (Westwood-Squibb)
DAPSONE—(Jacobus)
†DIETHYLCARBAMAZINE CITRATE USP—(University of Iowa School of Pharmacy)
§DILOXANIDE FUROATE—Furamide (Boots, United Kingdom)
§EFLORNITHINE (Difluoromethylornithine, DFMO)—Ornidyl (Aventis)
FURAZOLIDONE—Furoxone (Roberts)
§HALOFANTRINE—Halfan (GlaxoSmithKline)
P.190
IODOQUINOL—Yodoxin (Glenwood), others
IVERMECTIN—Stromectol (Merck)
MALATHION—Ovide (Medicus)
MEBENDAZOLE—Vermox (McNeil)
MEFLOQUINE—Lariam (Roche)
§MEGLUMINE ANTIMONATE—Glucantime (Aventis, France)
†MELARSOPROL—Mel-B (Specia)
METRONIDAZOLE—Flagyl (Searle), others
§MILTEFOSINE—(Zentaris)
†NIFURTIMOX—Lampit (Bayer, Germany)
*NITAZOXANIDE—Cryptaz (Romark)
§ORNIDAZOLE—Tiberal (Roche, France)
OXAMNIQUINE—Vansil (Pfizer)
PAROMOMYCIN—Humatin (Monarch); Leshcutan (Teva Pharmaceutical Industries, Ltd., Israel;
(topical formulation not available in U.S.)
PENTAMIDINE ISETHIONATE—Pentam 300, NebuPent (Fujisawa)
PERMETHRIN—Nix (GlaxoSmithKline), Elimite (Allergan)
PRAZIQUANTEL—Biltricide (Bayer)
PRIMAQUINE PHOSPHATE USP
§PROGUANIL—Paludrine (Wyeth Ayerst, Canada; AstraZeneca, United Kingdom); in combination
with atovaquone as Malarone (GlaxoSmithKline)
§PROPAMIDINE ISETHIONATE—Brolene (Aventis, Canada)
PYRANTEL PAMOATE—Antiminth (Pfizer)
PYRETHRINS and PIPERONYL BUTOXIDE—RID (Pfizer), others
PYRIMETHAMINE USP—Daraprim (GlaxoSmithKline)
§QUININE DIHYDROCHLORIDE
QUININE SULFATE—many manufacturers
†SODIUM STIBOGLUCONATE—Pentostam (GlaxoSmithKline, United Kingdom)
*SPIRAMYCIN—Rovamycine (Aventis)
†SURAMIN SODIUM—(Bayer, Germany)
THIABENDAZOLE—Mintezol (Merck)
§TINIDAZOLE—Fasigyn (Pfizer)
*TRICLABENDAZOLE—Egaten (Novartis, Switzerland)
TRIMETREXATE—Neutrexin (US Bioscience)
Footnotes
*Available in the U.S. only from the manufacturer.
§Not available in the U.S.
†Available under an Investigational New Drug (IND) protocol from the CDC Drug Service, Centers for
Disease Control and Prevention, Atlanta, Georgia 30333; 404-639-3670 (evenings, weekends, or
holidays: 404-639-2888).
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Nonbacterial Infections > Treatment of Viral Infections
Treatment of Viral Infections
A. HERPESVIRUS GROUP (Med Lett 2002;44:9.; NEJM 1999;340:1255.; Lancet 2001;357:1513.;
Med Lett 2002;44:95.)
Virus Regimen* Comment
HERPES SIMPLEX
Genital—primary Acyclovir: 400 mg po tid × Shortens duration of pain,
7–10 days, ($14) reduces viral shed-ding and
Severe: 5 mg/kg IV q8h × reduces duration of systemic
5–7 days symptoms (Med Lett
1995;37:117).
Avoid sex until no visible
lesions; effect of treatment
on transmission is unknown
Valacyclovir: 1 g po bid 7–10 Valacyclovir and acyclovir
days ($79) are equally effective (AAC
1995;35:181)
Famciclovir: 250 mg po tid ×
5–10 days ($55)
Genital—recurrent Acyclovir: 400 mg po tid × 5 Slight benefit, but only if
days ($11) started early (MMWR
1993;RR-14:23) preferably
within 24 hr (Arch Intern
Med 1996;156:1729)
Valacyclovir: 500 mg po qd × Higher doses may be
3 days ($11) required in HIV-infected
patients
Famciclovir: 125 mg po bid ×
5 days ($33)
Genital—prophylaxis Acyclovir: 400 mg po bid Indicated with C6
($43/mo) recurrences/yr. Good
Valacyclovir: 500–1000 mg efficacy and good safety
qd ($108/mo) profile with acyclovir
Famciclovir: 250 mg po bid prophylaxis up to 7 yr
($220/mo) (JAMA 1991;265:747; Arch
Immunocompromised: Dermatol 1993; 129:582;
acyclovir 200–400 mg po JID 1994;169:1338).
3–5×/d ($80/mo) Decreases HSV shedding

Docosanol 10% cream,
topical 5×/d (Med Lett
2000;42:108) ($14)
Encephalitis Acyclovir: IV-10–15 mg/kg High rates of long-term
q8h × 14–21 days morbidity in survivors (NEJM
1986;314:144)
Mucocuteaneous in Acyclovir: 5 mg/kg IV q8h × Alternatives: Acyclovir 400
immuno-competent host 5 days mg po 5×/d × 10 days
Valacyclovir 1 g po tid × 10
days
Famciclovir 500 mg po bid ×
7 days
Mucocutaneous Acyclovir: IV—5 mg/kg q8h × AIDS patients often require
progressive/compromised 7–14 days; po—400 mg po preventative therapy with
host 5×/d × 7–14 days acyclovir 200–400 mg po
Famciclovir: 250 mg po tid 3–5×/d indefinitely
Valacyclovir: 500 mg po bid
Burn wound Acyclovir: IV—5 mg/kg q8h ×
7 days; po—200 mg 5×/d ×
7–14 days
Prophylaxis—high- risk Acyclovir: IV—5 mg/kg q8h; Organ and bone marrow
pateients po—200–400 mg 3–5×/d transplant recipients; treat
seropositive patients for 1–3
mo post-transplant (NEJM
1989;320:1381)
Keratitis Trifluridine: Topical (1%) 1 Ophthalmologist should
drop q2h up to 9 drops day × supervise treatment.
10 days Alternative is vidarabine 3%
ointment, 1/2 inch ribbon
5×/d.
Acyclovir-resistant Foscarnet: IV—40 mg/kg/q8h Thymidine kinase deficient
× 14–21 days strains are most common
Topical trifluridine for cause of resistance and are
accessible lesions using 1% almost always from
ophthalmic solution tid immunosuppressed patients
(Lancet 1992;340:1040) unresponsive to acyclovir
(NEJM 1991; 325:551; NEJM
1989;320:293; J Infect Dis
1990;161:1078).
Most acyclovir-resistant
strains are also resistant to
famciclovir, penciclovir, and
ganciclovir, but respond to
foscarnet (CID
1998;27:1525)
Foscarnet-resistant HSV
may become acyclovir
susceptible (JID
1994;109:193); most
acyclovir-resistant HSV are
resistant to penciclovir
(Famciclovir) and ganciclovir
VARICELLA-ZOSTER (see Ann Intern Med 130:922, 1999)
Chickenpox, adult Valacyclovir: 1 g po tid × 5 Must treat within 24 hr of
immunocompetent days exantham; efficacy
established (Ann Intern Med
1992;117:358)
Chickenpox, adult Acyclovir: 10 mg/kg IV q8h Treat as quickly as possible
immunosuppressed × 7 days ($1058)
Pneumonia Acyclovir: IV 10–12 mg/kg Efficacy not clearly
q8h × 7 days ($1058) established but appears best
Valacyclovir: 1 g po tid × 10 if treatment is initiated
days ($267) within 36 hr of admissions
(RID 1990;12:788)
Dermatomal or Acyclovir: IV 10 mg/kg q8h Indications to treat are
disseminated zoster; × 7 days ($1075) greater for severe disease,
immunosup-pressed early disease, or zoster in
immuno-suppressed host
(NEJM 1983;308:1448; AmJ
Med 1988;85 Suppl 2A:84;
Infect Dis Clin Pract
1993;2:100)
Treatment can be started as
long as new lesions are
forming
Foscarnet for
acyclovir-resistant strains,
60 mg/kg IV 2–3 ×/day for
7–14 days (NEJM
1993;308:1448)
Normal host Valacyclovir: 1 g po tid × 7 Antiviral drugs hasten
days ($119) healing of cutaneous lesions
Acyclovir: 800 mg po 5×/d × and reduce pain including
7–10 days ($43) acyclovir (Am J Med
Famciclovir: 500 mg po tid × 1988;85:84; NZ Med J
7 days ($155) 1991; 10 Suppl 102:93);
Any of the above with or valacyclovir (AAC 1996;
without prednisone: 60 mg/d 39:1546); and famciclovir
po × 7 days, 30 mg/d days (Ann Intern Med
8–14, 15 mg/d days 15–21 1995;123:89)
(Ann Intern Med Patient > 50 yr and those
1996;125:376) with ophthalmic zoster are
Pain control: Tricyclics; other most likely to benefit
options—gabapentin, Ophthalmic zoster: Consult
carbamazepine, lidocaine ophthalmologist
patch, topical capsaicin, (Ophthalmology
regional nerve block, 1986;793:63)
acupuncture. Narcotics are Antiviral treatment should
effective and under-used be started within 72 hr of
rash onset or while lesions
are still forming
Meta-analysis of reports of
oral acyclovir in 691
patients with zoster showed
a 2-fold reduc-tion in
duration of pain (CID
1996;22:341)
Comparative trial of
acyclovir vs. valacyclovir
showed slight advantage
with valacyclovir (AAC
1995;39:1546)
Controlled trial showed
prednisone added to
acyclovir was associated
with more rapid healing,
more rapid return to normal
sleep, and more rapid return
to normal activity (Ann
Intern Med 1996;125:376).
Others have shown less
impressive results (NEJM
1994;330:896)
Valacyclovir is superior to
acyclovir for re-ducing
duration of pain (AAC
1995;39:1546)
Post-herpetic neuralgia:
Amitriptyline
Acyclovir resistant Foscarnet: 40 mg/kg q8h IV Most VZV strains resistant
strains × 10 days ($1061) to acyclovir are resistant to
ganciclovir and famciclovir
Exposure (zoster or Varicella-zoster immune Patient susceptible and has
chickenpox); globin, 625 units IM within substantial exposure (Ann
immunosup-pressed 96 hr of exposure Intern Med 1988;108:221);
Susceptible health care None alternative is to treat
workers chickenpox promptly with
acyclovir if it occurs
Must refrain from patient
contact during days 8–21
postexposure
Prophylaxis in organ Acyclovir: 5 mg/kg IV q8h or Lancet 1983;2:706; NEJM
transplant recipients 200 mg po q6h to 1yr 1989;320:1381
Acyclovir if CMV serology
D–R–(Otherwise
ganciclovir/valganciclovir ×
3–6 mo)
CYTOMEGALOVIRUS
Immunocompetent None
Immunosup-pressed Ganciclovir: Induction, 5 Valganciclovir gives serum
pneumonitis, esophagitis, mg/kg IV bid × 14–21 days, levels comparable to those
colitis, and CNS infection Maintenance, 6 mg/kg IV 5 achieved with IV ganciclovir
days/wk or oral (AAC 2000;44:2811)
($630–779/mo) or Efficacy of treatment is
valganciclovir (see below) established for CMV
Foscarnet: Induction, 60 pneumonitis, esophagitis
mg/kg IV q8h or 90 mg/kg and radiculopathy; response
q12h × 14–21 days, is less impressive with
Maintenance, 90 mg/kg IV qd enteritis and colitis (CID
($2425/mo) 1993;17:644; JID 1993;
Valganciclovir 900 mg po bid 167:278; JID
× 21 days, then 900 mg qd 1993;167:1184; JID 1995;
(maintenance—$1726/month) 172;622)
Cidofovir (Vistide) 5 mg/kg Foscarnet is therapeutically
IV q wk × 2, then 5 mg/kg IV comparable with ganciclovir
q 2 wk + probenecid for CMV colitis in AIDS
patients (Am J Gastroenterol
1993;88:542). Main problem
is poor quality of life
because of long hours of
infusions
Marrow transplant Ganciclovir: 7.5–10 mg/kg/d Ganciclovir plus
recipients IV × 20 days ± maintenance: hyperimmune globulin:
5 mg/kg 3–5×/wk for 8–20 Efficacy best supported for
doses or valganciclovir marrow recipients (Ann
CytoGam (Hyperimmune) in Intern 1988;109:777; Ann
dose of 100–150 mg/kg good Intern Med 1988;109:783;
for seven doses Transplant 1993;55:1339;
JID 1988;158:488; CID
1993;7:S392)
Ganciclovir monotherapy:
Response rates 22–50%
(Pharmacotherapy
1992;12:300) CMV
hyperimmune globulin
(CytoGam) added by some if
severe CMV disease,
infection of allograft,
recurrent disease, or
hypogammaglobulinemia
Solid organ transplants Ganciclovir, valganciclovir, Response rates to
and CytoGam (as above) ganciclovir in heart, liver,
and renal transplant
recipients in 14 reports:
67/85 (79%)
(Pharmacotherapy
1992;12:300). Maintenance
therapy used in 2 of 14
reports
Prophylaxis Marrow Allogenic transplant: D–R+: Recommendations of ECOG
transplant No prophylaxis D+ or R+ (Ann Intern Med 120:143,
Ganciclovir, 5–6 mg/kg IV 1994); D, donor; R,
5–7 days/wk × 3 mo or recipient; CMV
Acyclovir 10 mg/kg IV q8h × seropositive
1 mo, then 800 mg po qid × Optimal results are with
C 3 mo ganciclovir for 3–4 mo (Ann
IVIG 500 mg/kg q2wk × 3 Intern Med 1993;118:173;
mo + cultures for CMV × 120 Lancet 1994;343:749;
days, positive culture: Lancet 1995;341:1380)
Ganciclovir + IVIG to day Oral ganciclovir is superior
100 or until 2–3 wk after last to oral acyclovir for CMV
culture D–R–: No prophylaxis prophylaxis in renal
autologous transplant: R–: transplants (Transplantation
CMV neg-ative blood 1998;66:1682)
products or
leukocyte–filtered products
Organ transplant recipients
Renal Acyclovir 800 mg po qid × 3 Supporting data
mo or
Valacyclovir 1 g bid × 3 mo
Oral acyclovir in renal
transplants—NEJM
1989;320:1381
Liver Ganciclovir 1 g po tid × 2–3
IV ganciclovir in
mo or
marrow, liver, and
Ganciclovir 5–6 mg/kg IV
heart
5–7 days/wk × 3 mo
transplants—NEJM
1996;335:721
Oral ganciclovir in liver
transplants—Lancet
1997;350:1729
Heart Ganciclovir 5 mg/kg IV q12h
Meta-analysis of oral
× 2 wk, then 5–6 mg/kg IV 5
agents—Transplantation
d/wk to complete 3 mo
1998;65:641
Oral valacyclovir—NEJM
1999;340:1462
EPSTEIN-BARR VIRUS
Oral hairy leukoplakia Acyclovir 800 mg po 5×/d or Efficacy established. Relapse
valacyclovir rates high; ganciclovir is
also effective
EBV-associated No antiviral agent Acyclovir confers no benefit
lymphomas (NEJM 1984;311:1163)
Infectious mononucleosis No antiviral agent Prednisone (80 mg/d × 2–3
days, then taper over 2 wk)
in selected cases
HEPATITIS B
Chronic HBV (see p 199) Lamivudine: 100 mg/d po High rates of resistance with
indefinitely prolonged treatment with
Adofovir: 10 mg/d po lamivudine
indefinitely Adofovir is active vs
Interferon alfa-2b 5 mil lamivudine-resistant strains
units/d or 10 mil units 3×/wk and resistance rates are low
SC or IM 4 mo ($6820) Tenofovir is probably as
effective as adofovir, but
not FDA-approved for HBV
HEPATITIS C
Chronic HCV (see p 197) Pegylated interferon 1 Ng/kg
SC × 48 wks ($12,493) plus
ribavirin 1000–1200 mg po/d
× 48 wks ($16,531)
Interferon alfa 2b + ribavirin
1000–1200 mg po/d × 48
wks ($19,304)
INFLUENZA
Influenza A & B Zanamivir 10 mg bid × 5d by Efficacy of all four antivirals
treatment inhaler ($48) required initiation within 48
Influenza A treatment Oseltamivir 75 mg po bid × 5 hrs of onset of symptoms
days ($63) Efficacy in reducing
Rimantadine 200 mg po qd or flu-related complications
100 mg po bid × 5 days including pneumonia is
($20) unknown
Amantadine 100 mg po bid × There is cross-resistance
5 days or 100 mg/day if > 65 between amantadine and
yrs or renal failure ($1) ramantadine
Influenza A & B Oseltamivir: 75 mg/d Efficacy of amantadine or
prevention (see below) ($265/6 wks) ramantadine pro-phylaxis is
Ramantadine 100 mg po bid 70–90% (NEJM
or 200 mg qd ($171) 2000;343:1778)
Amantadine 100 mg po bid or Oseltamivir is FDA-approved
200 mg qd ($13) for prophylaxis, is effective
vs both influenza A and B,
and is less frequently
associated with resistance;
however, it is more
expensive
* Prices are AWP 2002 for lowest dose for designated duration
P.192
P.193
P.194
P.195
P.196
B. INFLUENZA (MMWR 2000;49(RR-3).)
1. PREVENTION
Vaccination: Preferred method to prevent influenza. Vaccine efficacy in healthy persons
shows 70–90% efficacy when there is a good match between vaccine strain and epidemic
strain. This has occurred in 13 of the last 14 seasons; the exception was the 1997–98
season when the epidemic was H N -Sydney. Vaccination “spin off” includes protection of
3 2
vulnerable elderly residents of nursing homes when the health care workers who serve
them have flu vaccine (JID 1997;75:.; Lancet 2000;355:93.). The optimal time to
vaccinate is Oct—mid November (see p 104 for vaccination guidelines)
Antiviral agents
Dose Cost
Agent (prophylaxis) Activity (/wk) Comment
Amantadine 200 mg/d × 6 wk Flu A $5 13% had CNS
a
toxicity
Rimantadine 200 mg/d × 6 wk Flu A $28 6% had CNS toxicity a
Oseltamivir 75 mg/d × 6 wk Flu A & $39 GI side effects in
B 10–20% b
a
NEJM 1982;307:580.
b
JAMA 1999;282:1240; NEJM 1999;341:1336.
2. DIAGNOSIS
a. Clinical: Physician diagnosed flu is about 70% specific, about the same as the rapid
tests. Key clues are fever, epidemic of influenza, and typical respiratory tract symptoms
(Arch Intern Med 2000;160;3082.).
b. Rapid tests for office use: Flu O1A (Biostar), QuickView (Quidel), and Zstatflu
(ZymaTx). These cost $15–20/test, results available in 10–20 min, and sensitivity of
57–77%. All three will distinguish influenza A and B. Medical Letter consultants
considered QuickVue to be “the easiest and fastest” (Med Lett 1999;41:121.)
3. TREATMENT MMWR 2000;49(RR-3).; JAMA 1999;282:1240.; Lancet 2000;355:1845.; BMJ
2003;326:1235..
Meta-analysis of published reports showed neuraminidase inhibitors for treatment had an
average 1–2 day reduction in symptoms and a 30% reduction in antibiotic use; for prevention
there was 69–92% efficacy for prevention (BMJ 2003;326:1235.)
P.197
Comparison of drugs for influenza treament
Amantadine Rimantadine Zanamivir Oseltamivir
FDA approval 1966 1993 1999 1999
Activity: A A A & B A & B
influenza
FDA approval
Prophylaxis + + - +
Therapy + + + +
In vivo efficacy
Healthy persons + + + +
High-risk - - - +
persons
Prophylaxis
efficacy 70–90% 70–90% 92% 82%
Treatment
duration 3–5 d 3–5 d 5 d 5 d
Need to treat
within 48 hr + + + +
Response–decrease
duration by 1–1.5 d 1–1.5 d 1–1.5 d 1–1.5 d
Treatment regimen
Age 14–64 100 mg bid 100 mg bid 10 mg bid 75 mg bid
>65 yr 100 mg/d 100 mg/d Same Same
Renal failure Dose change 100 mg/d Same 75 mg/d
Liver failure Standard 100 mg/d ND ND
Prophylaxis Same Same 10 mg/d 75 mg/d
regimen
Side effects CNS-moderate CNS-modest Bronchospasm GI
Cost/5 days
treatment (AWP) $2 $20 $48 $63
Cost/6 wks $13 $171 — $265
prevention
C. HEPATITIS VIRUSES
1. Hepatitis C: Current recommendations for management NIH Consensus Conference:
Managment of Hepatitis C, 2002 (http://consensus.nih.gov/cons/116/116cdc_statement.htm)
a. Natural history: 85% develop chronic infection (viral persistence > 6 mo usually with
elevated ALT). About 10–20% develop cirrhosis within 20 yr, and 1–5% develop
hepatocellular carcinoma within 20 yr (NEJM 1992;327:1906.; NEJM 1995;332:1463.).
Extrahepatic manifestations include arthritis, keratoconjunctivitis sicca, lichen planus,
glomerulonephritis, and essential mixed cryogobulinemia.
b. Laboratory tests (see J Clin Micro 2002;40:4407.)
1. EIA: Standard screening test: Reliable, inexpensive, and FDA arproved; 3rd
generation tests show sensitivity and specificity > 99% in immunocompetent
patients
False negatives: Rare, but seen with hemodialysis and HIV
False positives: Autoimmune disorders
Confirmatory tests: May be unnecessary with liver disease and risk.
Others—qualitative HCV RNA
2. Qualitative HCV RNA with threshold of detection of 50 IU/mL (100 viral
genes/mL)—Confirmatory test
Specificity: >98%, positive confirms EIA; negative may reflect transient decline and
should be repeated
Use: Confirmation of EIA and determination if acute infection cleared
P.198
3. Quantitative HCV RNA: Monitor response
Techniques: PCR (qPCR) or branched DNA (bDNA)
Units: IU is not actual viral particles
Use: Monitor response to therapy
Not useful for prognosis
4. ALT: Weak association with severity of liver disease; useful to monitor response to
treatment but pegylate interferon can cause elevated ALT. 30% with chronic HCV
have normal ALT levels, some progress to cirrhosis
5. Liver biopsy: Used to:
Detect other causes of liver disease; iron, steatosis, alcoholic liver disease, etc.
Baseline for subsequent evaluation
Basis for therapy (although the 80% response rate with genotype 2 or 3 may
preclude need for liver biopsy)
6. Hepatocellular carcinoma
Incidence: 0–3% per year with HCV—associated cirrhosis
Screening: alpha-fetoprotein or ultrasound; some screen with one or both q6
mo but no standard based on adequate study and no need in absence of
cirrhosis
c. Results with treatment using pegylated interferon + ribavirin (NEJM 2002;347:975.;
Lancet 2001;258:958.)
Clinical trials Genotype 1 Genotype 2,3
Pegylated interferon Pegylated interferon Interferon and pegylated
+ ribavirin vs. superior to interferon interferon are equivalent
interferon + ribavirin
Sustained viral 42–46% w/Rx 48 wks 76–82% w/Rx 24 wks
response (SVR)
d. Indications to treat
1. HCV RNA levels >50 IU/mL and
2. Liver biopsy showing portal or bridging fibrosis and at least moderate inflammation
and necrosis (most have persistently elevated ALT) and
3. No contraindications (especially active IDU, alcoholism, neuropsychiatric disorder
and other co-morbidities)
4. Decompensated liver disease—transplant is treatment choice
5. Acute HVC: Treat, but timing is unclear
6. Co-morbidities
Active IDU: Case-by-case decision
HIV: Case-by-case decison (Response is reduced and methods to sequence
treatment of HIV and HCV are unclear)
EtOH: Heavy consumption (>80 g/d compromises HCV Rx)
e. Treatment
1. Genotype 1: Pegylated interferon + ribavirin × 48 weeks*
2. Genotype 2 or 3: Pegylated interferon + ribavirin or interferon + ribavirin × 24
weeks*
3. Retreatment
Nonresponders: May have improved histology 15–20% of nonresponders to
interferon-ribavirin respond to pegylated interferon-ribavirin
Relapse: Most relapse again if given same regimen
4. Side effects of interferon: Dose related. Dose reduction is required in 10–40%;
treatment is discontinued because of side effects in 10–20%. The major side effects
follow.
P.199
Flu-like symptoms—fever, chills, headache, arthralgias, myalgia, tachycardia; most
patients experience these effects early in therapy, but they improve with continued
treatment and acetaminophen therapy.
Hematologic—reduced neutrophil and platelet counts may occur and require dose
reduction or supportive therapy.
Late side effects—fatigue, myalgias, bone marrow suppression, rash, autoimmune
thyroid disorders, alopecia, irritability, and neuropsychiatric effects (especially
depression).
Rare side effects—autoimmune disease, suicide risk, cardiac failure, renal failure,
hearing loss, pulmonary fibrosis, retinopathy.
Ribavirin—most patients develop hemolytic anemia that may require dose reduction.
Ribavirin may cause gout and is teratogenic.
2. Hepatitis B
Indications to treat: (1) detectable HBsAg±HBeAg; HBV DNA (usually >100,000 c/mL), and
(2) liver histology showing necroinflammation (Hepatology 2001;34:1225.). FDA approved
agents include interferon and nucleosides/nucleotides.
a. Interferon-alfa: Meta-analysis of 15 trials involving 837 patients with doses of 7–30
2
MU/m /wk showed trends favoring treatment in all studies, improvement in all disease
2
markers with treatment, and superior results with high doses (>5 MU/m /wk) (Ann Intern
Med 1993;119:312.). About 33% showed disappearance of HBeAg with interferon versus
12% in controls (NEJM 1997;336:347.). Current recommendations are:
5 million units/d or 10 million units SC 3 ×/wk × 4 mo (30–35 million units/wk).
Lower doses are less effective, and higher doses are usually too toxic. Drug costs
about $5,400 (AWP).
Monitor ALT levels at 2- to 4-wk intervals; HBsAg, HBeAg, and HBV DNA at baseline;
at end of treatment and 6 mo later. Increase in aminotransferase levels should not
lead to discontinuation.
Best response is with high baseline aminotransferase, low HBV DNA, active histologic
changes indicating inflammation and necrosis, fibrosis, short duration before
therapy, and absence of complicating disease (NEJM 1990;323:295.; Am J
Gastroenterol 1993;88:1887.; Ann Intern Med 1993:119:312.).
b. Nucleoside analogs:
1. Lamivudine (NEJM 1998;339:61.): Administration of 100 mg lamivudine (3TC) po for
1 yr was associated with ALT normalization in 72% of patients, HBeAg
seroconversion in 16%, improvement in hepatic necroinflammation in 56% of
patients and a sustained virologic response in about 50% at one year (NEJM
1998;339:61.; NEJM 1998;341:1256.). Low frequency of side effects make
lamivudine a first line therapy for chronic hepatitis B. However, drug resistance with
the YMDD mutation occurs at a rate of about 15% per yr (NEJM 2003;348:800.).
One recommendation is to treat patients with HBeAg until they are negative for e
antigen of there is drug resistance (BMJ 2003;323:1164.).
2. Adefovr (NEJM 2003;348:800.): Administration of 10 mg/d po × 48 wks showed
statistically significant improvement in HBV DNA quantitative counts and in
histologic changes. The optimal duration of treatment is unclear but may be lifelong.
Resistance in vitro is only about 2% with treatment × 1 year and the drug appears
to be well tolerated (NEJM 2003;348:800.; NEJM 2003;348:808.).
3. Tenofovir: Highly active against HBV but not FDA approved for this indication. Like
adofovir it is well tolerated and does not seem to induce resistance.
P.200
4. Combination: Despite the theoretical rationale for combination therapy, there are
few data to support the use of interferon and nucleoside analoges at present.
3. Chronic hepatitis D: Efficacy demonstrated for interferon-alfa in patients with the following
criteria: positive HBsAg, anti-HDV IgG and IgM, positive HDV RNA × 3, alanine
aminotransferase C 2 × upper limit of normal × 6 mo, histologic evidence of chronic hepatitis
and positive intrahepatic HDV antigen. Patients with advanced cirrhosis were excluded.
Optimal regimen was 9 million units IM 3 ×/wk for 48 wk. Response, which was generally
transient, was shown by normal alanine transferase and elimination of serum HDV RNA in 7 of
14 patients vs 0 of 13 placebo recipients (NEJM 1994; 330:88.; JAMA 1999;282:511.).
D. HANTAVIRUS PULMONARY SYNDROME
1. Definition (MMWR 2002;51 RR-9.; CID 2002;34:1224.)
Clinical features: HPS due to Sin Nombre virus has a median incubation period of 14–17 days,
a prodrome of 3–5 days, and clinical features consisting initially of myalgias, GI symptoms
(nausea, vomiting, diarrhea), and fever. A clue to the diagnosis in the prodrome stage is
thrombocytopenia. The second stage is characterized by cardiopulmonary involvement with
tachypnea, tachycardia, cough, and postural hypotension. The complete blood count is highly
characteristic with hemoconcentration, leukocytosis with a left shift, thrombocytopenia and
circulating immunoblasts that may resemble atypical lymphocytes. By 48 hours postadmission
most patients have DIC with typical x-ray changes. The mortality rate is 38% in 344 cases in
the U.S.
Diagnosis: The diagnosis is established with serology (EIA IgM) or RT-PCR for Hantavirus
during the first 10 days of illness.
Epidemiology: Rats and mice are hosts for Sin Nombre virus and transmit it by droppings,
saliva, and urine. In the U.S. there were 344 cases reported from 1992 to June 2003 from 31
states, primarily in June and July in the Four Corners area (Arizona, Colorado, New Mexico,
and Utah) (http://www.cdc.gov/ncidod/diseases/hanta.hantavirus.htm). Other areas with HPS
are Argentina, Boliva, Brazil, Canada, Chile, Panama, Paraguay, and Uruguay. The average
age was 37 years. Person-to-person with nosocomical spread was reported in Argentina
(Emerg Infect Dis 1997;3:171.).
Treatment: Supportive care. A trial with ribavirin was unsuccessful (CID 2002;34:304.).
E. SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
1. Case definition: CDC 7/11/03 (http://www.cdc.gov/ncidod/sars/casedefinition)
a. Clinical Criteria
1. Asymptomatic or mild respiratory illness
2. Moderate respiratory illness
Temperature of >100.4°F (>38°C)*, and
One or more clinical findings of respiratory illness (e.g., cough, shortness of
breath, difficulty breathing, or hypoxia).
3. Severe respiratory illness
Temperature of >100.4°F (>38°C)*, and
One or more clinical findings of respiratory illness (e.g., cough, shortness of
breath, difficulty breathing, or hypoxia), radiographic evidence of pneumonia,
respiratory distress syndrome, or autopsy findings consistent with pneumonia
or respiratory distress syndrome without an identifiable cause.
b. Epidemiologic Criteria
1. Travel (including transit in an airport) within 10 days of onset of symptoms
P.201
to an area with current or previously documented or suspected community
transmission of SARS, or
2. Close contact within 10 days of onset of symptoms with a person known or
suspected to have SARS. The last date for illness onset is 10 days (i.e., one
incubation period) after removal of a CDC travel alert. The case patient's travel
should have occurred on or before the last date the travel alert was in place.
c. Laboratory Criteria
1. Confirmed
Detection of antibody to SARS-CoV in specimens obtained during acute illness
or >28 days after illness onset, or
Detection of SARS-CoV RNA by RT-PCR confirmed by a second PCR assay, by
using a second aliquot of the specimen and a different set of PCR primers, or
Isolation of SARS-CoV.
2. Negative
Absence of antibody to SARS-CoV in convalescent serum obtained >28 days
after symptom onset.
3. Undetermined
Labatory testing either not performed or incomplete.
d. Case Classification
1. Probable case: Meets the clinical criteria for severe respiratory illness of unknown
etiology and epidemiologic criteria for exposure; laboratory criteria confirmed,
negative, or undetermined.
2. Suspect case: Meets the clinical criteria for moderate respiratory illness of unknown
etiology, and epidemiologic criteria for exposure; laboratory criteria confirmed,
negative, or undetermined.
2. Diagnostic Evaluation
a. Chest x-ray
b. Pulse oximetry
c. Blood cultures
d. Sputum gram stain and culture
e. Tests for influenza and RSV
f. “Consider” urinary antigen test for S. pneumoniae and Legionella
g. Acute and convalescent sera separated by >21 days for patients who meet definition of
SARS case sent to state or local health departments for testing at CDC
3. Prevention: Transmission occurs primarily by direct contact with infectious material including
large respiratory droplets; unlike TB, spread may also occur by direct contact with respiratory
secretions. The following recommendations are designed to prevent spread to health care
workers and to close contacts.
a. Precautions for hospitalized patients: This includes standard precautions (hand hygiene),
airborne precautions (N95 respirators), and contact precautions (gown and gloves).
b. Advice to close contacts: Be alert to detect fever or respiratory symtpoms. If symptoms
develop, avoid contact with others and seek medical attention.
c. Advice to travelers: Elective travel to epidemic areas should be avoided. If travel to
these areas is required, the traveler should carry a thermometer, household disinfectant,
surgical mask, and disposable alcohol-based hand rubs. It is also advised to check with
health insurance plans about medical care coverage.
d. Ambulatory care and emergency rooms: Screening should be done for possible cases
identified as the presence of fever, respiratory symptoms,
P.202
recent travel to endemic areas, and close contact with a suspected SARS patient.
e. Suspected cases should be evaluated in a separate area.
f. The suspected person with SARS should wear a surgical mask. Health care personnel
should wear an N95 respirator; if not available, a surgical mask should be worn.
F. WEST NILE VIRUS
West Nile Virus (WNV) Infection: Information for Clinicians [CDC
http://www.cdc.gov/ncidod/dvbid/westnile/resources/fact_sheet_clinicians.htm; accessed
7/26/03]: The following is a summary of WNV from the CDC website and other sources:
1. Clinical Features
a. Mild infection
1. About 80% are asymptomatic and 20% develop mild illness.
2. Incubation period is 3–14 days for those with clinical symptoms.
3. Symptoms usually last 3–6 days.
4. Clinical features are sudden onset of afebrile illness accompanied by malaise,
anorexia, nausea, vomiting, eye pain, headache, myalgias, rash and/or
lymphadenopathy.
b. Severe infection
1. About 1 in 150 cases will cause severe neurologic disease, most commonly
encephalitis and less commonly, meningitis
2. The major factor for severe neurologic disease is advanced age.
3. Features of severe disease are fever, weakness, GI symptoms, and a change in
mental status; a minority develop a maculopapular or morbilliform rash involving the
neck, trunk, arms, or legs.
4. A small number of patients have developed severe muscle weakness and flaccid
paralysis or Parkinson's syndrome
5. Neurologic presentations include ataxia, cranial nerve abnormalities, myelitis, optic
neuritis, polyradiculitis, and seizures.
c. Clinical suspicion
This diagnosis should be suspected in adults over 50 years who develop unexplained
encephalitis or meningitis in summer or early fall, especially if there are local cases or
travel to an implicated area.
d. Neurologic complications
1. Viral encephalitis, characterized by:
Fever = 38°C or 100°F, and
CNS involvement, including altered mental status (altered level of
consciousness, confusion, agitation, or lethargy) or other cortical signs (cranial
nerve palsies, paresis or paralysis, or convulsions), and
An abnormal CSF profile suggesting a viral etiology (a negative bacterial stain
3
and culture with a mononuclear pleocytosis [WBC 5–1500 cells/mm ] and/or
elevated protein level [>40 mg/dl]).
2. Aseptic meningitis (among persons aged 17 years and up), characterized by:
Fever = 38°C or 100°F, and
Headache, stiff neck and/or other meningeal signs, and
An abnormal CSF profile suggesting a viral etiology (a negative bacterial stain
3
and culture with a pleocytosis [WBC between 5 and 1500 cells/mm ] and/or
elevated protein level [=40 mg/dl]).
3. Poliomyelitis-like syndromes: acute flaccid paralysis or paresis, (which may
resemble Guillain-Barré syndrome), or other unexplained movement disorders such
as tremor, myoclonus or Parkinson's-like symptoms,
P.203
especially if associated with atypical features, such as fever, altered mental status,
and/or a pleocytosis. Afebrile patients with asymmetric weakness, with or without
areflexia, have also been reported in association with West Nile virus.
2. Diagnosis
1. The most efficient method is detection of IgM in serum which is usually positive at the
time of viral clearance and at the onset of neurologic disease.
2. False positive test may be a problem in patients recently vaccinated against or recently
infected with related flaviviruses including yellow fever, Japanese encephalitis, or
dengue.
a. Laboratory findings
Total leukocyte counts are normal or elevated with lymphopenia and anemia.
Some have hyponatremia.
CSF shows pleocytosis with predominance of lymphocytes, protein is universally
elevated and glucose is normal.
CT scans of the brain are usually normal, but about one third have MRI
demonstrated enhancement of the leptomeninges, the periventricular areas of
both.
3. Treatment: The usual treatment is supportive. There is an NIH-sponsored trial with
hyperimmune globulin, which should be started early.
G. Activity of Antivirals (adapted and updated from NEJM 1999;340:1255.)*
Agent Proven efficacy Possible efficacy
Acyclovir HSV, VZV, CMV EBV, herpes B
Adefovir HBV HIV
Amantadine Influenza A —
Cidofovir HSV, VZV, CMV, Small pox virus, monkey pox
Molluscum
Famciclovir HSV, VZV Hepatitis B
Foscarnet CMV, HSV, VZV HHV-8, HIV
Ganciclovir CMV, HSV HSV, VZV, EBV, HHV-8, HBV
Interferon-alfa HBV, HCV, HHV-8, Hepatitis D, SARS-CoA
HPV
Lamivudine HBV, HIV —
Oseltamivir Influenza A & B
Penciclovir HSV
Ribavirin Lassa fever, HCV RSV, paraflu, influenza A & B, measles,
Hantavirus, vaccinia
Rimantadine Influenza A
Valacyclovir HSV, VZV, CMV EBV
Valganciclovir CMV, HSV
Zanamivir Influenza A & B
* Antiretroviral agents for HIV are not included
Footnotes
*Failure to achieve early viral response (C2 log decrease in HCV RNA) at 12–24 weeks: stop therapy
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Sepsis and Sepsis Syndrome
Sepsis and Sepsis Syndrome
A. CONSENSUS CONFERENCE DEFINITIONS (Crit Care Med
1992;20:864.; Chest 1992;161:1644.; NEJM 2001;344:707.)
Systemic inflammatory response syndrome (SIRS). Two or
more:
1. Temperature >38°C
2. Heart rate >90 beats/min
3. Respiratory rate >20 breaths/min
3 3
4. White blood cell count >12,000/mm , <4,000/mm , or
>10% immature (bands) forms
Sepsis. SIRS plus a documented infection (positive culture for
organism).
Severe sepsis. Sepsis associated with organ dysfunction,
hypoperfusion abnormalities, or hypotension. Hypoperfusion
abnormalities include, but are not limited to, lactic acidosis,
oliguria, or an acute alteration in mental status.
Septic shock. Sepsis-induced hypotension despite fluid
resuscitation plus hypoperfusion abnormalities.
Culture negative populations.
Culture negative sepsis. SIRS plus empirical antibiotic
treatment for a clinically suspected infection but in whom all
cultures were negative.
Culture negative severe sepsis. SIRS associated with organ
dysfunction, hypoperfusion, or hypotension. However, all cultures
were negative.
Hypoperfusion abnormalities include, but are not limited to, lactic
acidosis, oliguria, or an acute alteration in mental status.
Culture negative septic shock. SIRS associated with
hypotension despite fluid resuscitation plus hypoperfusion
abnormalities. However, all cultures were negative.
B. EMPIRIC ANTIBIOTIC SELECTION FOR SEPSIS (Med Lett
2001;43:69.)
1. Life-threatening sepsis: Aminoglycoside (gentamicin,
tobramycin, or amikacin)plus one of the following:
Third-generation cephalosporin (cefotaxime, cefepime, or
ceftriaxone)
Ticarcillin-clavulanic acid or piperacillin-tazobactam
Imipenem or meropenem
Suspected methicillin-resistantS. aureus: Add vancomycin ±
rifampin
2. Intra-abdominal or pelvic infection:
Any of the following with or without an aminoglycoside:
Ticarcillin-clavulanic acid, piperacillin-tazobactam,
ampicillin-sulbactam, imipenem, cefoxitin, or cefotetan
3. Biliary tract source:
Piperacillin + metronidazole ± aminoglycoside
Piperacillin-tazobactam or ampicillin-sulbactam ±
aminoglycoside
4. Urinary tract infection (Nosocomial):
Third-generation cephalosporin ± aminoglycoside
Fluoroquinolone ± aminoglycoside
Ticarcillin/clavulanate or piperacillin/tazobactam ±
aminoglycoside
Imipenem or meropenem ± aminoglycoside
5. Meningitis
Community-acquired: Ceftriaxone or cefotaxime +
vancomycin 2–4 g/d, ± rifampin
Nosocomial: Ceftazidime + vancomycin 2–4 g/d
6. Nosocomial pneumonia: Aminoglycoside + cefepime, imipenem,
or meropenem ± vancomycin if MRSA suspected
7. Community-acquired pneumonia:
P.205
Ceftriaxone or cefotaxime + macrolide (azithromycin,
clarithromycin, or erythromycin)
Fluoroquinolone (levofloxacin, gatifloxacin, or moxifloxacin)
Aspiration pneumonia suspected: Add clindamycin or
metronidazole
8. Neutropenia + sepsis
Ceftazidime ± aminoglycoside
Imipenem, meropenem, or cefepime ± aminoglycoside
Piperacillin/tazobactam or ticarcillin/clavulanate, each with
amikacin
All of above: Add vancomycin if MRSA are suspected
9. Endocarditis: Vancomycin + gentamicin
C. DROTRECOGIN (XIGRIS)
Product: Activated protein C exerts antithrombotic effect by
inhibition of Factor Va and VIIIa, increases fibrinolysis and
inhibits TNF.
Indication: Severe sepsis with:
1. APACHE II score >25,
2. suspected or proven source of infection, and
3. G3 signs of systemic inflammation and G one spesis-induced
organ dysfunction.
Dose: 24 mcg/kg/hr by continuous infusion × 96 hr (No dose
modification for renal or hepatic failure)
Efficacy: In the major clinical trial the 28 day mortality was
25% in drotrecogen recipients compared to 31% in the placebo
group (p<0.05) (NEJM 1999;340:207.).
Side effects: Major toxicity causes bleeding; in the large clinical
trial the frequency of serious bleeding events was 3.5% in
drotrecogen recipients compared to 2% with placebo recipients.
Contraindication: Active, recent, or high risk of bleeding
include trauma, epidural catheter, or intracranial lesion. Drug
should be stopped 2 hours before invasive procedures and can be
started 12 hrs after major surgery if hemostatis is adequate.
D. INTRAVASCULAR CATHETER-RELATED INFECTION:
Recommendation of IDSA (CID 2001;32:1249.)
Nontunneled central venous catheters
1. Blood culture × 2, remove catheter, culture catheter tip and
insert new catheter over guidewire
2. Empiric antibiotics if seriously ill
3. Serious or complicated infection including septic
thrombophlebitis, endocarditis or osteomyelitis: Remove
CVC and treat 4–6 wks (6–8 wks for osteomyelitis)
4. Uncomplicated infection:
Coag-neg staph: Remove CVC and treat 5–7 days or
retain catheter and treat 10–14 days ± lock therapy
S. aureus: Remove CVC and treat 14 days; if TEE is
positive: treat for endocaraditis
GNB: Remove CVC and treat 10–14 days
Candida: Remove CVC and treat with antifungal × 14
days
Tunneled central catheters
1. Complicated infections such as port abscesses: Remove CVC
and treat with antibiotics 10–14 days
2. Other major complications such as septic thrombophlebitis,
endocarditis, or osteomyelitis: Remove CVC and treat with
antibiotics 4–6 wks or 6–8 wks for osteomyelitis
3. Uncomplicated infections:
Coag-neg staph: Retain CVC and treat with antibiotics
for 7 days + antibioitic lock therapy for 10–14 days. If
there is persistence or deterioration: Remove CVC.
P.206
S. aureus: Remove CVC and treat 14 days or keep CVC
and remove if there is clinical progression
GNB: Remove CVC and treat 14 days or retain CVC and
give systemic antibiotics + lock therapy. Failure to
respond: Remove CVC and treat 10–14 days
Candida: Remove CVC and treat with antifungal therapy
10–14 days
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Compromised Host
Compromised Host
PATHOGENS ASSOCIATED WITH
IMMUNODEFICIENCY
Condition Usual conditions Pathogens
Neutropenia (<500/mL) Cancer Bacteria: Aerobic
chemotherapy; GNB (coliforms
adverse drug and
reaction; pseudomonads);
leukemia S. aureus, Strep
viridans,
S. epidermidis
Fungi:
Aspergillus,
Candida sp
Cell-mediated immunity Organ Bacteria: Listeria,
transplantation; Salmonella,
HIV infection; Nocardia,
lymphoma mycobacteria (M.
(especially tuberculosis and
Hodgkin's M.
disease); avium),Legionella
corticosteroid Viruses: CMV, H.
therapy simplex,
varicella-zoster, JC
virus
Parasites:
Pneumocystis
carinii;
Toxoplasma;
Strongyloides
stercoralis;
cryptosporidia
Fungi: Candida,
Cryptococcus,
Histoplasma,
Coccidioides
Hypogamma-globulinemia Multiple Bacteria: S.
or myeloma; pneumoniae, H.
dysgamma-globulinemia* congenital or influenzae (type B)
acquired Parasites: Giardia
deficiency; Viruses:
chronic Enteroviruses
lymphocytic
leukemia
Complement deficiencies Congenital Bacteria: S.
C2, 3 pneumoniae, H.
C5 influenzae
C6–8 S. pneumoniae, S.
Alternative pathway aureus,
Enterobacteriaceae
Neisseria
meningitidis
S. pneumoniae, H.
influenzae,
Salmonella
Hyposplenism Splenectomy; S. pneumoniae, H.
hemolytic influenzae, DF-2
anemia
Defective chemotaxis Diabetes, S. aureus,
alcoholism, streptococci,
renal failure, Candida
lazy leukocyte
syndrome,
trauma, SLE
Defective neutrophilic Chronic Catalase-positive
killing granulomatous bacteria:S.
disease, aureus, E. coli;
myeloperoxidase Candida sp
deficiency
* Patients with primary immune deficiency disorders should receive
IV immunoglobulin (200 mg/kg monthly) (Med Lett 1992;34:116).
P.207
GUIDELINES FOR USE OF ANTIMICROBIAL
AGENTS IN NEUTROPENIC PATIENTS WITH
UNEXPLAINED FEVER
(Infectious Disease Society of America, CID 2002;34:730.; reprinted with
permission)
P.208
Definition: Fever is defined as a single oral temp of 38.3°C × 1 or
38.0°C for over one hour. Neutropenia is defined as an ANC
3 3 3
<500/mm or <1000/mm with a predicted decrease to <500/mm .
Evaluation for vancomycin need:
1. suspected catheter-related infection,
2. known colonization with beta-lactam resistant S. pneumoniae or
MRSA,
3. positive blood cultures for GP bacteria prior to identification, or
4. hypotension.
Assessment for possible oral antibiotic treatment: Patients at low risk
for complications may often be treated with oral antibiotics if there is
no focus of infection and lack of findings for systemic infection such
as rigors or hypotension. If outpatient treatment is to be used, there
must be access to medical care 24/7.
Risk assessment: Factors supporting low risk are an ANC exceeding
3 3
100/mm , absolute monocyte count exceeding 100/mm , normal chest
x-ray, nearly normal renal and hepatic tests, neutropenia less than 7
days, malignancy in remission, temperature peak less than 39°C,
early evidence of marrow recovery, and none of the following: IV
catheter site infection, neurologic or mental status changes,
appearance of illness, abdominal pain or cormorbidity/complications.
Antibiotic selection (Figure 1)
FIGURE 1: GUIDE TO INITIAL MANAGEMENT
1. Low risk, oral treatment: Ciprofloxacin plus
amoxicillin-clavulanate.
2. Low risk, IV therapy: Cefepime, ceftazidime, or carbapenem
3. High risk with no need for vancomycin: Monotherapy (see Figure
1) or dual therapy: aminoglycoside plus either an
antipseudomonal penicillin, cefepime, ceftazidime, or
carbapenem.
4. High risk and vancomycin needed: Vancomycin plus cefepime,
ceftazidime, or carbapenem plus/minus aminoglycoside.
P.209
Modifications of therapy based on response at 3–5 days (Figures 2 and
3)
Figure 2: Management of patients who become afebrile in first
3–5 days of initial antibiotic therapy.
Figure 3: Treatment of patients who have persistent fever after
3–5 days of treatment and for whom the etiology of the fever is
not found.
1. Response and pathogen defined: Adjust therapy based on
pathogen.
2. Response and no pathogen identified: Oral therapy should be
continued. IV therapy may be changed to oral ciprofloxacin plus
amoxicillin-clavulanate after 48 hours
3. Persistent fever at 3 days and no change in patient condition:
Continue same antibiotics, but consider discontinuing vancomycin
if there is no clear need for it.
4. Persistent fever at 3–5 days and progressive disease: Change
antibiotic regimen depending on the initial regimen. This includes
the addition of vancomycin if it was not initially used and there
are criteria for it, or consideration of discontinuing vancomycin if
it was included in the initial regimen.
5. Persistent fever at days 5–7: Consider antifungal agent such as
amphotericin B, lipid amphotericin B (no more effective, but
reduced toxicity), or fluconazole. Fluconazole is acceptable at an
institution where Aspergillus and azole-resistant Candida
infections are uncommon, where fluconazole was not used as
prophylaxis, and when there is no evidence of pulmonary disease
or sinusitis. Recent reviews have not shown clear advantages in
efficacy for empiric use of amphotericin B, lipid amphotericin,
itraconazole, or fluconazole.
Antibiotic discontinuation (Figure 4): Low risk patients may have
antibiotics discontinued when they are afebrile 5–7 days. If the ANC
increases above 500/mL, stop antibiotics at 4–5 days. If there is
3
persistent fever at day 3 and persistent ANC <500/mm , continue
antibiotics for 2 weeks and reasses.
FIGURE 4: DURATION OF ANTIBIOTIC THERAPY
P.210
Miscellaneous issues
Antiviral drugs: Not recommended unless there is laboratory or
clinical support for use.
Granulocyte transfusions: Not recommended.
G-CSF or GM-CSF: Not recommended for routine use, but may be
considered if there is an expected long delay in marrow recovery and
those with documented infections who do not respond to antibiotics.
Prophylaxis in neutropenic patients without fever: TMP-SMX is
sometimes recommended for PCP regardless of neutropenia. There are
good data supporting efficacy of prophylaxis with TMP-SMX,
quinolones, fluconazole, and itraconazole for reducing the number of
infectious complications of neutropenia, but the Panel recommends
against this prophylaxis due to the concerns for antibiotic resistance
and the failure of these studies to show reduction in mortality.
FIGURE 5: COMMON INFECTIONS BY TIME AFTER MARROW
TRANSPLANTATION*
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Toxic Shock Syndrome: Case Definition of
Cdc (MMWR 29:229, 1980)
Toxic Shock Syndrome: Case Definition
of Cdc (MMWR 29:229, 1980)
1. Fever: Temperature /38.9°C (102°F).
2. Rash: Diffuse macular erythroderma.
3. Desquamation: 1–2 wk after onset, especially palms and soles.
4. Hypotension: Systolic <90 mm Hg for adults or <5th percentile by age
for children or orthostatic syncope.
5. Involvement of three or more of the following organs.
GI: Vomiting or diarrhea at onset
Muscular: Severe myalgia or creatine phosphokinase >2× normal
Mucous membrane: Vaginal, oropharyngeal, or conjunctival
hyperemia
Renal: BUN or creatinine /2× normal or /5 WBC/HPF in absence
of UTI
Hepatic: Bilirubin or transaminase levels / 2× normal
Hematological: Platelets <100,000/mm3
CNS: Disoriented or altered consciousness without focal
neurologic signs when fever and neurologic signs are absent
6. Negative results for the following (if obtained): Cultures of blood,
throat, and cerebrospinal fluid; negative serology for Rocky Mountain
spotted fever, leptospirosis, or measles.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Group A Streptococcal Infections
Group A Streptococcal Infections
Classification and Definition of Group A Streptococcal Toxic Shock
Syndrome: Working Group on Severe Streptococcal Infections (CDC)
(Reprinted with permission from JAMA 269:390, 1993)
Proposed Case Definition for the Streptococcal Toxic Shock
Syndrome*
I. Isolation of group A streptococci (Streptococcus pyogenes)
A. From a normally sterile site (e.g., blood, cerebrospinal,
pleural, or peritoneal fluid, tissue biopsy, surgical
wound)
B. From a nonsterile site (e.g., throat, sputum, vagina,
superficial skin lesion)
II. Clinical signs of severity
A. Hypotension: Systolic blood pressure . 90 mmHg in
adults or <5th percentile for age in children and
B. 22 of the following signs
1. Renal impairment: creatinine 2177 6mol/L (22
mg/dL) for adults or greater than or equal to twice
the upper limit of normal for age. In patients with
preexisting renal disease, a 22-fold elevation over
the baseline level
2. Coagulopathy: platelets .100 × 10°/L
3
(.100,000/mm ) or disseminated intravascular
coagulation defined by prolonged clotting times, low
fibrinogen level, and the presence of fibrin
degradation products
3. Liver involvement: alanine amino-transferase
(SGOT), asparate amino-transferase (SGPT), or total
bilirubin levels greater than or equal to twice the
upper limit of normal for age. In patients with
preexisting liver disease a 22-fold elevation over
the baseline level
4. Adult respiratory distress syndrome defined by
acute onset of diffuse pulmonary infiltrates and
hypoxemia in the absence of cardiac failure, or
evidence of diffuse capillary leak manifested by
acute onset of generalized edema, or pleural or
peritoneal effusions with hypoalbuminemia
5. A generalized erythematous macular rash that may
desquamate
6. Soft-tissue necrosis, including necrotizing fasciitis or
myositis, or gangrene
* An illness fulfilling criteria IA and IIA and IIB can be defined as a
definite case. An illness fulfilling criteria IB and IIA and IIB can be
defined as a probable case if no other etiology for the illness is
identified.
Therapy of Streptococcal Infections of Skin and Soft Tissue
(NEJM 1996;334:240.; AAC 2003;423:104.)
1. Antibiotic: S. pyogenes is exquisitely sensitive to
beta-lactams; penicillin is preferred for pharyngitis,
erysipelas, impetigo, and cellulitis. Experimental models of
fulminant infections show clindamycin is superior, presumably
because it inhibits protein synthesis and activity is
independent of inoculum size. Clindamycin or clindamycin plus
penicillin is preferred for necrotizing fasciitis, myositis,
empyema, and streptococcal toxic shock syndrome. Studies in
the mouse myositis model show clindaymcin is superior to
penicillin for inhibiting streptococcal toxin production in vivo;
penicillin combined with clindamycin showed no antagonism
(AAC 1987;31:213; AAC 2003;423;104)
2. IVIG: Anecdotal studies support use for streptococcal toxic
shock syndrome at suggested dose of 1g/kg day 1 then
0.5g/kg on days 2 and 3 (CID 2003;37:333)
3. Surgery: Prompt and aggressive exploration and debridement
of deep-seated infections are important
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Anaerobic Infections
Anaerobic Infections
1. Susceptibility in vitroa
Bacteroides
B. fragilis (other),
Susceptibility group Prevotella Fusobacteria Peptostrep Clostridia
>95% Beta-lactam-BL Same as B. Same as B. Same as B. Ampicillin-sulbactam
inhibitors fragilis fragilis fragilis Chloramphenicol
Chloramphenicol Cefoxitin Penicillin G Penicillin G Imipenem
Imipenem Cefoperazone Piperacillin Piperacillin Penicillin G
Metronidazole Cefotaxime Trovafloxacin Ceftazidime Piperacillin
Clindamycin Moxifloxacin Cefotetan Cefotaxime
Trovafloxacin Cefotetan Cefoperazone Piperacillin
Moxifloxacin Cefoxitin Ceftriaxone
Gatifloxacin Trovafloxacin
Gatifloxacin
Moxifloxacin
Clindamycin
85–95% Cefoxitin Cefotetan Cefoperazone Metronidazole Cefotetan
Gatifloxacin Ceftazidime Cefotaxime Ciprofloxacin Cefoxitin
Moxifloxacin Ceftriaxone Moxifloxacin Levofloxacin Ceftriaxone
Gatifloxacin
Clindamycin
70–84% Piperacillin Penicillin G Ceftazidime Cefoxitin
Ceftizoxime Ciprofloxacin Clindamycin
Clindamycin
50–69% Cefotetan Levofloxacin — — Metronidazole
Cefoperazone Fluoroquinolones
Cefotaxime
Ceftazidime
Ceftriaxone
<50% Levofloxacin Ciprofloxacin Ceftazidime
Ciprofloxacin
Penicillin G
2. Outcome of Bacteroides bacteremia in 128 patients(CID 30:870, 2000)
Active drug Inactive drug P value for difference
Mortality 16% 45% 0.04
Clinical failure 22% 82% 0.002
Microbiological persistence 12% 42% 0.06
3. Susceptibility of anaerobic bacteria. Modified from National Committee for Clinical Laboratory Standards,
Working Group on Anaerobic Susceptibility Testing (J Clin Microbiol 26:1253, 1988.; updated Antimicrob Ag
Chemother 2001;45:1238.)
P.214
ESSENTIALLY ALWAYS ACTIVE
Metronidazole (except some nonsporulating GPB)
Chloramphenicol
Imipenem/meropenem
Beta-lactam-beta-lactamase inhibitor combinations (especially piperacillin-tazobactam)
USUALLY ACTIVE
Clindamycin (increasing in vitro resistance—AAC 2001;45:1238.; AAC 2003;47:148.)
Cefoxitin
Antipseudomonad penicillins
Trovafloxacin/moxifloxacin/gatifloxacin
UNPREDICTABLE ACTIVITY
Cephalosporins (other)
Penicillins (other—especially antistaphylococcal agents)
Vancomycin (Gram-positive anaerobes only)
Erythromycin (Fusobacteria often resistant)
Tetracyclines
VIRTUALLY NEVER ACTIVE
Aztreonam
Aminoglycosides
Trimethoprim-sulfamethoxazole
Footnote
aAdapted from: Principles and Practice of Infectious Diseases, AAC 1999;43:2231; AAC 1999;43:2320; CID
2000;30:870; AAC 2001;45:1238; Anaerobe 2001;7:285; CID 2002;35:S126; AAC 2003;47:148.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Fever of Unknown Origin
Fever of Unknown Origin
A. Definition
Classic (Medicine 1961;40:1.):
1. Illness × 0 3 wks,
2. Documented fever 5 101°F (38.3°C), and
3. Negative diagnostic evaluation with one week in hospital
Contemporary: 2 modifications
1. Emphasis on diagnostic evaluation in outpatient clinic
2. Emphasis on subtypes
Nosocomial: Posteroperative complications, drug fever, C, difficile, phlebitis pulmonary emboli,
ICU sinusitis (Brit J Hosp Med 1996;56:21.)
Immunodeficient (chemotherapy etc): Infection (JID 1990;161:381.)
HIV-associated (pre-HAART): MAC, CMV, PCP, TB, lymphoma, Bartonella (J Intern Med
1994;236:529.)
Elderly: Infections, tumors, and connective tissue diseases (especially temporal arteritis and
polymyalgia rheumatica) (J Am Geriatr Soc 1993;41:1187.)
Young patients: Many undiagnosed (30%) and long-term follow-up shows benign course (Arch
Inter Med 2003;163:1033.)
Prolonged fever (>1 year): Lymphoma, factitious, normal variant, granulomatous hepatitis
B. Etiologic diagnosis in the 5 standard categories: Infection, neoplasm, connective tissue, miscellaneous, and
undiagnosed:
Source Petersdorf1 Larson2 Barbado3 Knockaert4 Likuni5 DeKleijn6 Vander7
Period of 1952–57 1970–80 1968–81 1980–89 1982–92 1992–94 1991–99
review
Location U.S. U.S. Spain Belgium Japan Netherlands Belgium
Number 100 105 133 197 153 167 189
Diagnosis 91 84 78 74 88 69 52
made, %
Infection, %* 40 36 39 30 33 37 30
Neoplasm, %* 21 38 25 10 16 18 15
Connective 19 15 19 13 35 33 34
tissue, %*
Miscellaneous, 21 11 16 29 16 11 20
%*
* % in cases with a final diagnosis
1 Medicine 1961;40:1
2 Medicine 1982;61:269
3 J Med 1984;15:185
4 Arch Intern Med 1992;152:51
5 Intern Med 1994;33:67
6 Medicine 1997;76:392
7 Arch Intern Med 2003;163:1033
P.215
C. Major conditions within categories in most contemporary reviews (Arch Intern Med 2003;16:1033.)
1. Infection: Endocarditis, TB, UTI, and intra-abdominal abscess
2. Malignancy (“omas”): Hematologic, solid tumor with hepatic mets
3. Connective tissue: Still disease, polymyalgia rheumatica, and granulomatous disease (sarcoid, Crohn
disease, granulomatous hepatitis, and temporal arteritis)
4. Miscellaneous: Pulmonary emboli, drug fever, periodic fever, and “habitual hyperthermia”
5. No diagnosis: Long-term follow-up in 80 cases showed no late sequelae (Arch Intern Med 2003;163:1033.)
D. Diagnostic tests (Arch Intern Med 2003;163;545.)
Step 1: Confirm fever (daily temps)
Fever pattern: not helpful (Arch Intern Med 1979;139:1225.)
Stop meds: Fever resolves <72 hrs or there is another cause (Inf Dis Clin N Amer 1996;10:85.)
Step 2: Selected tests
CT abdomen: Cause found in 19% (Radiology 1980;136:407.) Repeat scan is not helpful
Nuclar scans: Variable
Endocarditis: Duke criteria-sensitivity 82% (CID 1995;21:905.)
Liver biopsy: Yield is 14–17% (Arch Intern Med 1977;137:1001.; J Clin Gastro 1993;17:29.) (but
usually with abnormal LFTs)
Temporal artery bx: 16% (J Am Gastric Soc 1993;41:1187.) (in age >50 yrs)
Leg doppler: 2–6% (Intern Med 1994;33:67.)
Tests that are usually not helpful: Ultrasound, bone scan, MRI, D-dimer assay, ESR, and CRP
E. Fever evaluation in critically ill patients Recommendations of the Society of Critical Care Medicine and the
ISDA (Clin Infect Dis 1998;26:1042.)
Blood culture: Two blood cultures (with 10–15 mL each) from separate sites drawn 510 minutes apart. For
skin preparation, povidine iodine (10%) should be allowed to dry 2 minutes and tincture of iodine (1–2%)
should be allowed to dry 30 seconds. Alcohol with no drying time is an alternative. With an intravenous
catheter, one peripheral vein sample and one through the catheter is an alternative to 2 peripheral vein
samples, but the results provide less precise information.
Intravascular catheters: The risk of fever with central venous catheters is 5–10 per 1000 catheter days
and for peripheral IV catheters the risk is <0.2 per 1000 catheter days. If there is evidence of tunnel
infection, emboli events, vascular compromise, or sepsis the catheter should be removed.
Pulmonary infection: The evaluation should include a chest x-ray, Gram stain, and culture of respiratory
secretions and pleural fluid evaluation (if present)
P.216
C. difficile: If 52 loose or watery stools/day there should be one stool sample sent for C. difficile toxin
assay. If this is negative a second specimen can be sent. If disease is severe and the toxin test is
negative or delayed, it is appropriate to treat empirically with metronidazole.
Sinusitis: If clinical findings support this diagnosis, there should be a CT scan. With evidence of sinusitis
on CT scan there should be puncture or aspiration of sinuses under sterile conditions for Gram stain and
culture for aerobes, anerobes, and fungi.
Urinary tract infection: Urine should be evaluated by quantitative culture for PMNs. Pyuria should be
tested by esterase dipstick and Gram stain of centrifuged urine sediment. Urine should be collected from
the urine port of a Foley catheter; UTIs almost always show >104 cfu/mL and pyuria with a catheter
collection. If the delay in culture of collected urine >1 hr it should be refrigerated or placed in a
preservative.
Postop fever: Noninfectious fever is common during the first 48 hrs. post-operative. Unexplained fever
>72 hrs post-operative should be evaluated with chest x-ray, urine culture and urinanalysis, and exam for
phlebitis, thrombosis, pulmonary emoblism, and wound infection.
Fever due to non-infectious causes: Blood products (especially RBC's & platelets), drugs, pancreatitis,
myocardial infarction, pulmonary emboli, and chemical phlebitis.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Treatment of Lyme Disease and Potential
Exposures
Treatment of Lyme Disease and
Potential Exposures
(Recommendations of Med Letter 2000;42:37.; MMWR 1997;46:532.; Ann
Intern Med 1998;128:37.)
Prevention: (NEJM 2003;348:2424.):
1. The vaccine (LYMErix has been withdrawn from the market due to
poor sales (Nat Med 2002;8:311.).
2. Removal of I. scapularis ticks within 36 hrs of attachment using
daily tick checks (regarded as most effective preventive strategy)
(JID 1997;175:996.; NEJM 2001;345:79.; Am J Epidemiol
1998;147;391.).
3. Prophylactic doxycycline for tick bites (see below).
4. Tick control with acaricide (cardaryl, cyfluthrin, or deltamethrin)
in early May reduces I. scapularis nymph population by 68–100%
(J Med Entomol 2001;38:344.).
5. Note that treatment of early Lyme disease (erythema migrans
stage) prevents late sequelae in >95% (Ann Intern Med
1983;99:22.; AAC 1995;39:661.; Am J Med 1992;92:396.; Ann
Intern Med 1996;124:785.; NEJM 1997;337:289.; Ann Intern
Med 2002;136:421.)
Tick bite: Prophylactic doxycycline 200 mg po × 1 reduces the risk of
Lyme disease if given within 72 hours of a bite from a I. scapularis
tick vector especially in a high incidence area, and with bites from
nymphal ticks that are partially engorged (NEJM 2001; 344:79).
Efficacy is 87%. GI intolerance to doxycycline dose is improved if
taken with meal
Epidemiology: In 2000 there were 17,730 cases of Lyme disease
reported in the U.S. The number of cases/incidence per 100,000
population by state: CT—3,773/110.8; RI—675/64.4, NJ—2,459/29.2;
NY—4,329/22.8; DE—167/21.3, PA—2,343/19.2; MA—1,158/18.2,
MD—688/13.0, and WI—631/11.8. The total cases reported for
1991–2000 was 132,438 and the incidence for the U.S. in 2000 was
6.3/100,000 (MMWR 2002; 51:29)
Diagnosis: Recommendations of American College of Physicians (Ann
Intern Med 1997;127:110.)
Clinical diagnosis: Patients from an endemic Lyme disease area
who present with erythema migrans do not require laboratory
confirmation. Seroconversion occurs in 27% with symptoms <7
days, 41% with symptoms 7–14 days and 88% with symptoms
>14 days (Ann Intern Med 2002;136:421.). Confirmation of late
Lyme disease requires objective evidence of Lyme disease plus
laboratory evidence
Culture: Erythema migrans—saline lavage needle aspiration or 2
mm punch biopsy
P.217
of the leading edge show B. burgderfori by culture or PCR in
60–80% (Ann Intern Med 2002;136:421.)
Serology (MMWR 1999;48 RR–7.; JAMA 1999;282:62.): ELISA
testing is standard—sensitivity = 89% and specificity = 72%;
when ELISA results are positive or indeterminant, use a Western
blot. A positive Western blot confirms the diagnosis and a
negative Western blot greatly decreases the probability of Lyme
so that treatment is not indicated.
Phases:
Erythema migrans
Early disseminated Lyme disease with carditis and
neurologic features including lymphocytic meningitis and
radiculoneuropathies
Late Lyme disease with peripheral neuropathies, chronic
encephalopathy, or arthritis with migratory polyarthritis
and/or monoarthritis. The term “chronic Lyme disease” (in
reference to debilitating fatigue) was first applied in 1985
and has no objective findings, but there is considerable
support from Internet site advocacy groups and some
physicians (Ann Intern Med 2002;136:413.). Multiple studies
indicate no evidence of Lyme disease and no benefit from
empiric treatment even with long courses of IV antibiotics
(NEJM 2001;345:85.; Ann Intern Med 1998;128:354.; JID
1995;171:356.; JID 1995;171:423.; CID 2000;31:1107.)
TREATMENT OF LYME DISEASE (Med Lett 2000;42:37.)
Stage Preferred Comment
Erythema Doxy 100 mg Goal is shorten duration of
migrans po bid × 21 d* rash and prevent late
(see footnote) sequelae
Amoxicillin 500 Doxy is effective vs Ehrlichia;
mg po bid × 21 beta-lactams are not
d Amoxicillin preferred for
Cefuroxime pregnant/lactating women
axetil 500 mg Babesiosis requires
po bid × 21 d clindamycin and quinine
Neurologic
Bells palsy Doxy 100 mg Oral treatment is sufficient
po bid × 21–28 for facial nerve palsy alone
d Accounted for 11/503 cases
Amoxicillin 500 (AM J Otolaryn 2002;23:25)
mg po bid ×
21–28 d
More Ceftriaxone 2 “More serious” category
serious g/d IV × 14–28 includes meningitis,
CNS d encephalitis, cranial nerve
Cefotaxime 2 g palsies, peripheral nerve
IV q8h × 14–28 palsies, etc.
d
Penicillin G
20–24 mil
units/d IV ×
14–28 d
Cardiac
1 st degree Doxy 100 mg PR interval <0.3 sec can be
po bid × 21–28 treated orally
d
Amox 500 mg
po tid × 21–28
d
More Ceftriaxone 2 PR >0.3 sec gets parenteral
serious g/d IV × 14–21 drug
d
Penicillin G
18–24 mil
units/d IV ×
14–21 d
Arthritis
Oral Doxy 100 mg Oral therapy usually
po bid × 28 d adequate for arthritis
Amox 500 mg Some require a second course
po tid × 28 d
Parenteral Ceftriaxone 2 Alternative to second month
g/d IV × 14–28 of oral therapy
d Arthroscopic synovectomy
Penicillin G may be useful in refractory
18–24 mil units arthritis of knee
IV × 14–28 d
* A subsequent study showed that doxycycline (200 mg/d) given
for 10 days was as effective as the same regimen given for 20
days or doxycycline given for 16 days with a single 2 g dose of
ceftriaxone (Ann Intern Med 2003;289:1533)
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Infections of Epidermis, Dermis, and Subcutaneous Tissue
Infections of Epidermis, Dermis, and Subcutaneous Tissue
Condition Agent Laboratory Treatment
diagnosis
Superficial erythematous lesions
Abscess S. aureus Culture and Drainage
Anaerobes Gram stain
Acne rosacea ? Appearance Doxycycline*
Metronidazole (0.75% topical)
Isotretinoin (Accutane)
Acne vulgaris Propionibacterium Appearance Tetracycline*
acnes Topical clindamycin 1% gel or
erythromycin 2% gel
Isotretinoin (Accutane)
Tretinoin (Retin-A)
Benzoyl peroxide
Azelaic acid cream (20%)
Adapalene 0.1% gel
Cellulitis: Diffuse Group A strep; S. Culture Penicillinase-resistant penicillin*,
spreading infection of aureus (Vibrio sp advanced edge vancomycin, clindamycin,
deep dermis without and Aeromonas sp of cephalosporin (first generation),
sharp demarcation with fresh or inflammation erythromycin, fluoroquinolone
saltwater (rarely MRSA: Vancomycin, daptomycin,
exposure; others— positive); linezolid
S. pneumoniae, H 3-mm dermal
influenzae, punch,
anaerobes, ulcerated
legionella, portal of
Erysipelothrix entry, blood;
rhusiopathiae, serial DNase
Helicobacter titer (Group A
cinaed) strep)
Erysipelas: Superficial Group A strep Appearance, Penicillin*, clindamycin, cephalosporin
infection with raised (Groups B, C, and often at sites (first generation)
and sharply G strep; S. of
demarcated edge aureus) lymphedema
Lymphangitis Group A strep As above As above
Folliculitis: Infected S. aureus (P. Culture and Local compresses or topical antibiotics.
hair follicle(s) aeruginosa Gram stain Fever, cellulitis, or mild face
whirlpools, hot (usually involvement—treat as furunculosis
tubs, etc) unnecessary)
Furunculosis/carbuncle: S. aureus Culture and Drainage ± penicillinase-resistant
Abscess that starts in Gram stain penicillin*, clindamycin, vancomycin,
hair follicle; carbuncle cephalosporin (first generation),
is deeper and more erythromycin, amoxicillin-clavulanate
extensive MRSA: Vancomycin, daptomycin,
linezolid
Mycobacterial M. fortuitum Culture Disease of compromised host especially
furunculosis negative boils organ transplant recipients and
is clue-culture customers of nail salons (NEJM
for 2002;346:1366)
mycobacteria
at 30° & 37° C
Recurrent furunculosis S. aureus Bathe with hexachlorophene. May be
controlled with chronic clindamycin 150
mg qd × 3 mo*
Nasal carriers of staph—mupirocin to
anterior nares or rifampin 300 mg bid
× 5 days
Paronychia: Infection S. aureus Culture and S. aureus: Incision and drainage ±
of nail fold Gram stain antistaph antibiotic Candida: Topical
nystatin or miconazole
Impetigo: Infection of Group A strep Culture and Dicloxacillin, cloxacillin, cephalexin, or
epidermis with vesicles often with S. Gram stain amoxicillin + clavulanate; topical
(cid:1) pustules on exposed aureus Average yield mupirocin (Am J Dis Child 144:1313,
areas ± of strep even 1990; Arch Dermatol 125:1069, 1989)
lymphadenopathy with biopsy is
only 25%
Whitlow: Infection of S. aureus Culture and Penicillinase-resistant penicillin*,
distal phalanx finger Gram stain clindamycin, cephalosporin (first
generation)
H. simplex Viral culture, Acyclovir
Tzanck prep,
or FA stain
Fungal infections: Candida—red, Scrapings for Skin: Topical antifungal
moist, satellite KOH prep, agent—Miconazole, clotrimazole,
lesions, especially culture on econazole, naftifine, or ciclopirox
skin folds Sabouraud
medium
Dermatophytes: Scrapings for Skin: Topical agents (as above) or oral
Epidermophyton, ketoconazole. Nail: Griseofulvin or
Trichophyton, ketoconazole. Scalp: Selenium sulfide
Microsporum, shampoo + griseofulvin
“ringworm”
Keratinized KOH prep and
tissue—skin, nails, hair culture:
Tinea versicolor: Skin: Topical agents (as above), oral
(see p 161) Wood's light
Malas-sezia ketoconazole, or topical selenium
furfur— red or sulfide
hypo-pigmented
macules
Bites
Dog and cat (NEJM P. multocida: Culture and Risk for tetanus and rabies
340:85, 1999) Anaerobes, Gram stain Lesions should be left open if not
fusobacteria, potentially disfiguring, if arms or legs
bacteroides, involved, or if bite was >6–12 hr
porphyromonas, before treatment
Prevotella Use of prophylactic antibiotics is
streptococci, controversial (NEJM 340:138, 1999)
Capnocytophaga Amoxicillin + clavulanic acid
canimorus, S. (Augmentin)*, cefuroxime +
aureus metronidazole; TMP-SMX + clindamycin
Human, including Oral flora (strep, Culture and Human bites are usually left open
clenched-fist injury anaerobes) Gram stain Amoxicillin-clavulanic acid
S. aureus, (Augmentin)*, penicillin V ± cephalexin
Eikenella
corrodens
Rat Streptobacillus S. Penicillin*, tetracycline
moniliformis moniliformis:
Giemsa stain
of blood or
pus; culture;
serology
Spirillum minus S. minus: Penicillin*, tetracycline
Giemsa stain
of blood or
exudate
Cat-scratch disease Bartonella Warthin-Starry Efficacy of therapy not established.
henselae stain of biopsy Ciprofloxacin; sulfa-trimethoprim;
amoxicillin-clavulanate; macrolides
Burns S. aureus, GNB, Quantitative Removal of eschar. Topical sulfa (silver
Candida albicans, culture and sulfadiazine or mafenide)
Aspergillus, stain of biopsy Empiric antibiotics: Aminoglycoside +
Herpes simplex, nafcillin, antipseudomonad penicillin,
group A strep ticarcillin-clavulanate, vancomycin or
cephalosporin
H. simplex—acyclovir
Sinus tract
Osteomyelitis S. aureus, S. Culture of Antibiotics optimally based on bone
epidermidis, GNB, sinus tract biopsy
anaerobes drainage does
not reliably
reflect
agent(s) of
osteomyelitis
Lymphadenitis S. aureus Culture and Antistaphylococcal agent
Gram strain
Mycobacteria AFB smear TB—antituberculous drugs MOTT: See
(scrofula) and culture pp 185–186
Actinomycosis A. israelii, A. FA stain, Penicillin G*, amoxicillin, clindamycin,
naeslundii, A. anaerobic tetracycline
odontolyticus, culture
Arachnia
proprionica
Madura foot (tumor Actinomycotic: Culture Antibiotics selected by in vitro
masses with draining Nocardia, including AFB sensitivity tests
sinuses) Actinomadura stain, culture
madurae, A. for Nocardia
pelletieri, S.
somaliensis
Fungi: KOH, culture Fungal: Surgical excision; azoles are
Pseudallescheria on possibly effective
boydii (esp U.S.) Sabouraud's
Madurella agar
mycetomatis,
Phialophora
verrucosa
Nodules/ulcers
Sporotrichoid Sporothrix Histology Oral SSKI Rifampin + ethambutol,
(cutaneous inoculation schenckii (thorns) (PAS, GMS), Minocycline/doxycycline, TMP-SMX
with lymphatic spread) M. marinum (tidal culture on
water, swimming Sabouraud's
pool, or tropical agar
fish tank) Histology, AFB
stain and
culture (at
30–32°C)
TMP-SMX
Nocardia Histology, AFB Sulfonamide, TMP-SMX
stain; culture
for Nocardia
Nodules/ulcers (from Blastomycosis: Culture biopsy Ketoconazole, amp
hematogenous Endemic area on itraconazole
dissemination) Sabouraud's
agar
Cryptococcus: Blood for Amphotericin B, fluconazole
Defective cryptococcal
cell-mediated antigen and
immunity culture;
histopathology
and culture of
biopsy
Candida: Defective Blood culture; Amphotericin B
cell-mediated histopathology
immunity and culture of
biopsy
Diabetic foot ulcer and Mixed aerobes: Culture and Local care: Debridement, bed rest
decubitus ulcer Anaerobes Gram stain of Antibiotics: For moderately severe
S. aureus wound edge or infection oral—cephalexin, clindamycin,
Group A strep dermal punch moxifloxacin, gatifloxacin, levofloxacin,
biopsy amoxicillin-clavulanate;
parenteral—beta-lactam-beta-lactamase
inhibitor, ciprofloxacin ± clindamycin,
levofloxacin ± clindamycin,
gatifloxacin, cefepime. For severe
infection—imipenem, vancomycin +
metronidazole; severe infections with
MRSA—vancomycin, daptomycin,
linezolid
* Preferred regimen
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Deep Serious Soft Tissue Infections
Deep Serious Soft Tissue Infections
(From Cecil Textbook of Medicine, Philadelphia: Saunders, 1992:1679)
Synergistic Infected
Gas-forming necrotizing “Streptococcal” Necrotizing vascular
cellulitis cellulitis Gas gangrene myonecrosis fasciitis gangrene Streptococcal
Predisposing Traumatic Diabetes, prior Traumatic or Trauma, Diabetes, Arterial Traumatic or
conditions local lesions, surgical wound surgery trauma, surgery, insufficiency surgical wound
perirectal lesions perineal infection
Incubation >3 days 3–14 days 1–4 days 3–4 days 1–4 days >5 days 6 hr–2 days
period
Etiologic Clostridia, Mixed Clostridia, esp C. Anaerobic Mixed Mixed S. pyogenes
organism(s) others aerobic-anaerobic perfringens streptococci aerobic-anaerobic aerobic-anaerobic
flora flora flora
Systemic Minimal Moderate to Severe Minimal until Moderate to Minimal severe
toxicity Severe late in course severe
Course Gradual Acute Acute Subacute Acute to Subacute Acute
subacute
Wound Minimal Moderate to Severe Late only Minimal to Variable Severe
findings, severe moderate
local pain
Skin Swollen, Erythematous or Tense and Erythema or Blanched, Erythema or Erythema,
appearance minimal gangrene blanched, yellow-bronze erythema, necrosis necrosis
discoloration yellow-bronze, necrosis with
necrosis with hemorrhagic
hemorrhagic bullae
bullae
Gas Abundant Variable Usually present Variable Variable Variable No
Muscle No Variable Myonecrosis Myonecrosis No Myonecrosis No
involvement limited to area of
vascular
insufficiency
Discharge Thin, dark, Dark pus or Serosanguineous, Seropurulent Seropurulent or Minimal None or
sweetish, or “dishwater,” sweet or foul “dishwater,” serosan-guineous
foul odor putrid odor putrid PMNs,
mixed flora
Gram stain PMNs, PMNs, mixed Sparse PMNs, PMNs, PMNs, mixed PMNs,
Gram-positive flora Gram-positive Gram-positive flora Gram-positive
bacilli bacilli cocci cocci in chains
Surgical Debridement Wide filleting Extensive Excision of Wide filleting Amputation Debridement of
therapy incisions excision, necrotic muscle incisions necrotic tissue
amputation
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Bone and Joint Infections
Bone and Joint Infections
I. Osteomyelitis
A. Classification and Management: Cierney–Mader classification
Comp Orthop 10:17, 1985; see Osteomyelitis. Current Opinion 2:187, 2000
Stage Example Microbiology Therapy
1. Hematogenous Monomicrobial: S. Antibiotics × 4–6
Medulary Infected intramedulary aureus wk a ± surgery;
rods (hematogenous), S. rod–remove when
epid GNB joint is stable
2. Exposed bone at bed of Polymicrobial: Debridement +
Superficial soft tissue wound: Anaerobes, GNB P. antibiotics
Diabetic food ulcer aeruginosa
Decubitus ulcer Streptococci
3. Entire cortex involved: Polymicrobial: GNB, Debridement b +
Localized Infected plates for S. aureus antibiotics × 4–6
stabilizing fracture streptococci wk a
4. Diffuse Through-and-through Polymicrobial: GNB Debridementb +
osteo: Non-union S. aureus, strep antibiotics × 4–6
a
wk
a
Antibiotics often given parenterally × 2 wk, then orally × 4 wk.
b
Debridement requires removal of necrotic bone; dead space created may be filled
with cancellous bone grafts or tissue flaps or antibiotic impregnated beads. Beads are
usually replaced by bone grafts at 2–4 wk.
Empiric treatment:
1. Infected prosthetic material: Vancomycin
2. Hemoglopathy: Nafcillin/oxacillin + ampicillin
3. Vascular insufficiency, diabetic foot ulcer, decubitus ulcer: Ciprofloxacin +
clindamycin (po or lV), ciprofloxacin + metronidazole (po or lV), imipenem,
piperacillin-tazobactam, cefoxitin, gatifloxacin (po)
4. Human bite: Ampicillin-sulbactam, ceftriaxone
B. Diagnosis: Surgical sampling or needle biopsy is preferred. Swabs of fistula tracts or ulcers
are less reliable (JAMA 239:2772, 1978) The preferred nuclear imaging method is
technetium-99 (sensitivity 70–100%; specificity 20–80%). Favored scans CT and MRI
(sensitivity 30–100%; specificity 80–90%; best test with diabetic foot or decubitus ulcer:
Probe wound for bone, sensitivity 66%, specificity 85% (see JAMA 273: 721, 1995)
C. Treatment (CID Suppl 1:S155, 1992; NEJM 336:99, 1997)
ANTIBIOTIC TREATMENT OF OSTEOMYELITIS
Adapted from NEJM 336:999 1997
Pathogen Preferred (parenteral) Alternative
S. aureus
Methicillin Nafcillin or oxacillin 2 g q6h Cephalosporin—1st gen;
sensitive clindamycin, vancomycin
Methicillin Vancomycin 1 g q12h
resistant
Streptococci Pen G 4 mil units q6h Clindamycin, vancomycin
S. epidermidis Vancomycin 1 g q12h
Enterobacteriaceae Quinolone–ciprofloxacin 750 third generation
mg q12h cephalosporin
P. aeruginosa Ceftazidime 2 g q8h plus Imipenem, piperacillin, or
aminoglycoside L 2 wk cefepime plus aminoglycoside
L2 wk
Anaerobes Clindamycin 600 mg IV q6h Metronidazole,
beta-lactam-beta-lactamase
inhibitor,
imipenem/meropenem
Mixed aerobic Imipenem 500 mg q6h or Ciprofloxacin + clindamycin
anaerobic beta-lactam-beta-lactamase
inhibitor
P.225
Empiric treatment:
1. Settings in which S. aureus is anticipated pathogen
Preferred: Nafcillin or oxacillin, vancomycin, or clindamycin
2. Patient with hemoglobinopathy
Preferred: Nafcillin or oxacillin plus ampicillin
Alternatives: Nafcillin or oxacillin plus cefotaxime or ceftriaxone
3. Osteomyelitis with vascular insufficiency, decubitus ulcer, diabetic foot ulcer, etc
Preferred: Ciprofloxacin plus clindamycin or metronidazole, cefoxitin,
imipenem, or beta-lactam-beta-lactamase inhibitor
Alternatives: Aztreonam plus clindamycin
4. Animal or human bite
Preferred: Ampicillin or ampicillin-sulbactam
Alternative: Ceftriaxone or doxycycline
II. Bone and joint infections: Associations
Condition Bones/joints Bacteriology
Sickle cell disease Multiple bones Salmonella, S.
pneumoniae
Injection drug use Disc space or S. aureus
sternoclavicular joint P. aeruginosa
Penetrating injury of foot Foot bones P. aeruginosa
Hemodialysis Ribs S. aureus
Thoracic vertebrae
Ingestion of unpasteurized Knee, hip, sacroiliac joint Brucella
dairy products
Rash and arthritis Multiple N. gonorrhoeae
N. meningitis
H. influenzae
Moraxella osloenia
Streptobacillus
moniliformis
Diabetic foot ulcers Site of ulcer Streptococci, anaerobes,
GNB
Foreign body Site of prosthesis Staphylococcus
epidermidis
Dog bite or cat bite Site of trauma Pasteurella multocida
Anaerobes
Human bite Site of trauma Eikenella corrodens,
Anaerobes
Tick exposure Large joints esp knees Borrelia burgdorferi
P.226
III. Septic arthritis (see CID 20:225, 1995)
A. Acute Monarticular Arthritis
1. Differential diagnosis: Septic arthritis, rheumatoid arthritis, gout, and
chondrocalcinosis (pseudogout). All may cause predominance of PMNs in joint fluid. Need
joint fluid aspiration for stain culture and analysis for crystals.
3
2. Joint analysis: WBC > 50,000/mm with > 90% PMNs, protein > 3 g/mL, glucose
<60%, poor mucin clot, positive Gram stain and culture
3. Septic arthritis in adults
Agent Treatment (alternatives) a Comment
S. aureus Methicillin-sensitive: Accounts for 50–80% of
Nafcillin/oxacillin or cefazolin non-gonococcal septic
× 3 wk MRSA or beta-lactam arthritis cases
allergy: Vancomycin × 3 wk
N. Ceftriaxone (1 g IV daily); Most common cause of
gonorrhoeae alternatives are cefotaxime (1 monarticular arthritis in
g IV q8h), ceftizoxime (1 g IV young sexually active
q8h), or spectinomycin (2 g adults. Skin lesions rarely
IM q12h) until 24–48 hr after present and blood cultures
symptoms have resolved, usually negative with
then cefixime (400 mg po bid) gonococcal monarticular
or ciprofloxacin (500 mg po arthritis; genital or joint
bid) to complete 1 wk fluid culture often positive
Doxycycline 100 mg po bid × Doxycycline or azithromycin
1 wk for presumed C. trachomatis
infection
Streptococci Penicillin (cephalosporin-first Accounts for 10–20% of
generation, vancomycin, non-gonococcal septic
clindamycin) × 2 wk arthritis cases. Group A is
most common; groups B, C,
or G, S. milleri and S.
pneumoniae are occasional
causes
Gram-negative Based on in vitro sensitivity Accounts for 10–20% of
bacilli tests. Treat × 3 wk non-gonococcal septic
arthritis cases. Most
commonly in chronically
debilitated host,
immunosuppressed, prior
joint disease, and elderly.
Heroin addicts prone to
sacroiliac or sternoclavicular
septic arthritis caused by
Pseudomonas aeruginosa
a
Duration of antibiotic treatment is 2–4 wk; the exception is gonococcal septic
arthritis.
P.227
4. Other therapy:
a. Drainage: Joint aspiration usually advocated (NEJM 312:764, 1985); repeat needle
aspiration at 5–7 days often beneficial. Persistence of effusion >7 days is indication
for surgical drainage (CID 20:225, 1995)
b. Weight bearing: Avoid until inflammation resolves
c. Passive range of motion first week, active ROM at 1–2 wk
d. Controversies: Duration of antibiotics; oral vs parenteral route of antibiotics;
splinting vs passive ROM; optimal drainage—aspiration, open drainage, or
arthroscopy
5. Prosthetic joint
a. Bacteriology: S. aureus (20–30%), S. epidermidis (20–30%), streptococci
(15–25%), Gram-negative bacilli (15–25%), anaerobes (5–10%)
b. Classification:
1. Acute contiguous within 6 mo of surgery: Presumably reflects contamination at
time of surgery;
2. chronic contiguous at 6–24 mo after surgery: Presumably also because of
contamination at the time of surgery;
3. hematogenous at L2 yr after surgery
c. Diagnosis: A common presentation is loosening that could be septic but is most
commonly mechanical (Curr Opinion 2:2000, 2000). Overlying inflammation or
drainage facilitates the distinction. When this is not present diagnostic tests include
ESR, C reactive protein, imaging (x-ray, bone scan, MRI, CT scan) and/or joint
aspiration. None of these are considered consistently reliable—the best method is
biopsy at surgery showing inflammation and culture (Curr Opinion 2:2000,2000)
d. Management
Single stage revision: Remove all foreign and necrotic material, replace
prosthesis with antibiotic impregnated cement, and give antibiotics × 6 wk.
Success rate is 20–30%. Relative contraindications: Resistant bacteria,
especially Candida, GNB, enterococci
Two stage revision (usually preferred): Remove all foreign and necrotic
material, give IV antibiotics 6 wk, then replace prosthesis using
antibiotic-impregnated spacer. Success rate: 70–80%
Resection arthroplasty: Removal of all foreign and necrotic material and fuse
joint. Indication is contraindication or refusal for replacement of prosthesis
Medical management: Debridement cultures and antibiotics. Antibiotics are
primarily oral and given L6 mo to lifelong. This is advocated only when patient
is an extremely poor surgical candidate or refuses preferred procedures
e. Antibiotics: Selection is based on culture and in vitro sensitivity tests. Favored
drugs for S. epidermidis—vancomycin; S. aureus—nafcillin, oxacillin, cefazolin,
vancomycin; GNB—fluoroquinolones, betalactams.
P.228
Duration is 4–8 wk, usually 6 wk. Role of antibiotic-impregnated polymethyl
metuacrylate “cement” (tobramycin and vancomycin) is unclear (Am J Orthop
27:201, 1998; Clin Orthop 295:96,1993).
B. Chronic Monarticular Arthritis
1. Bacteria: Brucella, Nocardia
2. Mycobacteria: M. tuberculosis, M. kansasii, M. marinum, M. avium-intracellulare, M.
fortuitum (see pp 166–176).
3. Fungi: Sporothrix schenckii (soil contact), Coccidioides immitis (endemic area,
non-Caucasian immunocompromised men), Blastomyces dermatitidis (endemic area),
Candida sp (intraarticular steroids or systemic candidiasis), Pseudallescheria boydii
(penetrating trauma), Scedosporium (penetrating trauma) (see pp 151–164).
C. Polyarticular Arthritis
1. Bacteria: Neisseria gonorrhoeae (usually accompanied by skin lesions, positive cultures
of blood and/or genital tract, negative joint cultures); N. meningitidis; Borrelia
burgdorferi (Lyme disease, see pp 213–214); pyogenic (10% of cases of septic arthritis
have two or more joints involved).
2. Viral: Hepatitis B (positive serum HBsAg, seen in pre-icteric phase, ascribed to
immune-complexes often in association with urticaria, symmetric arthritis involving hands
most frequently, then knees and ankles); rubella (usually small joints of hand, women
more than men, simultaneous rash, and tenosynovitis also seen with rubella vaccine in up
to 40% of susceptible postpubertal women); Parvovirus B 19 (symmetric arthritis
involving hands/wrists and/or knees; adults more than children; women more than men);
mumps (0.5% of mumps cases, large and small joints, accompanies parotitis, men more
than women); lymphocytic choriomeningitis virus (adults with aseptic meningitis);
arthropod-borne alpha virus: Chikungunya (East Africa, India), O'nyong-nyong (East
Africa), Ockelbo agent (Sweden), Ross River agent (Australia), Barmah Forest virus
(Australia).
3. Miscellaneous: Acute rheumatic fever (Jones' criteria including evidence of preceding
streptococcal infection); Reiter's syndrome (conjunctivitis and urethritis, associated
infections—Shigella, Salmonella, Campylobacter, Yersinia).
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Ocular and Periocular Infections
Ocular and Periocular Infections
N. gonorrhoeae Ceftriaxone, 125 mg IM × 1 Evaluation—4 tests—(1) acuity,
(2) external exam, (3) slit lamp
biomicroscopy, and (4)
diagnostic tests (see below)
Most are viral and self-limited
C. trachomatis Doxycycline 100 mg bid × 7–14 Pharyngoconjunctival
d fever—adenovirus 3 and 7 in
Azithromycin 1 g po × 1 children
Epidemic
keratoconjunctivitis—adenovirus
8
Adenovirus None (highly contagious) Diagnostic tests—Culture if
(types 8, 11 & 19 severe or recurrent purulent
in adults) conjunctivitis, especially if not
responsive. Smears for special
stains and cytology—bacteria—
PMNs, viral—mononuclear;
herpetic—multi-nucleated cells;
chlamydia—mixed;
allergic—eosinophils
Allergic or Topical steroids C. trachomatis: Inclusion
immune-mediated conjunctivitis and trachoma
Unknown Topical sulfacetamide or S. pneumoniae: may cause
(empiric) neomycin-bacitracin-polymyxin epidemic conjunctivitis (NEJM
or bacitracin-polymyxin 2003;348:1112)
Keratitis S. aureus, S. P. aeruginosa (contact lens): Guidelines: American Academy
pneumoniae, P. topical gentamicin, tobramycin of Ophthalmology 2000:
aeruginosa, or ciprofloxacin eye drops Management of bacterial
Moraxella, q15–60 min. kerititis requires the expertise
Serratia Staphylococcus, S. of an ophthalmologist due to
pneumoniae, coliforms: topical the risk of vision loss
cefazolin, gentamicin, Pain; no discharge; decreased
tobramycin, vancomycin + vision
ceftazidime q15–60 min. Lab—Culture with corneal
infiltrate that extends to deep
stroma, is chronic or is
unresponsive to broad spectrum
antibiotics or has features
suggesting fungi, amoeba, or
mycobacterial infection. Use
alginate swab or conjunctival
scrapings for stain (Gram,
Giemsa, PAS, calcofluor white
and methenamine silver) +
culture for bacteria and fungi
Herpes simplex Trifluridine 1 drop qh (9×/d) Systemic antibiotics for deep
for G21 d or vidarabine corneal ulcers with bacterial
ointment 5×/d G21 d; if infection Supportive care with
recurrent—oral acyclovir 400 cytoplegics, use of
mg bid corticosteroids controversial
Herpes zoster Valacyclovir 1 g po tid, For topical antibiotics use
acyclovir 800 mg 5×/d or solutions
famciclovir 500 mg tid ×10 d
Fungal: Topical natamycin, (5%) or Herpes simplex is most common
Fusarium solani, amphotericin B (0.05–0.15%) Risks for bacterial keratitis:
Aspergillus, contact lens, diabetes
Candida,
Acanthamoeba
Parasitic: Topical propamadine Acanthamoeba: Risks or trauma
Acanthamoeba isethionate, 0.1%/ and soft contact lens. Diagnosis
(contact lens) neomycin/gramicidin/polymyxin by scraping stained with
or polyhexamethylene calcofluor white (CID
biguanide 0.02% or chexadine 2002;35:434)
0.2%: drops qh while awake ×
1 wk, then taper
Endophthalmitis Bacteria: Emergent intravitreal Lab: Aspiration of aqueous and
Post-ocular antibiotics, and vitrectomy vitreous cavity for stain (Gram,
surgery:S. Empiric: Intravitreal Giemsa, PAS, methenamine
aureus, vancomycin 1 mg + amikacin silver) and culture for bacteria
Pseudomonas, S. 0.4 mg or ceftazidime 2 mg and fungi
epidermidis, P. Requires immediate
acnes ophthalmology consult:
Penetrating vitrectomy + intravitreal
trauma: Bacillus antibiotics
sp. Acute: P. aeruginosa and S.
Hematogenous: aureus most common
S. pneumoniae, Chronic: P. acnes, S. aureus,
N. meningitidis and S. epidermiditis most
(others) common
Injection drug
use: Candida, B.
cercus
Retinitis Fungus: IV amphotericin + topical
Post-ocular natamycin ± corticosteroids;
surgery vitrectomy (Ophthalmol
Neurospora, 85:357, 1978)
Candida, IV amphotericin B + flucytosine
Scedosporium, (Arch Ophthalmol 98:1216,
Paecilomyces 1980) Aspergillus—removal of
Hematogenous: infected vitreous (Arch
Candida, Ophthalmol 98:859, 1980)
Aspergillus Systemic corticosteroids
Histoplasmosis
Parasites: Systemic + local
Toxoplasmosis corticosteroids ±
Toxocara pyrimethamine and sulfadiazine
Systemic or intraocular
corticosteroids
Acute reclinal Virus: Herpes Acyclovir 10–15 mg/kg IV q8h
necrosis zoster (Herpes (CID 1997;24:603)
simplex)
Periorbital
Lid Topical corticosteroid ± topical For rosacea—doxycycline po
Blepharitis Multifactorial: bacitracin or erythromycin
Seborrhea, Lid hygiene

Lacrimal Anaerobes, Topical penicillin by irrigation
apparatus especially
Canaliculitis Actinomyces
Dacryocystitis Acute: S. aureus Systemic antistaphylococcal
agent; then digital massage +
antibiotic drops
Chronic: S. Systemic antibiotics; digital
pneumoniae, S. massage
aureus,
Pseudomonas,
mixed
Orbital S. aureus, (S. IV antibiotics: Cephalosporin, Over 80% have associated
pneumoniae, S. cefuroxime or third generation sinusitis Treat sinusitis
pyogenes) (ceftriaxone or cefotaxime)
Fungi: Amphotericin B + surgery
Phycomycosis,
Aspergillus,
Bipolaris,
Curvularia,
Drechslera
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Infections of Central Nervous System
Infections of Central Nervous System
I. Cerebrospinal Fluid
A. Normal Findings
1. Opening pressure: 5–15 mmHg or 65–195 mmH O
2
3
2. Leukocyte count: <10 mononuclear cells/mm (5–10/mL suspect); 1 PMN (5%)
Bloody tap: Usually 1 WBC/700 RBC with normal peripheral RBC and WBC counts; if
abnormal: true CSF WBC = WBC (CSF) - WBC (blood) × RBC (CSF)/RBC (blood)
Note: WBCs begin to disintegrate after 90 min
3. Protein: 15–45 mg/dL (higher in elderly)
Formula: 23.8 × 0.39 × age + 15 mg/100 mL or (more simply) less than patient's age
(>35 yr)
Traumatic tap: 1 mg/1000 RBCs
4. Glucose: 40–80 mg% of CSF/blood glucose ratio >0.6 (with high serum glucose, usual
ratio is 0.3)
B. Abnormal CSF with Noninfectious Causes
1. Traumatic tap: Increased protein; RBCs; WBC count and differential proportionate to
RBCs in peripheral blood; clear and colorless supernatant of centrifuged CSF.
2. Chemical meningitis (injection of anesthetics, chemotherapeutic agents, air,
radiographic dyes): Increased protein, lymphocytes (occasionally PMNs).
3. Cerebral contusion, subarachnoid hemorrhage, intracerebral bleed: RBCs,
increased protein (1 mg/1000 RBCs), disproportionately increased PMNs (peak at 72–96
hr), decreased glucose (in 15–20%).
4. Vasculitis (SLE, etc): Increased protein (50–100 mg/dL), increased WBCs (usually
mononuclear cells, occasionally PMNs), normal glucose.
3 3
5. Postictal (repeated generalized seizures): RBCs (0–500/mm ), WBCs (10–100/mm
with variable percentage PMNs with peak at 1 day), protein normal or slight increase.
6. Tumors (especially glioblastomas, leukemia, lymphoma, breast cancer, pancreatic
cancer): Low glucose, increased protein, moderate PMNs.
7. Neurosurgery: Blood; increased protein; WBCs (disproportionate to RBCs with
predominance of mononuclear cells) up to 2 wk post-op.
3
8. Sarcoidosis: Increased protein; WBCs (up to 100/mm predominately mononuclear
cells); low glucose in 10%.
C. CSF with Pyogenic Meningitis (NEJM 1993;328:21.; Lancet 1995;346:1675.)
3
1. Findings: Opening pressure >300 mmH O - 40%; WBC > 100/mm - 90%; % PMNs >
2
20%–98%, most >80%; 80%; protein > 45 mg/dL - 96%; glucose < 40 mg/dL - 50%;
Gram stain pos - 60%, culture positive 73%.
2. Etiologic diagnosis: Sensitivity of Gram stain 60–80%; antigen assays most helpful in
patients with prior antibiotic treatment (Pediatr Emerg Care 1994; 10:67.).
3. Predictors of bacterial meningitis: Glucose <34 mg/dL, CSF/serum glucose ratio
<0.23, protein >220 mg/dL, WBC >2000 mg/dL or 1180 neutrophils/dL each predict
bacterial meningitis with 99% certainty (JAMA 1989;262:2700.).
4. Response: CSF cultures should become sterile within 24–36 hr of appropriate therapy
(Pediatr Infect Dis J 1992;11:423.).
D. Practical Issues in Management
1. Need for scan prior to LP: Review of 301 adult cases of suspected pyogenic meningitis
showed evidence that pre-LP scans delayed antibiotic admin
P.234
istration by an average of 2 hrs, and showed mass effect in only 2% (NEJM
2001;345:1727.). The recommendation was to do the LP with a #22 or #25 needle to
minimize risk and restrict pre-LP CT scans to those likely to have an intracranial mass or
elevated CSF pressure as indicated by immunosuppression, dilated or poorly reactive
pupils, papilledema, ocular palsy, hemiparesis, recent history of seizures, rapid decrease
in consciousness, bradycardia, irregular respirations, tonic seizures, or decrebrate or
decorticate posture (NEJM 2001;345:1768.; Arch Dis Child 1992;67:1417.)
2. Dexamethasone in adults with pyogenic meningitis: Controlled trial showed
significant benefit with dexamethasone 10 mg given 15–20 min before first dose of
antibiotics and repeated q6h × 4 days. The dexamethasone recipients showed a superior
outcome with reduced mortiliaty (11/157 [7%] vs 21/144 [15%]) in placebo recipients
(NEJM 2002;347:1549.)
II. Meningitis
A. Pyogenic meningitis: Microbiology
(NEJM 1993;328:21.)
Community Mortality
acquired (253 Nosocomial (151 (meningitis
Agent cases) cases) related)
S. pneumoniae 97 (38%) 8 (5%) 25%
Gram-negative 9 (4%) 57 (38%) 23%
bacilli
N. meningitidis 35 (14%) 1 (1%) 10%
Streptococci 17 (7%) 13 (9%) 17%
S. aureus 13 (5%) 13 (9%) 28%
Listeria 29 (11%) 5 (3%) 21%
H. influenzae 9 (4%) 6 (4%) 11%
S. epidermidis 0 13 (9%) 0
Culture negative 34 (13%) 16 (11%) 7%
B. Updated review: 80 cases, Edmonton Canada, 1985–1996 (Medicine 2001;79:360.)
1. Etiology: S. pneumoniae—42; Listeria—10, H. influenzae—6, S. aureus—5.
3
2. CSF WBC > 100/mm —90%; PMN > 50%–91%; glucose < 50 mg/dL—72%; protein <45
mg/dL—99%; Gram stain positive—48%
3. Mortality: 15%
Mortality in series of pneumococcal meningitis cases was 15/109 (15%) and was
unrelated to penicillin susceptibility of the implicated strain.
P.235
C. Initial management

Algorithm for initial management of patient with acute bacterial meningitis. Reprinted
from Lancet 1995;346:1675 (with permission).
P.236
D. Doses of antimicrobial agents
Cephalosporins:
Cefotaxime: 12 g/d in six doses
Ceftizoxime: 9 g/d in three doses
Ceftriaxone: 2–4 g/d in two doses
Ceftazidime: 6–12 g/d in three doses
Chloramphenicol: 4–6 g/d in four doses
Penicillins: Ampicillin: 12 g/d in six doses
Ticarcillin: 18–24 g/d in six doses
Mezlocillin: 18–24 g/d in six doses
Piperacillin: 18–24 g/d in six doses
Nafcillin: 9–12 g/d in six doses
Oxacillin: 9–12 g/d in six doses
Penicillin G: 20–24 mil units/d in six doses
Aztreonam: 6 g/d in four doses
Trimethoprim-sulfamethoxazole: 15–20 mg/kg/d (trimethoprim) in four doses
Metronidazole: 2 g/d in two to four doses
Vancomycin: 2 g/d in two doses
Intrathecal/intraventricular doses:
Gentamicin 4–8 mg q24h
Tobramycin 4–8 mg q24h
Amikacin 5.0–7.5 mg q24h
Vancomycin 5–20 mg q24h
E. Meningitis: Empiric treatment (adapted from Med Lett 1999;41:95.; NEJM 1996;334:54.)
1. Adults—immunocompetent
Cephalosporin: Cefotaxime 2 g q4h IV or ceftriaxone 2 g q12h IV plus vancomycin 1 g IV
q12h ± rifampin 300 mg po or IV bid.
Note: If isolate is susceptible to cephalosporins, discontinue vancomycin and rifampin.
2. L. monocytogenes: Ampicillin 2 g q4h IV ± aminoglycoside plus cefotaxime or ceftriaxone
+ vancomycin
3. Penicillin allergy: Cefotaxime or ceftriaxone plus vancomycin ± rifampin. If
cephalosporins contraindicated then chloramphenicol plus vancomycin ± rifampin. For
Gram-negative bacilli then aztreonam. For Listeria then TMP-SMX
4. Adjunctive corticosteroid therapy: Dexamethasone (0.15 mg/kg IV q6h × 4 days) has
significant benefit in multiple studies in children for reduction of neurologic sequelae,
especially hearing loss (NEJM 1991;324:1525.; Pediatr Infect Dis J 1995;14:490.). One
study showed a reduction in mortality rates in adults (Pediatr Infect Dis J 1989;8:848.).
A. Tunkel and M. Scheld recommend adjunctive dexamethasone for high-risk adult
patients: Impaired mental status, cerebral edema, or very high intracranial pressure
(Lancet 1995;346:1675.). Dexamethasone reduces vancomycin levels in CSF so rifampin
should be added for suspected or established pneumococcal meningitis pending in vitro
sensitivity tests (AAC 1995;39:2171.).
Note: Dexamethasone should be given about 30 min before first dose of antibiotics (NEJM
1991;324:1525.).
P.237
F. Treatment by Organism
(CID 1993;17:603.; Infect Dis Clin Pract 1995;4:423.)
Organism Antibiotic selection Comment
S. pneumoniae Preferred Meningitis is the only
Pen-sensitive Penicillin clinical condition in
(MIC <0.1 Sg/mL) Cefotaxime which intermediate
Ceftriaxone penicillin reistance is
Alternative relevant
Chloramphenicol Rates of penicillin
resistance in U.S.:
Intermediate and
high level (MIC T 0.1
Sg/mL): 40–50%
Rates of cefotaxime
resistance in U.S.
(1998–2002),
intermediate and
high level: 5–10%
(CID 1998;27:764;
CID 2003; 36:783;
Pen-resistant Preferred
CID 2003;36:1013;
(MIC T 0.1 Sg/mL) Vancomycin ± rifampin
AAC 2002;46: 2651;
Alternative
AAC 2003;47:1790);
Chloramphenicol
great variation by
Quinupristin/-dalfopristin
geography
Linezolid
Rate of vancomycin
resistant—0 (Nat Med
2003;9:424)
Treat T10 days
LP at 24–36 hr to
document eradication
of pathogen,
especially if
cephalosporin
resistant
N. meningitidis Preferred Pencillin resistance is
Pen-sensitive Penicillin rare and found
Alternative almost exclusively
Cefotaxime outside U.S.
Ceftriaxone Vaccine reduces
infection rate but
does not affect
outcome (CID
2002;35:1376)
Risk in college
freshman in dorms
(JAMA
2001;286:1894)
Intimate and
household contacts
should receive
ciprofloxacin 500 mg
Beta-lactamase-producing Chloramphenicol
× 1 (adults) or
rifampin 600 mg po
bid × 2 days
(adults); 10 mg/kg
po bid × 2 days
(children)
Treat T7 days
H. influenzae Preferred Rate of
Ampicillin-sensitive Ampicillin beta-lactamase
Alternative production 30–40%
Cefotaxime by type B and
Ceftriaxone nontypable strains
Chloramphenicol (CID 2001; 32:S81)
Type B strains:
Unvaccinated
Ampicillin-resistant Preferred
household contacts
Cefotaxime
<4 yr—rifampin 10
Ceftriaxone
mg/kg po bid × 2
Alternative
days
Chloramphenicol
Treat T 10 days
Listeria monocytogenes Preferred Cephalosporins are
Ampicillin ± gentamicin active in vitro but are
Alternative not active in vivo
Trimethoprim-sulfamethoxazole Treat 14–21 days
Penicillin or
ampicillin are 100
fold more potent
when combined with
aminoglycoside (J
Antimicrob
Chemother
1998;41:417) There
is no consensus on
the need for adding
gentamicin to
ampicillin.
Carbapenems and
fluoroquinolones are
active in vitro but
activity intracellularly
is not known (J
ClinMicro
2003;41:483)
Review of 1808 cases
of listerosis showed
47% had CNS
infecction with 74%
immunocompromised,
mean age of 50–76
yrs, and mortality of
36% (Emerg Infect
Dis 2002;8:305)
Enterobacteriaceae Preferred In vitro sensitivity
Cefotaxime or ceftriaxone tests required
±aminoglycoside Bactericidal activity
Alternative desired
Aztreonam Chloramphenicol
Antipseudomonad penicillin or lacks bactericidal
ampicillin ± aminoglycoside activity vs GNB—not
Trimethoprim-sulfamethoxazole recommended
Aminoglycoside given
systemically ±
intrathecally
Effectiveness of
quinolones,
imipenem, and
aztreonam in
meningitis is
unknown
Ceftazidime use is
usually restricted to
GNB resistant to
other 3rd gen
cephalosporins
Treat T21 days
P. aeruginosa Preferred In vitro sensitivity
Aminoglycoside + ceftazidime tests required
Alternative Aminoglycoside given
Aminoglycoside + systemically ±
antipseudomonad penicillin intrathecally
Aminoglycoside + aztreonam Effectiveness of
quinolones,
imipenem, and
aztreonam in
meningitis is
unknown
Staph aureus Preferred Usually post
Methicillin-sensitive Antistaphylococcal penicillin neurosurgery (Eur J
(oxacillin, nafcillin) ± rifampin Clin Micro Inf Dis
Alternative 2002;21:864)
Vancomycin + rifampin Efficacy of high dose
Trimethoprim-sulfa + rifampin IV and intrathecal
Cefuroxime cefuroxime (Scand J
Inf Dis 2003;35:311)
Methicillin-resistant Preferred
Vancomycin + rifampin
Alternative
Linezolid
Daptomycin
S. epidermidis Preferred
Vancomycin + rifampin
Alternative
Linezolid
Daptomycin
P.238
G. Differential diagnosis of chronic meningitis*
(Adapted from Infect Dis Clin Pract 1992;1:158.)
Infectious disease Neoplastic Miscellaneous
Bacteria Leukemia Systemic lupus**
M. tuberculosis Lymphoma Wegener's
Atypical mycobacteria Metastatic granulomatosis**
Treponema pallidum** Breast CNS vasculitis
Borrelia burgdorferi** Lung Granulomatous
Leptospira Thyroid vasculitis
Brucella** Renal Sarcoidosis
Listeria Melanoma Behçet's syndrome
Actinomyces/Arachnia Primary CNS Vogt-Koyanagi and
Nocardia Astrocytoma Harada's syndromes
Parasites Glioblastoma Benign lymphocytic
Toxoplasma gondii Ependymoma meningitis
Cysticerus Pinealoma
Angiostrongylus Medulloblastoma
Spinigerum
Schistosoma
Fungi
Cryptococcus
Coccidioides**
Histoplasma**
Blastomyces
Sporotrichum
Pseudoallescheria
Alternaria
Fusarium
Aspergillus
Zygomycetes
Cladosporium
Viruses
HIV
Echovirus
HSV (chronic lymphocytic
meningitis and Mollaret's
meningitis)
* Defined as illness present for T4 wk with or without therapy; CSF analysis usually
shows lymphocytic pleocytosis. Analysis of 83 previously healthy persons in New
Zealand showed 40% had tuberculosis, 7% had cryptococcosis, 8% had malignancy,
and 34% were enigmatic (Q J Med 1987;63:283).
** Evaluation: Culture, serum serology, CT scan, or MRI (brain abscess, cysticercosis,
toxoplasmosis), cytology CSF (lymphoma, metastatic carcinoma), eosinophilic
(parasitic, coccidioidomycosis), CSF serology or antigen (cryptococcosis,
coccidioidomycosis, syphilis, histoplasmosis), blind meningeal biopsy (rarely positive),
empiric treatment (TB, then penicillin, then amphotericin B, then ? corticosteroids).
P.239
H. Aseptic meningitis: infectious and noninfectious causes*
(from American Academy of Pediatrics, Pediatrics 1986;78 Suppl:970 and updated)
Infectious Agents and Diseases
Bacteria: Partially treated meningitis, Mycobacterium tuberculosis, parameningeal
focus (brain abscess, epidural abscess), acute or subacute bacterial endocarditis
Viruses: Enteroviruses, mumps, lymphocytic choriomeningitis, Epstein-Barr,
arboviruses (Eastern equine, Western equine, St. Louis), cytomegalovirus,
varicella-zoster, herpes simplex, HIV
Rickettsiae: Rocky Mountain spotted fever
Spirochetes: Syphilis, leptospirosis, Lyme disease
Mycoplasma: M. pneumoniae, M. hominis (neonates)
Fungi: Candida albicans, Coccidioides immitis, Cryptococcus neoformans
Protozoa: Toxoplasma gondii, malaria, amebas, visceral larval migrans (Taenia
canis)
Angiostrongylus cantonensis: Esophinophilic meningitis (NEJM 2002;346: 688.)
Treat with steroids (CID 2000;31:660.)
Nematode: Rat lung worm larvae (eosinophilic meningitis)
Cestodes: Cysticercosis
Noninfectious Diseases
Malignancy: Primary medulloblastoma, metastatic leukemia, Hodgkin's disease
Collagen-vascular disease: Lupus erythematosus
P.240
Trauma: Subarachnoid bleed, traumatic lumbar puncture, neurosurgery
Granulomatous disease: Sarcoidosis
Direct toxin: Intrathecal injections of contrast medium, spinal anesthesia
Adverse drug reactions: NSAIDs (Arch Intern Med 1991;151:1309.) and rofecoxib
(Arch Intern Med 2002;162:713.)
Poison: Lead, mercury
Adverse drug reaction: High dose (2 g/kg) IV immunoglobulin (Ann Intern Med
1994;121:259.)
Autoimmune disease: Guillain-Barré syndrome
Unknown: Multiple sclerosis, Mollaret's meningitis, Behçet's syndrome,
Vogt-Koyanagi syndrome, Harada's syndrome, Kawasaki disease
III. Brain Abscess (CID 1997;25:763.)
Associated Likely pathogens Treatment
condition
Sinusitis Anaerobic, microaerophilic and Metronidazole + penicillin or
aerobic streptococci, Bacteroides cefotaxime + metronidazole
sp.
Otitis Bacteroides fragilis, Bacteroides Metronidazole + penicillin +
sp., streptococci, ceftazidime
Entero-bacteriaceae, P.
aeruginosa
Post-neurosurgery Staph. aureus Vancomycin + ceftazidime
S. epidermidis
Enterobacteriaceae
P. aeruginosa
Trauma Staph. aureus Nafcillin + cefotaxime or
Enterobacteraceae ceftriaxone
Endocarditis Staph. aureus Penicillinase-resistant
penicillin or vancomycin
Streptococcus sp. Penicillin or penicillin +
aminoglycoside
Cyanotic heart Streptococcus sp. Penicillin or metronidazole +
disease penicillin
P.241
RESPIRATORY TRACT INFECTIONS: Recommendations of two panels—one representing the CDC
and the other representing the American College of Physicians/American Society of Internal
Medicine. Both groups published their recommendations in the same issue of Annals of Internal
Medicine. They covered the same infections (pharyngitis, bronchitis, sinusitis, and viral URIs).
Panel membership overlapped between the two groups, and both said essentially the same thing.
CITATIONS
Topic Source Citation
URIs ACP/ASIM Ann Intern Med 134:487, 2001
CDC Ann Intern Med 134:490, 2001
Pharyngitis ACP/ASIM Ann Intern Med 134:506, 2001
CDC Ann Intern Med 134:509, 2001
Sinusitis ACP/ASIM Ann Intern Med 134:495, 2001
CDC Ann Intern Med 134:498, 2001
Bronchitis ACP/ASIM Ann Intern Med 134:518, 2001
CDC Ann Intern Med 134:521, 2001
Acute exacerbations, chronic bronchitis ACP/ASIM Ann Intern Med 134:595, 2001
SUMMARY OF RECOMMENDATIONS (ADULT PATIENTS ONLY)
Diagnosis Issue ACP/ASIM CDC
Sinusitis Diagnosis Clinical, no imaging Same
Cultures None None
Antibiotics
Indications Nasal pus and face Same
pain/tenderness, + severe
symptoms or symptoms >7
d
Agents Amoxicillin, doxycycline Agents active vs H.
TMP-SMX influenzae and S.
pneumoniae
Bronchitis Diagnosis Rule out pneumonia Same
X-ray if abnormal vital signs
or cough >3 wk or rales
Culture None None
Antibiotic None None
Exception: Pertussis ? Same
influenza
Pharyngitis Strep 10% 5–15%
Diagnosis Antigen test Antigen test
No culture No culture
Antibiotic Centor 2–3* + pos Strep Same
antigen
Centor 3–4 alone
Antibiotic Penicillin Penicillin
Alternative Erythromycin Erythromycin
* Centor criteria (Med Decis Making 1981;1:239): 1) Tonsillar exudates, 2) cervical
adenopathy; 3) fever; 4) absence of cough. If 0–1: No test, no antibiotics; 2–3: Antigen
assay-antibiotic (penicillin) for positives; 3–4: empiric penicillin. Note: The IDSA
guidelines for managing pharyngitis do not accept centor criteria as adequate because of a
high rate of false positives using clinical criteria (CID 2002;35:113). These guidelines call
for evidence of Group A streptococci by culture or rapid antigen detection test. This
approach requiring pathogen detection appears to be the most cost effective strategy (Ann
Intern Med 2003;139:113)
Exacerbations, ACP/ASIM only (Ann Intern Med 2001;134:595)
chronic bronchitis Diagnosis: Chest x-ray–hospitalized patients and EW
Spirometry–not useful to dx
Medication: Inhaled B-2 agonist (albuterol) and/or
anticholinergic bronchodilator (ipratropium) Severe: Steroids,
O , and/or positive pressure ventilation
2
Antibiotics: Only for severe cases–increased sputum, sputum
purulence, and dyspnea (Anthonism, Ann Intern Med
1987;106:196)
Agents: Amoxicillin, doxycycline, TMP-SMX
P.242
Footnote
* Aseptic meningitis is defined as meningitis in the absence of evidence of a bacterial pathogen
detectable in CSF by usual laboratory techniques.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Upper Respiratory Tract Infections
Upper Respiratory Tract Infections
Conditions Usual pathogens Preferred treatment Alternatives Comment
EAR AND MASTOIDS
Acute otitis media S. pneumoniae Amoxicillin Failure at 3–5 days: Tympanocentesis rarely
(Red Book 2000 pg H. influenzae Amoxicillin + clavulanate indicated
457) M. catarrhalis Cefdinir Less frequent pathogens: S.
(35% sterile) Erythromycin + sulfisoxazole aureus, Strep. pyogenes,
Cefuroxime axetil GNB, and anaerobes
Parenteral: Ceftriaxone Oral or nasal decongestants
single dose ± antihistamine
Penicillin–allergy:
Erythromycin–sulfisoxazole,
clarithromycin, azithromycin
Chronic suppurative Pseudomonas Neomycin/polymyxin/hydrocortisone Chloramphenicol otic drops Persistent effusion:
otitis media Staph. aureus otic drops Myringotomy
Malignant otitis P. aeruginosa Ciprofloxacin Tobramycin + ticarcillin, Surgical drainage and/or
externa piperacillin, mezlocillin, debridement sometimes
cefoperazone, ceftazidime, required
aztreonam, cefepime, imipenem, Treat 4–8 wk or longer
or ciprofloxacin Oral regimen—see J Arch
Otolaryngol Head Neck Surg
1989;115:1063
Acute diffuse otitis P. aeruginosa Topical neomycin + polymyxin otic Boric or acetic acid (2%) drops Initially cleanse with 3%
externa (“swimmer's Coliforms drops Topical chloramphenicol saline or 70–95% alcohol +
ear”) Staph. aureus acetic acid Systemic
antibiotics for significant
tissue infection
Otomycosis Aspergillus niger Boric or acetic acid drops Cresylate acetic otic drops Surgery required for abscess
Acute mastoiditis S. pneumoniae Same as for acute otitis media Cefotaxime or ceftriaxone IV in mastoid bone
H. influenzae S. aureus is occasional
S. pyogenes pathogen, especially in
subacute cases
Chronic mastoiditis Anaerobes None Surgery often required
Pseudomonas sp Pre-op: Tobramycin +
Coliforms ticarcillin or piperacillin
S. aureus
SINUSITIS
Acute sinusitis H. influenzae Amoxicillin 500 mg tid (up to 1 g tid) Telithromycin 800 mg qd × 5 d; Indications to treat:
(symptoms >4 wk) S. pneumoniae amoxicillin + clavulanate 875 mg Symptoms severe or
(see p 241) M. catarrhalis po bid symptoms <7 days
S. aureus Cefditoren 200–400 mg bid Most are viral infections;
Cefuroxime 250 mg bid bacterial superinfection in
Levofloxacin 500 mg qd 0.2–10%
Moxifloxacin 400 mg qd Frequency of
Gatifloxacin 400 mg qd beta-lactamase-producing
Clarithromycin 500 mg bid or 1 g bacteria is 20–30%, but
qd amoxicillin appears as
Azithromycin 500 mg, then 250 effective as alternative
mg × 5 days ±; repeat at day agents according to a 1999
14–18 meta-analysis of
Cefpodoxime 200 mg bid antimicrobial trials
Cefprozil 500 mg bid (www.ahcpr.gov/clinic/)
Cefdinir 300 mg bid Bacterial pathogens detected
Doxycycline 100 mg bid in sinus aspirates in about
50%; dominant are S.
pneumoniae (41%), H.
influenzae(35%), anaerobes
(7%), M. catarrhalis (4%),
and S. aureus(3%) (CID
1997;23:1209)
No response after 48–72
hours should lead to an
alternative agent such as
telithromycin,
fluoroquinolones or
amoxicillin + clavulanate*
Frequency of penicillin or
macrolide resistant isolates of
Streptococcus pneumoniae is
26 or 31% respectively.
Consider local resistance
rates before making empiric
antibiotic selections*
Chronic sinusitis Anaerobes Penicillin or amoxicillin Amoxicillin + clavulanate Usually reserve antibiotic
(symptoms >3 mo) S. aureus Clindamycin treatment for acute flares
S. epidermidis Role of anaerobes is
controversial (J Clin Microbiol
1991;29:2396; Am J
Otolaryngol 1995;16:303)
Endoscopic surgery may be
required
Nosocomial sinusitis Pseudomonas Aminoglycoside + antipseudo-monad Imipenem, ceftazidime Complication of nasal
Coliforms penicillin or aminoglycoside + intubation
cephalosporin-3rd generation
(ceftazidime)
PHARYNX Strep. pyogenes
A. hemolyticum Penicillin po (strep only) × 10 days or Erythromycin × 10 days
C. diphtheriae, benzathine penicillin IM × 1 Cephalosporin × 5–10 days
groups C and G (cefditoren, ceftibutin,
strep cephalexin, cefaclor, cefadroxil,
cefuroxime, cefixime, cefditoren,
cefdinir, cefpodoxime)
Clarithromycin × 10 days
Azithromycin × 5 days
N. gonorrhoeae Ceftriaxone 125 mg IM × 1 or ciprofloxacin 500 po × 1
Mycoplasma, C. Tetracycline or erythromycin (?)
pneumoniae
Viruses (EBV etc) None except influenza: Amantadine, rimantadine, zanamivir, or oseltamivir
If compliance questionable,
use benzathine penicillin G ×
1 IM
Penicillin preferred for strep
due to established efficacy in
preventing rheumatic fever
and absence of any penicillin
resistance
A study of 4782 cases of
strep pharyngitis showed a
5-day course of penicillin was
as effective as the standard
10-day course (JID
2000;182: 509)
Causes: Viral 50–80%, strep
10%, EBV–1%
M. pneumoniae 2–5%, C.
pneumoniae 2–5%, N.
gonorrhoeae 1%
(JAMA 2000;284: 2912)
Carrier rate S. pyogenes
(adults) 2–4% (Scand J Prim
HC 1997;15:149)
Macrolides: About 5% of
group A strep are resistant
HIV HAART Acute retroviral syndrome
established plasma HIV RNA
or p24 Ag
Peritonsillar or Strep. pyogenes Penicillin G Clindamycin Drainage necessary
pharyngitis tonsillar Peptostreptococci
abscess
Membranous C. diphtheriae Penicillin or erythromycin Diphtheria: Antitoxin
pharyngitis
Epstein-Barr None Mononucleosis associated
virus with airway closure or severe
toxicity should be treated
with prednisone
Vincent's angina Metronidazole or clindamycin Penicillin, amoxicillin, or
(anaerobes) amoxicillin-clavulanate
Epiglottitis H. influenzae Cefotaxime, ceftizoxime, ceftriaxone, cefuroxime Ensure patent airway (usually
S. pyogenes Ampicillin-sulbactam with endotracheal tube)
Viruses Rifampin prophylaxis for
household contacts <4 yr (×4
days)
Laryngitis Viruses For M. catarrhalis:
(M. catarrhalis) Trimethoprim-sulfa,
erythromycin,
amoxicillin-clavulanate, or
cefaclor
PERIMANDIBULAR
Actinomycosis A. israelii Penicillin G or V Clindamycin Treat for 3–6 mo
Tetracycline
Erythromycin
Parotitis S. aureus Penicillinase-resistant penicillin Cephalosporin-1st gen Surgical drainage usually
(anaerobes) Clindamycin, vancomycin required
Space infections Anaerobes Clindamycin Cefoxitin Surgical drainage required
Penicillin + metronidazole Amoxicillin-clavulanate
Cervical adenitis
Acute Strep. pyogenes Penicillin Erythromycin
Anaerobes Clindamycin Amoxicillin + clavulanate
S. aureus Penicillinase-resistant penicillin Oral cephalosporin (not
cefixime)
Chronic Mycobacteria TB: INH, rifampin, PZA + Etham Noninfectious causes include
MOTT: see pp 170–171 tumors, lymphoma, sarcoid
cysts
Cat-scratch disease Bartonella Ciprofloxacin TMP-SMX Role of antibiotics is unclear
henselae Erythromycin Treat 2 wk
Confirm diagnosis with
serology
DENTAL
Periapical abscess Anaerobes Penicillin Metronidazole × penicillin Metronidazole often preferred
Gum boil Streptococci Clindamycin Amoxicillin-clavulanate for periodontal disease, i.e.,
Gingivitis gingivitis, periodontitis
Pyorrhea
STOMATITIS Oral nystatin (swish and swallow) or Ketoconazole po
Thrush C. albicans clotrimazole troches Fluconazole po
Vincent's angina Anaerobes Penicillin Metronidazole ± penicillin
Clindamycin Amoxicillin-clavulanate
Aphthous stomatitis No pathogen Topical corticosteroid (Topicort gel), Systemic corticosteroids Miles' solution: 60 mg
identified dyclonine (Dyclone) (Prednisone 40 mg/d, then rapid hydrocortisone, 20 mL
Miles' solution, viscous lidocaine taper) nystatin, 2 g tetracycline,
Silver nitrate and 120 mL viscous lidocaine
Herpetiform ulcers H. simplex Acyclovir Treatment usually reserved
Valacyclovir or famciclovir for immunocompromised
hosts
UPPER RESPIRATORY Influenza Influenza: Amantadine, rimantadine, Antiviral therapy for influenza
INFECTION (common Parainfluenza oseltamivir, or zanamivir must be started within 48 hr
cold) (J Clin Microbiol Rhinovirus Ipratropium (see comments) of onset of symptoms.
1999;36:1721; NEJM Coronovirus Nasal decongestants (see comments) Amantadine and rimantadine
2000;343:1715; Ann are active against influenza
Intern Med A; oseltamivir and zanamivir
2001;134:487; Arch are active against influenza A
Intern Med 2003;163: and B
278) Allergic rhinitis—Loratadine
10 mg qd; nasal steroids;
avoid allergens
Naproxen 500 mg tid × 5
days
Ipratropium nasal spray (2
sprays each nostril 3–4 ×/day
× 4 days
OTC preparations with
dexbromphen-iramine 6 mg +
pseudoephedrine 120 mg bid
× 1 wk
Controversial—aspirin and
acetaminophen, vitamin C,
zinc gluconate lozenges
Pleconaril is active vs.
rhinovirus but failed FDA
approval (CID 2003;36:
1523)
* PROTEKT US 2000–01
P.244
P.245
P.246
P.247
P.248
P.249
COMPARISON OF COMMONLY USED ORAL ANTIMICROBIALS FOR RESPIRATORY TRACT INFECTIONS
Regimen commonly used Antimicrobial activity*** Adverse drug reactions (%)****
Pill
count Cost
(10 AWP** Strep. Gr A Staph. Nausea, Therapy
Drug Regimen* days) (10 days) pneumo H. flu strep aureus Anae-robes vomiting Diarrhea Rash stopped Other
Amox-clavulan 875 mg 20 $117 ++½ +++ +++ +++ +++ 1–2 5–10 1 1–3
bid
Amoxicillin 500 mg 30 $13 ++½ + +++ + ++ 1–2 5 1 2
tid
Azithromycin 250 mg 6 $48 ++ +++ +++ +++ ++ 1–3 3–4 0.2 1
qd
Cefaclor 250–500 30 $60–130 ++ +++ +++ +++ ++ 1–4 2–6 1–2 2 Serum
mg tid sickness
Cefdinir 300 mg 20 $90 ++½ +++ +++ +++ ++ 3 16 1 3
bid
Cefditoren 200–400 40 $75 +++½ +++ +++ +++ ++ 1–6 11–15 — 2–3
mg bid
Cefixime 200 mg 20 $88 + +++ +++ ++ + 5–7 15–20 1–2 2–3
bid
Cefpodoxime 200 mg 20 $108 ++½ +++ +++ +++ ++ 1–2 4 1–2 2
bid
Cefprozil 250–500 20 $90–180 ++½ +++ +++ +++ ++ 1–2 — — —
mg bid
Cefuroxime 250–500 20 $106–196 ++ +++ +++ +++ ++ 2–5 4–8 1 —
mg bid
Cephalexin 250–500 40 $56 + +++ +++ +++ ++ 2–4 1–6 1 1
mg qid
Ciprofloxacin 500 mg 20 $116 ++½ +++ +++ +++ ++ 2–5 1–2 1–2 1–3
bid
Clarithromycin 250–500 20 $92 ++ ++ +++ +++ ++ 3–4 3 — 4 Taste
mg bid change
Clindamycin 150–300 40 $100–200 ++½ — +++ +++ +++ 1–2 10–20 — 5–15 C. difficile
mg qid colitis
Doxycycline 100 mg 20 $20 ++ +++ ++ ++ ++ 2–5 1–2 — 1–2
bid
Erythromycin 250–500 40 $11 ++ + +++ ++ ++ 5–30 5 1 5–20 GI
mg qid intolerance
Gatifloxacin 400 mg 10 $94 +++ +++ +++ +++ +++ 1–2 1–2 — 1
qd
Levofloxacin 500 mg 10 $106 +++ +++ +++ +++ + 1–2 1–2 — 1
qd
Loracarbef 400 mg 20 $128 ++ +++ +++ +++ + 2 4 1 1–2
bid
Moxifloxacin 400 mg 10 $98 +++ +++ +++ +++ 111 1–2 1–2 — 1
qd
Penicillin V 500 mg 40 $9 ++ + +++ + ++ 3 3 1 2–3
qid
Telithromycin 800 mg 20 $92 est. +++ +++ +++ +++ ++ 2–8 10–11 — 4 Headache,
qd dizziness
TMP-SMX 1 DS bid 20 $24 + +++ ++ +++ — 10 — 5–10 4–10 Rash
* Typical regimen for respiratory tract infections (otitis, sinusitis, exacerbations of bronchitis, “walking pneumonia”).
** AWP, average whole price Sept 2003.
*** In vitro activity against common respiratory tract community-acquired bacterial pathogens: — indicates minimal activity, + indicates modest activity, ++
indicates moderate activity, +++ indicates activity against nearly all strains or indicates a preferred choice based on clinical trials.
**** Adverse reactions according to package inserts (summarized in Infect Dis Clin Pract 4:S103, 1995); “therapy stopped” indicates percentage that
discontinued treatment because of adverse drug reaction.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Pulmonary Infections
Pulmonary Infections
A. Specimens and Tests for Detection of Lower Respiratory Pathogens (CID 1998;26:611.)
Test
Microscopy Culture Serology Other
Organism Specimen (stain)
Bacteria
Aerobic Expectorated Gram stain X Pneumococcal
sputum, blood, Quellung for S. urine antigen
TTA, empyema pneumo (JCM
fluid 2003;41:2810)
Anaerobic TTA, empyema Gram stain X
fluid
Legionella sp. Sputum, BAL, FA (L. X IFA Urinary antigen
pleural fluid pneumophila) (L. pneumophila
gr1), PCR
(experimental)
Nocardia sp. Expectorated Gram and X
sputum, bronchial modified carbol
washing, BAL fuchsin stain
fluid, tissue
Chlamydia sp. Nasopharyngeal — Xa CF for C. PCR for C.
swab psittaci MIF pneumoniae
for C. (experimental)
pneumo >
1:64
Mycoplasma sp. Nasopharyngeal — Xa EIA, CF, cold PCR
swab agglutinins (experimental)
in 30–60%
Mycobacteria Expectorated or Fluorochrome X PPD
induced sputum, stain or carbol
bronchial washing, fuchsin
BAL fluid
Fungi
Deep-seated
Blastomyces Expectorated, KOH with X CF, ID
sp. sputum, induced phase contrast;
sputum, BAL Calcofluor
white
Coccidioides As above As above X CF, ID, LA
sp.
Histoplasma As above As above X CF, ID Antigen assay
sp. BAL, blood, urine
Opportunistic
Aspergillus Lung biopsy H&E, GMS, X ID CT scan; EIA
sp. Calcofluor expected soon
white
Candida sp. Lung biopsy H&E, GMS, X
Calcofluor
white
Cryptococcus Respiratory H&E, GMS, X LA Serum or BAL
sp. secretions, serum, Calcofluor antigen assay
Lung biopsy white
Zygomycetes Expectorated H&E, GMS, X
sputum, tissue Calcofluor
white
Pneumocystis Induced sputum or Toluidine blue, Giemsa, FA, or GMS stain
carinii bronchial
brushings,
washings, BAL
fluid
Viruses
Influenza Nasopharyngeal FA: Influenza X CF, EIA, LA, Z-Stat Flu
aspirate and RSV FA
Paraflu, RSV Nasopharyngeal aspirate CMV: Shell viral
culture, FA stain
of BAL or biopsy
CMV Bronchial aspirate, BAL, or biopsy
SARS CoV Respiratory EM X IFA, EIA RT-PCR
secretions (BSL-3
lab)
CF, complement fixation; PPD, purified protein derivative; ID, immunodiffusion; LA, latex agglutination; H&E,
hematoxylin and eosin; CIE, coun-terimmunoelectrophoresis; EIA, enzyme immunoassay; FA, fluorescent
antibody stain; IFA, indirect fluorescent antibody; MIF, microimmunofluorescence test.
a Few clinical microbiology labs offer these cultures, and those that do infrequently recover the indicated
organisms.
P.251
B. Empiric Treatment of Lower Respiratory Tract Infections
1. Community-acquired pneumonia: Guidelines of Infectious Diseases Society of America (modified from
CID 2003;37:405.)
Outpatient
Generally preferred: Macrolide*, telithromycin,† fluoroquinolone**, or doxycycline
Modifying factors
Suspected penicillin-resistant S. pneumoniae: Fluoroquinolone**, telithromycin†
Suspected aspiration: Amoxicillin-clavulanate
Hospitalized Patient
General medical ward
Generally preferred: Beta-lactam*** + macrolide* or fluoroquinolone** (alone)
Hospitalized in the intensive care unit for serious pneumonia
Generally preferred: Erythromycin, azithromycin, or fluoroquinolone** plus cefotaxime or
ceftriaxone
Modifying factors
Structural disease of lung: Antipseudomonal penicillin, carbapenem, or cefepime + macrolide or
fluoroquinolone** + aminoglycoside
Penicillin allergy: fluoroquinolone** + clindamycin
Suspected aspiration: fluoroquinolone + clindamycin or beta-lactam-beta-lactamase inhibitor
(alone)
2. Nosocomial pneumonia
a. Etiologic diagnosis: Diagnosis of pneumonia based on clinical criteria of fever, x-ray evidence of an
infiltrate, and purulent respiratory secretions is often erroneous based on quantitative brush catheters of
bronchoscopic aspirates (Ann Intern Med 2000;132:621.). The debate with ventilator associated pneumonia
is empiric treatment vs quantitative bronchoscopic specimens (Lancet 2000;356:874.).
b. Empiric treatment (Med Letter 1999;41:95.)
Third generation cephalosporin (cefotaxime, ceftizoxime, ceftriaxone, or ceftazidime), cefepime,
ticarcillin-clavulanate, piperacillin-tazobactam, meropenem, or imipenem
With or without aminoglycoside (tobramycin, gentamicin, amikacin)
Special considerations
Probable P. aeruginosa (especially ICU): Cefepime, meropenem, or imipenem plus aminoglycoside
Probable S. aureus: Add vancomycin
3. Lung abcess
a. Anaerobic bacteria (recommendations of IDSA, CID 2000;31:347.)
1. Clindamycin
2. Beta-lactam-beta-lactamase inhibitor
3. Imipinem/meropenem/ertapenem
P.252
b. Other microbial pathogen—see next section
4. Acute bronchitis (Recommendations of ACP and CDC: Ann Intern Med 2001; 134:479 and 521)
Evaluation of acute cough should focus on ruling out pneumonia
Chest x-ray if:
1. Abnormal vital signs,
2. “asymetrical lung sounds,” or
3. cough >3 wks
Antibiotics are not recommended regardless of duration of cough. Most are viral and self-limited
Treatment is symptomatic with antipyretics, analgesics, beta-agonist inhalers, antitussives, or vaporizers
Influenza: Amantadine, rimantadine, zanamivir, or oseltamivir (must start within 48 hr of onset of flu
symptoms)
Pertussis: Erythromycin 500 mg po qid × 14 days or TMP-SMX DS bid × 14 days Antibacterial agents have
no documented benefit and should be avoided except with suspected or established pertussis (Am J Med
1999;107:62.)
5. Exacerbations of chronic bronchitis (Recommendations of ACP: Ann Intern Med 2001;134:600.)
a. Chest x-ray: Useful in hospitalized patients (up to 23% show new findings) and it may be useful in EW
visits; there are not data for or against its use in office practice
b. Treatment—hospitalized patients
Inhaled anticholinergic bronchodilators or short-acting beta2-agonists; anticholinergics are used first
and to maximum dose because of fewer side effects
Systemic steroids for up to 2 weeks
Noninvasive positive-pressure ventilation supervised by trained physician
Cautious administration of O2 to hypoxemic patients
c. Antibiotic decision-making
Reserve antibiotics for severe exacerbations
If used, the preference is narrow-spectrum agents. Prior placebo-controlled trials favored amoxicillin,
TMP-SMX, and tetracycline but they were done prior to emergence of multidrug resistant bacteria and
excluded nursing home patients and recent hospital discharges
Interventions without documented benefit: mucolytic therapy, chest physiotherapy, and methylxanthine
bronchodilators (the latter two may be harmful)
P.253
C. Treatment of Pneumonia by Pathogen (modified from CID 2003;37:405.)
Agent Preferred antimicrobial Alternative antimicrobial Comment
S. pneumoniae
Penicillin-sensitive Penicillin G or amoxicillin Telithromycin† Doses for severe
(MIC S 1.0 Tg/mL) Cefuroxime Cephalosporins: Cefepime, diseases:
Ceftriaxone Cefotaxime Penicillin G 0.5–2
Oral cephalosporins: mil units IV q4h
cefditoren, cefpo-doxime, Ceftriaxone 1–2 g/d
cefprozil, cefuroxime, cefdinir IV
Macrolides* Cefotaxime 2 g IV
Ampicillin q6h
Doxycycline Resistance:
Clindamycin Penicillin—15%;
Imipenem/meropenem/ertapenem TMP-SMX—23%;
erythromycin—25%;
clindamycin—6%;
cefotaxime—2%;
doxycycline—6%;
levofloxacin—1%;
vancomycin—0 Data
from CDC
surveillance with
10,000 strains of S.
pneumoniae from in
diverse regions of
U.S. in 2000–02
(Antimicrob Ag
Chemother
2003;47:1790)
Penicillin resistance Vancomycin Based on in vitro susceptibility Definition of
(MIC > 4 Tg/mL) Fluoroquinolone** tests resistance: Penicillin
Telithromycin† Imepenem/meropenem/ertapenem resistance is defined
Clindamycin as an MIC >4 Tg/mL
Linezolid based on achievable
serum levels with
nonmeningeal
pneumococal
infections
Risk for resistance:
Geographic region;
children,
immuno-suppressed,
chronic antibiotic
exposure, clustering
(day care, prison,
hospital etc),
international travel
Major resistant
serotypes: 6A, 6B,
14, 19A, 19F, 23F
(five of six included
in vaccine)
H. influenzae Azithromycin Doxycycline Betalactamase
Cephalosporin—2nd or 3rd Fluoroquinolone** production by
generation Clarithromycin 30–40% of strains
TMP-SMX Beta-lactam-beta-lactamase Most are nontypable
Telithromycin inhibitor strains
Moraxella Cephalosporin—2nd or 3rd Macrolide*: Fluoroquinolone** Beta-lactamase
catarrhalis gen production by >90%
TMP-SMX
Amoxicillin-clavulanate
Telithromycin
Anaerobes Clindamycin Penicillin G or V Clindamycin is
Beta-lactam-beta-lactamase Ampicillin/amoxicillin ± superior to penicillin
inhibitor metronidazole in putrid lung
abscesses (Ann
Intern Med
1983;98:466; Arch
Intern Med
1990;158:2525)
Metronidazole should
not be used as a
single agent (CID
1993;16:S248).
Antibiotics other
than penicillin,
clindamycin, and
metronidazole have
not been studied
S. aureus Methicillin Nafcillin/oxacillin ± Cefazolin or cefuroxime Beta-lactamase
sensitive rifampin or gentamicin Vancomycin, clindamycin, production by >90%.
TMP-SMX, fluoroquinolone** Methicillin
sensitive: >90%
community-acquired
strains and 60–70%
of nosocomial
strains
Methicillin resistant Vancomycin ± rifampin or Requires in vitro testing: Linezolid
gentamicin
Enterobacteriaceae Cephalosporin—2nd or 3rd Aztreonam, imipenem, In vitro sensitivity
(Coliforms: E. coli gen ± aminoglycoside beta-lactam-beta-lactamase tests needed
Klebsiella, Proteus, Carbapenem*** inhibitor
Enterobacter, etc) Fluoroquinolone**
P. aeruginosa Aminoglycoside + Aminoglycoside + aztreonam, Need in vitro activity
anti-pseu-domonal imipenem, or ciprofloxacin test results
beta-lactam: ticar-cillin,
piperacillin, mezlocillin,
ceftazidime, cefepime, or
cefoperazone
Ciprofloxacin +
antipseudomonal
beta-lactam
Legionella Fluoroquinolone** Macrolide* Fluoroquinolones are
Azithromycin Doxycycline superior to
erythromycin in
animal models
Initial erythromycin
dose: 4 g/d IV, oral
therapy (2 g/d)
when
improved—total
duration 2–3 wk
Mycoplasma Doxycycline Fluoroquinolone** Treat 1–2 wk
pneumoniae Macrolide*
Telithromycin
Chlamydia Doxycycline Fluoroquinolone** Treat for 2 wk
pneumoniae Macrolide*
Telithromycin
Chlamydia psittaci Doxycycline Erythromycin, chloramphenicol
Nocardia Sulfonamide Imipenem ± amikacin
TMP-SMX Doxycycline or minocycline
Sulfonamide + minocycline
or amikacin
Coxiella burnetii Tetracycline Chloramphenicol
(Q fever)
Influenza (see pp Amantadine, rimantadine, zanamivir, or oseltamivir Should be started
196) within 48 hr of onset
of symptoms.
Oseltamivir and
zanamivir are
effective against
influenza A and B
Hantavirus (see p Supportive care Ribavirin (33 mg/kg
200) IV, then 16 mg/kg
q6h × 4 days, then 8
mg/kg q8h × 3
days)—experimental.
Call CDC
800-532-9929
Cytomegalovirus Ganciclovir × IVIG or CMV Foscarnet
(see p 194) hyperimmune globulin Cidofovir
* Macrolide: Erythromycin, clarithromycin, azithromycin; for H. influenzae, azithromycin or clarithromycin.
** Fluoroquinolone: Levofloxacin, moxifloxacin, or gatifloxacin show enhanced S. pneumoniae and atypical agents.
*** Carbapenems: Imipenem, meropenem and ertapenem.
† Telithromycin is active against multi-drug resistant Streptococcus pneumoniae.
Footnotes
*Macrolide: Azithromycin, clarithromycin, or erythromycin
**Fluoroquinolone: Levofloxacin, sparfloxacin, gatifloxacin, or moxifloxacin or other fluoroquinolone with enhanced
activity versus S. pneumoniae. Preferably reserve for high-risk patients including those with recent antibiotic exposure,
the elderly and those with associated underlying diseases such as CHF, chronic lung disease, renal failure or diabetes.
†Telithromycin is also active against multi-drug resistant Streptococcus pneumoniae.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Endocarditis
Endocarditis
I. DUKE CRITERIA FOR DIAGNOSIS OF INFECTIVE ENDOCARDITIS (Am J Med 1994;96:200.;
CID 2000;30:633.)
Note: The Duke criteria have become generally accepted (Am J Med 1994;96:200.) and multiple
reviews show a specificity of 99% and a negative predictive value of 92% (Am Heart J
1994;128:1200.; CID 1998;26:1302.).
A. Definite Infective Endocarditis
1. Pathologic criteria
Microorganisms: Demonstrated by culture or histology in a vegetation, or in a
vegetation that has embolized, or in an intracardiac abscess, or
Pathologic lesions: Vegetation or intracardiac abscess present, confirmed by
histology showing active endocarditis
2. Clinical criteria (using specific definitions listed below under “Definitions of
Terminology”)
Two major criteria, or one major and three minor criteria, or five minor criteria
B. Possible Infective Endocarditis 1 major + 1 minor or 3 minor
C. Rejected
1. Firm alternate diagnosis for manifestations of endocarditis, or
2. Resolution of manifestations of endocarditis with antibiotic therapy for 4 days or less, or
3. No pathologic evidence of infective endocarditis at surgery or autopsy, after antibiotic
therapy for 4 days or less
Definitions of Terminology
1. Major Criteria
a. Positive blood culture for infective endocarditis
1. Typical microorganism for infective endocarditis from two separate blood
cultures
a. Viridans streptococci, Streptococcus bovis, HACEK group, or
b. Community-acquired enterococci, in the absence of a primary focus,
or
c. S. aureus bacteremia that is community acquired or nosocomial and
with or without a primary focus
2. Persistently positive blood culture, defined as recovery of a microorganism
consistent with infective endocarditis from
a. Blood cultures drawn more than 12 hr apart or
b. All of three or a majority of four or more separate blood cultures, with
first and last drawn at least 1 hr apart
3. Single positive blood culture for Coxiella burnetii or antiphase I IgG
antibody titer >1:800
b. Evidence of endocardial involvement
1. Positive echocardiogram for infective endocarditis
a. Oscillating intracardiac mass, on valve or supporting structures, or in
the path of regurgitant jets, or on implanted material in the absence
of an alternative anatomic explanation, or
b. Abscess or
c. New partial dehiscence of prosthetic valve, or
2. New valvular regurgitation (increase or change in preexisting murmur not
sufficient)
2. Minor Criteria
a. Predisposition: Predisposing heart condition or IV drug use
b. Fever: I38.0°C (100.4°F)
P.257
c. Vascular phenomena: Major arterial emboli, septic pulmonary infarcts, mycotic
aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions
d. Immunologic phenomena: Glomerulonephritis, Osler's nodes, Roth spots,
rheumatoid factor
e. Microbiologic evidence: Positive blood culture but not meeting major criterion
as noted previously or serologic evidence of active infection with organism
consistent with infective endocarditis
f. Echocardiogram: Consistent with infective endocarditis but not meeting major
criterion as noted previously (recommended for deletion)
II. ANTICIPATED AGENTS, ECHO, RISKS
A. Microbiology of endocarditis: Based on literature review (NEJM 2001;345:1318.)
Prosthetic valve
Time postoperative
Native valve >16 <60 2–12 mo >12 mo
yrs days
Streptococcus species 40–65 1 7–10 30–33
Staph. aureus 22–30 20–24 10–15 15–20
Staph. epidermidis 3–8 10–15 2–4 4–7
Enterococcus 5–17 5–10 10–15 8–12
Fungi 1–3 5–10 10–15 1
Gram-negative bacilli 4–10 10–15 2–4 8–12
HACEK and culture 3–10 3–7 3–7 3–8
negative
B. Culture negative endocarditis
Microbe Methods to establish pathogen
Atiotrophia 1) Grow in thioglycolate, and 2) as colonies around S.
(nutritionally deficient aureus in media supplemented with pyridoxal HCI or
strep) L-cysteine
Bartonella 1) Serology, 2) Lysis-centrifugation, and 3) PCR of valve or
embolized vegetation (may require > 1 month to culture)
Coxiella burnetti 1) Serology, and 2) PCR, Giemsa stain, or immunohistologic
stains of op specimen
HACEK Blood cultures to day 7; may require larger incubation and
subculture
Chlamydia Blood culture using specialized technique described
T. whipplei 1) Silver or PAS stain of valve, and 2) PCR or culture of
vegetation
Legionella 1) Subculture of blood, 2) Lysis-centrifugation pellet from
blood cult, 3) BCYE agar for valve, 4) FA stain of valve, and
5) serology
Brucella Serology
Fungi 1) Blood culture-Candida, 2) Antigen assay urine or blood
for H. capsulatum or blood for C. neoformans, and 3)
culture and histology of valve
P.258
C. Echocardiography
Transthoracic echo is inadequate in up to 20% of adults due to obesity, chronic lung disease,
and chest wall deformities. The sensitivity for vegetations is 60–70% (J Am Coll Cardiol
1991;18:391.; Am J Med 1996;100:90.). Transesophageal echo increases sensitivity for
detecting vegetations to 75–95% and shows specificity of 85–98% (Am J Med
1999;107:198.). Guidelines for use (J Am Coll Cardiol 1997;29:862.) suggest the preference
for transthoracic echo to evaluate native valves in patients who are good candidates for
imaging, especially if the probability of endocarditis is less than 4%. For patients with a
probability of 4–60%, initial use of transesophageal echo is more cost-effective. TEE is more
sensitive for evaluating periovascular extension in myocardial abscesses.
S. aureus bacteremia: Endocarditis is found in 13–25% (CID 2002;30:633.). TEE is useful in
determining the duration of therapy in patients with uncomplicated,
intravascular-catheter-associated S. aureus bacteremia (Am J Med 1999;107:198.; Ann Intern
Med 1999;130:810.; CID 1999;28:106.).
D. Endocarditis risk/100,000 person years*
Native valve: 1.7–6.2
Prosthetic valve: 60 months: 2,000–3,000
Injection drug use: 700
III. TREATMENT OF ENDOCARDITIS
A. Medical Management by Microbial Pathogen (Committee on Rheumatic Fever, Endocarditis
and Kawasaki Disease of the American Heart Association's Council on Cardiovascular Disease
in the Young: Antimicrobial Treatment of Infective Endocarditis due to Viridans Streptococci,
Enterococci, and Staphylococci. JAMA 274:1706, 1995)
1. Streptococci
a. Penicillin-sensitive streptococci (minimum inhibitory concentration <0.1 Pg/mL)
1. Penicillin only: Aqueous penicillin G, 12–18 mil units/day either continuously
or in 6 equally divided doses × 4 wk.
(Preferred regimen for patients with a relative contraindication to streptomycin
including age >65 yr, renal impairment, or prior 8th cranial nerve damage.)
2. Ceftriaxone: 2 g once daily IV × 4 wk
3. Two-week course: Aqueous penicillin G 12–18 mil units either continuously or in
6 equally divided doses plus gentamicin 1 mg/kg IM or IV q8h. Peak gentamicin
level (1 hr after start of 20- to 30-min infusion) should be 3 Pg/mL; trough
should be <1 Pg/mL. Two-week regimen is not recommended for complicated
cases, e.g., extracardiac foci or intracardiac abscesses. Aqueous penicillin G,
q12h. (Advocated as most cost-effective regimen by Mayo Clinic group for
uncomplicated cases with relapse rates of <1%.)
4. Penicillin allergy: Vancomycin, 30 mg/kg/d IV × 4 wk in 2–4 doses not to
exceed 2 g/d unless serum levels are monitored. Vancomycin levels 1 hr post
dosing should be 30–45 Pg/mL with twice daily dosing. Infuse vancomycin over
I60 min.
Note:
Streptococcus bovis and tolerant streptococci with MIC <0.1 Pg/mL may receive
any of these regimens
Nutritionally deficient should be treated as enterococcal endocarditis
Prosthetic valve endocarditis: IV penicillin for 6 wk and gentamicin for at least
2 wk
P.259
Immediate reaction to penicillin or other beta-lactam is major indication for
vancomycin
Penicillin tolerant strains with MBCs that greatly exceed MICs (>32-fold):
Recommend usual therapy, meaning routine MBC determination is not
recommended for streptococci
Gentamicin is now the most frequently used aminoglycoside because of ability
to monitor levels and ability to give IV or IM. If streptomycin is preferred, test
for high-level resistance (I1000 Pg/mL)
Two-week treatment regimen is not recommended for complicated cases, e.g.,
shock, extracardiac foci of infection, or intracardiac abscess
Desired peak serum levels if obtained: Streptomycin—20 Pg/mL, gentamicin—3
Pg/mL, vancomycin—20–35 Pg/mL (qid), or 30–45 Pg/mL (bid)
Ceftriaxone plus gentamicin once daily × 2 wk may be adequate
Expected bacteriologic cure rate: >95%; expected survival rate: >90%
b. Viridans streptococci and Streptococcus bovis relatively resistant to
penicillin G (minimum inhibitory concentration I0.1 Pg/mL and T0.5 Pg/mL)
1. Aqueous penicillin G, 18 mil units/d IV either continuously or in 6 divided doses
plus gentamicin 1 mg/kg IM or IV q8h × 4 wk
2. Penicillin allergy: Vancomycin 30 mg/kg/d × 4 wk in 2 daily doses not to exceed
2 g/d
3. Penicillin allergy, cephalosporins: Cefazolin, 1 g IM or IV q8h × 4 wk
c. Penicillin-resistant streptococci including enterococci and strains with
minimum inhibitory concentrations of >0.5 /g/mL
1. Aqueous penicillin G 18–30 mil units/d IV either continuously or in 6 divided
doses plus gentamicin, 1 mg/kg IM or IV q8h × 4–6 wk
2. Ampicillin 12 g/d IV either continuously or in 6 divided doses plus gentamicin 1
mg/kg IM or IV q8h × 4–6 wk
3. Penicillin allergy: Vancomycin 30 mg/kg/d IV in 2 doses not to exceed 2 g/24 hr
unless serum levels are monitored plus gentamicin 1 mg/kg IM or IV q8h × 4–6
wk. Gentamicin is not required for viridans streptococci
Note:
Streptococci, groups B, C, and G: Some recommend routine use of
penicillin or cephalosporin × 4–6 wk plus gentamicin × 2 wk
Strep bovis endocarditis is associated with colonic carcinoma
Patients with symptoms for over 3 mo before treatment and those with
prosthetic valve endocarditis should receive combined treatment for 6 wk
Aminoglycosides: Gentamicin is usually preferred; MIC should be
T500–2000 Pg/mL for gentamicin or T2000 Pg/mL for streptomycin.
Serum levels should be monitored: Desirable peak levels are streptomycin
20 Pg/mL and gentamicin 3 Pg/mL. Some authorities recommend
gentamicin 1.5 mg/kg q8h with goal for peak serum concentration of 5
Pg/mL. Usual dose of streptomycin is 7.5 mg/kg IM q12h, not to exceed
500 mg. Streptomycin is more ototoxic, which is often irreversible.
Gentamicin is more often nephrotoxic, which is usually reversible
For enterococcal endocarditis, shorter courses of aminoglycosides (2–3 wks
vs. 4–6 wks) may be adequate (CID 2002;34:159.)
Expected bacteriologic cure rate: >95%; expected survival rate: >90%
2. Staphylococcus aureus or S. epidermidis
a. No prosthetic device—methicillin-sensitive
1. Nafcillin or oxacillin 2 g IV q4h × 4–6 wk with optional addition of gentamicin 1
mg/kg IV or IM q8h × 3–5 days.
2. Penicillin allergy, cephalosporin: Cefazolin 2 g IV q8h × 4–6 wk with optional
addition of gentamicin 1 mg/kg IV or IM q8h × 3–5 days (should not be used
with immediate-type penicillin hypersensitivity).
3. Penicillin allergy or methicillin-resistant strains: Vancomycin 30 mg/kg/d
P.260
in two daily doses (not to exceed 2 g/d unless serum levels monitored) × 4–6
wk. With inadequate response, add aminoglycoside × 3–5 days.
4. Parenteral drug abuse with tricuspid valve endocarditis: Oxacillin or nafcillin +
tobramycin parenterally × 2 wk (Ann Intern Med 1988;109:619.; Eur J Clin
Microbiol Infect Dis 1994;13:559.). Vancomycin is not an adequate substitute
for nafcillin in this 2-week course (Eur J Clin Microbiol Infect Dis
1994;13:533.). Abbreviated course is not recommended for HIV-positive
patients or those with persistent fever >7 days or with vegetations >1–2 cm
(NEJM 2001;345:1318.).
b. Prosthetic valve or prosthetic material
1. Methicillin-sensitive strains: Nafcillin or oxacillin 2 g IV q4h × I6 wk plus
rifampin 300 mg po q8h × I6 wk plus gentamicin 1 mg/kg IV or IM q8h (not to
exceed 80 mg) × 2 wk.*
2. Methicillin-resistant strains: Vancomycin 30 mg/kg/d in 2–4 doses (not to
exceed 2 g/d unless serum levels monitored) × I6 wk plus rifampin 300 mg po
q8h × I6 wk plus gentamicin 1 mg/kg IV or IM q8h (not to exceed 80 mg) × 2
wk.*
Note:
Methicillin-resistant staphylococci should be considered resistant to cephalosporins
Vancomycin is considered inferior to oxacillin or nafcillin for methicillin-sensitive
strains of S. aureus (Ann Intern Med 1991;115:674.)
Tolerance has no important effect on antibiotic selection
The occasional strains of staphylococci that are sensitive to penicillin G at <0.1
Pg/mL may be treated with regimens advocated for penicillin-sensitive streptococci
Use of rifampin in prosthetic valve endocarditis will increase required dose of
coumadin
For native valve endocarditis, the addition of gentamicin to nafcillin or oxacillin
causes a more rapid clearing of bacteremia in patients with left-sided endocarditis
(2.5 vs 4.0 days) but has no impact on cure rates; use of gentamicin (or rifampin)
with either methicillin-sensitive or methicillin-resistant strains is sometimes
advocated for the first 3–5 days of treatment with a beta-lactam or vancomycin (CID
1993;17:313.)
Duration of treatment: 4–6 wk, 6 wk commonly recommended for left-sided
staphylococcal endocarditis
Coagulase-negative strains infecting prosthetic valves should be considered
methicillin-resistant unless sensitivity is conclusively demonstrated
Aminoglycoside selection for coagulase-negative strains should be selected on the
basis of in vitro sensitivity tests; if not active, these agents should be omitted
Expected outcome: CID 1992;15:589.
Bacteriologic cure Survival
Left sided >80% >50%
Right sided >90% >90%
3. HACEK group: Haemophilus parainfluenzae, H. aphrophilus, Actinobacillus
actinomycetem comitans, Cardiobacterium hominis, Eikenella corrodens, and
Kingella kingae
a. Ceftriaxone 2 g once daily IM or IV × 4 wk
b. Ampicillin 12 g/d IV either continuously or in 6 divided doses plus gentamicin 1
mg/kg IM or IV q8h × 4 wk
c. Recent studies show the most active antibiotics in vitro are third generation
P.261
cephalosporins, cefepime, meropenem, rifampin, and fluoroquinolones (Diagn
Microbiol Infect Dis 1999;34:73.)
4. Fungi (Candida sp and Aspergillus sp)* (not included in committee recommendations)
a. Amphotericin B 0.8–1.0 mg/kg/d IV + flucytosine 100–150 mg/kg/d po
b. Fluconazole 400 mg/d IV or po (susceptible Candida sp. only: Experience limited,
but anecdotal experience favorable; experience with fluconazole in combination with
flucytosine, rifampin, etc also is limited)
5. Organisms with special culture requirements: HACEK (see above), Coxiella burnetii
(serology), Brucella, N. gonorrhoeae, Legionella, Bartonella, corynebacteria, Listeria,
nutritionally variant streptococci, nocardia, mycoplasma, chlamydia, and mycobacteria
B. Outpatient Treatment
1. Ceftriaxone once daily for penicillin-sensitive viridans streptococci
2. Use of portable computerized pumps for multiple dose or continuous-infusion therapy.
3. Dual-lumen central catheter with two portable pumps permits combination therapy.
C. Empiric Treatment for Acute Endocarditis Recommendations of Mayo Clinic (Mayo Clin Proc
1997;72:532.)
Setting Antibiotic regimen Alternative
Acute onset, Nafcillin or oxacillin (2 g IV Vancomycin (1 g IV q12h) plus
native valve q4h) plus aminoglycoside* aminoglycoside*
Subacute Ampicillin-sulbactam (2 g Vancomycin (1 g IV q12h) plus
Native valve q4–6h) (ampicillin) plus ceftriaxone (2 g IV q12h) or
aminoglycoside* cefotaxime (4 g IV q6h) +
aminoglycoside*
Prosthetic Nafcillin or oxacillin (2 g IV q4h) plus aminoglyco-side* plus
valve rifampin 300 mg IV q12h)
Intravenous Nafcillin or oxacillin (2 g IV Vancomycin (1 g IV q12h) +
drug use q4h) plus aminoglycoside* aminoglycoside*
* Aminoglycoside—usually gentamicin 1 mg/kg IV q8h to achieve peak serum levels of
about 3Pg/mL.
D. Monitoring:
1. Serumcidal activity: Not recommended for routine use—may be useful with unusual
etiology or unconventional therapy.
2. Blood culture: To verify response and post-treatment to assure cure. Relapses occur
within 4 wk.
3. Most relapses occur within 2 months of discontinuing antibiotic treatment
P.262
IV. INDICATIONS FOR CARDIAC SURGERY IN PATIENTS WITH ENDOCARDITIS (Am J Med
1985;78(suppl 6B):138.)
A. Indications for Urgent Cardiac Surgery*
Severe heart failure (especially with aortic insufficiency)
Vascular obstruction
Uncontrolled infection
Fungal endocarditis
Persistent bacteremia (or persistent signs of sepsis)
Lack of effective antimicrobial agents
Unstable prosthetic valve
B. Relative Indications for Cardiac Surgery
1. Native valve
Bacterial agent other than susceptible streptococci (especially P. aeruginosa,
Brucella, Coxiella, fungi, and resistant enterococci)
Relapse (especially if nonstreptococcal agent)
Evidence of intracardiac extension
Rupture of sinus of Valsalva or ventricular septum
Ruptured chordae tendineae or papillary muscle
Heart block (new conduction disturbance)
Abscess shown by echo or catheterization
Two or more emboli
Vegetations demonstrated by echo (especially large vegetation or aortic valve
vegetations)
Mitral valve preclosure by echo (correlates with severe acute aortic insufficiency)
2. Prosthetic valve: Surgical therapy is usually superior to medical treatment (Ann Thorac
Surg 1994;58:1073.)
Early postoperative endocarditis (<8 wk)
Nonstreptococcal late endocarditis
Periprosthetic leak
Two or more emboli
Relapse
Evidence of intracardiac extension (see above)
Miscellaneous: Heart failure, aortic valve involvement, new or increased regurgitant
murmur or mechanical valve versus bioprosthesis
C. Echocardiographic Findings that Suggest Potential Need for Surgery (AHA Committee
on Infectious Endocarditis—Circulation 1998; 98:2936.):
1. Persistent vegetations after major embolic event
2. Large vegetations (>1 cm) mitral valve
3. Increase vegetation size after 4 wk of therapy
4. Acute mitral insufficiency
5. Valve perforation or rupture
6. Periannular extension of infection
D. Point system: Urgent surgery should be strongly considered with five accumulated points
(indications for surgery in infective endocarditis. In Sande MA, Kaye D (Eds). Contemporary
Issues in Infectious Disease. New York: Churchill Livingstone, 1984:201–212).
INDICATIONS FOR EMERGENT SURGERY*
Native valve Prosthetic valve
Heart failure
Severe 5 5
Moderate 3 5
Mild 1 2
Fungal etiology 5 5
Persistent bacteremia 5 5
Organism other than susceptible strep 1 2
Relapse 2 3
One major embolus 2 2
Two or more systemic emboli 4 4
Vegetations by echocardiography 1 1
Ruptured chordae tendineae or papillary mm 3 —
Ruptured sinus of Valsalva 4 4
Ruptured ventricular septum 4 4
Heart block 3 3
Early mitral valve closure by echo 2 —
Unstable prosthesis — 5
Early prosthetic valve endocarditis — 2
Periprosthetic leak — 2
*Criterion is I5 points.
Note: This point system above has never been validated.
Alternative: An alternative point system is based on 6 factors that predict mortality within 6
months: mental status—4; Charlison co-morbidity score—1–6*; CHF-3, pathogen other than
Strep. viridans—6–8; and medical vs surgical treatment—5.
P.263
Footnotes
*NEJM 2001;345:1318; JID 2002;185:1761
*Surgery often required. If strain is resistant to aminoglycosides, avoid these drugs; use
fluoroquinolone if susceptible. If surgery performed, examine in vitro sensitivities because these often
change during treatment.
*Early surgery virtually always required
*Note: The validity of these criteria for surgery have never been shown (JAMA 2003;289:1933)
*1 = myocardial infarct, stroke, dementia, ulcer, mild liver disease, diabetes, chronic lung disease; 2 =
severe renal disease, complicated diabetes, hemiparesis, tumor; 3 = severe liver disease; 6 =
metastatic cancer, immunodeficiency
Validity testing in 513 patients showed the following mortality data at 6 mo: <6: 6%; 7–11: 17%,
12–15: 31%, >15: 63% (JAMA 2003;289:1933). (This system predicts mortality rather than indications
for surgery, but the authors suggest utility in surgical decisions.)
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Viral Hepatitis
Viral Hepatitis
Types, clinical features, and prognosis
(MMWR 34:313, 1985; MMWR 37:341, 1988; MMWR 39:1, 1990; MMWR 40(RR-12):1, 1991)
Type Seroprevalence Incubation Diagnosis* Prognosis/comments
period
A (HAV) Person-to-person 15–50 days Acute HAV: IgM Self-limited: >99%
fecal-oral Avg: 28 days anti-HAV Fulminant and fatal:
Contaminated Prior HAV: Total 0.6%
food and water (IgM and IgG) No carrier state or
(epidemic) anti-HAV chronic infection
Seroprevalence: Sequence: Viral Severity increases
Anti-HAV in transmission (cid:1) with age
adults HAV viremia and IgM + elevated ALT is
U.S.: 40–50% fecal shedding at presumptive evidence
Acute viral 2 wk, IgM-HAV at for acute HAV. IgM
hepatitis: 2 wk, IgG-HAV at remains elevated 3–9
40–60% 8–16 wk mo; IgG persists for
Fulminant life
hepatitis: 8%
B (HBV) Sexual contact 45–160 days Acute HBV: HBsAg Fulminant and fatal:
or contaminated Avg: 120 days +, IgM anti-HBc+, 1.4%
needles from anti-HBc+, Carrier state (defined
HBsAg carrier anti-HBs– as HBsAg-pos, 2×
source Chronic HBV: separated by 6 mo or
(transmission HBsAg+ × 6 mo, HBsAg pos and IgM
via blood anti-HBc+ IgM anti-HBc neg):
transfusions is anti-HBc+, Develops in 6–10%
rare due to anti-HBs– of infected adults,
HBsAg HBsAg “window”: 25–50% of children
screening) IgM anti-HBc+, <5 yr
Efficiency of anti-HBc+, Chronic carriers:
transmission HBsAg–, 25% develop chronic
increased if anti-HBsAg– active hepatitis that
source is HBeAg Prior HBV: progresses to
positive anti-HBc+, cirrhosis in 15–30%,
Seroprevalence anti-HBs+, fatal cirrhosis in
(any marker, HBsAg– 1%/yr, and/or fatal
U.S.) (see p HBV vaccine hepatocellular
116) response: carcinoma in
General anti-HBs+, 0.25%/yr
population: anti-HBc–, Perinatal with
3–14% HBsAg–, IgM HBsAg-pos and
blacks: 14%; anti-HBc– HBeAg-pos mother:
whites: 3% Sequence: Viral 70–90% acquire
IV drug abuse: transmis-sion (cid:1) perinatal HBV
60–80% HBsAG at 1–2 mo infection and 85–90%
Gay men: (cid:1) IgG anti–HBc, of these will become
35–80% anti–HBe at 3 mo chronic carriers;
Hemodialysis (cid:1) anti–HBs at 4 >25% of these
patients: mo carriers will develop
20–80% cirrhosis or
Health care hepatocellular
workers carcinoma;
(unvaccinated, perinatal
frequent blood transmission rate is
exposure): <10% if anti-HBe pos
15–30% Risk of transmission
(unvaccinated, with needlestick from
no frequent HBsAg-pos source:
blood exposure): 6–30%; highest with
3–10% HBeAg pos source
Chronic carriers
(HBsAg) U.S.:
0.1–0.2%;
developing
world: 10–30%
Acute viral
hepatitis:
30–40%
Chronic liver
disease: 10–15%
C (HCV) Contaminated 15–150 days Tests: Fulminant and fatal
(parenterally transfused (mean 50 Anti-HCV-EIA-third <1%
transmitted blood: 10%; days) generation tests Acute infection:
non-A, non-B) IVDA—40%; show specificity Usually mild with
also causes heterosexual and sensitivity of moderate elevation
sporadic NANB contact—10%; >99%;can confirm ALT
hepatitis unknown—40% with qualitative Chronic hepatitis:
Seroprevalence HCV RNA (or 85%; cirrhosis: in
(U.S.): 1.8% quan-titative HCV 10–20% within 20 yr
Blood donors: RNA) Associated with
0.2–0.6% Acute HCV: HCV hepatocellular
General RNA pos 1–3 wk, carcinoma:
population: 2% anti-HCV at 10–14 1–4%/year with
Hemophiliacs: wk HCV associated
60–90% Active HCV cirrhosis
IV drug abuse: infection: Evaluation: 1)
60–90% Excluded if J 2 Confirmed diagnosis
Dialysis negative with positive EIA ±
patients: HCV RNA assays positive qualitative
15–20% over 6 mo HCV RNA; 2) liver
Gay men: Sequence: Viral function test—ALT;
2–6%; transmission (cid:1) 3) candidates for
Health care PCR pos for HCV interferon
workers: at 1–3 wk, therapy—quantitative
0.5–2.0% increased ALT at HCV RNA genotype
Sex contacts 4–6 wk and and liver biopsy
of HCV patients: anti-HCV at 10–14 Patients with
1–10% wk anti-HCV should be
Chronic considered
hepatitis: 40% infectious: should
Acute sporadic not be blood or organ
hepatitis in U.S.: donors; risk with
17% sex is
Genotype 1: low—seroconversion
70–75% rate is 0–0.6%/yr
in discordant
couples;
risk with
needlestick injury
from HCV
infected source is
2%; perinatal
transmission rate is
2–7%
Delta Defective virus Superinfection: Acute HBV-HDV Acute co-infection
that requires 30–60 days co-infection: with HBV: 1–10%
presence of Co–infection: HDAg+, HBsAg+, acute fatality; <5%
active HBV, e.g., same as HBV IgM anti-HDV+, chronic hepatitis
co-infection IgM anti-HBc+, Acute superinfection:
with HBV or HBV DNA ± HDV 5–20% acute fatality,
superinfection in RNA >75% develop
HBsAg carrier; Acute HDV chronic hepatitis,
main source is superinfection: with 70–80%
blood (IV drug HDAg+, developing cirrhosis
abuse, HBsAg±, IgM Epidemics in
hemophilia) antiHDV+, underdeveloped
Epidemics: anti-HDV+, IgM countries:
Amazon Basin antiHBc–, HBV Fulminant fatal
and Central DNA hepatitis in 10–20%
Africa ± HDV RNA of children
Endemic areas Chronic HDV: Chronic delta
(Mediterranean HBsAg+, hepatitis: Worsens
Basin, Middle anti–HDV+, prognosis of chronic
East, Amazon and HDV Ag HBV infection; most
Basin): 20–40% in liver or HDV likely chronic
Nonendemic RNA in serum hepatitis to cause
areas (U.S.): cirrhosis
uncommon
Medical care
workers and gay
men:Low
E (HEV) Epidemic 20–60 days Anti-HEV (IgM or Mortality <2% except
(enterally fecal-oral (mean 40 documented for pregnant women
transmitted (Burma, Borneo, days) seroconversion). who have mortality of
non-A, non-B, Mexico, Somalia, Assays not yet 10–20%
or ET-NANB) Pakistan, China, licensed in U.S. Usually mild disease
India, Russia, but available from predominantly in
Peru, throughout CDC adults >15 yr;
Africa) (404-639-3048) chronic liver disease
Sporadic Sequence: Viral has not been
(developing transmission (cid:1) reported
countries) HEV Ag in blood (cid:1) No chronic infection
U.S.: no IgM-anti-HEV at Often cholestatic with
documented 4–8 wk (cid:1) high alkaline
cases originating IgG-anti-HEV at phosphatase
in U.S. 6–10 wk; duration
of IgG-Ab is
unknown
Non A–E Cause unknown Unknown Exclude hepatitis Candidate virus is
Fulminant A–E SEN virus
hepatitis
30–40%
Chronic hepatitis
15–20%
* Symptoms or signs of viral hepatitis, serum aminotransferase >2.5 × upper limit of normal, and
absence of other causes of liver injury.
CDC Hepatitis Hotline: Automated telephone information system concerning modes of transmission,
prevention, serologic diagnosis, statistics, and infection control 404-332-4555.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Intra-Abdominal Sepsis: Antibiotic Selection
Intra-Abdominal Sepsis: Antibiotic Selection
I. PERITONITIS
A. Recommended antibiotics for community-acquired intra-abdominal infections
(Guidelines of the Infectious Diseases Society of America, CID—2003;37:997)
1. Single agent regimens
a. Beta-lactam-beta-lactamase inhibitors
Ampicillin—sulbactam
Piperacillin—tazobactam*
Ticarcillin—clavulanate
b. Carbapenems
Ertapenem
Imipenem*
Meropenem*
2. Combination regimens
a. Cephalosporin-based regimens
Cefazolin or cefuroxime + metronidazole
Cefotaxime, ceftriaxone, ceftizoxime, ceftazidime or cefepime + metronidazole*
b. Fluoroquinolone-based regimens
Ciprofloxacin, levofloxacin, moxifloxacin, or gatifloxacin, each in combination with
metronidazole
c. Monobactam-based regimen
Aztrenam + metronidazole
B. Miscellaneous recommendations
1. Nosocomial intra-abdominal sepsis (healthcare associated): Anticipate resistant
pathogens with emperic treatment including P. aeruginosa Enterobacter, MRSA,
enterococci and Candida. Treatment should be based on local resistance patterns
(emperic) and culture results (pathogen directed)
2. Anaerobes especially B. fragilis: Cefoxitin and cefotetan can no longer be recommended
3. Oral therapy of mixed infections:
Quinolone + metronidazole
Amoxicillin-clavulanate
4. Microbiology
Anaerobes: Culture and sensitivity testing is usually unnecessary. Resistance is
increasing to clindamycin, cefoxitin, cefotetan, piperacillin, and fluoroquinolones.
Consider in vitro sensitivity testing for anaerobes that persist, cause bacteremia, or
require prolonged therapy
Blood cultures: Not generally recommended
Gram stain: Not recommended for community acquired infections. May be
recommended for healthcare associated infections to detect MRSA and enterococci
5. Treatment of specific pathogens
Candida: Antifungal therapy is generally not warranted unless there is
immunosuppression, transplantation or with post-op patient
Enterococcus: Community acquired infection—do not treat; healthcare associated—treat
based on in vitro susceptibility tests
6. Biliary tract: Direct therapy at Enterobacteraceae, not enterococci; cover anaerobes only
with bile duct—bowel anastomosis
P.268
7. Necrotizing pancreatitis: Antibiotics as advocated for intra-abdominal sepsis
8. Duration of antibiotics: Until clinical signs of infection resolve including fever and
leukocytosis plus a functioning GI tract
C. Monomicrobial infections
1. Spontaneous peritonitis or “primary peritonitis” (Arch Intern Med 97:169, 1994)*
a. Aztreonam 1 g IV q8h × 14 days ± agent for Gram-positive bacteria
b. Cefotaxime 1.5–2.0 g IV q6h or ceftriaxone 1–2 gm IV qd, each ± ampicillin 2 g IV
q6h × 14 days
c. Ticarcillin-clavulanate 3 g IV q6h × 14 days
d. Gentamicin or tobramycin 2 mg/kg IV, then 1.7 mg/kg q8h plus a beta-lactam:
1. Cefoxitin 2 g IV q6h;
2. cefotaxime 1.5–2.0 mg IV q6h; or
3. piperacillin 4–5 g IV q6h × 14 days
2. Candida peritonitis (diagnostic criteria and indications to treat in absence of peritoneal
dialysis are nebulous): Amphotericin B 200–1000 mg (total dose), 1 mg over 6 hr, then
maintenance dose of 20–30 mg/d; utility of fluconazole is not established
3. Tuberculous peritonitis (see p 166)
II. LOCALIZED INFECTIONS
A. Intra-abdominal abscess(es) not further defined: Use regimens recommended for
polymicrobial infections with peritonitis (See “I. Peritonitis” above).
B. Liver Abscess
1. Amebic
a. Preferred: Metronidazole 750 mg po or IV tid × 10 days plus diloxanide furoate,
500 mg po tid × 10 days or paromomycin 500 mg po bid × 7 days
b. Alternative: Emetine 1 mg/kg/d IM × 5 days (or dehydroemetine 1.0–1.5 mg/kg/d
× 5 days) followed by chloroquine 500 mg po bid 2 days, then 250 mg po bid × 3 wk
plus iodoquinol 650 mg po tid × 20 days
2. Pyogenic: Metronidazole plus ampicillin plus 1) an aminoglycoside, 2) third generation
cephalosporin, or 3) aztreonam
C. Biliary Tract Infections
1. Cholecystitis
a. Combination treatment: Gentamicin or tobramycin 2.0 mg/kg IV then 1.7 mg/kg
IV q8h plus ampicillin 2 g IV q6h, piperacillin 2–5 g IV q6h, or cefoperazone 1–2 g
IV q12h*
b. Single agent: Cefoperazone 1–2 g IV q12h*. Ampicillin + sulbactam, 1–2 g
(ampicillin) IV q6h; ticarcillin-clavulanate 3 g IV q6h; for mild infections the usual
recommendation is cefazolin 1–2 g IM or IV q8h, or ampicillin 1–2 g IV q6h
c. Medical Letter consultants (Med Lett, 41:95, 1999):
1. Piperacillin or mezlocillin plus metronidazole,
2. piperacillin-tazobactam or ampicillin-sulbactam ± aminoglycoside
2. Ascending cholangitis, empyema of the gallbladder, or emphysematous cholecystitis:
Treat with regimens advocated for peritonitis or intra-abdominal abscess
P.269
D. Appendicitis: Recommendations of the Surgical Infection Society (Arch Surg 127:83,
1992)
Antibiotic treatment is started pre-op using regimens advocated for peritonitis (p 127)
1. Appendix is normal or inflamed but not perforated: Discontinue antibiotics
2. Gangrene or perforation: Continue antibiotics until clinical improvement with return of
3
bowel function, patient is afebrile, and WBC is <12,000/mm
E. Diverticulitis: Recommendations of the Surgical Infection Society (Arch Surg 127:83,
1992)
1. Hospitalized patients: Use regimens advocated for peritonitis (p 267)
2. Outpatients:
a. Amoxicillin + clavulanate
b. Fluoroquinolone plus metronidazole
c. Trimethoprim-sulfamethoxazole
Footnotes
*Includes severe infections
*Antibiotics should be adjusted according to sensitivities of implicated strain; rate of positive cultures is
30–40% with blood cultures, 40–65% routine culture of ascites fluid, and 90% with ascites fluid
inoculated into blood culture bottles (Gastroenterology 95:1351, 1988).
*Other cephalosporins (second and third generation) are probably equally effective. Some authorities
add ampicillin (1–2 g IV q6h) to cephalosporin-containing regimens.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Helicobacter pylori: Treatment of Peptic Ulcer Disease
Helicobacter pylori: Treatment of Peptic Ulcer Disease


Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Infectious Diarrhea
Infectious Diarrhea
Source: Guidelines from Infectious Diseases Society of America (CID 2001;32:331.)
A. Antimicrobial Treatment
Microbial agent Preferred Alternative* Comment
BACTERIA Usually none; if Tetracycline 500 mg po qid Y × Efficacy of treatment
Aeromonas treated: 5 days not established and
hydrophila Sulfa-trimethoprim Gentamicin 1.7 mg/kg IV q8h should be reserved
1 DS bid × 3 days × 5 days forpatients with
Ciprofloxacin 500 severe disease,
mg po bid or immunosuppression,
ofloxacin 300 mg extraintestinal
po bid or infection, or
norfloxacin 400 mg prolonged diarrhea
po bid × 3 days
Campylobacter Erythromycin Doxycycline 100 mg po bid × 7 May not alter course
jejuni 250–500 mg po qid days unless given early or
× 5 days Furazolidone 100 mg po qid × for severe symptoms
7 days Indications include
Ciprofloxacin 500 mg po bid × acutely ill, persistent
3–5 days fever, bloody
diarrhea, >8
stools/day,
dehydration,
symptoms <4 days or
to prevent
transmission.
Resistance to
erythromycin has
been
described.Clinical
course not altered in
trials when treatment
started >4 days after
onset of symptoms
Resistance:
Fluoroquinolone
resistance is an
increasing problem in
the U.S. and other
parts of the world
(NEJM
340:1525,1999). In
Thailand, Spain, and
Taiwan the rate of
fluoroquin olone
resistance is 60–80%
(Emerg Infect Dis
7:24, 2001)
Clostridium Metronidazole 500 Vancomycin 125 mg po q6h × Diagnosis: standard
difficile mg po tid or 250 10–14 days is cytotoxin assay for
mg po qid× 10 Bacitracin 25,000 units po qid toxin B (most
days × 10–14 days sensitive)or EIA for
toxin A and B (less
sensitive but more
rapid and more
generally available)
Metronidazole is
preferred because of
cost, comparable
efficacy in clinical
trials, and concern
for
vancomycin-resistant
E. faceum in
nosocomial cases
Discontinuation of
implicated antibiotic
is often adequate.
Some strains are
resistant to
metronidazole and
bacitracin. Expected
response is afebrile
in 24 hr and
resolution of diarrhea
in mean of 4–5 days
When oral treatment
is not possible
metronidazole 500
mg q8h IV(efficacy
not established)
Antiperistaltic
agents:
Contraindicated
Multiple relapses Vancomycin or Vanco 500 mg qid × 10 days, Frequency of
metronidazole day 7 Saccharomyces relapse: 5–50%
(above doses; ×10 boulardii500 mg bid × 4 wk (average 25%) with
days, then Vanco or metro treatment, any antibiotic
cholestyramine 4 g then lactobacillus GG treatment
po tid + (“Culturella”) 75 mg bid ×1 mo S. boulardii and
lacto bacillus 1 g IVIG 200–300 mg/kg q3wk lactobacillus GG are
qid × 4–6 wk or not FDA approved
vancomycin 125 and are not readily
mg po every other available
day × 4–6 wk) Experience with IVIG
is limited but
supported by studies
showing importance
of humoral immune
response (NEJM
342:390,
2000;Lancet
357:189, 2001)
E. coli Ciprofloxacin 500 Trimethoprim 200 mg po bid × Laboratory
Enterotoxigenic E. mg po bid or 3 days confirmation E.
coli (ETEC) and ofloxacin 300 mg Bismuth subsalicylate 1048 mg coli-associated
enteroadherent E. po bid or qid × 5 days diarrhea is usually
coli (EAEC) norfloxacin 400 mg unavailable
po bid × 3 days Efficacy of antibiotic
TMP-SMX DS po bid treatment
× 3 days established for ETEC
(traveler's diarrhea)
Diagnosis requires
demonstration of LT
or ST toxins (EIA,
DNA probe, rabbit
loop, etc). Many
ETEC strains are now
resistant to
doxycycline and
TMP-SMX (see
traveler's diarrhea,
pp 141–142)
Enterohemorrhagic None None Diagnosis: Culture E.
E. coli (EHEC) coli 0157:H7 using
sorbitol—MacConkey
agar; for non-0157
species test stool or
supernatant with EIA
for Shiga toxin
Antibiotic treatment
is contraindicated
presumably because
of increased toxin
release with higher
rate of HUS in
children Life
threatening
complications: HUS
Antiperistaltic
agents:
Contraindicated and
TTP, esp at age
extremes
Enteroinvasive E. Usually none, if Ampicillin 500 mg po or 1 g IV Presentation is
coli (EIEC) treated: qid × 5 days dysentery as with
Sulfa-trimethoprim, Shigella. Efficacy of
1 DS po bid × 5 treatment not
days established
Ciprofloxacin 500
mg po bid or
ofloxacin 300 mg
po bid or
norfloxacin 400 mg
po bid × 5 days
Enteropathogenic Usually none, if Neomycin 50 mg/kg/d po × Efficacy of treatment
E. coli (EPEC) treated: 3–5 days not established.
Sulfa-trimethoprim, Furazolidone 100 mg po qid × Sensitivity testing
1 DS po bid × 3–5 3–5 days necessary
days
Ciprofloxacin 500
mg po bid or
ofloxacin 300 mg
po bid or
norfloxacin 400 mg
po bid × 3 days
Food poisoning: None Self-limited and
Clostridium toxin-mediated:
perfringens, S. antimicrobial
aureus, Bacillus treatment is not
cereus, Listeria indicated (see p 279)
Plesiomonas Usually none, but if Tetracycline, 500 mg po qid × Efficacy of treatment
shigelloides treated: 5 days is not established
Sulfa-trimethoprim and should be
1 DS po bid × 3 reserved for patients
days with extraintestinal
Ciprofloxacin 500 infection, prolonged
mg po bid or diarrhea, or
ofloxacin 300 mg immunosuppression
po bid or
norfloxacin 400 mg
po bid × 3 days
Salmonella typhi Chloramphenicol 50 Ceftriaxone 1–2 g/d IV× 10–14 Steroids: For severe
mg/kg/d IV× days toxicity high-dose
10–14 days Sulfa-trimethoprim, 1–2 DS po antibiotics plus
Ciprofloxacin 500 bid × 10–14 days dexamethasone (3
mg po bid × 10–14 mg/kg × 1, then 1
days mg/kg q6h × 48 hr)
or prednisone (60
mg/d with taper to
20 mg/d over 3
days) (NEJM 310:82,
1984)
Salmonella(other) Usually none, if Ampicillin 2–6 g/d po or IV × Antibiotic treatment
Enteric fever indicated: 14 days is contraindicated
(non-typhoid Fluoroquinolone: Amoxicillin 2–4 g/d po × 14 except with the
Salmonella) Ciprofloxacin 500 days following: Severe
Metastatic mg po bid; Chloramphenicol 3–4 g/d IV or disease, age > 50 yr,
infection ofloxacin 300 mg po × 14 days valvular heart
Chronic po bid or Sulfa-trimethoprim 1 DS po bid disease, sever
bacteremia norfloxacin 400 mg × 14 days eatherosclerosis,
Enterocolitis in po bid × 5–7 days malignancy, or
compromised host Cephalosporin: uremia
See comment Ceftriaxone, 1–2 Duration: 5–7 days
g/d IV up to 4 g/d unless there is
× 14 days relapsing disease in
compromised
host—treat O14 days
Carrier (S. typhi)* Amoxicillin 6 g/d Rifampin 300 mg bid + Definition of carrier:
po + probenecid 2 TMP-SMX 1 DS id × 6 wk Positive cultures for
g/d × 6 wk 1 yr
Ciprofloxacin Cholecystectomy for
500–750 mg po bid cholelithiasis and
× 6 wk carriers who relapse
Shigella Ciprofloxacin 500 Ampicillin 500 mg po or 1 g IV Most important of
mg po bid or qid × 3–5 days bacterial enteric
norfloxacin 400 mg Nalidixic acid 1 g po qid ×5–7 pathogens to treat
po bid or days because of severe
ofloxacillin 300 mg Cefoperazone 1–2 g IV q12h × disease and risk of
po bid × 3 days 5–7 days transmission
Sulfa-trimethoprim Ampicillin-resistant
1 DS po bid × 3 strains are common;
days for
ampicillin-susceptible
strains, amoxicillin
should not be used
Sulfa-trimethoprim
resistance is
increasing and is
common in strains
from some
underdeveloped
areas. Use only if
susceptibility shown
Ciprofloxacin in
single, 1 g dose is
effective for Shigella,
other than S.
dysenteriae (Ann
Intern Med 117:727,
1992)
Vibrio cholerae Tetracycline 500 mg po qid × 3 Rare cause of
daysDoxycycline 300 mg po × 1 travelers' diarrhea
Sulfa-trimethoprim 1 DS po bid × 3 days Oral rehydration
Fluoroquinolone often critical
Vibrio sp. (V. Usually none, if Ciprofloxacin 500 mg po bid × Efficacy of treatment
parahaemolyticus, indicated: 5 days is not established
V. fluvialis, V. Tetracycline (as and should be
mimicus, V. above—see reserved for severe
hollisae, V. comment) disease
furnissii, V.
vulnificus)
Yersinia Sulfa-trimethoprim Efficacy of treatment
enterocolitica 1 DS po bid × 3 for enterocolitis or
days mesenteric adenitis
Gentamicin 1.7 is not established,
mg/kg IV q8h × 3 especially when
days instituted late; major
Ciprofloxacin indications are
500–750 mg po bid bacteremia or
× 3 days infection in
Doxycycline 100 compromised host
mg po bid × 7 days Withhold
desferoxamine
PARASITES Usually none or Nitrazoxanide 500 mg bid Diagnosis: Stool for
Cryptosporidia symptomatic (Unimed Pharmaceuticals, acid-fast stain or
treatment: Buffalo Grove, IL)—not monoclonal
Loperamide, approved by FDA immunoflu-orescent
lomotil etc plus Compromised host (AIDS): stain; concentration
nutritional support Paromomycin 1 g bid + techniques increase
Compromised host: azithromycin 600 mg po qd × 4 yield
Paro-momycin 500 wk then paro-momycin 500 mg Treatment: Only for
mg po tid × 7 days po tid chronic diarrhea in
compromised host.
Paromomycin is only
modestly effective
(Am J Med 100:370,
1996)
Main treatments in
AIDS patient are
supportive care and
HAART Atovaquone
or azithromycin as
single agents have
not shown good
results
Balantidium coli* Tetracycline 500 Iodoquinol 650 mg tid × 21 No antimicrobial
mg po qid × 10 days agent has
days Metronidazole 500 mg po tid × established efficacy
10 days
Cyclospora Trimethoprim-sulfamethoxazole Treatment: Efficacy
cayetanenis* 1 DS bid × 3 days of TMP-SMX is
established
Diagnosis: Stool for
acid-fast stain
Reporting: Health
departments that
identify cases of
Cyclospora infection
should contact CDC
770-488-7760
Blastocystis Metronidazole Iodoquinol 650 mg tid × 20 Role as enteric
hominis* (see 1.5–2.0 g/d × 7 days pathogen is unclear
comments) days
Entamoeba Metronidazole 750 Dehydroemetine 1.0–1.5 Diagnosis: Stool
histolytica mg po or IV tid × mg/kg/d IM × 5 days, then exam × 3 ±
5–10 days then iodoquinol 650 mg po tid × 21 endoscopy with
iodoquinol 650 mg days biopsy or scraping;
po tid × 21 days or serology (IHA) for
paromomycin 500 colitis or hepatic
mg tid × 7 days disease. Patients
with colitis or
extraintestinal
disease need drug
for tissue phase
(metronidazole or
dehydroemetine),
then a luminal agent
(iodoquinol, or
paromomycin)
Cyst passer No need to treat
because most cases
are caused by
nonpathogenic
organisms now
reclassified as E.
dispar
Giardia lamblia (G. Metronidazole, Quinacrine 100 mg po tid × Diagnosis: Stool EIA
intestinalis) 250–750 mg po tid 7–10 days Metronidazole is less
× 7–10 days Furazolidone 8 mg/kg/d po × effective than
10 days quinacrine, but
Tinidazole 1.5–2.0 g single better GI tolerance
dose and preferred for
empiric therapy.
Pregnancy: Consider
paromomycin 25–30
mg/kg/d × 5–10
days
Isospora belli Sulfa-trimethoprim, Pyrimethamine 25 mg + folinic Diagnosis: Acid-fast
2 DS po bid × 7–10 acid, 5–10 mg/d × 1 mo stain of stool.
days Patients with AIDS
and other
immunosuppressive
disorders usually
require prolonged
maintenance
treatment
Microsporidia Albendazole 400 — Rare disease in
mg po bid × 3 wk immunocompetent
host
Response to
albendazole is
minimal; main
treatment in patients
with AIDS is support
and HAART
P.272
P.273
P.274
P.275
P.276
P.277
APPROACH TO INFECTION DIARRHEA
Figure. No caption available
Guidelines from the IDSA (CID 2001; 32:331). (Reprinted with permission)
1. Seafood exposure: culture for vibrio
2. Travelers diarrhea: evaluate if unresponsive to fluoroquinolone or TMP-SMX
3. Abdominal pain: Test for Yersinia and enterohemorrhagic E. coli
4. Proctitis in gay men: sigmoidoscopy
5. HUS: Test for enterohemorrhagic E. coli
6. Outbreaks: Notify health department
7. Fecal lactoferrin test or microscopy
8. Blood diarrhea: Some experts avoid antimicrobials
9. Common tests for parasites: Fluorescence and EIA for Giardia and Crypto-sporidium, Cyclospora or
Mycobacteria; chromotrope of microsporidia
P.278
B. Nonantibiotic Management
1. Cholera-like illness: Oral rehydration therapy with Ceralyte, Pedialyte, or generic solutions
prepared by mixing in 1L—3.5 g NaCl, 2.5 g NaHCO , 1.5 g KCl, and 20 g glucose
3
2. Foods matched to form of stool: Watery—soups, broth, yogurt, soft drinks, vegetables, fresh fruit,
Jell-O ± saltine crackers; some form—rice, bread, baked potato, broiled fish or broiled chicken
(avoid milk, fried food, spicy food)
3. Drugs: Antiperistaltics are contraindicated with diarrhea because of enterohemorrhagic E. coli or
Clostridium difficile
a. Loperamide 4 mg, then 2 mg/diarrheal stool up to 16 mg/d (avoid with fever and dysentery)
b. Diphenoxylate (no more effective plus potential for opiate toxicity and anti-cholinergic
effects)
c. Bismuth subsalicylate: 30 mL (2 tabs) q 30 min × 8 doses, 1–2 days (good safety profile)
d. Attapulgite: 1.2 g (30 cc) with each diarrheal stool up to 8.4 g (good safety profile and
preferred to kaolin/pectin)
C. Fecal Leukocyte Exam (Lactoferrin test or stool microscopy)
Often present Variable Not present
Campylobacter jejuni Salmonella Vibrio cholerae
Shigella Yersinia Enteroadherent E. coli
Enteroinvasive E. coli Vibrio Enterotoxigenic E. coli
parahaemolyticus
Exacerbations of C. difficile Food poisoning: S. aureus, B.
inflammatory bowel disease Aeromonas Aeromonas cereus, C. perfringens
Plesiomonas Viral gastroenteritis
Enterohemorrhagic E. Parasitic infection: Giardia, E.
coli* histolytica*, Cryptosporidia,
Isospora
Small bowel overgrowth
“AIDS enteropathy”
* Frequently associated with blood.
D. Empiric Antibiotic Treatment (IDSA Guidelines—CID 32:331, 2001)
1. Domestically acquired infectious diarrhea
1. Acute diarrhea: Fever and acute diarrhea (nonbloody)—treat for shigellosis
2. Chronic diarrhea: Diarrhea >10–14 days—treat for giardiasis
3. Antibiotic treatment in these settings is arbitrary; antibiotic treatment with diarrhea caused by
enterohemorrhagic E. coli may be harmful.
2. Travelers' diarrhea (CID 2000; 31:1079)
1. Severity
Mild (1–2 stools/24 hr) no systemic sx: No therapy or loperamide or bismuth
Moderate (>2 stools/24 hr) + no systemic sx: Loperamide or bismuth
Moderate (>2 stools/24 hr) + “distressing sx”: Loperamide + fluoroquino-lone until
diarrhea stops (up to 3 days)
Severe (>6 stools/24 hr), fever and/or bloody stools: Fluoroquinolone for 1–3 days
3. Agents
Loperamide 4 mg × 1 then 2 mg with each loose stool (V16 mg/d) or bismuth subsalicylate
(Pepto-Bismol 2 tabs qid, each loose stool)
Antibiotic regimens: Norfloxacin 400 mg bid × 1–3 days or ciprofloxacin 500 mg bid × 1–3
days or levofloxacin 500 mg qd × 1–3 days
Alternative antibiotics: TMP-SMX 2 DS × 1 or 1 DS bid × 3 days or azithromycin 1000 mg × 1
or 500 mg qd × 3 days
P.279
E. Clinical Features of Diarrhea
Small bowel Colon
Pathogens E. coli (ETEC, EPEC, EAEC), Shigella, C. difficile, C. jejuni, E. coli
cholera, Salmonella, viruses, 0157:H7
Cryptosporidium, Cyclospora, Enteroinvasive E. coli, Aeromonas,
Giardia Yersinia, E. histolytica
V. parahemolyticus
Pain Mid abdomen and modest Lower abdomen with severe cramps
Painful defecation
Stools Watery, large volume Bloody or mucoid, small volume and frequent
Stool WBC Negative WBC positive; E. histolytica and E. coli
and RBC 0157:H7—bloody
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Foodborne Outbreaks
Foodborne Outbreaks
(Source: MMWR 2001;50(RR-2).)
Incubation
Agent period Syndrome Confirmation*
BACTERIAL
Bacillus anthracis 2 days–wk Nausea, vomiting, Blood culture
bloody diarrhea, acute
abd pain × wks
Bacillus cereus
Vomiting toxin 1–6 hr Vomiting ± diarrhea Test stool or food for
toxin
Diarrhea toxin 10–16 hr Watery diarrhea × Test stool or food for
24–48 hr toxin
Brucella 7–21 days Fever, headache, Blood culture and
sweats, myalgias, serology
diarrhea, bloody
stools×wks
C. jejuni 2–5 days Diarrhea, abd pain, Stool culture
fever, vomiting × 2–10
days
C. botulinum 12–72 hr Diploplia, blurred Detect toxin in
vision, descending serum, stool, or food
paralysis—bilateral Detect C. botulinum
vomiting, diarrhea × in stool or food
days–months
C. perfringens 8–16 hr Diarrhea, cramps × Isolate from stool
24–48 hr (>10 6 /g) or food
5
(>10 /g) Detect
enterotoxin in stool
E. coli 1–8 days Diarrhea—often Stool culture for E.
0157:H7 (EHEC) bloody, cramps no coli 0157:H7 or stool
fever × 5–10 days assay for Shiga toxin
Enterotoxigenic days 1–3 Watery diarrhea, Isolate ST or LT
(ETEC) cramps, nausea × producing E. coli
5–10 days from stool
Listeria 2–6 wk Meningitis, fever Isolate from normally
Invasive (elderly, compromised) sterile site—blood,
disease CSF
Diarrhea 9–48 hr Diarrhea, cramps, Listerolysin O
fever antibody
Salmonela 1–3 days Diarrhea, cramps, Stool culture
Non-typhoid fever × 4–7 days
Salmonella typhi 3–60 days, Fever, malaise, Stool culture
usually 7–14 headache, chills
Shigella 24–48 hr Diarrhea ± blood, Stool culture
cramps, fever × 4–7
days
S. aureus 1–6 hr Vomiting, cramps ± Toxin/organism in
diarrhea × 24–48 hr stool, food, and
vomitus
Streptococcus group A 1–4 days Fever, pharyngitis Isolate organism of
same M or T type
from C2 people
Vibrio cholera 24–72 hr Severe watery diarrhea Stool culture for V.
01 or 0139 ± vomiting × 2–5 days cholerae
Vibrio parahemolyticus 2–48 hr Diarrhea, cramps, Stool culture for V.
vomiting × 2–5 days parahaemolyticus
Vibrio vulnificus 1–7 days Vomiting, diarrhea, Stool and blood
cramps, bacteremia culture
(esp liver disease and
comp host) × 2–8 days
Yersinia enterocoliticus 24–48 hr Diarrhea and cramps Isolate organism
Appendicitis-like from stool or food
symptoms with fever,
abd pain × 1–3 wk
PARASITIC 2–28 days Diarrhea, nausea, Detect organism in
Cryptosporidia cramps ± fever × stool or food/water
days–weeks
Cyclospora 1–11 days Protracted diarrhea, Demonstrate
fatigue organisms in stool
E. histolytica 2 days–4 wk Bloody diarrhea, abd Stool exam
pain × months
Giardia 1–4 wk Diarrhea, gas, cramps, Demonstrate
nausea × wks organism or antigen
in stool
Toxoplasma gondii 6–10 days Usually asymptomatic Serology IgM
compromised host
CNS, myo-carditis,
pneumonia × months
Trichinella Intestinal Nausea, vomiting, Positive serology or
phase 1–2 diarrhea, cramps, then demonstrate larvae in
days fever × mo muscle of patient or
Systemic in meat sources;
phase 2–4 eosinophilia
wk
VIRAL 15–50 days, Fatigue, anorexia, Detect IgM, ALT
Hepatitis A median 28 nausea, jaundice,
days abnormal LFTs
Norwalk agent 24–48 hr Vomiting, cramps, Seroconversion
watery diarrhea ×
24–60 hr
Astrovirus calicivirus 10–70 hr Vomiting, cramps, Demonstrate virus by
diarrhea, headache immune electron
fever × 2–9 days mi-croscopy, PCR,
etc.
CHEMICAL 2–6 hr GI symptoms, then Demonstrate toxin in
Marine toxins paresthesias lips, fish or typical
Ciguatoxin (esp tongue, throat, presentation
snapper, grouper, or extremities × days–wk
barracuda)
Scromboid toxin 1 min–3 hr Flushing, dizziness, Demonstrate
(histamine)(mahi-mahi, usually <1 burning mouth, histamine in food or
scromboidei fish order) hr headache, GI typical presentation
symptoms, urticaria,
pruritis × 3–6 hr
Paralytic or 30 min–3 hr Parenthesias of lips Detect toxin in food
neurotoxic shellfish mouth, face or water
poison extremities, GI
symptoms × days,
weakness, dyspnea
Puffer fish < 30 min Parenthesias of lips Demonstrate toxin in
mouth, face, fish or clinical
ex-tremities, ascending presentation
paralysis, death in 4–6
hr
Heavy metal: Antimony, 5 min–8 hr Vomiting and metallic Demonstrate metal in
cadmium, copper, iron, usually <1 taste ± diarrhea food
tin, zinc hr
Monosodium glutamate 3 min–2 hr Burning of chest, neck, Clinical presentation
(MSG) usually < 1 abdomen, or plus ingestion of food
hr with MSG
extremities
Mushroom toxins < 2 hr Vomiting and diarrhea, Clinical syndrome in
Short-acting confusion, salivation, patients who have
hallucinations, visual eaten mushrooms
problems, disulfiram that represent toxic
reaction types
Longer-acting 6–24 hr Diarrhea and cramps, Clinical syndrome in
Amanita sp × 24 hr, then hepatic patients who have
and renal failure; often ingested the
lethal implicated mushroom
Pesticides Min–few hr Nausea, vomiting, Analysis of food and
cramps, diarrhea, blood
blurred vision,
twitch-ing convulsions
Nitrite poisoning 1–2 hr Nausea, vomiting, Food analysis
dizzy, weak,
uncon-scious,
chocolate-colored
blood
Mercury C 1 wk Numbness, leg paresis, Analysis of blood and
spastic paralysis, hair
blindness
Arsenic Few hrs Vomiting, diarrhea, Urine test
cramps
Shellfish toxins Minutes–48 GI symptoms, Detect toxins in
hr parethesis, CNS shellfish
Sodium floride Minutes–2 Soapy taste, vomiting, Test vomitus and
hr diarrhea, shock food
* Confirmation to implicate a cause of an outbreak usually requires documentation in C2
persons or demonstration of the organism or toxin in the implicated food.
P.280
P.281
P.282
P.283
FOODBORNE ILLNESS BY CLINICAL PRESENTATION
MMWR 2001;50(RR-2).
Watery diarrhea: ETEC, V. cholera, enteric virus, Cryposporidium, Cyclospora
Dysentery: Shigella, Salmonella, C. jejuni, EIEC, EHEC, Vibrio parahaemolytica, Yersinia
enterocolitica
Persistent diarrhea (C14 days): Cyclospora, Cryptosporidium, E. histolytica, Giardia
Neurologic syndromes (paresthesias, respiratory suppression): Botulism, poisoning by
organophosphate pesticides, thallium, scombroid, ciguatera, tetrodon fish, neurotoxic shellfish,
amnesic shellfish, mushroom poisoning, Guillain-Barré syndrome
Systemic illness: Listeria, Brucella, Trichinella, Toxoplasma, V. vulnificans, hepatitis A
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Urinary Tract Infections
Urinary Tract Infections
I. Classicication based on guidelines established by the infectious Diseases Society of America
(CID 15:S216, 1992; CID 29:745, 1999)
Criteria for stated category
Category Clinical Laboratory a Treatment
Acute, Dysuria, urgency, >10 WBC/mm 3 All drugs active vs GNB show
uncomplicated frequency, >10 3 cfu/mL cure rates >80%
UTI in women suprapubic pain; uropathogen in Single dose: No longer favored
no urinary MSU 3-day treatment: Generally
symptoms in last preferred. Expected cure
4 wk; no fever or rate b ;>85% at 5–9 days;
flank pain >65% at 4–6 wk
Acute, Fever, chills, >10 WBC/mm 3 Mild symptoms: Oral with
uncomplicated dysuria, urgency, >10 4 cfu/mL agent active vs the
pyelonephritis frequency, uropathogen in uropathogen
suprapubic pain, MSU Seriously ill: Parenteral
CVA tenderness, therapy with agent active vs
and/or flank pain the uropathogen until afebrile
Other diagnoses 24–48 hr followed byoral
excluded. No agent × 2 wk total therapy.
history of urologic Expected cure rate b :>95% at
abnormalities 3–6 days, >80% at 5–9 days
post treatment
UTI in male Any combination >10 WBC/mm 3 UTI in men: Assume tissue
of findings in >10 5 cfu/mL in invasion—renal or prostate
above categories MSU Regimens: TMP-SMX,
trimethoprim or
fluoroquinolone for 2–6 wk
b
Expected cure rate : >90% at
3–5 days and 50% at 4–6 wk
Complicated Above × catheter As above Regimen: Parenteral—oral or
UTI associated, oral using agent active vs
postvoiding uropathogen × 2 wk. Expected
residual>100 mL, cure rate b : >90% at 3–5 days,
calculi, azofemia, >65% at 5–9 days, and >40%
or reflux at 4–6 wk
Asymptomatic No urinary >10 Indications for treatment:
symptoms WBC/mm 3 > Pregnant women, diabetic
10 5 cfu/mL patients, immunocompromised
uropathogen × patients, and children
2 separated by Expected cure rates: >95% at
24 hr 3–5 days, >75% at 5–9 days,
and >50% at 4–6 wk
a
WBC, white blood cells (unspun urine); MSU, midstream urine culture.
b
Expected cure refers to eradication of uropathogen andelimination of symptoms. Data
provided are expectations based on prior studies with evaluationsduring treatment at 5–9
days post-treatment and 4–6 wk post-treatment. Positive cultures post-treatment are
classified as relapse (same strain), usually indicating renal or prostatic nidus of infection
or reinfection indicating new uropathogen.
II. Treatment of cystitis and pyelonephritis Recommendations of SD Fihn (NEJM 2003;349:3.) and
IDSA guidelines (CID 1999;29:745.)
A. UNCOMPLICATED BACTERIAL CYSTITIS IN NON-PREGNANT WOMEN
Based on recommendations of SD Fihn (NEJM 2003;349:3.)
1. Diagnostic tests: The urinary dipstick has largely replaced the urine culture and urine
microscopy because it is cheaper, faster, and more convenient. The relative merits of
these tests are summarized in the following table:
a. Diagnostic Tests
Sensitivity Specificity
Pyuria 95% 71%
Bacteria on Gram stain 40–70% 85–95%
Urinary dipstick 75% 82%
Urine culture 50% High
Many patients do not need any testing, but can be managed by telephone
consultation. Published protocols include women at low risk for complicated
infection, who do not have symptoms suggesting vaginitis or cervicitis and in some
cases are limited to women >55% years of age (Am J Med 1999;106:636.; Br J Gen
Prat 2000;50:635.; J Fam Pract 2001;50:589.).
2. Treatment: (see table below) TMP-SMX for three days results in sterile urine within seven
days and about 94%; longer courses do not improve efficacy and increase side effects
while the single dose is less effective (CID 1999;29:745.). The alternative for patients
with sulfa allergy is trimethoprim, but this may also cause hypersensitivity, and TMP
rashes are commonly misidentified as sulfa reactions in patients who get TMP-SMX
(Allergy 1992;47:340.). In some areas the pathogens cultured from urine in acute
cystitis show rates of TMP-SMX resistance of up to 18% (JAMA 1999;281:736.; NEJM
2001;345:1007.), especially if this drug has been given within the previous six months (J
Gen Intern Med 1999;14:606.). The recommendation is to use alternative drugs if the
patient has recently received antibiotics or if the local prevalence of urinary isolates
exceeds 15–20%. Nevertheless, clinical and bacteriologic cure rates of 80–85% are
expected even when the resistance rates approach 30% (Ann Intern Med 2001;135:41.).
The major alternative is a fluoroquinolone, but it is not considered “first line” because of
its high cost and concern for abuse. Nitrofurantoin is another option, preferably using the
monohydrate macrocrystal formulation because it is taken just twice daily and causes
less GI toxicity compared to the macrocrystalline formulation. This drug may assume
more importance if there is increasing resistance to fluoroquinolones. Fosfomycin is less
effective than the other agents and should only be used when the others cannot be used
(CID 1999;29:745.). The expected response rate is symptom relief in 90% within 72
hours and negative cultures (if done)at 7 days in over 90%. Severe dysuria may be
treated with phenazopyridine (Pyridium or Uristat) which is now available
over-the-counter. Routine follow-up including urine culture is generally not necessary.
3. Regimens:
Retail Pregnancy Major ADRs
Agent Cost Rating
Acute uncomplicated cystits
TMP/SMX 1 DS bid × 3 d $2 C GI intol, rash
Trimethoprim 100 mg bid × 3 $4 C GI intol
d
Norfloxacin 250 mg bid × 3 d $25 C Dizzy, GI intol,
vaginitis
Levofloxacin 250 mg qd × 3 d $44 C As above
Ciprofloxacin 250 mg bid × 3 $54 C As above
d
Gatifloxacin 400 mg qd × 3 d $22 C As above
or 400 mg × 1 $8
Nitrofurantoin monohydrate $30 B GI intol, pulmonary
macrocrystals 100 mg bid × 7 and liver toxicity
d
Fosfomycin 3 g po × 1 $34 B GI intol
P.285
B. PYELONEPHRITIS
1. Agent
a. Oral therapy
Oral agent Comment
Fluoroquinolone Preferred oral agent for empiric treatment
TMP-SMX Preferred if pathogen is known to be sensitive
b. Single parenteral dose followed by oral agent Parenteral agent: Ceftriaxone,
gentamicin, or fluoroquinolone
Oral agent Comment
Gram-positive pathogen Amoxicillin or amoxicillin-clavulanate
Gram-negative pathogen Base on in vitro susceptibility tests
P.286
c. Hospitalized patients: Parenteral therapy
Parenteral fluoroquinolone (ciprofloxacin was superior to TMP-SMX in terms of
clinical response, bacteriologic response, and side effects (JAMA 283:1583, 2000))
Aminoglycoside ± ampicillin
Parenteral extended spectrum cephalosporin ± aminoglycoside
Gram-positive pathogen: Ampicillin-sulbactam ± aminoglycoside
After afebrile 48–72 hr: Oral agent based on susceptibility tests
GNB: Fluoroquinolone or TMP-SMX
GPC: Amoxicillin or amoxicillin-clavulanate
2. Duration: 14 days; 7 days may be adequate in mild or moderately severe case (JAMA
283:1583,2000)
C. MANAGEMENT OF BLADDER CATHETER (Infect Dis Clin Pract 1995;4:446.)
Incidence of infection: 3–10%/day
Prevention
Prevention of infection: Maintain closed system
Prevention of complications of bacteruria: Antibiotics are ineffective
Prevention of catheterization: Condom catheters; intermittent catheterization ±
instillations of povidone-iodine and chlorhexidine; suprapubic catheterization
Treatment: Treat only symptomatic infections (fever and/or signs of
bacteremia)(symptoms are rare in this population—Ann Intern Med 160:668, 2000)
Treat 7–10 days: Parenteral or oral antimicrobial
D. PROSTATITIS (Guidelines of Assoc Genitourinary Med Society of Venereal Disease London
2002)
1. Acute prostatitis
a. Diagnosis: Midstream urine culture and blood culture; do not do prostatic massage
(Pathogens are virtually always in urine)
b. Treatment
1. Initial antibiotic treatment: Cefotaxime or ceftriaxone + gentamicin—switch to
pathogen-specific therapy when sensitivity data available
2. Oral antibiotics: Switch to oral agent when clinically improved. Usual agent:
Ciprofloxacin; alternative: TMP-SMX or trimethoprim × 28 days.
3. Adjunctive treatment: Catheterize for urinary retention, hydration, analgesics
(NSAIDs)
c. Failure to respond: Possible prostatic abscess—transrectal ultrasound or CT scan.
Treatment—perineal or transurethral drainage
2. Chronic prostatitis
Diagnosis: Symptoms P6 months.
Urinary localization procedure (Not often done)
Patient preparation: No antibiotics × 1 month, no ejaculation × 2 days and no
distended bladder
Specimens: 5–10 mL first voided urine (VB#1), void 100–200 mL then
midstream(VB#2), vigorous prostatic massage × 1 minute, then post prostatic
massage (PPM) urine of 5–10 mL (VB#3). All three samples have microscopy and
quantitative urine cultures.
Interpretation
1. Bacterial infection: Culture of VB#3 P10 × that of VB#2 and VB#1 Dx: “chronic
bacterial prostititis”
2. Inflammation: >10 PMNs/HPF in prostatic massage specimen or in VB#3. Dx:
“Chronic bacterial prostatitis” or “chronic abacterial prostatitis/chronic pelvic
pain syndrome—inflammatory”
3. Culture and WBC assessment are negative. Dx: “Chronic abacterial
prostatitis/chronicpelvic pain syndrome—inflammatory”.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Sexually transmitted diseases
Sexually transmitted diseases
Recommendations from the CDC (MMWR 2002;51:RR-6.)
I. Neisseria gonorrhoeae (Gonococcal Infections)
A. Treatment Recommendations for Uncomplicated Localized Infections (urethral, endocervical, and
rectal) (CID 1995;20:S47.; Med Lett 1995;37:117.)
Ceftriaxone 125 mg IM × 1 or
Ciprofloxacin* 500 mg po × 1 or
Ofloxacin* 400 mg po × 1 or
Levofloxacin 250 mg × 1 or
Cefixime 400 mg po × 1
All of the above should be combined with treatment for C. trachomatis unless this has been ruled out:
Doxycycline 100 mg po bid × 7 days; azithromycin (1 g po × 1) is an alternative.
Alternative: 1) Spectinomycin 2 g IM × 1. (Spectomycin may not be commercially available), 2)
Cefotaxime 500 mg IM, 3) Gatifloxacin 400 mg po × 1 or norfloxacin 800 mg po. Azithromycin in a
dose of 2 g is effective treatment for both gonorrhea and C. trachomatis, but GI side effects are
frequent, cost is high, and gonococcal cure rates are relatively low (93%)
B. Special Considerations
1. Syphilis: All patients with gonorrhea should be screened for syphilis at initial visit. Regimens with
ceftriaxone or a 7-day course of doxycycline or erythromycin may cure incubating syphilis.
2. Follow-up: Patients who respond need no follow-up. Patients with persistent symptoms should have
culture for N. gonorrhoeae and in vitro susceptibility testing; mostare due to re-infection, indicating
need for partner referral or nongonococcal urethritis. Expected response rate B95%.
3. Infection control: Patients should avoid sexual intercourse until the patient and partner (see below)
are cured. This means no sexual contact until therapy is completed and both are asymptomatic.
4. Sex partners: Partners should be referred for evaluation and treatment of N. gonorrhoeae and C.
trachomatis. This includes sex partners within 30 days for symptomatic infection and those within 60
days for asymptomatic infection.
5. Reporting: All states require reporting of N. gonorrhoeae.
6. Pregnancy: Quinolones and tetracyclines are contraindicated. For N. gonorrhoeaea a cephalosporin or
spectinomycin is preferred. For C. tracho matis, amoxicillin or erythromycin is preferred.
7. HIV infection: Standard recommendations apply.
C. Gonococcal Infections at Selected Sites*
1. Pharyngitis: Ceftriaxone 125 mg IM or ciprofloxacin 500 mg po (both withdoxycycline 100 mg po bid ×
7 days) or azithromycin 1 g po
2. Conjunctivitis*: Ceftriaxone 1 g IM × 1 plus lavage of infected eye × 1
3. Disseminated gonococcal infections*
a. Hospitalization is recommended, especially for noncompliant patients, uncertain diagnosis,
patients with purulent synovial effusions, or other complications.
b. Recommended treatment: Ceftriaxone 1 g IV or IM daily
Alternative regimens: Cefotaxime 1 g IV q8h or ceftizoxime 1 g IV q8h,
P.289
ciprofloxacin 400 mg IV q12h, ofloxacin 400 mg IV q12h, levofloxacin 250 mg IV/d, or
spectinomycin 2 g IM q12h
Duration of parenteral treatment: 24–48 hr after symptoms resolve, then cefixime 400
mg po bid, ciprofloxacin 500 mg po bid, ofloxacin 500 mg po bid, or levofloxacin 500 mg po
qd
Duration of oral treatment: To complete a full week of antibiotic treatment
4. Meningitis*: Ceftriaxone 2 gm IV q12h × 10–14 days
5. Endocarditis*: Ceftriaxone 2 gm IV qd × 4 wk
6. Salpingitis: See pelvic inflammatory disease
II. Syphilis
A. Classification
1. Primary: Ulcer or chancre at site of infection
2. Secondary: Rash, mucocutaneous lesions, adenopathy
3. Tertiary (late): Cardiac, neurologic, ophthalmic, auditory, or gummatous lesions
4. Latent syphilis: No evidence of disease
Early latent: Acquired syphilis within 1 yr based on seroconversion B4–fold increase in titer, history of
primary or secondary syphilis, or sex partner with primary, secondary, or early latent syphilis
Late latent: Infection >1 yr; syphilis of unknown duration should be managed as late latent syphilis
B. Diagnosis
1. Direct exam (lesion exudate or tissue): Dark-field or direct fluorescent antibody tests
2. Serology: Requires treponemal and nontreponemal tests for diagnosis
a. Treponemal: Fluorescent treponemal antibody absorbed FTA-ABS or microhemagglutinin for
antibody (MHATP). Reported as reactive or nonreactive, titers do not correlate with assay disease
activity; patients who react usually remain reactive for life regardless of treatment or disease
activity
b. Nontreponemal: Venereal Disease Research Laboratory (VDRL) or rapid plasma reagin (RPR).
Results should be reported quantitatively. Titers correlate with disease activity. 4-fold changes in
titer are required to demonstrate a significant difference. Sequential tests should be done in the
same lab. VDRL and RPR are equally valid, although quantitative results cannot be directly
compared. It is expected that this test will become nonreactive with treatment, but some stay
reactive for long periods, e.g., serofast reaction
c. Neurosyphilis:
(1) Positive CSF VDRL or RPR is considered diagnostic if specimen is not contaminated with
blood. This test is negative in about one-third with neurosyphilis. Some advocate CSF
FTA-ABS, which is less specific but thought to be highly sensitive
(2) CSF leukocytosis (>5 WBC/mm3) is expected in active neurosyphilis and is a sensitive
measure of effectiveness of therapy
d. HIV: Standard serologic tests are usually accurate but rare false negatives are reported. There is
an increased risk of neurosyphilis
C. Treatment: Penicillin G is preferred for all stages
1. Primary and secondary
P.290
a. Benzathine penicillin G 2.4 mil units IM × 1
b. Follow-up: Patients should be re-examined clinically and serologically at 6 and12 mo. Patients
with HIV should have evaluations at 2, 3, 6, 9, 12 and 24 mo ± LP at 6 mo. Treatment failure or
reinfection is diagnosed if symptoms persist, symptoms recur, or 4-fold increase in VDRL or RPR
titer by 6–12 mo: 1) Evaluate for HIV, 2) perform LP, and 3) retreat with benzathine penicillin
2.4 mil units IM × 3 (weekly)
c. If titer does not decrease by 4-fold at 6 mo then 1) evaluate for HIV, 2) follow-up clinical and
serologic exams at 6 mo (3-mo intervals for HIV-infected patients), and 3) retreat if follow-up
cannot be assured—benzathine penicillin 2.4 mil units IM × 3 (weekly)
d. HIV serology: Indicated in all patients with syphilis; patients in high prevalence areas for HIV
should be retested at 3 mo
e. LP: Indicated in primary and secondary syphilis only if there are clinical signs and symptoms of
neurologic involvement (ophthalmic, auditory symptoms, cranial nerve palsies) or with
therapeutic failures
Ophthalmic disease (uveitis): Slit lamp exam
f. Penicillin allergy:
Doxycycline 100 mg po bid × 2 wk or tetracycline 500 mg po qid × 2 wk
Intolerance to tetracyclines (acceptable only in HIV-negative patients):
Erythromycin 500 mg po qid × 2 wk or ceftriaxone 1 g/d for 8- to 10-day course
Pregnancy: Skin test; if positive, desensitize and treat with penicillin*
g. HIV infection: Benzathine penicillin G: 2.4 mil units ×1
h. Jarisch-Herxheimer reaction: Acute febrile reaction accompanied by head ache and myalgias.
There are no proven methods to prevent this. Anti pyretics are recommended for treatment. The
reaction may induce early labor and cause fetal distress in pregnant women
2. Latent syphilis (see “Classification” above)
a. Early latent (syphilis >1 yr): Diagnosis—documented seroconversion, unequivocal history of
primary or secondary syphilis >1 yr previously or sex partner with syphilis>1 yr. Treatment:
Benzathine penicillin G 2.4 mil units IM × 1; penicillin allergy, doxycycline 100 mg bid × 4 wk
b. Late latent (syphilis >1 yr or unknown duration): Benzathine penicillin G 2.4 mil units IM × 3 at
weekly intervals; penicillin allergy, doxycycline 100 mg bid × 4 wk
c. Follow-up: VDRL or RPR at 6, 12, and 24 mo. Patients who develop signs or symptoms of syphilis
have a 4-fold increase in titer or an initial titer of B1:32 that fails to decrease 4-fold in 12–24
mo should have LP and be retreated
d. Indications for LP:
Neurologic or ophthalmic signs or symptoms (ophthalmic, auditory, cranial nerve symptoms)
Other evidence of active disease (aortitis, gumma, iritis, etc)
Treatment failure
HIV infection
P.291
Infection >1 yr or unknown duration plus titer B1:32
Infection >1 yr or unknown duration and nonpenicillin treatment planned
e. HIV serology: Advocated for all syphilis patients
f. Penicillin allergy (nonpregnant patients)
Infection >1 yr: Doxycycline 100 mg po bid or tetracycline 500 mg po qid × 2 wk
Infection >1 yr or unknown duration: Doxycycline 100 mg po bid or tetracycline 500 mg po
qid × 4 wk
Pregnancy: Skin test; if positive, desensitize and treat with penicillin* (MMWR
1993;42(RR-14):44.)
g. HIV infection: LP, if normal—benzathine penicillin 2.4 mil units IM × 3 (weekly)
h. Evaluation: Patients with latent syphilis should be evaluated for tertiary disease—aortitis,
neurosyphilis, gummas, or iritis
3. Neurosyphilis and ocular syphilis
a. Preferred: Aqueous penicillin G 12–24 mil units/d given as 3–4 mil units q4h × 10–14 days
b. Alternative if outpatient compliance is assured: Procaine penicillin IM 2.4 mil units/d plus
probenecid 500 mg po q6h for 10–14 days
c. Penicillin allergy:
Ceftriaxone 2 g/d IV or IM × 10–14 days
Skin test; if positive, desensitize and treat with penicillin*
d. Follow-up: If CSF initially showed pleocytosis, repeat LP q6mo until normal. Also evaluate CSF
VDRL and protein, but these respond less rapidly and are of less certain significance. If cell count
has not decreased by 6 mo or CSF is abnormal at 2 yr then retreat.
4. Late syphilis (other than neurosyphilis): Gumma, cardiovascular syphilis, etc
LP: All patients
Benzathine penicillin 2.4 mil units × 3 at weekly intervals
Penicillin allergy: Doxycycline 100 mg po bid × 4 wk
D. Sex partners
1. Patients sexually exposed to primary secondary or early latent syphilis should be evaluated clinically
and serologically: Contacts should be treated if seropositive or if seronegative and exposed <90 days.
Presumptive treatment should also be given if exposure was >90 days, serologic test results are
unavailable, and source had primary, secondary, or early latent syphilis. Patients with syphilis of
unknown duration with a nontreponemal test titer of × 1:32 are considered to have early syphilis for
purposes of partner notification
2. Long-term partners of patients with late syphilis should be evaluated clinically and serologically
3. Time periods used to identify at-risk sex partners are 3 mo plus duration of symptoms for primary
syphilis, 6 mo plus duration of symptoms for secondary syphilis, and 1 yr for early latent syphilis
E. Pregnancy
1. Testing: All women should have screening tests for syphilis in early pregnancy; this should be
repeated at 28 wk and at delivery in areas of high prevalence or women with high risk
2. Treatment: Penicillin regimens as summarized above. Penicillin allergy: skin test and desensitize if
positive. Note: Some experts recommend a second dose of benzathine penicillin2.4 mil units at 1 wk
for pregnant women with primary, secondary, or early latent syphilis
3. Jarish-Herxheimer reaction: Pregnant women treated for syphilis in the second half of pregnancy who
have a Jarish-Herxheimer reaction have increased risk of premature labor and fetal distress
MANAGEMENT OF SYPHILIS: SUMMARY
Initial Follow-up Expectation Indications to
Form treatment LP VDRL/RPR VDRL/RPR retreat
Primary Initial: Neuro 3 and 6 4-fold Titer increases
syphilis Benzathine symptoms mo decrease at 3 4-fold
penicillin 2.4 Treatment HIV: mo Titer fails to
mil units IM failure 2,3,6,9, decrease
× 1 12 and 24 4-fold at 3 mo
Retreatment: mo +
Benzathine noncompliance
penicillin 2.4 or HIV
mil units IM infection
× 3 (weekly) Symptoms
persist or
recur
Secondary Initial: Neuro 3 and 6 4-fold Titer increases
syphilis Benzathine symptoms mo decrease at 6 4-fold
penicillin 2.4 Treatment HIV: mo Titer fails to
mil units IM failure 2,3,6,9, decrease
× 1 and 12 4-fold at 6 mo
Retreatment: mo +
Benzathine noncompliance
penicillin or HIV
2.4 mil units infection
IM × 3 Symptoms
(weekly) persist or
recur
Early latent Initial: Neuro 6, 12 mo 4-fold Titer increases
(<1 yr) Benzathine symptoms and q6mo decrease if 4-fold
P.292
P.293
III. Chlamydia Trachomatis (MMWR 1993;42(RR-12).)
A. Spectrum of disease
Men: Nongonococcal urethritis, epididymitis, proctitis, and proctocolitis (renal intercourse)
Women: Mucopurulent cervicitis, salpingitis (PID), postpartum endometritis, cystitis (acute
dysuria-pyuria or urethral syndrome), perihepatitis (Fitz-Hugh-Curtis syndrome), proctitis, and
proctocolitis
Infants (postexposure): Conjunctivitis and pneumonitis
Miscellaneous: Reiter's syndrome (reactive arthritis, conjunctivitis, and urethritis), chronic
conjunctivitis, pharyngeal colonization (but not pharyngitis)
B. Screening candidates
Mucopurulent cervicitis
Sexually active women <20 yr
Women 20–24 yr who meet the following criteria and those >24 yr who meet both criteria:
Inconsistent use of barrier contraceptives or new or >1 sex partner in past 3 mo
Pregnant females during third trimester
Screening women is the major element of a chlamydial prevention program.
Verification of initial positive test should be performed if the test was not a positive culture and the
patient is considered low risk.
C. Detection
1. Polymerase chain reaction (PCR) (Roche Molecular Systems, Branchburg, NJ) and ligase chain reaction
(LCR) (Abbott Laboratories, Abbott Park, IL). These assays require about 8 hr and show sensitivity of
86–98%; specificity is 99–100%, and they can be performed on urine. The cost is $14–28/specimen
(although commercial labs charge more)
2. Conditions that warrant presumptive diagnosis of chlamydial infection*
Condition Chlamydia patients Prevalence in partners
Nongonococcal urethritis 30–40% 10–43%
Pelvic inflammatory disease 8–54% 36%
Epididymitis (<35 yr) 50% 10–43%
Gonococcal infection: Men 5–30% 40%
Gonococcal infection: Women 25–50% Unknown
3. Conditions that may not warrant presumptive diagnosis of chlamydial infection
Condition Chlamydia patients Prevalence in partners
Mucopurulent cervicitis 9–51% 2–27%
Proctitis (homosexual men) 8–16% Unknown
Acute urethral syndrome 13–63% Unknown
P.294
D. Treatment (CID 1995;20:S66.)
1. Preferred*
Azithromycin 1 g po × 1 day
Doxycycline 100 mg po bid × 7 days (contraindicated in pregnancy and growing children)
2. Alternatives
Levofloxacin 500 mg po qd × 7 days or ofloxacin 300 mg po bid × 7 days (Both are
contraindicated in pregnancy and children > 17 yr)
Erythromycin ethylsuccinate 800 mg po qid × 7 days
Erythromycin base 500 mg po qid × 7 days
3. Pregnancy
Preferred: Erythromycin base 500 mg po qid × 7 days or amoxicillin 500 mg po tid × 7 days
Erythromycin ethylsuccinate 800 mg po qid × 7 days or
Erythromycin ethylsuccinate 400 mg po qid × 14 days or
If amoxicillin or erythromycin not tolerated: Azithromycin 1 g po
4. HIV infection: As above
E. Follow-up: Not indicated unless symptoms persist or recur or erythromycin is used. Failure rates with
doxycycline regimen are 0–3% for men and 0–8% for women.
F. Disease prevention: Patient should avoid sex for 7 days from initiation of treatment, and until all
partners are treated and cured
G. Partner referral: Evaluation and treatment of partners within 60 days. Last sex partner should be
evaluated, tested, and treated regardless of the time interval
H. Reporting: C. trachomatis has required reporting in most states
I. Prevention of ophthalmic neonatorum (N. gonorrhoeae and C. trachomatis): Instill into the eye <1
hr after birth: Silver nitrate (1%) aqueous solution ×1or erythromycin (0.5%) ophthalmic ointment ×1
IV. Lymphogranuloma Venereum
A. Agent: Biovar (strain) of C. trachomatis, invasive serotypes L1, L2, L3
B. Symptoms: Tender inguinal and/or femoral lymphadenopathy; protocolitis in women and gay men
C. Diagnosis: Serology: CF titer B1:64
D. Treatment:
1. Drainage: Bubos may require incision or aspiration
2. Preferred antibiotic: Doxycycline 100 mg po bid × 21 days
3. Alternatives: Erythromycin 500 mg po qid × 21 days
Expected responses: 50% have healed ulcers at 7 days, 80% at 14 days, and 100% at 28 days.
Relapse rate is 3–5%
4. Pregnancy: Use erythromycin regimen
P.295
5. Sex partners: Examine and treat partners of 30 days prior to onset of symptoms
6. HIV infection: As above
E. Sex Partners: Examine, test, and treat partners within 30 days
F. Reporting: Required in most states
V. Genital Herpes Simplex
A. Treatment
Duration Acyclovir Valacyclovir Famciclovir
First episode 7–10 days 400 mg tid 1 g bid 250 mg tid
Recurrent 5 days 400 mg tid or 800 mg bid 500 mg bid 125 mg bid
Suppressive >5 yr 400 mg bid 500 mg qd or 1 g/d 250 mg bid
Severe disease 2–7 days* 5–10 mg/kg IV q8h
* Then oral therapy to complete 10 days
1. First episode: Acyclovir treatment shortens duration of pain, viral shedding, and systemic symptoms.
Treatment has no effect on rate or frequency of relapses
2. Recurrent episodes: Should be started with the prodrome or within 1 day of onset of lesions
3. Prophylaxis: Consider with > 6 recurrences/yr: Safety and efficacy are documented for continuous
prophylaxis up to 10 yr without cumulative toxicity or risk of resistance (JID 1994;169:1338.). There
is also a significant reduction in viral shedding. Suppressive treatment is contra indicated in
pregnancy
4. HIV infection
Duration Acyclovir Valacyclovir Famciclovir
Recurrent 5–10 days 400 mg tid 1 g bid 500 mg bid
Suppression — 400–800 mg 2–3 ×/d 500 mg bid 500 mg bid
5. Pregnancy: Registry to report exposure experiences with acyclovir or valacyclovir: 800-722-9292, ext
58465. To date the experience shows no risk to the infant with 601 exposures to acyclovir; this
sample size is adequate to detect a 2-fold teratogenic risk over the 3% baseline rate of birth defects
(MMWR 1993;42:806.). There are sparse data about famciclovir or valacyclovir in pregnant women, so
acyclovir is preferred. Indications for acyclovir in pregnancy:
First episode of genital herpes
Severe genital HSV or extragenital HSV disease (encephalitis, disseminated disease, etc.)
6. Perinatal infections: Most perinatal HSV infections occur with mothers who have no history of HSV.
Risk of transmission is highest with delivery at the time the mother has primary HSV (30–50%); risk
with recurrent HSV at the time of delivery is about 3%. Women at risk (HSV negative pregnant woman
and HSV infected partner) should be warned of risk of unprotected sexual contact in late pregnancy
P.296
B. Management of pregnancies complicated by genital herpes simplex
1. No signs of genital HSV at onset of delivery—vaginal delivery
2. HSV lesions at onset of labor—most recommend C-section
3. eSvere genital HSV during pregnancy—oral or IV acyclovir
C. Neonatal herpes: Treat infant with acyclovir 30–60 mg/kg/d ×10–21 days
VI. Chancroid
A. Agent: Haemophilus ducreyi
B. Clinical features: Painful genital ulcers ± tender inguinal adenopathy with or without suppuration;
uncommon in U.S. (MMWR 1995;44:567.)
C. Diagnosis: Culture requires specialized media that are not commercially available. Even with these media,
the yield is <80%. PCR may soon be available. Presumptive diagnosis: Typical clinical findings plus no
evidence of syphilis (dark-field of lesion exudate or negative serology at least 7 days after onset of ulcer)
and atypical for herpes simplex or negative tests for herpes simplex. Presence of suppurative inguinal
adenopathy is nearly diagnostic
D. Treatment (CID 1995;20:539.)
1. Preferred:
Azithromycin 1 g po × 1 or
Ceftriaxone 250 mg IM × 1 or
Erythromycin base 500 mg po qid × 7 days
Ciprofloxacin 500 mg po bid × 3 days (contraindicated in pregnant or lactating women and with
age <18 yr)
2. Alternatives: None
3. HIV infection: All regimens are less effective—azithromycin and multiple dose regimens are preferred
(STD 1994;21:231.)
E. Follow-up: Symptoms improve within 3 days, and objective improvement is seen within 7 days. Examine
3–7 days after treatment. If not improved, consider wrong diagnosis, co-infection (10% coinfected with
HSV or T. pallidum), HIV infection, noncompliance, H. ducreyi, resistance to (rare with recommended
treatments), need for needle aspiration of fluctuant adenopathy.
F. Partner referral: Examine and treat partners <10 days
G. HIV infection: Longer treatment or close follow-up
VII. Granuloma inguinale (Donovanosis)
A. Agent: Calymmatobacterium granulomatis
B. Geography: Rare in U.S.; endemic in India, Australia, South Africa, New Guinea
C. Clinical presentation: Painless, progressive genital ulcer that is highly vascularized (beefy red) and
bleeds easily
D. Treatment
Trimethoprim-sulfamethoxazole 1 DS bid until healed (B21 days)
Doxycycline 100 mg bid until healed (B21 days)
Alternative: Ciprofloxacin 750 mg bid × 21 days, erythromycin 500 mg po qid × 21 days, or
azithromycin 1 g/wk × 3
P.297
E. Sex partners: Examine partners within 60 days and treat those with symptoms
F. Pregnancy: Erythromycin ±aminoglycoside (gentamicin)
G. HIV infection: Consider adding gentamicin to treatment regimen
VIII. Pediculosis Pubis (Pubic Lice)
A. Teatment
Permethrin (1%) cream rinse (Nix) applied to affected area and washed after 10 min or
Lindane (1%) shampoo applied 4 min and then thoroughly washed off (not recommended for pregnant
or lactating women) or
Pyrethrins and piperonyl butoxide (nonprescription) applied to affected areas and washed off after 10
min
Note: Permethrin has less potential toxicity with inappropriate use; lindane is least expensive and
non-toxic if used correctly
B. Adjunctive: Retreat after 7 days if lice or eggs are detected at hair–skin junction. Clothes and bed linen
of past 2 days should be decontaminated (machine washed or machine dried using hot cycle or dry
cleaned) or removed from body contact at least 12 hr
C. Follow-up: Evaluate at 1 wk if symptoms persist. Retreat if lice or eggs are seen at hair–skin junctions
D. Pregnancy: Permethrin or pyrethrins
E. Sex partners: Treat sex partners within preceding month as above
IX. Scabies (Sarcoptes scabiei)
A. Symptoms: Pruritus
B. Recommended: Permethrin (5% cream, 30 g) massaged and left 8–14 hr(preferred—Semin Dermatol
12:22, 1993). Lindane considered preferable drug for scabies byMedical Letter consultants (Med Lett
1995;37:117.)
C. Alternatives: Lindane (1%) 1 oz lotion or 30 g cream applied thinly to all areas of the body below neck
and washed thoroughly at 8 hr (not recommended for pregnantor lactating women) or sulfur (6%)
ointment applied thinly to all areas nightly×3; wash off previous application before new applications and
wash thoroughly 24 hr after last application. Ivermectin (200 Tg/kg po ×1 or 0.8% topical solution)
appears to be effective (NEJM 1995;333:26.)
D. Sex partners and close household contacts: Treat as above
E. Pregnancy: Avoid lindane
F. Adjunctive: Clothing and bed linen contaminated by patient should be decontaminated (machine washed
or machine dried using hot cycle or dry cleaned or removed from body contact ×72 hr)
G. Outbreaks: Control can usually be achieved only by treating the entire population at risk
X. Hepatitis B Rates and risk of HBV are high in patients with STDs. Serologic tests of STD clinic patients show
evidence of past infection in 28% of persons B25 yr and
P.298
7% in those B25 yr. HBV vaccination is recommended for 1) sexually active homosexual and bisexual men; 2)
men and women diagnosed with another STD, and 3) persons with more than one sex partner in the prior 6 mo
(MMWR 1999;48:33.) Usual regimen is three doses at 0, 1, and 6 mo at a cost of about $50/dose (see p 114).
XI. Human Papillomavirus: Warts
A. Types: Exophytic warts are usually benign and caused by HPB types 6 and 11. Types 16, 18, 31, 33, and
35 are associated with genital dysplasia and carcinoma; these types are usually subclinical
B. Treatment goals: No treatment is known to eradicate HPV, reduce risk of cervical dysplasia or cervical
carcinoma, or prevent recurrence (CID 1995;20:S91.). The goal of therapy is to eliminate the symptoms
and emotional distress associated with exophytic warts
C. Treatments: Determined by wart area, wart count, anatomic site, morphology, cost, patient preference,
and provider experience. Most treatments are 60–70% effective in clearing exophytic warts and show
recurrence rates >25% (Int J Dermatol 1995;34:29.)
1. Patient applied
Podofilox 0.5% soln or gel (Condylox) apply bid × 3 days, then no therapy × 4 days; repeat cycle
up to 4 times. This treatment is relatively brief, inexpensive, safe, and simple. Local pain is
common. The wart area should be <10 cm2 and the total volume of podofilox should be <0.5 mL
Imiquimod 5% (Aldara) cream (see Med Lett 1997;39:118.)Apply hs 3×/wk—daily for up to 16
wk. Wash with mild soap and water 6–10 hr after application. Local inflammation is common.
More expensive than podofilox (AWP $432/16 wk vs $56/4 wk for podofilox)
2. Provider applied
Cryotherapy: liquid nitrogen or cryoprobe, repeat q1–2wk. Requires technical expertise
Podophyllin resin 10–25% applied to wart and air-dried. Repeat weekly
Trichloroacetic acid or bichloroacetic acid 80–90% applied to wart and air-dried
3. Alternative treatments
Laser surgery
Intralesional interferon: Rarely recommended because of systemic reactions and requirement for
multiple visits
Management by anatomical site
Cervical warts: Must consult expert to exclude high-grade SIL
Vaginal warts: Cryotherapy or podophyllin
Meatal warts: Cryotherapy or podophyllin 10–25%
Anal warts: Cryotherapy, surgical removal, or TCA/BCA 80–90%
Oral warts: Cryotherapy or surgical removal
D. Follow-up: Not mandatory after warts have cleared
E. Sex partners: Not necessary because there is no curative therapy and treatment does not reduce
transmission.
F. Pregnancy: Use of podofilox, podophyllin, and imiquimod is contra indicated in pregnancy. HPV types 6
and 11 can cause laryngeal papillomatosis in offspring, but mechanism of transmission is unclear. Cesarean
section should not be performed to prevent this complication.
P.299
G. Subclinical warts: Indirect tests are Pap smear, colposcopy, biopsy, or acetic acid application; definitive
diagnosis requires detection of HPV DNA or RNA or capsid proteins. Pap smear diagnosis does not correlate
well with detection by HPV DNA in cervical cells; cell changes caused by HPV are similar to mild dysplasia
and often regress spontaneously. Therefore, screening for subclinical HPV with nucleic acid or capsid
antigen tests for detection of HPV is not recommended. Management is based on results of dysplasia on
Pap smear.
H. Education: Genital HPV infection is common, usually sexually transmitted, and has a variable incubation
period. Most warts are benign; exophytic genital warts are not associated with carcinoma. Recurrence in 3
months post-treatment is common; likelihood of transmission post-therapy is unknown. The value of
disclosure to prior partners is also unknown.
XII. Genital Ulcer Disease
Agents Diagnosis Treatment* Comment
Herpes Culture or antigen test for HSV See p 295 Most common cause in U.S.
simplex
Syphilis Dark-field exam or direct See p 288 Second most common
immuno-fluorescence test identifiable cause in U.S.
Chancroid Culture for H. ducreyi See p 296 Most labs do not have the
appropriate media; rare in U.S.
* Based on results of above tests. About 25% will have no laboratory confirmed diagnosis; in this case
treat for the most likely agent.
XIII. Urethritis
A. Diagnosis: Any of the following
Mucoid or purulent urethral discharge
Positive leukocyte esterase test on first voided urine or microscopic exam of first voided urine
showing > 10 WBC/HPF
Urethral Gram stain showing >5 WBC/HPF
B. Microbiology: Evaluate for gonococcal and chlamydial infection.
Gonococcal: Presumptive evidence is urethral discharge with >5 WBC/HPF plus typical Gram-negative
diplococci.
Nongonococcal: C. trachomatis (20–55%), Ureaplasma urealyticium (20%), Trichomonas vaginalis
(2–5%), HSV (rare)
C. Management
1. Gram stain of discharge
a. Gram-negative intracellular displococci +>5 WBC/HPF: Treat for N. gonorrhoeae and C.
trachomatis; refer partners
b. Negative Gram stain + >5 WBC/HPF: Test for N. gonorrhoeae and C. trachomatis; treat for C.
trachomatis; refer partners if tests are positive
c. Negative tests: Test for N. gonorrhoeae, and C. trachomatis; defer treatment pending test
results unless patient is at high risk and unlikely to return: treat patient and partner for N.
gonorrhoeae and C. trachomatis
P.300
2. Gram stain unavailable: Test for N. gonorrhoeae and C. trachomatis; treat for N. gonorrhoeae and C.
trachomatis; refer partners if tests are positive
3. Nongonococcal urethritis: Treat for C. trachomatis
D. Sex partners: Evaluate and treat sex partners within V60 days of symptomatic patients or last sex
partner if last sex preceded intervals.
E. Follow-up and disease prevention: Avoid sex until patient and partner have completed 7 days of therapy.
F. Persistent or recurrent urethritis
1. Reexposure or noncompliance with original regimen: Retreat
2. Compliant and no reexposure: Intraurethral swab for wet mount and culture for T. vaginalis.
Treatment is metronidazole 2 g po × 1 plus either
Erythromycin base 500 mg po qid × 7 days or
Erythromycin ethylsuccinate 800 mg po qid ×7 days
XIV. Epididymitis
A. Microbiology
Men <35 yr: N. gonorrhoeae, C. trachomatis; gay men are likely to have enteric pathogens as well
Men >35 yr: E. coli and other urinary tract pathogens
P.301
B. Diagnosis: (1) Urethral smear for Gram stain for N. gonorrhoeae and nongonococcal urethritis (B5
WBC/OIF) suggests gonococcal infection, (2)urine LCR for N. gonorrhoeae, and C. trachomatis, (3)
uncentrifuged urine for WBCs and Gram stain for GNB.
C. Treatment
N. gonorrhoeae: Ceftriaxone 250 mg IM × 1 plus doxycycline, 100 mg po bid × 10 days
C. trachomatis: Ofloxacin 300 mg po bid × 10 days or levofloxacin 500 mg qd
D. Follow-up: Expect improvement within 3 days; swelling >1 wk—evaluate for testicular cancer, TB, fungal
infections, abscess, or infarction.
E. Sex partners: Evaluate and treat sex partners with sexually transmitted epididymitis if contact was within
60 days and gonococci or C. trachomatis is suspected or confirmed. Patient should avoid sexual intercourse
until patient and partner are cured.
XV. Proctitis, Proctocolitis, and Enteritis
A. Classification
Condition Symptoms Microbiology
Proctitis* Anorectal pain, tenesmus, N. gonorrhoeae, C. trachomatis, syphilis,
constipation, rectal discharge HSV
Proctocolitis* Symptoms of proctitis plus Shigella, E. histolytica, Campylobacter sp,
diarrhea ± cramps and LGV; C. trachomatis (rare)
inflammation of colonic mucosa
to 12 cm
Enteritis Diarrhea without signs of Giardia; HIV infection—CMV, M. avium,
proctitis or colitis microsporidia, Cryptosporidium-Isospora,
Salmonella
* Proctitis indicates inflammation limited to the distal 10–12 cm of the colon. Proctocolitis shows
inflammation extending beyond 12 cm.
B. Diagnosis (proctitis): Anoscopy with evaluation of anorectal pus for PMNs, Gram stain, and evaluation
for gonococci, C. trachomatis, syphilis, and HSV
C. Treatment (proctitis with history of recent receptive anal intercourse plus anorectal pus):
Ceftriaxone 125 mg IM plus doxycycline 100 mg po bid ×7 days
XVI. Mucopurulent Cervicitis (MPC)
A. Agents: Can be caused by N. gonorrhoeae or C. trachomatis, but most cases involve neither. Most women
with gonococcal and chlamydial infections do not have MPC. MPC is not a sensitive predictor of infection.
B. Diagnosis: Yellow endocervical exudate in endocervical canal or in an endocervical swab specimen. Some
women have no symptoms, some have vaginal discharge, and some have abnormal vaginal bleeding,
especially postcoital bleeding.
C. Test: Chlamydia trachomatis and N. gonorrhoeae
D. Treatment: Recommendations based on results of tests of N. gonorrhoeae and C. trachomatis unless
likelihood of infection with either organism is high or patient is unlikely to return for treatment.
1. Gonococcal endocervicitis: see p 288
2. Chlamydia endocervicitis: see p 293
3. Treat for both if high prevalence of both infections, e.g., many STD clinics
4. Treatment may be delayed for laboratory test results if prevalence of both infections is low and
compliance with return visit is likely
E. Sex partners: Partners of women treated for gonorrhea or C. trachomatis should be examined and
treated; patients should avoid sex until treated, i.e., 7 days.
XVII. Pelvic Inflammatory Disease
A. Conditions: PID includes endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis.
B. Microbiology: Most common—N. gonorrhoeae and C. trachomatis; less common—endogenous bacteria
including anaerobes, Gram-negative bacilli, and streptococci. Role of mycoplasma is unclear.
C. Diagnosis: Sexually active women with uterine/adnexal tenderness or cervical motion tenderness.
Additional supporting findings are: (1) oral temperature B101°F, (2) cervical/vaginal mucopurulent
discharge, (3) WBC's in vaginal secretions, (4) increased ESR, (5)elevated CRP, or (6) lab documentation
of N. gonorrhoeae or C. trachmatis
D. Indications for hospitalization and/or parenteral antibiotics:
1. Surgical emergency such as possible acute appendicitis
2. Pregnancy
3. Patient failed oral therapy
4. Patient is unable to follow or tolerate oral therapy
5. Severe illness as indicated by high fever, nausea, and vomiting
6. Tubo-ovarian abscess
E. Treatment
1. Parenteral regimen
Cefoxitin 2 g IV q6h or cefotetan 2 g IV q12h until at least 24 hr after clinical improvement plus
doxycycline 100 mg bid po or IV × 14 days*
Clindamycin 900 mg IV q8h plus gentamicin 2 mg/kg IV or IM followed
P.302
by 1.5 mg/kg q8h at least 24 hr after clinical improvement then doxycycline 100 mg po bid × 14
days or clindamycin 450 mg po qid × 14 days clindamycin preferred for tubo-ovarian abscess)
Alternatives/parenteral regimen
Ofloxacin 400 mg IV q12h or levofloxacin 500 mg IV qd plus metronidazole 500 mg IV q12h
Ampicillin/sulbactam 3 g IV q6h plus doxycycline 100 mg IV or po q12h
Ciprofloxacin 200 mg IV q12h plus doxycycline 100 mg IV or po q12h plus metronidazole 500 mg
IV q12h
2. Oral therapy
Single dose parenteral plus oral:
Ceftriaxone 250 mg IM × 1 or cefotaxime or
Cefoxitin 2 g IM plus probenecid 1 g po
Plus metronidazole 500 mg po bid × 7 days or
Oral regimen: Ofloxacin 400 mg po bid or levofloxacin 500 mg qd × 14 days plus metronidazole
500 mg po bid × 14 days
F. Follow-up: Patients should show substantial clinical improvement within 3 days. Outpatient evaluation:
Follow-up in 72 hr with expectation of substantial clinical improvement or hospitalization. Patients should
be examined 7–10 days after therapy.
G. Sex partners: Examine all sex partners and treat for N. gonorrhoeae and C. trachomatis.
H. Expected clinical cure rates with suggested antibiotic regimens: 85–95% for PID with most failures
ascribed to tubo-ovarian abscesses (CID 1994;19:720.). Response expected within 3 days. Major concern
is late sequelae with infertility (16%) and ectopic pregnancy (9%) (STD 1992;19:185.)
XVIII. Vaginitis/Vaginosis:
A. Diagnostic tests:
Requirement: pH paper and 2 slides for microscopy—one with 2 drops of normal saline and the second
with 10% KOH
Interpretation
pH >4.5: Bacterial vaginosis or trichomoniasis
Saline mount—T. vaginalis or clue cells of bacterial vaginosis
KOH—Candida pseudohyphae or release of amine odor with bacterial vaginosis
B. Trichomoniasis(almost always an STD)
1. Clinical features: Women—malodorous yellow-green discharge with vulvar irritation
2. Diagnosis: Wet mount or culture. PMNs, pH >4.7, and a positive amine odor test. Sensitivity of wet
mount is 60–70%; culture is more sensitive.
3. Usual treatment: Metronidazole 2 g po as single dose
Alternative: Metronidazole 375 mg or 500 mg po bid × 7 days
Allergy to metronidazole: Desensitization (Am J Obstet Gynecol 174:934, 1996).
Topical metronidazole is not recommended.
4. Treatment failure: Repeat metronidazole 2 g/d ×3–5 days; if treatment fails again consult CDC
770-488-4115 or http://www.cdc.gov/std
5. Asymptomatic women: Treat as above
6. Pregnant women: Metronidazole 2 g ×1. Note: Treatment of asymptomatic trichomoniasis in pregnant
women does not reduce
P.303
preterm delivery and may do harm. Routine screening and treatment should not be done (NEJM 2001;
345:487)
7. Lactating women: Treat with 2 g metronidazole and suspend breastfeeding × 24 hr
8. Sex partners: Treat with 2 g metronidazole or 500 mg po bid × 7 days
9. Disease prevention: Patient and partner should avoid sex until both are cured
10. Treatment failures: Retreat with metronidazole 500 mg po bid × 7 days Persistent failures: 2 g dose
daily × 3–5 days
C. Bacterial vaginosis
1. Etiology: Dysbiosis of the vaginal flora with reduction in H2O2 producing lactobacilli by anaerobic
bacteria, G. vaginalis, and Mycoplasma hominis. Cause is unknown. Frequency is increased with
multiple sex partners, but rare cases are seen in virgins. Treatment of male sex partners is not
helpful.
2. Frequency: Frequency in sexually active women in STD and gynecology clinics is 5–20% (J Obstet
Gynecol 1993;169:446.).
3. Clinical symptoms: Malodorous vaginal discharge; over half of cases are asymptomatic.
4. Diagnosis: Three of the following:
1. Homogeneous, white non-inflammatory discharge that adheres to vaginal walls
2. Presence of clue cells
3. pH of vaginal fluid >4.5
4. Fishy odor of vaginal discharge with or without addition of 10% KOH (“whiff test”)
5. Microscopic exam shows no polymorphonuclear cells, sparse lactobacclli, and numerous coccobacillary
forms on epithelial cells (clue cells). Cultures are not indicated.
6. Complications: There is an association between BV and adverse outcome of pregnancy (postpartum
endometritis, amnionitis, preterm delivery, preterm labor, premature rupture of membranes) and
infectious complications of gynecologic surgery. A large trial designed to examine this issue failed to
demonstrate any benefit with metronidazole therapy (NEJM 2000;342:534.).
7. Goals of treatment:
Non-pregnant women: Relieve symptoms.
Pregnant women: Relieve symptoms and prevent adverse outcome of pregnancy (especially those with
prior preterm birth or maternal age >50).
8. Treatment
a. Non-pregnant:
Metronidazole 500 mg po bid × 7 days
Clindamycin 2% (5 g) intravaginal hs × 7 days
Metronidazole gel 0.75% (5 g) intravaginal bid × 5 days
Alternative: Metronidazole 2 g po × 1 or clindamycin 300 mg po bid × 7 days or clindamycin
ovules 100 mg intravaginally qd hs × 3 days Cure rates for preferred regimens: 75–84%
b. Pregnant: Bacterial vaginosis is associated with increased risk of preterm delivery. Some studies
show treatment is associated with reduced rates of preterm delivery (NEJM 1995;333:1732.; Am
J Obstet Gynecol 1994;171:345.) and some do not (NEJM 2000;342:5334.). Therefore, some
recommend screening and treatment at the first visit. Recommendations for treatment are:
P.304
Preferred: Metronidazole 250 mg po tid × 7 days
Alternatives
Metronidazole 2 g po × 1
Clindamycin 300 mg po bid × 7 days
Metronidazole gel 0.75% (5 g) intravaginal bid × 5 days
Metronidazole 250 mg po tid ×7 days
9. Sex partners: No evaluation
D. Vulvovaginal candidiasis (not considered an STD)
Includes CDC 2002 guidelines and IDSA Guidelines (CID 2000;30:672.)
1. Clinical features: Vaginal discharge and vulvar pruritis
2. Diagnosis: Vulvovaginal erythema and white discharge. KOH wet prep or Gram stain showing yeast or
pseudohyphae, or positive culture. (Culture is non-specific) Vaginal pH is usually <4.7 and PMNs
increased. About 10–20% of healthy women harbor Candida sp in the genital tract.
3. Classification: (CID 2000;30:672.) Uncomplicated–mild to moderate severity, sporadic, C. albicans,
normal host. Complicated: Severe disease, recurrent, non-albicans species, abnormal host
(uncontrolled diabetes, immuno sup pres sion, corticosteroids, HIV, etc)
4. Treatment: Douching is contraindicated (Obstet Gynecol 1993;81:601.) Intravaginal preparation (3-
to 7-day regimens are usually more effective than single dose). Topical agents are oil based and may
weaken latex condoms and diaphragms. Longer regimens and azoles are advocated for complicated
cases.
Topical agents
Butoconazole 2% cream (5 g)* at hs × 3 days or 2% sustained release (5%) × 1
Clotrimazole 1% cream* (5 g)* daily × 7–14 days.
Clotrimazole 100 mg vaginal tab* daily × 7 days or 2 tabs daily × 3 days or 500 mg tab × 1.
Miconazole 2% cream* (5 g) daily × 7 days.
Miconazole 200 mg supp* daily × 3 days or 100 mg supp* daily × 7 days.
Nystatin 100,000 unit vaginal tablet, one/day × 7–14 days.
Tioconazole 6.5% ointment (5 g)* × 1.
Terconazole 0.4% cream (5 g) daily × 7 days or 0.8% cream (5 g) daily × 3 days.
Terconazole 80 mg supp daily × 3 days.
Systemic agents:
Preferred: Fluconazole 150 mg po × 1
Alternatives: Itraconazole 200 mg bid × 1 day or ketoconazole 500 mg po × 5 days (CID
2000;30:672.)
Severe disease:
Topical azole × 7–14 days
Fluconazole 150 mg po and repeat at 3 days
5. Expected response rate: 70–90% within 48–72 hr. Patients may be classified as uncomplicated
vulvovaginitis (mild to moderate, sporadic, normal host, and sensitive C. albicans) vs complicated
vulvovaginitis (severe disease, abnormal host, reduced susceptibility of Candida). Uncomplicated
disease responds well to azoles including single dose and short course (7 days). Patients with
complicated vulvovaginitis often require longer therapy (10–14 days).
6. Sex partners: No evaluation
P.305
7. Pregnancy: Topical azoles (clotrimazole, miconazole, butoconazole, and terconazole) × 7 days
8. HIV serology: Not indicated for vaginal candidiasis per se.
9. Recurrent or complicated and refractory vulvovaginal candidiasis:
Topical agent × 7–14 days or fluconazole 150 mg po and repeat 3 days later ±maintenance:
Clotrimazole 500 mg topically q wk × 6 mo or itraconazole 400 mg q month or itraconazole 100 mg po
qd × 6 mo. IDSA guideline is for azole therapy po in standard dose > 2 wk, then fluconazole 150 mg q
wk, ketoconazole 100 mg qd, itraconazole 100 mg qod, or daily topical azole. Treatment of sex
partners is not effective and should not be conducted unless there is symptomatic balanitis or penile
dermatitis
10. HIV infection: Incidence of vaginal candidiasis is increased, but response to therapy isusually good.
Standard treatment should be given
XIX. Pap Smears
A. Frequency (American College of Obstetrics/Gynecology and American Cancer Society): Annually for
sexually active women
B. HIV infection: Pap smear on initial evaluation; at least one additional Pap smear should be obtained in
the next 6 mo to rule out a false-negative test. If negative, repeat testing at least annually. Results of Pap
smears should be managed similarly to those from patients without HIV infection
C. Classification of results (Bethesda System, JAMA 1989;262:931.; JAMA 1994;271:1866.):
Low-grade squamous intraepithelial lesion (SIL): Includes cellular changes associated with HPV and mild
dysplasia/cervical intraepithelial neoplasia 1 (CIN 1)
High-grade SIL: Includes moderate dysplasia/CIN 2, severe dysplasia/CIN 3, and carcinoma in situ
(CIS/CIN 3)
D. Results:
Severe inflammation with reactive cellular changes: Repeat within 3 mo, then repeat every 4–6 mo
until there are three consecutive negative smears
Low-grade SIL or atypical squamous cells of undetermined significance (ASCUS): Referral for
colposcopy; an acceptable alternative is repeat Pap smear every 4–6 mo for 2 yr until there are three
consecutive negative smears. If smears are persistently abnormal, refer for colposcopy and biopsy
High-grade SIL or persistent low-grade SIL or ASCUS: Refer to physician who can perform colposcopy
XX. Pregnancy
Hepatitis B: Screen for HBsAg (surfase antigen) at first visit
N. gonorrhoeae: Screen in first trimester; repeat in third trimester for high-risk patients
C. trachomatis: Screen in first trimester; repeat in third trimester for high-risk patients
HIV: Test with informed consent at first visit
Bacterial vaginosis: Screen with Gram stain at first visit if history of preterm delivery
Pap smear: First visit if none in prior year
Herpes simplex: Routine cultures are not indicated; see p 295
XXI. Sexual Assault
A. Evaluation
1. Initial evaluation
P.306
a. Cultures of any sites of penetration or attempted penetration for N. gonorrhoeae and C.
trachomatis (a non-culture test that is positive for C. trachomiatis must be confirmed with
another test using different technol ogy)
b. Wet mount for T. vaginalis. If vaginal discharge: Examine wet mount for bacterial vaginosis and
Candida sp
c. Serum sample for HIV, hepatitis B, and syphilis
Follow-up evaluation at 2 wk: Repeat evaluation
Subsequent evaluation: Serology for syphillis and HIV at 6, 12, and 24 wk
B. Treatment
Ceftriaxone 125 mg IM × 1
Metronidazole 2 g po × 1
Azithromycin 1 g po × 1 or doxycycline 100 mg po bid × 7
Hepatitis B vaccination
Footnots
*Quinolones are contraindicated in persons <17 yr, during pregnancy, and during nursing; they are ineffective vs
incubating syphilis; increasing resistance to fluoroquinolones has been reported. (Lancet 2003;262:495)
*Standard recommendations apply for disease control (abstinence from sexual intercourse until treatment
completed), partner referral, and concurrent treatment for presumed infection with C. trachomatis (doxycycline 100
mg po bid × 7 days).
*Skin test (see desensitization schedule see p 77)
*Patients with these conditions should be immediately treated, including an antibiotic for chlamydia. Sex partners
should be treated without waiting for results of tests. Chlamydia tests are encouraged even if a presumed diagnosis
is made to 1) ensure proper care, especially if symptoms persist; 2) facilitate counseling; 3) provide better grounds
for partner notification; and 4) improve compliance.
*Azithromycin has the advantage of single dose observed therapy. A comparative trial with doxycycline for PID
showed azithromycin was significantly better, presumably because of reduced compliance with tetracycline. Ofloxacin
is equally effective compared with azithromycin and doxycycline but is relatively expensive and offers no dosing
advantage. Erythromycin is less efficacious than azithromycin or doxycycline and causes substantial gastrointestinal
toxicity.
*Available over-the-counter.
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Duration of Antibiotic Treatment
Duration of Antibiotic Treatment
Location Diagnosis Duration (days)
Actinomycosis Cervicofacial 4–6 wk IV, then po × 6–12 mo
Arthritis septic S. aureus, GNB 14–28 days
Streptococci, H. influenzae 14 days
N. gonorrhoeae 7 days
Bacteremia Gram-negative bacteremia 10–14 days
S. aureus, portal of entry 2 wk
known 4 wk
S. aureus, no portal of entry 3–5 days (post-removal)
Line sepsis: Bacteria Candida :10 days (post-removal)
Vascular graft 4 wk (post-removal)
Bone Osteomyelitis, acute 4–6 wk IV
chronic :3 mo or until ESR is normal
Bronchi Exacerbation of chronic 7–10 days
bronchitis
Brucella Brucellosis 6 wk
Bursitis S. aureus 10–14 days
Central nervous Cerebral abscess 4–6 wk IV, then oral 10 days
system Meningitis: Listeria 14–21 days
N. meningitidis 7 days
S. pneumoniae 10–14 days
Ear Otitis media, acute 5–10 days (JAMA 1998; 279:1736)
Gastrointestinal Diarrhea:C. difficile 10 days
C. jejuni 7 days
E. histolytica 5–10 days
Giardia 5–7 days
Salmonella 14 days
Shigella 3–5 days or single dose
Traveler's 3 days
Gastritis, H. pylori 10–14 days
Typhoid fever 5–14 days
Sprue 6 mo
Whipple's disease 1 yr
Heart Endocarditis: Pen-sensitive 14–28 days
strep 4 wk
Pen-resistant strep 4 wk
S. aureus 4 wk
Microbes, other :6 wk
Prosthetic valve 28 days
Pericarditis (pyogenic)
Intra-abdominal Cholecystitis 3–7 days post-cholecystectomy
Primary peritonitis 10–14 days
Peritonitis/intra-abdominal F7 days after surgery
abscess
Joint Septic arthritis, gonococcal 7 days
Pyogenic, non-gonococcal 3 wk
Prosthetic joint 6 wk
Liver Pyogenic liver abscess 4–16 wk
Amebic 10 days
Lung Pneumonia: C. pneumoniae 10–14 days
Legionella 14–21 days
Mycoplasma 10–14 wk
Nocardia 6–12 mo
Pneumococcal Until febrile 3–5 days
Pneumocystis 21 days
Staphylococcal :21 days
Tuberculosis 6–9 mo
Lung abscess Until x-ray clear or until small
stable residual lesion; usually >3
mo
Nocardia Nocardiosis 6–12 mo
Pharynx Pharyngitis—group A strep 10 days
Pharyngitis, gonococcal 1 dose
Diphtheria 7–14 days
Prostate Prostatitis, acute chronic 2 wk 3–4 mo
Sexually transmitted Cervicitis, gonococcal 1 dose
diseases Chancroid 7 days
Chlamydia 7 days (azithromycin—1 dose)
Disseminated gonococcal 7 days
infection 7–10days
H. simplex 21 days
Lymphogranuloma venereum 10–14 days
Pelvic inflammatory disease 10–21 days
Syphilis 1 dose
Urethritis, gonococcal
Sinus Sinusitis, acute 10–14 days
Systemic Brucellosis 6 wk
Listeria: Immunosuppressed 3–6 wk
host 14–21 days
Lyme disease 7–10 days
Meningococcemia Until afebrile, 2 days
Rocky Mountain spotted fever 10–14 days
Salmonellosis :3–4 wk
Bacteremia 4–6 wk
AIDS patients 6 wk
Localized infection 6–9 mo
Carrier state 9 mo
Tuberculosis, pulmonary 7–14 days
extrapulmonary
Tularemia
Urinary tract Cystitis 3 days
Pyelonephritis 14 days
Vaginitis Bacterial vaginosis 7 days or 1 dose
Candida albicans Single dose fluconazole
Trichomoniasis 7 days or 1 dose
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Table of Contents > Specific Infections > Trade Names of Antimicrobial Agents
Trade Names of Antimicrobial Agents
For: For trade names see Antimicrobial Agents pp 1–16
Trade name Generic name
Abelcet amphotericin lipid complex
Abreva docosanol
Achromycin tetracycline
A-cillin amoxicillin
Aerosporin polymyxin B
Aftate tolnaftate
Agenerase amprenavir
A-K-chlor chloramphenicol
Ala-Tet tetracycline
Albamycin novobiocin
Albenza albendazole
Alferon N interferon alfa-n3
Alinia nitazoxide
AmBisome amphotericin liposome
Amcap ampicillin
Amficot ampicillin
Amikin amikacin
Amoxil amoxicillin
Amphotec amphotericin lipid complex
Amplin ampicillin
Ancef cefazolin
Ancobon flucytosine
Anspor cephradine
Antepar piperazine
Antiminth pyrantel pamoate
Aoracillin B penicillin G
Aralen chloroquine
Arsobal melarsoprol
Atabrine quinacrine
Augmentin amoxicillin + clavulanic acid
Avelox moxifloxacin
Azactam aztreonam
Azulfidine sulfasalazine
Bactrim trimethoprim/sulfamethoxa-zole
Bactroban mupirocin
Beepen-VK penicillin V
Biaxin clarithromycin
Bicillin benzathine peni-cillin G
Biltricide praziquantel
Bio-cef cephalexin
Bitin bithionol
Brodspec tetracycline
Cancidas caspofugin
Capastat capreomycin
Caropen-VK penicillin V
Ceclor cefaclor
Cedax ceftibutin
Cefadyl cephapirin
Cefanex cephalexin
Cefizox ceftizoxime
Cefobid cefoperazone
Cefotan cefotetan
Ceftin cefuroxime axetil
Cefzil cefprozil
Ceptaz ceftazidime
Chero-Trisulfa-V trisulfa- pyrimidines
Chloromycetin chloramphenicol
Cinobac cinoxacin
Cipro ciprofloxacin
Claforan cefotaxime
Cleocin clindamycin
Cloxapen cloxacillin
Cofatrim TMP-SMX
Coly-Mycin M colistimethate
Combivir zidovudine/lamivudine
Concidas caspofungin
Copegus ribavirin
Cotrim TMP-SMX
Crixivan indinavir
Cytovene ganciclovir
D-Amp ampicillin
Daraprim pyrimethamine
Declomycin demeclocycline
Diflucan fluconazole
Doryx doxycycline
Doxy-caps doxycycline
Doxy-D doxycycline
Duricef cefadroxil
Dycill dicloxacillin
Dynabac dirithromycin
Dynapen dicloxacillin
E-mycin erythromycin
EES erythromycin ethylsuccinate
Elimite permethrin
Emtet-500 tetracycline
Epivir lamivudine
Erothricin erythromycin
ERYC erythromycin
Ery-Tab erythromycin
Erythrocot erythromycin
Eryzole erythromycin-sulfisoxazole
Factive gemifloxacin
Famvir famciclovir
Fansidar pyrimethamine + sulfadoxine
Fasigyn tinidazole
Femstat butoconazole
Flagyl metronidazole
Floxin ofloxacin
Flumadine rimantadine
Fortaz ceftazidime
Fortovase saquinavir
Forvade cidofovir gel
Foscavir foscarnet
Fulvicin griseofulvin
Fungizone amphotericin B
Furacin nitrofurazone
Furadantin nitrofurantoin
Furamide diloxanide furoate
Furatoin nitrofurantoin
Furoxone furazolidone
G-Mycin gentamicin
Gantanol sulfamethoxazole
Gantrisin sulfisoxazole
Garamycin gentamicin
Geocillin carbenicillin indanyl sodium
Germanin suramin
Grifulvin griseofulvin
Grisactin griseofulvin
Gulfasin sulfisoxazole
Halfan halofantrine
Hepsera adofovir
Herplex idoxuridine
Hetrazan diethyl-carbamazine
Hiprex methenamine hippurate
HIVID zalcitabine
Humatin paromomycin
Ilosone erythromycin estolate
Ilotycin erythromycin
Intron A interferon alfa-2b
Invanz ertapenem
Invirase saquinavir
Jenamicin gentamicin
Kaletra lopinavir/rectonavir
Kantrex kanamycin
Keflex cephalexin
Keflin cephalothin
Keftab cephalexin
Kefurox cefuroxime
Kefzol cefazolin
Ketek telithromycin
Kwell lindane
Lamisil terbinafine
Lampit nifurtimox
Lamprene clofazimine
Lanacillin penicillin V
Lariam mefloquine
Ledercillin VK penicillin V
Levoquin levofloxacin
Lice-Enz pyrethins
Lincocin lincomycin
Lincorex lincomycin
Lorabid loracarbef
Lotrimin clotrimazole
Lyphocin vancomycin
Macrobid nitrofurantoin
Macrodantin nitrofurantoin
Malarone atovaquone and proguanil
Mandelamine methenamine mandelate
Mandol cefamandole
Marcillin ampicillin
Maxaquin lomefloxacin
Maxipime cefixime
Mectizan ivermectin
Mefoxin cefoxitin
Mepron atovaquone
Merrem meropenem
Metric metronidazole
Metro-IV metronidazole
Mezlin mezlocillin
Minocin minocycline
Mintezol thiabendazole
Monocid cefonicid
Monodox doxycycline
Monistat miconazole
Monurol fosfomycin
Myambutol ethambutol
Mycelex clotrimazole
Mycobutin rifabutin
Mycostatin nystatin
MyE erythromycin
Nafcil nafcillin
Nallpen nafcillin
Natacyn natamycin
Nebcin tobramycin
NebuPent pentamidine aerosol
NegGram nalidixic acid
Netromycin netilmicin
Neutrexin trimetrexate
Niclocide niclosamide
Nilstat nystatin
Nix permethrin
Nizoral ketoconazole
Noroxin norfloxacin
Nor-Tet tetracycline
Norvir ritonavir
Nydrazid INH
Nystex nystatin
Omnipen ampicillin
Ornidyl eflornithine
Ovide malathion
Paludrine proguanil
Panmycin tetracycline
PAS aminosalicylic acid
Pathocil dicloxacillin
Pediamycin erythromycin ethylsuccinate
Peflacine pefloxacin
Pen G penicillin G
Pen-V penicillin V
Pen-VK penicillin V
Penamp ampicillin
Penetrex enoxacin
Pentam 300 pentamidine isethionate
Pentids penicillin G
Pentostam sodium stibogluconate
Permapen penicillin G benzathine
Pipracil piperacillin
Plaquenil hydroxychloroquine
Polycillin ampicillin
Polymox amoxicillin
Povan pyrvinium pamoate
Priftin rifapentine
Primaxin imipenem + cilastatin
Principen ampicillin
Proloprim trimethoprim
Pronto pyrethrins
Prostaphlin oxacillin
Protostate metronidazole
Pyopen carbenicillin
Rebetrol ribavirin
Rebetron ribavirin
Relenza zanamivir
Rescriptor delavirdine
Retrovir zidovudine
RID pyrethrins
Rifadin rifampin
Rifamate rifampin-INH
Rifater rifampin, INH, pyrazinamide
Rimactane rifampin
Robicillin VK penicillin V
Robimycin erythromycin
Robitet tetracycline
Rocephin ceftriaxone
Rochagan benznidazole
Roferon-A interferon alfa-2a
Rovamycine spiramycin
Seromycin cycloserine
Silvadene silver sulfadiazine
Soxa sulfisoxazole
Spectrobid bacampicillin
Spectracef cefditoren
Sporanox itraconazole
Staphcillin methicillin
Sterostim somatropin
Storz-G gentamicin
Stoxil idoxuridine
Stromectol ivermectin
Sulfamar TMP-SMX
Sulfamylon mafenide
Sulfamethoprim TMP-SMX
Sulfimycin erythromycin-sulfisoxazole
Sumycin tetracycline
Suprax cefixime
Suspen penicillin V
Sustiva efavirenz
Symadine amantadine
Symmetrel amantadine
Synercid quinupristin-dalfopristin
Tamiflu oseltamivir
TAO troleandomycin
Tazicef ceftazidime
Tazidime ceftazidime
Teebactin aminosalicylic acid
Tegopen cloxacillin
Teline tetracycline
Tequin gatifloxacin
Terramycin oxytetracycline
Tetracap tetracycline
Tetracon tetracycline
Tetralan tetracycline
Tetram tetracycline
Tiberal ornidazole
Ticar ticarcillin
Timentin clavulanic acid + ticarcillin
Tinactin tolnaftate
Tobrex tobramycin
Trecator SC ethionamide
Triazole TMP-SMX
Trimox amoxicillin
Trimpex trimethoprim
Trisulfam TMP-SMX
Trizivir AZT and 3TC and ABC
Trobicin spectinomycin
Trovan trovafloxacin
Truxcillin penicillin G
Ultracef cefadroxil
Unasyn ampicillin/sulbactam
Unipen nafcillin
Urex methenamine hippurate
Uri-tet oxytetracycline
Uroplus TMP-SMX
V-Cillin penicillin V
Valcyte valganciclovir
Valtrex valacyclovir
Vancocin vancomycin
Vancoled vancomycin
Vansil oxamniquine
Vantin cefpodoxime proxetil
Veetids penicillin V
Velosef cephradine
Vermox mebendazole
Vfend voriconazole
Vibramycin doxycycline
Vibratabs doxycycline
Videx didanosine
Vira-A vidarabine
Viracept nevirapine
Viramune nelfinavir
Virazole ribavirin
Viroptic trifluridine
Vistide cidofovir
Vitravene fomivirsen
Wesmycin tetracycline
Win-cillin penicillin V
Wintrocin erythromycin
Wyamycin S erythromycin
Wycillin penicillin G
Wymox amoxicillin
Xigris drotrecogin
Yodoxin iodoquinol
Zagam sparfloxacin
Zartan cephalexin
Zefazone cefmetazole
Zentel albendazole
Zerit stavudine (d4T)
Ziagen abacavir
Zinacef cefuroxime
Zolicef cefazolin
Zosyn piperacillin/tazobactam
Zovirax acyclovir
Zithromax azithromycin
Zyvox linezolid
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > A
A
Abdominal hysterectomy, antibiotic prophylaxis for 127–128
Abelcet See Amphotericin B lipid complex
Abortion, antibiotic prophylaxis for 128
Abreva See Docosanol
Abscesses 18 30 219
brain 30 240
intra-abdominal 267
liver 25 30 268 307
lung 251
periapical 247
peritonsillar 246
skin 30
tonsillar 246
Acanthamoeba 174 230
Achromycin See Tetracycline(s)
Acinetobacter baumannii 17
Acne 31
Acne rosacea 219
Acne vulgaris 219
Acquired immunodeficiency syndrome See HIV/AIDS
Actinobacillus actinomycetemcomitans 17 260
Actinomyces israelii 17 222 246
Actinomyces naeslundii 17
Actinomyces odontolyticus 17
Actinomycosis 17 222 246 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
Acute cervical adenitis 246
Acute diffuse otitis externa 243
Acute mastoiditis 243
Acute monarticular arthritis 226–228
Acute otitis media 243
Acute sinusitis 244
Acute urethral syndrome 293
Acyclovir
adverse reactions 58
antiviral activity of 203
cost of 1
for cytomegalovirus 194
during dialysis 53
dosing regimens for 1
drug interactions 79
for Epstein-Barr virus 195
genital 191 295
for herpes simplex 191 192
for ocular infections 230
in renal failure 41
for stomatitis 247
for varicella-zoster 137 192
for whitlow 220
Adapalene 219
Adefovir
adverse reactions 58
antiviral activity of 203
cost of 1
during dialysis 53
dosing regimens for 1
drug interactions 79
for hepatitis B 199
Adenitis, cervical 246–247
Adenoidectomy 129
Aeromonas hydrophila 17 271 278
Aerosporin See Polymyxin B
Afipia felix See Bartonella henselae
Aftate See Tolnaftate
Agammaglobulinemia 136
Age
antimicrobial dosing regimens in renal failure and 39
vaccines and 97
AIDS See HIV/AIDS
Albamycin See Novobiocin
Albendazole
adverse reactions 58
cost of 1
dosing regimens for 1
for infectious diarrhea 276
for parasitic infections 174 175 176 177 179 181–182 182
in renal failure 41
Albenza See Albendazole
Alcaligenes xylosoxidans 17
Alcoholics, immunization of 101 123
Aldara See Imiquimod
Amantadine
adverse reactions 58 197
antiviral activity of 203
for bronchitis 251
for common cold 248
cost of 1
dosing regimens for 1
drug interactions 79
for influenza 196
for pneumonia 255
in renal failure 41
AmBisome See Amphotericin B liposomal
Amdinocillin
during dialysis 53
in renal failure 41
Amebiasis 174
Amebic meningoencephalitis 174
Amikacin
for abscesses 30
P.314
adverse reactions 58
for brain abscess 30
cost of 1
during dialysis 53
for disseminated infection 28
dosing regimens for 1
for liver abscess 30
for Mycobacterium abscessus 171
for Mycobacterium avium 170
for Mycobacterium fortuitum 170
for Mycobacterium smegmatis 171
for Mycobacterium ulcerans 171
for nocardiosis 30
for ocular infections 230
for pneumonia 17 255
for pulmonary infection 28 29 30
in renal failure 39 40 41
for sepsis 17 204–205 267
for skin abscess 30
for soft tissue infections 28
for tuberculosis 29 164
for wound infection 28
Amikin See Amikacin
Aminoglycosides See also specific agent
adverse reactions 58
for anaerobic infections 213
for arthritis, septic 27
for bacteremia 21 25 28
for burns 221
drug interactions 79
for endocarditis 21 26 27 259–261
for extra-intestinal infection 31
intra-abdominal 24 25 27 31 204 267
for intra-abdominal sepsis 24 25 27 31 204 267
for liver abscess 268
for meningitis 17 237
for mesenteric adenitis 37
for ocular infections 28
once daily 40
for osteomyelitis 225
for pneumonia 22 24 25 27 28 254
for pyelonephritis 286
in renal failure 39–40
for sepsis 24 26 204 205
for septic arthritis 27
for septicemia 17 18 22 25 27 31 37
for sinusitis 245
in surgery 126
for tuberculosis 29
for urinary tract infections 22 24 25 27 28 31
for wound infection 22 23 24 25 28 31
Aminosalicylic acid
adverse reactions 59
dosing regimens for 1
drug interactions 79
for tuberculosis 29
Amoxicillin
for actinomycosis 17 222
for bite wounds 23
for bronchitis 252
for chlamydia 294
cost of 1
for dental infection 31
during dialysis 53
for diarrhea, infectious 274
dosing regimens for 1
for endocarditis prophylaxis 139
for gynecologic infection 31
for Lyme disease 19 217
for oral infections 23 31
for otitis 243
for peptic ulcer disease 26 270
for pharyngitis 246
for pneumonia 36 253
for pulmonary infection 31
for pyelonephritis 286
in renal failure 41
for respiratory tract infections 249
for sepsis 31
for sinusitis 244
for urinary tract infections 24 34 286
Amoxicillin-clavulanate
for abscesses 30
for adenitis 246
adverse reactions 59
for bite wounds 23 30 221
for brain abscess 30
for cat scratch disease 19 221
cost of 1
for dental infection 247
during dialysis 53
for diverticulitis 269
dosing regimens for 1
for furunculosis 220
for impetigo 220
for liver abscess 30
for melioidosis 20
for nocardiosis 30
for oral infections 23
for otitis 27 243
for periodontal disease 21
for pharyngitis 246
for pneumonia 251 254
for pneumonitis 27
for pulmonary infection 30
P.315
for pyelonephritis 286
in renal failure 41
for respiratory tract infections 249
for septicemia 20
for sinusitis 27 244
for skin abscess 30
for stomatitis 247
for tonsillitis 21
for ulcers 222
for urinary tract infections 286
Amoxil See Amoxicillin
Amphotec See Amphotericin B lipid complex
Amphotericin B
adverse reactions 59
cost of 1
during dialysis 53
dosing regimens for 1
drug interactions 79–80
for endocarditis 261
for fungal infections 147–158 157–158 160
for intra-abdominal sepsis 267
for nodules 222
for ocular infections 230
for parasitic infections 174 177
in renal failure 41
for ulcers 222
Amphotericin B lipid complex
adverse reactions 59
cost of 1
dosing regimens for 1
in renal failure 41
Amphotericin B liposomal
cost of 2
dosing regimens for 2
guidelines for 41
Ampicillin
for actinomycosis 17
for bacteremia 28 30
for biliary tract infections 268
for bite wounds 23
cost of 2
for dental infection 31
during dialysis 53
for diarrhea, infectious 273 274
dosing regimens for 2
for endocarditis 24 259 261
prophylaxis 139–140
for gas gangrene 22
for gynecologic infection 31
for leptospirosis 27
for liver abscess 268
for meningitis 28 30 236 237
for mesenteric adenitis 37
for oral infections 23 31
for pelvic inflammatory disease 302
for pericarditis 30
for pneumonia 30 253 254
for pulmonary infection 31
in renal failure 41
for sepsis 22 24 25 31 267–268
for septicemia 25 28 31 37
for typhoid fever 33
for urinary tract infections 24 31 34
for wound infection 23 24 25 28 31
Ampicillin sodium 2
Ampicillin-sulbactam
adverse reactions 60
for biliary tract infections 268
for bite wounds 23
cost of 2
during dialysis 53
dosing regimens for 2
for endocarditis 261
for epiglottis 246
for oral infections 23
for pneumonia 17
for pyelonephritis 286
in renal failure 42
for sepsis 17 204
Amputation of leg 130
Anaerobic infections 213–214
Ancef See Cefazolin
Ancobon See Flucytosine
Ancylostoma caninum 174
Ancylostoma duodenale 177
Angiomatosis 19
Angiostrongyliasis 174
Angiostrongylus cantonensis 174
Angiostrongylus costaricensis 174
Animal bite wounds 30 221 See also Bite wounds
Anisakiasis 174
Anspor See Cephradine
Antepar See Piperazine
Anthrax, treatment of 18
Antibiotic-associated colitis 22
Antibiotic-associated diarrhea 22
Antibiotics See also specific agent
duration of treatment with 306–308 (includes Sexually transmitted
diseases and Duration of Antibiotic Treatment)
for pelvic inflammatory disease 301–302
Antifungal agents See Fungal infections; specific agent
Antimicrobial agents See also specific agent
adverse reactions 58–78
ambulatory patient prophylaxis 133–137
cost of 1–16
P.316
during dialysis 53–56
dosing regimens for 1–16
in hepatic disease 57
for infectious diarrhea 271–276
in neutropenic patients 207–211
in renal failure 39–57
for respiratory tract infections 249
in surgery 124–132
trade names of 309–311
for traveler's diarrhea 141–142
Antiminth See Pyrantel
Antimycobacterial agents See Mycobacterial infections; specific agent
Antiparasitic agents See Parasitic infections; specific agent
Antiviral agents See Viral infections; specific agent
Aphthous stomatitis 247
Appendectomy 127
Appendicitis 269
Arachnia propionica 17
Aralen HCl See Chloroquine
Aralen hydrochloride see Chloroquine
Aralen PO4 See Chloroquine PO4
Aralen-primaquine See Primaquine-chloroquine
Areanobacterium haemolyticum 18
Arsenic 282
Arthritis
acute monarticular 226–228
chronic monarticular 228
polyarticular 228
septic
antibiotic treatment for 307
description of 226–228
treatment of 27 30 218
Arthritis-dermatitis 30
Ascariasis 174
Aspergillus sp. 147–148
in endocarditis 261
in endophthalmitis 230
in meningitis 239
in otomycosis 243
Asplenia
antimicrobial prophylaxis for 134
immunization in 101 123
Atabrine See Quinacrine hydrochloride
Athlete's foot 161
Atovaquone
adverse reactions 60
cost of 2
during dialysis 53
dosing regimens for 2
drug interactions 80
for malaria prevention 143
for parasitic infections 178–179 180
in renal failure 42
Atovaquone-proguanil
adverse reactions 60
cost of 2
dosing regimens for 2
in renal failure 42
A/T/S See Erythromycin
Augmentin See Amoxicillin-clavulanate
Avelox See Moxifloxacin
Azactam See Aztreonam
Azelaic acid 219
Azithromycin
adverse reactions 60
for bronchitis 26
for chancroid 26 296
for chlamydia 294
cost of 2
during dialysis 53
for diarrhea, infectious 275
dosing regimens for 2
drug interactions 80
for endocarditis prophylaxis 139
for endocervicitis 21
for epididymitis 21
for gonococcal infections 286
for Legionnaires' disease 27
for lymphogranuloma venereum 21
for Mycobacterium avium 170
for otitis 26 27 243
for pelvic inflammatory disease 21
for pharyngitis 245
for pneumonia 251 253 255
for pulmonary infection 28
in renal failure 42
for respiratory tract infections 249
in sexual assault treatment 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
for sinusitis 26 244
for trachoma 21
for urethral syndrome 21
for urethritis 21
Azo-Gantanol See Sulfamethoxazole phenazopyridine
Azo-Gantrisin See Sulfisoxazole-phenazopyridine
Aztreonam
adverse reactions 60
for anaerobic infections 213
for bacteremia 28
cost of 2
during dialysis 53
dosing regimens for 2
P.317
for extra-intestinal infection 31
in hepatic disease 57
intra-abdominal 25 27 31 32 267–268
for intra-abdominal sepsis 25 27 31 32 267–268
for liver abscess 268
for meningitis 236 237
for otitis 243
for pneumonia 17 22 27 28 32 33 254
in renal failure 42
for sepsis 17
for septicemia 25 27 31 32 33
for urinary tract infections 22 25 27 28 31 32 33
for wound infection 25 28 31
Azulfidine See Sulfasalazine
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > B
B
Babesia microti 18
Babesiosis 18 178
Bacampicillin 42
Baciguent See Bacitracin
Baci-IM See Bacitracin
Bacillary angiomatosis 19
Bacillus sp.
in endophthalmitis 230
treatment of 18
Bacillus anthracis 18 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
Bacillus cereus
in food poisoning 273 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
treatment of 18
Bacitracin
adverse reactions 60
cost of 2
for diarrhea, infectious 271
dosing regimens for 2
for ocular infections 229 231
Bacteremia
in neutropenic host 21
treatment of 17 18 21 24 25 28 30 35 306 (includes Sexually
transmitted diseases and Duration of Antibiotic Treatment)
Bacterial infections See also Antibiotics
diarrhea 271–278 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
Bacterial vaginosis 303–304 308
Bacteroides bivius 18
Bacteroides distasonis 18
Bacteroides fragilis 18 213
Bacteroides melanogenicus 19
Bacteroides ovatus 18
Bacteroides thetaiotaomicron 18
Bacteroides vulgatus 18
Bactocill See Oxacillin
Bactrim See Trimethoprim-sulfamethoxazole
Bactroban See Mupirocin
Balantidiasis 175
Balantidium coli 175
Bartonella bacilliformis 19
Bartonella henselae 19 247
Bartonella quintana 19
Bartonellosis 19
Bay Hep B 8
Bay Rab 8
Baylisascariasis 175
Baylisascaris procyonis 175
BCG vaccine 93
Beepen VK See Penicillin V
Benzathine penicillin
cost of 2
dosing regimens for 12
for syphilis 292
Benzoyl peroxide, for acne 219
Beta-lactam-beta-lactamase inhibitors
for abscesses 18 251
for anaerobic infections 213
for arthritis, septic 30
for bacteremia 18 21 28 35
for bronchitis 26
for cat bites 21
for cellulitis 35
for cystitis 285
for dog bites 21
for female genital tract infections 18 19
for infected prosthetic devices 34
for intra-abdominal sepsis 18 25 27 31 267
for lung abscess 251
for osteomyelitis 225
for otitis 26
for pneumonia 27 28 34 251 253 254
for sepsis, intra-abdominal 18 25 27 31 267
for septic arthritis 30
for septicemia 25 27 30 31 34
for sinusitis 26
for ulcers 222
for urinary tract infections 27 28 31
for wound infection 25 28 31
Betapen VK See Penicillin V
Biaxin See Clarithromycin
Biaxin XL See Clarithromycin
Bicillin See Benzathine penicillin
Biliary tract infections 268
Biliary tract surgery, antibiotic prophylaxis for 126
Biltricide See Praziquantel
Bipolaris 231
P.318
Bismuth subsalicylate
for diarrhea
infectious 272 278
traveler's 142
for peptic ulcer disease 26 270
Bite wounds 21 23 30 221
Bithionol
adverse reactions 60
for parasitic infections 176
Bladder catheter 286–287
Blastocystis hominis 175 276
Blastomyces sp. 148
Blastomyces dermatitidis
in chronic meningitis 239
in chronic monarticular arthritis 228
Blepharitis 231
Bone infections
antibiotic treatment for 306 (includes Sexually transmitted diseases and
Duration of Antibiotic Treatment)
description of 224–228
Bone marrow transplantation
antimicrobial prophylaxis for 135–136
herpes simplex and 192
immunization in 101
infections after 211
Bordetella pertussis 19
Borrelia burgdorferi 19 See also Lyme disease
in bone infections 226
in chronic meningitis 239
in polyarticular arthritis 228
Borrelia recurrentis 19
Botulism
immune globulins in 121
treatment of 22
Brachial artery surgery 125
Brain abscess 30 240
Branhamella catarrhalis 27
Brodspec See Tetracycline(s)
Bronchitis 241
acute 251–252
chronic 252
treatment of 26 251–252
Brucella 20 279 (includes Infectious Diarrhea and Foodborne Outbreaks)
antibiotic treatment for 306 (includes Sexually transmitted diseases and
Duration of Antibiotic Treatment)
in chronic meningitis 239
in chronic monarticular arthritis 228
in endocarditis 261
in joint infections 225
Brucellosis 20 308
Brugia malayi 176
Burkholderia cepacia 20
Burkholderia pseudomallei 20
Burn wound sepsis 17
Burns 221
Butenafine, for fungal infections 161
Butoconazole
cost of 2
dosing regimens for 2
for vulvovaginal candidiasis 304
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > C
C
Calymmatobacterium granulomatis 20
Campylobacter fetus 20
Campylobacter jejuni 20 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
in infectious diarrhea 271 278
Canaliculitis 231
Cancidas See Caspofungin
Candida sp.
in aseptic meningitis 239
in chronic monarticular arthritis 228
in ocular infections 230
treatment of 148–151 220 308
Candidiasis, vulvovaginal 304
Capastat See Capreomycin
Capillariasis 175
Capnocytophaga canimorus 21
Capnocytophaga ochracea 21
Capreomycin
adverse reactions 60
cost of 2
dosing regimens for 2
drug interactions 80
in renal failure 42
for tuberculosis 29 164
Carbapenem, for pneumonia 254
Carbenicillin
cost of 2
during dialysis 53
in renal failure 42
Carbenicillin indanyl sodium 2
Carbuncle 220
Cardiobacterium sp. 21
Cardiobacterium hominis 260
Cardiothoracic surgery, antibiotic prophylaxis for 124–125
Caropen VK See Penicillin V
Carotid artery surgery, antibiotic prophylaxis for 125
Caspofungin
adverse reactions 60
cost of 2
during dialysis 53
dosing regimens for 2
drug interactions 80
for fungal infections 147–148 158 160
guidelines for 42
in hepatic disease 57
Cat bites 21 221 See also Bite wounds
Cat scratch disease 19 221 247
Catheter, bladder 286–287
Ceclor See Cefaclor
P.319
Ceclor CD See Cefaclor
Ceclor ER see Cefaclor
Cedax See Ceftibutin
Cefaclor
cost of 3
during dialysis 53
dosing regimens for 3
for pharyngitis 245
in renal failure 42
for respiratory tract infections 249
Cefadroxil
cost of 3
during dialysis 53
dosing regimens for 3
for endocarditis prophylaxis 139
for pharyngitis 245
in renal failure 42
Cefadyl See Cephapirin
Cefamandole
cost of 3
during dialysis 53
dosing regimens for 3
in renal failure 42
Cefanex See Cephalexin
Cefazolin
for arthritis, septic 226
for biliary tract infections 268
cost of 3
during dialysis 53
dosing regimens for 3
for endocarditis 259
for pneumonia 254
for prosthetic joint 227
in renal failure 42
for septic arthritis 226
in surgery 124–132
Cefdinir
cost of 3
during dialysis 53
dosing regimens for 3
for otitis 243
for pharyngitis 245
for pneumonia 253
in renal failure 42
for respiratory tract infections 249
for sinusitis 244
Cefditoren
adverse reactions 249
cost of 3 249
dosing regimens for 3 53 244–245 249
drug interactions 80
guidelines for 38 42
for pneumonia 253
Cefepime
for bacteremia 28
cost of 3
during dialysis 53
dosing regimens for 3
for endocarditis 261
for otitis 243
for pneumonia 17 22 24 27 28 32 34 251 253
in renal failure 43
for sepsis 17 24 27 32 204 205
for septicemia 22 27 31 32 34
for ulcers 222
for urinary tract infections 22 28 31 32
for wound infection 22 24 28 34
Cefixime
for arthritis, septic 226
cost of 3
during dialysis 53
dosing regimens for 3
for genital tract infections 30
for gonococcal infections 288
for pharyngitis 245
in renal failure 43
for respiratory tract infections 249
for septic arthritis 226
Cefizox See Ceftizoxime
Cefmetazole
for abscesses 25
for anaerobic infections 213
for dental infection 25
for female genital tract infections 19
for intra-abdominal sepsis 267
for liver abscess 25
for oral infections 25
for pulmonary infection 25
in renal failure 43
for sepsis, intra-abdominal 267
in surgery 127
Cefobid See Cefoperazone
Cefonicid
during dialysis 53
in renal failure 43
Cefoperazone
for anaerobic infections 213
for biliary tract infections 268
cost of 3
during dialysis 53
for diarrhea, infectious 274
dosing regimens for 3
in hepatic disease 57
for otitis 243
for pneumonia 254
in renal failure 43
for urinary tract infections 32
Ceforanide 43
P.320
Cefotan See Cefotetan
Cefotaxime
for abscesses 30 240
for acute mastoiditis 243
for anaerobic infections 213
for arthritis 26
for bacteremia 30
for brain abscess 30
for cellulitis 26
cost of 3
during dialysis 53
dosing regimens for 3
for endocarditis 261
for epiglottis 26 246
for genital tract infections 30
for gonococcal infections 288
for liver abscess 30
for Lyme disease 19
for meningitis 26 35 236 237
for nocardiosis 30
for ocular infections 35
for otitis 243
for pericarditis 30
for pneumonia 26 30 35 251 253
for pulmonary infection 30
in renal failure 43
for sepsis 204 267–268
for septicemia 37
for skin abscess 30
for wound infection 37
Cefotetan
for abscesses 25
for anaerobic infections 213
cost of 3
for dental infection 25
during dialysis 54
dosing regimens for 3
for female genital tract infections 18
for liver abscess 25
for oral infections 25
for pelvic inflammatory disease 301
for pulmonary infection 25
in renal failure 43
for sepsis 204 267
in surgery 127
Cefoxitin
for abscesses 18 25
for anaerobic infections 213
for bacteremia 18
cost of 3
for dental infection 25
during dialysis 54
dosing regimens for 3
for genital tract infections 18 19 30
for intra-abdominal sepsis 18 204 267
for liver abscess 25
for mycobacterial infections 170
for Mycobacterium abscessus 171
for Mycobacterium chelonae 171
for Mycobacterium fortuitum 170
for oral infections 25
for pelvic inflammatory disease 301
for periodontal disease 21
for pulmonary infection 25 28
in renal failure 43
for sepsis, intra-abdominal 18 204 267
for skin infections 28
for soft tissue infections 28
in surgery 127
for tonsillitis 21
for wound infection 28
Cefpodoxime
cost of 3
during dialysis 54
dosing regimens for 3
for genital tract infections 30
for pharyngitis 245
for pneumonia 253
in renal failure 43
for respiratory tract infections 249
for sinusitis 244
Cefprozil
cost of 3
during dialysis 54
dosing regimens for 3
for pneumonia 253
in renal failure 43
for respiratory tract infections 249
for sinusitis 244
Ceftazidime
for anaerobic infections 213
for brain abscess 240
cost of 3
during dialysis 54
dosing regimens for 3
for melioidosis 20
for meningitis 17 236 237
for ocular infections 230
for osteomyelitis 225
for otitis 243
for pneumonia 17 20 32 254
in renal failure 43
for sepsis 17 32 204
for septicemia 17 20 32
for sinusitis 245
for urinary tract infections 32
Ceftibutin
adverse reactions 61
P.321
cost of 3
during dialysis 54
dosing regimens for 3
in renal failure 43
Ceftin see Cefuroxime axetil
Ceftizoxime
for anaerobic infections 213
for arthritis, septic 226
cost of 4
during dialysis 54
dosing regimens for 4
for epiglottis 246
for genital tract infections 30
for meningitis 236
in renal failure 43
for sepsis 204
for septic arthritis 226
Ceftriaxone
for abscesses 30
for anaerobic infections 213
for arthritis 26
for bacteremia 30
for brain abscess 30
for cellulitis 26
for chancroid 26 296
cost of 4
during dialysis 54
for diarrhea, infectious 273 274
dosing regimens for 4
for endocarditis 259
for epididymitis 300
for epiglottis 26 246
for genital tract infections 30
for gonococcal infections 288 289
in hepatic disease 57
for liver abscess 30
for Lyme disease 217
for meningitis 26 30 35 236 237
for meningococcal disease prevention 134
for nocardiosis 30
for ocular infections 35 229
for otitis 243
for pericarditis 30
for pharyngitis 245
for pneumonia 26 30 35 251 253
for proctitis 300
for pulmonary infection 30
in renal failure 44
for sepsis 204 205 267
in sexual assault treatment 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
for skin abscess 30
for syphilis 36
for typhoid fever 33
Cefuroxime
for abscesses 30
for arthritis 26
for bacteremia 30
for brain abscess 30
for cat bites 221
for cellulitis 26
cost of 4
during dialysis 54
for dog bites 221
dosing regimens for 4
for epiglottis 26 246
for liver abscess 30
for meningitis 26 30
for nocardiosis 30
for ocular infections 232
for pericarditis 30
for pharyngitis 245
for pneumonia 26 30 35 253 254
for pulmonary infection 30
in renal failure 44
for respiratory tract infections 249
for sinusitis 244
for skin abscess 30
in surgery 124 125
Cefuroxime axetil
cost of 4
dosing regimens for 4
for Lyme disease 19 217
for otitis 243
in renal failure 44
Cefzil See Cefprozil
Cell-mediated immunity 206 (includes Sepsis and Sepsis Syndrome and
Compromised Host)
Cellulitis
gas-forming 223
synergistic necrotizing 223
treatment of 17 26 35 219
Central nervous system infections
antibiotic treatment for 306 (includes Sexually transmitted diseases and
Duration of Antibiotic Treatment)
description of 233–240
Cephalexin
cost of 4
during dialysis 54
dosing regimens for 4
for endocarditis prophylaxis 139
for impetigo 220
for pharyngitis 245
in renal failure 44
for respiratory tract infections 249
for ulcers 222
Cephalosporins See also specific agent
for abscesses 268
for actinomycosis 17
for adenitis 246
P.322
adverse reactions 61
for anaerobic infections 213
for arthritis, septic 27 30 226
for bacteremia 17 21 28 30
for bite wounds 21 23 30
for bronchitis 26
for brucellosis 20
for burns 221
for cat bites 21
for cellulitis 17 219
for dental infection 30
for diarrhea, infectious 274
for dog bites 21
drug interactions 80–81
for endocarditis 21 25 26 27 35 259 261
for enterocolitis 37
for erysipelas 219
for extra-intestinal infection 31
for furunculosis 220
and gonococcal infections 288
for gynecologic infection 30
for infected prosthetic devices 34
for meningitis 30 236
for mesenteric adenitis 37
for myositis 17
for ocular infections 28 232
for oral infections 23 30
for osteomyelitis 17 30 224 225
for otitis 26 28
for parotitis 246
for pelvic inflammatory disease 302
for pericarditis 30
for periodontal disease 21
for pharyngitis 245
for pneumonia 22 24 25 27 30 33–34 35 251 253 254
for pneumonitis 27
for pulmonary infection 30
for sepsis 24 25 26 27 30 31 204
for septic arthritis 27 30 226
for septicemia 22 25 27 30 31 33–34 34
for sinusitis 26 28
in surgery 125
for tonsillitis 21
for urinary tract infections 22 24 25 27 28 31 33–34 34
for whitlow 220
for wound infection 22 23 24 25 28 31 34
Cephalothin
during dialysis 54
in renal failure 44
Cephapirin, in renal failure 44
Cephradine
cost of 4
dosing regimens for 4
in renal failure 44
Ceptaz See Ceftazidime
Cerebrospinal fluid
infections of 233–234
shunt, antibiotic prophylaxis for 130
Cervical adenitis
acute 246
chronic 247
Cervicitis 307
Cesarean section, antibiotic prophylaxis for 128
Chagas' disease See Trypanosomiasis
Chancroid
diagnosis of 296
and genital ulcers 298
treatment of 26 296 307
Chemotaxis, defective 206 (includes Sepsis and Sepsis Syndrome and
Compromised Host)
Chinese liver fluke 176
Chlamydia pneumoniae 21 245 255
Chlamydia psittaci 21 255
Chlamydia trachomatis 21 293–294
detection of 293
and gonococcal infections 288
in lymphogranuloma venereum 294
in mucopurulent cervicitis 301
in pelvic inflammatory disease 301
pregnancy and 288 294
presumptive diagnosis of 293
prevention of 294
screening criteria 293
sex partners and 295
spectrum of 293
treatment of 229 294 307
and urethritis 299
Chloramphenicol
adverse reactions 61
for anaerobic infections 213
for arthritis 26
for bacteremia 30
for bartonellosis 19
for brucellosis 20
for cellulitis 26
cost of 4
for dental infection 31
during dialysis 54
for diarrhea, infectious 273 274
dosing regimens for 4
drug interactions 81
for epiglottis 26
for female genital tract infections 18
P.323
for gas gangrene 22
for gynecologic infection 31
in hepatic disease 57
for infected prosthetic devices 35
for melioidosis 20
for meningitis 20 26 30 35 236 237
for murine typhus 32
for oral infections 31
for otitis 243
for pericarditis 30
for plague 37
for pneumonia 26 30 255
for psittacosis 21
for pulmonary infections 31
for Q fever 23 32
in renal failure 44
for Rocky Mountain spotted fever 32
for scrub typhus 32
for sepsis 22 24 31
for septicemia 20 31 35 37
for tickbite fever 32
for trench fever 32
for tularemia 26
for typhoid fever 33
for typhus 32
for urinary tract infections 24
for vascular infections 20
for wound infection 24 37
Chloramphenicol sodium succinate 4
Chloromycetin See Chloramphenicol
Chloromycetin palmitate See Chloramphenicol
Chloroquine 4
adverse reactions 61
cost of 4
for liver abscess 268
for malaria prevention 143
in renal failure 44
Chloroquine PO4
dosing regimens for 4
for parasitic infections 179
Cholecystitis 268 307
Cholera
description of 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
treatment of 37
vaccine
route of administration of 93
for travelers 102
Cholestyramine, for infectious diarrhea 272
Chromomycosis 151
Chronic bronchitis 252
Chronic cervical adenitis 247
Chronic mastoiditis 244
Chronic monarticular arthritis 228
Chronic sinusitis 244
Chronic suppurative otitis media 244
Ciclopirox 161 220
Cidofovir
adverse reactions 61
antiviral activity of 203
cost of 4
for cytomegalovirus 194
dosing regimens for 4
drug interactions 81
for pneumonia 255
in renal failure 44
Cinobac See Cinoxacin
Cinoxacin
dosing regimens for 4
in renal failure 44
Cipro See Ciprofloxacin
Cipro IV See Ciprofloxacin
Ciprofloxacin
adverse reactions 62 69
for anaerobic infections 213
for arthritis, septic 226
for brucellosis 20
for cat scratch disease 19 221 247
for chancroid 296
cost of 4
during dialysis 54
for diarrhea, infectious 271 272 273 274 275 278
for disseminated infection 28
dosing regimens for 4
for endocarditis 259
for gonococcal infections 288 289
for granuloma inguinale 296
for meningococcal disease prevention 134
for Mycobacterium avium 170
for Mycobacterium fortuitum 170
for Mycobacterium genavense 171
for Mycobacterium haemophilum 171
for Mycobacterium smegmatis 171
for otitis 243
for pelvic inflammatory disease 302
for pharyngitis 245
for pneumonia 32 254
for pulmonary abscess 32
for pulmonary infection 28
for pyelonephritis 286
in renal failure 44
for respiratory tract infections 249
for sepsis 32
for septic arthritis 226
for septicemia 32 37
for soft tissue infections 28
in surgery 131
for traveler's diarrhea 142 278
P.324
for tuberculosis 29
for tularemia 25
for ulcers 222
for urinary tract infection 32 286
for wound infection 28
Cirrhosis 136
Citrobacter diversus 22
Citrobacter freundii 22
Claforan See Cefotaxime
Clarithromycin
adverse reactions 62
for bronchitis 26
cost of 4
for disseminated infection 28
dosing regimens for 4
drug interactions 81
for endocarditis prophylaxis 139
for Legionnaires' disease 27
for Mycobacterium abscessus 171
for Mycobacterium avium 170
for Mycobacterium chelonae 171
for Mycobacterium fortuitum 170
for Mycobacterium genavense 171
for Mycobacterium gordonae 171
for Mycobacterium kansasii 170
for Mycobacterium malmoense 171
for Mycobacterium marinum 171
for Mycobacterium xenopi 171
for otitis 26 27 243
for peptic ulcer disease 27 270
for pharyngitis 245
for pneumonia 253
for pneumonitis 27
for pulmonary infection 28
in renal failure 45
for respiratory tract infections 249
for sinusitis 26 27 244
for skin infections 28
for soft tissue infections 28
for wound infection 28
Cleocin see Clindamycin
Cleocin HCl See Clindamycin
Cleocin pediatric See Clindamycin
Cleocin PO4 See Clindamycin PO4
Cleocin PO see Clindamycin PO
4 4
Cleocin T See Clindamycin topical gel
Cleocin VC See Clindamycin vaginal cream
Clindamycin
for abscesses 18 25 246 251
for acne 31 219
for actinomycosis 17 222 246
for adenitis 246
adverse reactions 62
for anaerobic infections 213
for arthritis, septic 226
for babesiosis 18
for bacteremia 18 21 28 35
for bacterial vaginosis 303
for cat bites 21 221
for cellulitis 35 219
cost of 5
for dental infection 19 25 28 31 247
during dialysis 54
for diphtheria 22
for dog bites 21 221
dosing regimens for 5
drug interactions 81
for endocarditis 17
prophylaxis 139
for erysipelas 219
for female genital tract infections 18
for furunculosis 220
for gas gangrene 22
for gynecologic infection 31
for Haverhill fever 35
in hepatic disease 57
intra-abdominal 31 267
for intra-abdominal sepsis 18 31 267
for leptospirosis 27
for liver abscess 25
for oral infections 19 25 28 31
for osteomyelitis 224 225
for parasitic infections 178–179
for parotitis 246
for pelvic inflammatory disease 301
for periodontal disease 21
for peritonsillar abscess 246
for pharyngitis 246
for pneumonia 34 35 251 253 254
for pulmonary infection 19 25 31
for Q fever 23
for rat-bite fever 35
in renal failure 45
for respiratory tract infections 249
for sepsis 22
for septic arthritis 226
for septicemia 18 34
for sinusitis 244
for stomatitis 247
in surgery 125 127 128 129
for systemic infection 31
for tonsillar abscess 246
for tonsillitis 21
for ulcers 222
for vaginitis 25
for whitlow 220
for wound infection 28 34
Clindamycin palmitate 5
Clindamycin PO 5
4
P.325
Clindamycin topical gel
cost of 5
dosing regimens for 5
Clindamycin vaginal cream
cost of 5
dosing regimens for 5
Clofazimine
cost of 5
during dialysis 54
dosing regimens for 5
for mycobacterial infections 171
for Mycobacterium abscessus 171
for Mycobacterium gordonae 171
for Mycobacterium smegmatis 171
for skin infections 28
for soft tissue infections 28
Clonorchis sinensis 176
Clostridium sp. 22 213
Clostridium difficile
description of 22 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
in infectious diarrhea 271–272
Clostridium perfringens 273 278 279 (includes Infectious Diarrhea and
Foodborne Outbreaks)
Clotrimazole
cost of 5
dosing regimens for 5
for fungal infections 148–149 161 220
for thrush 247
for vulvovaginal candidiasis 304
Cloxacillin
during dialysis 54
for impetigo 220
in renal failure 45
Cloxapen See Cloxacillin
CMV See Cytomegalovirus
Coactin See Amdinocillin
Coccidioidomycosis 152–153
Cockcroft-Gault equation 39
Cofatrim See Trimethoprim-sulfamethoxazole
Cold, common 248
Colistimethate
adverse reactions 62
cost of 5
dosing regimens for 5
Colistin
for pneumonia 17
in renal failure 45
for sepsis 17
Colitis
antibiotic-associated 22
treatment of 33
Colorectal surgery, antibiotic prophylaxis for 127
Coly-Mycin M See Colistimethate
Coly-Mycin S See Colistimethate
Common cold 248
Compound fracture, antibiotic prophylaxis for 130
Condylox See Podofilox
Conjunctivitis
in gonococcal infections 288
inclusion, treatment of 21
Coronary bypass, antibiotic prophylaxis for 124
Corticosteroids, for ocular infections 231
Corynebacterium diphtheriae
in pharyngitis 245 246
treatment for 22
Corynebacterium jeikeium 23
Corynebacterium minutissimum 23
Corynebacterium ulcerans 23
Cotrim See Trimethoprim-sulfamethoxazole
Co-trimoxazole see Trimethoprim-sulfamethoxazole
Coxiella burnetii 23 255 261
Craniotomy, antibiotic prophylaxis for 130
Crotamiton
cost of 5
dosing regimens for 5
Cryptococcus sp. 153–154 239
Cryptosporidiosis 175 279 (includes Infectious Diarrhea and Foodborne
Outbreaks) 280
Crysticillin See Penicillin; Procaine
Cubicin
adverse reactions 62
cost of 5
dosing regimens for 5
Curvularia 232
Cutaneous larva migrans 175
Cyclacillin, in renal failure 45
Cycloserine
adverse reactions 62
cost of 5
for disseminated infection 28
dosing regimens for 5
drug interactions 81–82
for Mycobacterium haemophilum 171
for Mycobacterium scrofulaceum 171
for pulmonary infection 28
in renal failure 45
for tuberculosis 29 164
Cyclospora infection
description of 175 279 (includes Infectious Diarrhea and Foodborne
Outbreaks)
in infectious diarrhea 276 281
Cysticercosis See Tapeworm infection
Cysticercus cellulosae 181
Cystitis 285 308
Cystocele repair, antibiotic prophylaxis for 128
Cytomegalovirus
in aseptic meningitis 239
immune globulins for 121
in pneumonia 255
P.326
treatment of 194–195
Cytovene See Ganciclovir
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > D
D
Dacryocystitis 232
Dapsone
adverse reactions 62
cost of 5
dosing regimens for 5
drug interactions 82
for parasitic infections 180
in renal failure 45
Daptomycin
adverse reactions 62
for bacteremia 24
for cellulitis 34 219
cost of 5
dosing regimens for 5
during dialysis 54
drug interactions 82
for endocarditis 23
for furunculosis 220
in hepatic disease 57
for infected prosthetic devices 35
for meningitis 238
in renal failure 45
for septicemia 23 34 35
for systemic infections 24
for ulcers 222
for wound infection 34
Daraprim See Pyrimethamine
Declomycin See Demeclocycline
Decubitus ulcer 222
Deep serious soft tissue infections 223
Defibrillator implant, antibiotic prophylaxis for 124
Dehydroemetine, for infectious diarrhea 276
Demeclocycline
adverse reactions 72
cost of 5
dosing regimens for 5 14
Denavir See Penciclovir
Dental infections See also Oral infections
description of 247
treatment of 19 25 28 31
Dermis infections 219–222
Diabetes mellitus 101 123
Diabetic foot ulcer 222
Diarrhea
antibiotic-associated, treatment of 22
infectious 271–278
traveler's 141–142 278
treatment of 17 20 25 31 37
duration of 306–307 (includes Sexually transmitted diseases and
Duration of Antibiotic Treatment)
Dicloxacillin
cost of 5
during dialysis 54
dosing regimens for 5
for impetigo 220
in renal failure 45
Dientamoeba fragilis 175
Diethylcarbamazine
adverse reactions 62
cost of 5
dosing regimens for 5
for parasitic infections 176 182
Diflucan See Fluconazole
Diloxanide
adverse reactions 63
dosing regimens for 5
for liver abscess 268
for parasitic infections 174
Diphtheria
immune globulins in 122
treatment of 22 307
Diphyllobothrium latum 181
Dipylidium caninum 181
Dirithromycin
adverse reactions 63
cost of 5
dosing regimens for 5
in renal failure 45
Disseminated gonococcal infections 288–289 307
Diverticulitis 269
Docosanol
cost of 6
dosing regimens for 6
Dog bites, treatment of 21 221 See also Bite wounds
Donovanosis 20 296
Doryx See Doxycycline
Doxy 100 See Doxycycline
Doxy 200 See Doxycycline
Doxy caps See Doxycycline
Doxy tabs See Doxycycline
Doxy Vibra-tabs see Doxycycline
Doxycycline
for acne rosacea 219
adverse reactions 72
for arthritis, septic 226
for bacillary angiomatosis 19
for bronchitis 252
for brucellosis 20
for chlamydia 294
for Chlamydia trachomatis 294
cost of 6
during dialysis 54
for diarrhea, infectious 271 274 275
P.327
dosing regimens for 6 14
for ehrlichiosis 23
for endocarditis 19
for genital tract infections 29
for gonococcal infections 288
for granuloma inguinale 296
for human granulocyte ehrlichiosis 23
for human monocyte ehrlichiosis 23
for Legionnaires' disease 27
for Lyme disease 217
for lymphogranuloma venereum 294
for malaria prevention 143
for meningitis 17
for murine typhus 32
for Mycobacterium fortuitum 170
for Mycobacterium marinum 171
for Mycobacterium smegmatis 171
for osteomyelitis 19
for parasitic infections 179
for peliosis hepatitis 19
for pelvic inflammatory disease 302
for pneumonia 35 251 253 255
for proctitis 301
for pulmonary infection 28
for Q fever 32
for Q fever endocarditis 23
for relapsing fever 19
in renal failure 45
for respiratory tract infections 249
for Rocky Mountain spotted fever 32
for scrub typhus 32
for septic arthritis 226
for septicemia 17
for sinusitis 244
for skin infections 28
for soft tissue infections 28
for sporotrichosis 222
in surgery 128
for tickbite fever 32
for trench fever 19 32
for typhus 32
for wound infection 28
Doxyx See Doxycycline
Dracunculus medinensis infection 175
Drechslera 232
Drotrecogin 6 205
Drug abusers, immunization in 100
Drug interactions 79–92
DT vaccine 93
DTP vaccine 93
Duricef See Cefadroxil
Dycill See Dicloxacillin
Dyclone, for aphthous stomatitis 247
Dynabac See Dirithromycin
Dynapen See Dicloxacillin
Dysgammaglobulinemia 206 (includes Sepsis and Sepsis Syndrome and
Compromised Host)
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > E
E
E. coli
in infectious diarrhea 272–273 278 279 (includes Infectious Diarrhea
and Foodborne Outbreaks)
in pneumonia 254
treatment for 25
in urinary tract infections 285
Echinococcus granulosus 181
Echinococcus multilocularis 181
Econazole, for fungal infections 161 220
Eczema vaccinatum 120–121
EES See Erythromycin ethylsuccinate
Eflornithine
adverse reactions 63
dosing regimens for 6
for parasitic infections 182
Ehrlichia chaffeensis 23
Ehrlichia phagocytophia 23
Ehrlichiosis 23
Eikenella corrodens 23 226 261
in endocarditis 261
eIPV vaccine 94
Elimite See Permethrin
Emetine
adverse reactions 63
for liver abscess 268
Emetine hydrochloride 6
Emgel See Erythromycin
Emtet 500 See Tetracycline(s)
E-mycin See Erythromycin
Encephalitis 120
Encephalitozoon cuniculi 179
Encephalitozoon hellem 180
Encephalitozoon intestinalis 180
Endocarditis 256–263
antimicrobial prophylaxis for 138–140
aseptic meningitis and 239
Candida in 151
gonococcal infections and 289
indications for cardiac surgery in 262–263
Q fever, treatment of 23
treatment of 17 19 21 24 25 27 35 258–261 307
Endocervicitis 21
Endophthalmitis 151 230
Engerix See Hepatitis B vaccine
Enoxacin
adverse reactions 69
cost of 6
for gonococcal infections 288
in renal failure 45
Entamoeba histolytica 276 278
in amebiasis 174
in infectious diarrhea 276 278
P.328
Entamoeba polecki infection 176
Enteritis 300–301
Enterobacter aerogenes 24
Enterobacter cloacae 24
Enterobius vermicularis infection 176
Enterococcus faecalis 24
Enterococcus faecium 24
Enterocolitis 37
Enterocytozoon bieneusi 179
Eosinophilic enterocolitis 174
Epidermis infections 219–222
Epididymitis 300
chlamydia and 293
treatment of 21
Epiglottis 26 246
Epivir See Lamivudine
Epstein-Barr virus
aseptic meningitis and 239
in pharyngitis 246
treatment of 195
Ertapenem 6 42 54 82
ERYC See Erythromycin
Erycette See Erythromycin
Erygel See Erythromycin
Erysipelas 219
Erysipelothrix rhusiopathiae 25
Ery-Tab See Erythromycin
Erythrasma 23
Erythro See Erythromycin
Erythrocin lactobionate See Erythromycin lactobionate
Erythrocin stearate See Erythromycin stearate
Erythrocot See Erythromycin
Erythromycin
for actinomycosis 17 246
adverse reactions 63
for anaerobic infections 213
for bacillary angiomatosis 19
for bronchitis 251
for cat scratch disease 247
for cellulitis 219
for chancroid 26 296
for chlamydia 294
cost of 6
during dialysis 54
for diarrhea 20
infectious 271 278
for diphtheria 22
for donovanosis 20
dosing regimens for 6
drug interactions 82
for endocarditis 17 19
for endocervicitis 21
for epididymitis 21
for erythrasma 23
for furunculosis 220
for granuloma inguinale 20
for Haverhill fever 35
for inclusion conjunctivitis 21
for infectious diarrhea 271 278
for Legionnaires' disease 27
for leptospirosis 27
for lymphogranuloma venereum 21 294
for ocular infections 229 231
for osteomyelitis 19
for otitis 243
for peliosis hepatitis 19
for pelvic inflammatory disease 21
for periodontal disease 21
for pertussis 19
for pertussis prevention 135
for pharyngitis 23 245 246
for pneumonia 251 255
for Q fever 23
for rat-bite fever 34
for relapsing fever 19
in renal failure 45
for respiratory tract infections 249
for skin infections 28
for soft tissue infections 28
in surgery 127
for tonsillitis 21
for trachoma 21
for trench fever 19
for urethral syndrome 21
for urethritis 21 300
Erythromycin estolate 6
Erythromycin ethylsuccinate 6
Erythromycin gluceptate 6
Erythromycin lactobionate 6
Erythromycin stearate 6
Erythromycin-sulfisoxazole
dosing regimens for 6
for otitis 243
Eryzol See Erythromycin-sulfisoxazole
Escherichia coli See E. coli
Ethambutol
adverse reactions 63
cost of 6
during dialysis 54
for disseminated infection 28
dosing regimens for 6
for Mycobacterium avium 170
for Mycobacterium genavense 171
for Mycobacterium gordonae 171
for Mycobacterium kansasii 170
for Mycobacterium malmoense 171
for Mycobacterium marinum 171
for Mycobacterium smegmatis 171
for Mycobacterium ulcerans 171
P.329
for Mycobacterium xenopi 171
for pulmonary infection 28 29
in renal failure 46
for soft tissue infections 28
for sporotrichosis 222
for tuberculosis 29 162 163
Ethionamide
adverse reactions 63
cost of 7
dosing regimens for 7
drug interactions 82
for Mycobacterium avium 170
for pulmonary infection 28
in renal failure 46
for tuberculosis 29 164
Eurax See Crotamiton
Extra-intestinal infection 31
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > F
F
Factive see Gemifloxacin
Famciclovir
adverse reactions 63
antiviral activity of 203
cost of 7
during dialysis 54
dosing regimens for 7
drug interactions 82
for genital herpes simplex 295
for hepatitis B 198
for herpes simplex 191
in renal failure 46
for stomatitis 247
for varicella 193
Famvir See Famciclovir
Fansidar See Pyrimethamine-sulfadoxine
Faran See Nitrofurantoin
Fasciola hepatica 176
Fasciolopsis buski 176
Female genital tract infections 18 19 29 31
Femstat See Butoconazole
Fever of unknown origin 214–216 (includes Anaerobic Infections and Fever
of Unknown Origin)
Filariasis 176
Flagyl See Metronidazole
Floxin See Ofloxacin
Fluconazole
adverse reactions 64
cost of 7
during dialysis 54
dosing regimens for 7
drug interactions 83
for endocarditis 261
for fungal infection 148–158 157–158 158 160
in renal failure 46
for sepsis 267
for stomatitis 247
Flucytosine
adverse reactions 64
cost of 7
during dialysis 54
dosing regimens for 7
for endocarditis 261
for fungal infections 147–148 151 157–158 158 160
for ocular infections 229 231
in renal failure 46
Fluke infection 176
Flumadine See Rimantadine
Fluorescent treponemal antibody absorbed test (FTA-ABS), for syphilis 289
Fluoroquinolones See also specific agent
adverse reactions 70
for bacteremia 17 21 28
for bite wounds 21 23
for bronchitis 26
for cat bites 21
for cellulitis 17 219
for chancroid 26
for cholera 37
for colitis 33
for diarrhea 17 20 25 31
for diverticulitis 269
for dog bites 21
for donovanosis 20
drug interactions 83–84
for endocarditis 261
for extra-intestinal infection 31
for gonococcal infections 288
for granuloma inguinale 20
in hepatic disease 57
for infected prosthetic devices 34
for infectious diarrhea 274
for meningitis 20
for mesenteric adenitis 37
for murine typhus 32
for myositis 17
for oral infections 23
for osteomyelitis 17 225
for otitis 26 27
for periodontal disease 21
for pneumonia 17 20 21 22 24 27 28 32 33 34 35 251 253 254
255
for pneumonitis 27
for prosthetic joint 227
for pyelonephritis 286
for Q fever 23 32
for Rocky Mountain spotted fever 32
for scrub typhus 32
for sepsis 17 24 25 27 31
for septicemia 18 20 22 25 27 31 32 33 34
P.330
for sinusitis 26 27
for tickbite fever 32
for tonsillitis 21
for traveler's diarrhea 142
for trench fever 32
for typhus 32
for urinary tract infections 22 24 25 27 28 31 32 33 34 284 286
for vascular infections 20
for wound infection 22 23 25 28 31 34
Folinic acid, for infectious diarrhea 276
Folliculitis 219
Food poisoning 18 273 278 279–283 (includes Infectious Diarrhea and
Foodborne Outbreaks)
Foot ulcer, diabetic 222
Fortaz See Ceftazidime
Fortovase See Saquinavir
Foscarnet
adverse reactions 64
antiviral activity of 203
cost of 7
for cytomegalovirus 194
dosing regimens for 7
drug interactions 84
for herpes simplex 192
for pneumonia 255
in renal failure 46
for varicella 193
Foscavir See Foscarnet
Fosfomycin
adverse reactions 64
cost of 7
for cystitis 286
dosing regimens for 7
for urinary tract infections 286
Francisella tularensis 25
FTA-ABS See Fluorescent treponemal antibody absorbed test
Fulvicin See Griseofulvin
Fungal infections 147–161 220
Fungizone See Amphotericin B
Furacin See Nitrofurazone
Furadantin See Nitrofurantoin
Furalan See Nitrofurantoin
Furamide See Diloxanide
Furatoin See Nitrofurantoin
Furazolidone
adverse reactions 64
for diarrhea 20
infectious 271 276
for infectious diarrhea 273
for parasitic infections 177
Furoxone See Furazolidone
Furunculosis 220
Fusobacterium 25 213
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > G
G
Gamimune-N see IVIG
Gammagard see IVIG
Ganciclovir
adverse reactions 65
antiviral activity of 203
cost of 7
for cytomegalovirus 194–195
during dialysis 54
dosing regimens for 7
drug interactions 84
for pneumonia 255
in renal failure 47
Gangrene
gas 22 223
infected vascular 223
Gantanol See Sulfamethoxazole
Gantrisin See Sulfisoxazole
Garamycin See Gentamicin
Gardnerella vaginalis 25 303
Gas gangrene 22 223
Gas-forming cellulitis 223
Gastroenteritis 23
Gastrointestinal surgery, antibiotic prophylaxis for 125–127
Gatifloxacin
for abscesses 18
adverse reactions 70
for anaerobic infections 213
for bacteremia 18
cost of 7
for dental infection 31
dosing regimens for 7
for gynecologic infection 31
for Legionnaires' disease 27
for oral infections 31
for pneumonia 251
for pulmonary infection 31
in renal failure 47
for respiratory tract infections 249
for sepsis 18 31
for sinusitis 244
for tuberculosis 164
for ulcers 222
Gemifloxacin 7 47
Gender, and antimicrobial dosing regimens in renal failure 39
Genital herpes simplex
perinatal infection 295
and pregnancy 296
management of 296
prophylaxis for 295
treatment of 295–296
Genital tract infections See Female genital tract infections
Genital ulcer disease 298
P.331
Gentamicin
adverse reactions 58
for anthrax 18
for biliary tract infections 268
for brucellosis 20
for cat scratch disease 19
cost of 7
during dialysis 54
for diarrhea 17
infectious 271 275
dosing regimens for 7
for endocarditis 24 35 258 259 261
prophylaxis 140
for meningitis 20 27 237
for pelvic inflammatory disease 301
for plague 37
for pneumonia 33 254
in renal failure 39 40 47
for sepsis 204 267
for septicemia 20 22 27 33
in surgery 125 127 129
for tularemia 25
for urinary tract infections 33
for vascular infections 20
Geocillin See Carbenicillin; Carbenicillin indanyl sodium
Giardia lamblia 177 276 278 281
Giardiasis 177
Gingivitis 247
G-Mycin See Gentamicin
Gnathostoma spinigerum 177
Gnathostomiasis 177
Gonococcal infections 288–289
chlamydia and 293
disseminated 288–289
at selected sites 288–289
special considerations 288
treatment of 288–289 307
Granuloma inguinale 20 296–297
Grepafloxacin, in renal failure 47
Grifulvin See Griseofulvin
Grisactin See Griseofulvin
Grisactin Ultra See Griseofulvin
Griseof see Griseofulvin
Griseofulvin
adverse reactions 65
cost of 7
dosing regimens for 7
drug interactions 84
for fungal infections 161 220
in renal failure 47
Griseofulvin V see Griseofulvin
Gris-PEG See Griseofulvin
Guillain-Barr, syndrome 106
Gum boil 247
Gynecologic infections See Female genital tract infections
Gynecologic surgery, antibiotic prophylaxis for 127–128
Gyne-Lotrimin See Clotrimazole
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > H
H
Haemophilus aphrophilus 26 260
Haemophilus ducreyi 26 296
Haemophilus influenzae 26 260
in endocarditis 260
in epiglottis 246
family exposure to 98
in mastoiditis 244
in meningitis 234 237
in otitis 243
in pneumonia 253
vaccine
in asplenia 101
bone and joint infections and 225
route of administration of 94
Hafnia alvei See Enterobacter aerogenes
Halofantrine
adverse reactions 65
for parasitic infections 178
Haloprogin, for fungal infections 161
Hantavirus pulmonary syndrome 200
Haverhill fever 35
Head surgery, antibiotic prophylaxis for 129
Helicobacter pylori 26 270
Hepatitis, peliosis 19
Hepatitis A
immune globulins for 8 122
infectious diarrhea in 281
viral 264
Hepatitis A vaccine 113–114
cost of 113
for drug abusers 100 114
for family members 99
for homosexual men 100 114
during pregnancy 98
route of administration of 93–94
for travelers 102–103 113
Hepatitis B
description of 199 297–298
immunoglobulins for 8 122
viral 228 264
Hepatitis B vaccine 114–119
adverse reactions 115
cost of 8 115
for drug abusers 100 117
for family members 99 117
for health care workers 99 117
for homosexual men 100 117
for immigrants and refugees 100 117
in institutions for mentally retarded 99 117
P.332
during pregnancy 98 117
for prison inmates 99 117
in renal failure 101 123
route of administration of 93–94
in sexual assault treatment 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
for travelers 103
Hepatitis C
treatment of 197–199
viral 265
Hepatitis D 200 265–266
Hepatitis E 266
Hepsera see Adefovir
Herpes, neonatal 296
Herpes simplex 191–192 See also Genital herpes simplex
in aseptic meningitis 239
genital
perinatal infection 295
and pregnancy 296
prophylaxis for 295
treatment of 295–296
and genital ulcers 299
in keratitis 230
in stomatitis 247
Herpes zoster See also Varicella-zoster
in aseptic meningitis 239
in keratitis 230
treatment of 192–193
Herplex see Idoxuridine
Heterophyes heterophyes 176
Hetrazan See Diethylcarbamazine
Hiprex See Methenamine hippurate
Histoplasmosis
in meningitis 239
treatment of 154–156
HIV/AIDS
aseptic meningitis and 239
cytomegalovirus in 194
donovanosis and 296
fungal infections in, treatment of 148 152 153 154 155 157
herpes simplex in 191
immunization in 100–101 123
meningitis in 239
pap smears and 305
smallpox vaccination considerations 120
syphilis and 289 291
tuberculosis in 162
prevention of 168–170 169–170
Homeless persons 99
Homosexual men 100
Hookworm infection 177
Human granulocyte ehrlichiosis 23
Human immunodeficiency virus See HIV/AIDS
Human monocyte ehrlichiosis 23
Human papillomavirus 298–299
Humatin See Paromomycin
Hydatid cyst See Tapeworm infection
Hydroxychloroquine
cost of 7
dosing regimens for 7
for Q fever endocarditis 23
Hymenolepis nana 181
Hypogammaglobulinemia 206 (includes Sepsis and Sepsis Syndrome and
Compromised Host)
Hyposplenism 206 (includes Sepsis and Sepsis Syndrome and
Compromised Host)
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > I
I
Idoxuridine 7
Ilosone See Erythromycin estolate
Ilotycin gluceptate See Erythromycin gluceptate
Imipenem
for abscesses 18 25 31 251
for anaerobic infections 213
for arthritis, septic 30
for bacteremia 17 18 21 28
for brain abscess 30
for cat bites 21
cost of 8
for dental infection 19 25 31
for dog bites 21
drug interactions 84
for extra-intestinal infection 31
for female genital tract infections 18
for gas gangrene 22
for gynecologic infection 31
for infected prosthetic devices 34
intra-abdominal 18 24 25 27 31 32 204 267
for intra-abdominal sepsis 18 24 25 27 31 32 204 267
for invasive disease 18
for liver abscess 25 30
for meningitis 17 20
for Mycobacterium abscessus 171
for Mycobacterium fortuitum 170
for Mycobacterium smegmatis 171
for nocardiosis 30
for ocular infections 28
for oral infections 19 25 31
for osteomyelitis 225
for otitis 243
for periodontal disease 21
for pneumonia 17 20 22 24 27 28 32 33 251 253 254 255
for pulmonary abscess 32
for pulmonary infection 19 25 28 31
for sepsis 17 22 24 25 204
P.333
for septic arthritis 30
for septicemia 17 18 20 22 25 27 30–31 31 32 33 34
for sinusitis 245
for skin abscess 30
for skin infections 28
for soft tissue infections 28
for tonsillitis 21
for urinary tract infections 22 24 25 27 28 31 32 34
for vascular infections 20
for wound infection 22 24 25 28
Imipenem/cilastatin
adverse reactions 65
during dialysis 55
dosing regimens for 8
in renal failure 47
Imiquimod 298
Immigrants 100
Immunizations See Vaccines
Immunoglobulins 8 121–122
Imogam Rab 8
Imovax See Rabies vaccine
Impetigo 220
Inclusion conjunctivitis 21
Infected prosthetic devices 34
Infected vascular gangrene 223
Infection(s) 28
after bone marrow transplantation 211
anaerobic 213–214
bacterial, diarrhea 271–278 279–280 (includes Infectious Diarrhea and
Foodborne Outbreaks)
bone 224–228 306 (includes Sexually transmitted diseases and Duration
of Antibiotic Treatment)
central nervous system 233–240
dental
description of 247
treatment of 19 25 28 31
dermal 219–222
epidermal 219–222
female genital tract 18 19 29 31
fungal 147–161 220
joint 224–228 307
mycobacterial 162–173
ocular 229–232
oral 19 23 25 28 31
parasitic
diarrhea 275–276 280–281
treatment of 174–190
perimandibular 246–247
periocular 229–232
pulmonary 19 25 28 29–30 31 250–255
respiratory tract 241–255
antimicrobials for 249
lower 250–255
upper 243–248
soft tissue
deep serious 223
streptococcal 212
treatment of 28
streptococcal 212 223
subcutaneous tissue 219–222
travel-associated 141–146
urinary tract 284–287
antimicrobial prophylaxis for 134–135
treatment of 22 24 25 27 28 31 32 33–34 34–35 308
viral
diarrhea 281
hepatitis 264–266
treatment of 191–203
Infection control 288
Infectious diarrhea 271–278
Influenza
prevention of 196
treatment of 195–197
Influenza vaccine 104–106
adverse reactions 106
contraindications 106
in diabetes 101 123
for family members 99
for health care workers 100 105
for HIV patients 101 123
for homeless 99
in nursing homes 99 105
during pregnancy 98 106
recommendation by age 97
in renal failure 101 123
route of administration of 93–94
for travelers 103–104
Inguinal hernia repair, antibiotic prophylaxis for 132
INH
for disseminated infection 28
for Mycobacterium genavense 171
for Mycobacterium gordonae 171
for Mycobacterium scrofulaceum 171
for tuberculosis 29
Interferon alfa
adverse reactions 65 198
antiviral activity of 203
cost of 8
during dialysis 55
guidelines for 47
for hepatitis B 199
for hepatitis C 198
Interferon alfa-2a 8
Interferon alfa-2b 8
Intra-abdominal sepsis 18 24 25 27 31 32 204 267–268 307
P.334
Intron A See Interferon alfa; Interferon alfa-2b
Invanz see Ertapenem
Invasive disease 18
Invirase See Saquinavir
Iodoquinol
adverse reactions 66
cost of 8
dosing regimens for 8
for infectious diarrhea 275 276
for liver abscess 268
for parasitic infections 174 175
Isoniazid
adverse reactions 66
cost of 9
during dialysis 55
dosing regimens for 9
drug interactions 84–85
in hepatic disease 57
in renal failure 47
for tuberculosis 162 163
Isoniazid-rifampin 9
Isoniazid-rifampin-pyrazinamide 9
Isospora belli 276
Isosporiasis 177
Isotretinoin, for acne 219
Itraconazole
adverse reactions 66
cost of 9
during dialysis 55
dosing regimens for 9
drug interactions 85
for fungal infections 147–158 157–158 158 160
in hepatic disease 57
for nodules 222
in renal failure 47
for ulcers 222
Ivermectin
adverse reactions 66
cost of 9
dosing regimens for 9
for parasitic infections 175 176 177 181
in renal failure 47
IVIG
adverse reactions 66
dosing regimens for 8
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > J
J
Japanese B encephalitis vaccine
route of administration of 94
for travelers 103
Jarish-Herxheimer reaction
pregnancy and 291
syphilis and 290
Jenamicin See Gentamicin
Jock itch 161
Joint infections
antibiotic treatment for 307
description of 224–228
Joint replacement, antibiotic prophylaxis for 129
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > K
K
Kanamycin
cost of 9
during dialysis 55
dosing regimens for 9
for mycobacterial infections 171
in renal failure 47
for tuberculosis 29 164
Kantrex See Kanamycin
Keflex See Cephalexin
Keflin See Cephalothin
Keftab See Cephalexin
Kefurox See Cefuroxime
Kefzol See Cefazolin
Keratitis 230
Ketek
adverse reactions 72
dose 15
drug interactions 90
hepatic disease 57
pneumonia 251 253
renal failure 51
respiratory tract infections 249 251 253–255
spectrum 21 26 27 34 36
Ketoconazole
adverse reactions 66
cost of 9
during dialysis 55
dosing regimens for 9
drug interactions 85–86
for fungal infections 147–158 157–158 158 160 161 220
for nodules 222
in renal failure 48
for stomatitis 247
for ulcers 222
Kingella sp. 27 260
Klebsiella sp. 27
Klebsiella pneumoniae 27 254
Kwell See Lindane
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > L
L
Lacrimal apparatus infection 231–232
Lamisil See Terbinafine
Lamivudine
antiviral activity of 203
during dialysis 55
guidelines for 48
for hepatitis B 199
Lampit See Nifurtimox
Lamprene See Clofazimine
P.335
Lanacillin VK See Penicillin V
Lansoprazole 26 270
Lariam See Mefloquine
Laryngitis 246
Ledercillin VK See Penicillin V
Leg amputation 130
Legionella sp. 27 255
Legionnaires' disease 27
Leishmaniasis 177
Leptospira sp. 27 239
Leuconostoc 28
Levofloxacin
adverse reactions 70
for anaerobic infections 213
cost of 9
during dialysis 55
dosing regimens for 9
for Legionnaires' disease 27
for pneumonia 251 253
for pulmonary infection 28
in renal failure 48
for respiratory tract infections 249
for sinusitis 244
for traveler's diarrhea 142
for tuberculosis 164
for ulcers 222
for urinary tract infections 286
Levoquin See Levofloxacin
Lice 178
pubic 297
Lice-ENZ See Permethrin
Ligase chain reaction (LCR), for Chlamydia trachomatis 293
Limvudine 9
Lincocin See Lincomycin
Lincomycin 9
Lindane
cost of 9
dosing regimens for 9
for pubic lice 297
for scabies 297
Linezolid
adverse reactions 67
cost of 9
during dialysis 55
dosing regimens for 9
drug interactions 86
in hepatic disease 57
for infected prosthetic devices 35
for meningitis 237
for pneumonia 34 253 254
in renal failure 48
for septicemia 34
for wound infection 34
Liquifilm see Idoxuridine
Listeria
in endocarditis 260
in food poisoning 273 280
in meningitis 234 236 237–238 239
Listeria monocytogenes 27
Liver abscess
antibiotics for 307
description of 268
treatment of 25 30
Loa loa 176
Lobectomy, antibiotic prophylaxis for 125
Lomefloxacin
adverse reactions 70
cost of 10
dosing regimens for 10
in renal failure 48
Loperamide
for infectious diarrhea 275 278
for traveler's diarrhea 142 278
Lorabid See Loracarbef
Loracarbef
cost of 10
dosing regimens for 10
in renal failure 48
for respiratory tract infections 249
Lotrimin See Clotrimazole
Lower respiratory tract infections 250–255
Lung abscess
antibiotic treatment for 307
description of 251
Lung fluke 176
Lyme disease See also Borrelia burgdorferi
aseptic meningitis and 239
treatment of 19 216–218 (includes Fever of Unknown Origin and
Treatment of Lyme Disease and Potential Exposures)
LYMErix See Lyme disease
Lymphadenitis 221
Lymphangitis 219
Lymphogranuloma venereum 21 294–295 307
Lyphocin See Vancomycin
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > M
M
Macrobid See Nitrofurantoin
Macrodantin See Nitrofurantoin
Macrolides See also specific agent
for actinomycosis 17
for cat scratch disease 221
for dental infection 31
for gynecologic infection 31
for infected prosthetic devices 34
for oral infections 31
for pneumonia 21 36 251 253 254 255
for pulmonary infection 31
for sepsis 31
for septicemia 22 31 34
Madura foot 222
P.336
Mafenide 10
Malaria
aseptic meningitis and 239
countries with risk of 144
prevention of 142–146 179
treatment of 178–179
Malarone See Atovaquone-proguanil
Malassezia furfur 156
Malignant otitis externa 243
Mandelamine See Methenamine mandelate
Mandol See Cefamandole
Mansonella ozzardi 176
Mansonella perstans 176
Mansonella streptocerca 176
Mastectomy, antibiotic prophylaxis for 132
Mastoiditis
acute 243
chronic 244
Maxaquin See Lomefloxacin
Maxipime See Cefepime
Measles vaccine 106–107 See also MMR vaccine
for health care workers 100 107
for HIV patients 100
for homeless 99
for immigrants and refugees 100
during pregnancy 98
recommendation by age 97
route of administration of 95
for travelers 104
Mebendazole
adverse reactions 67
cost of 10
dosing regimens for 10
drug interactions 86
for parasitic infections 174 175 176 177 182
Mefloquine
adverse reactions 67
cost of 10
dosing regimens for 10
drug interactions 86
for malaria prevention 143
for parasitic infections 178 179
in renal failure 48
Mefoxin See Cefoxitin
Melarsoprol
adverse reactions 67
for parasitic infections 182
Melioidosis 20
Membranous pharyngitis 246
Meningitis 234–240
aseptic 239–240
bacterial 235
chronic 239
fungal 151 153 154
gonococcal infections and 289
pyogenic 234
treatment of 17 20 26 27 30 35 236–239
Meningococcal disease, antimicrobial prophylaxis for 133–134
Meningococcal vaccine
in asplenia 101 123
for family members 99
route of administration of 95
for travelers 104
Mepron See Atovaquone
Mercury 282
Meropenem
for abscesses 25 251
adverse reactions 67
for anaerobic infections 213
for arthritis, septic 30
for bacteremia 17 21 28
for cat bites 21
cost of 10
for dental infection 25 31
for dog bites 21
dosing regimens for 10
drug interactions 86
for endocarditis 261
for extra-intestinal infection 31
for female genital tract infections 18
for gas gangrene 22
for gynecologic infection 31
for infected prosthetic devices 34
for intra-abdominal sepsis 24 25 27 31 32 204 267
for invasive disease 18
for liver abscess 25
for meningitis 17
for oral infections 25 31
for osteomyelitis 225
for periodontal disease 21
for pneumonia 17 20 22 24 27 28 32 253
for pulmonary infection 25 31
in renal failure 48
for sepsis 17 22 24 25 204
intra-abdominal 24 25 27 31 32 204 267
for septic arthritis 30
for septicemia 17 18 20 22 25 27 30 32 34
for tonsillitis 21
for urinary tract infections 22 27 28 32
for wound infection 22 24 25 28
Merrem See Meropenem
Mesenteric adenitis 37
P.337
Metagonimus yokogawai 176
Methenamine hippurate
cost of 10
dosing regimens for 10
in renal failure 48
Methenamine mandelate
adverse reactions 67
dosing regimens for 10
in renal failure 48
Methicillin
for endocarditis 259
for meningitis 237
in renal failure 48
Metorchis conjunctus 176
Metric See Metronidazole
Metro IV See Metronidazole
Metrogel-vaginal See Metronidazole
Metronidazole
for abscesses 18 25 240 268
for acne rosacea 219
adverse reactions 67
for anaerobic infections 213
for bacteremia 18
for bacterial vaginosis 303
for cat bites 221
for colitis 22
cost of 10
for dental infection 19 25 31 247
during dialysis 55
for diarrhea 22
infectious 271 272 275 276
for diverticulitis 269
for dog bites 221
dosing regimens for 10
drug interactions 87
for female genital tract infections 18
for gas gangrene 22
for gastritis 27
for gynecologic infection 31
in hepatic disease 57
for infectious diarrhea 271 272 275 276
intra-abdominal 18 31 204 267
for intra-abdominal sepsis 18 31 204 267
for liver abscess 25
for meningitis 236
for oral infections 19 25 31
for osteomyelitis 225
for parasitic infections 174 175 177 182
for pelvic inflammatory disease 302
for pelvic vaginitis 302
for peptic ulcer disease 27 270
for pharyngitis 246
for pneumonia 254
for pulmonary infection 19 25 31
in renal failure 48
for sepsis 22
in sexual assault treatment 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
for stomatitis 247
in surgery 127 128
for urethritis 300
for vaginitis 25
Mezlin See Mezlocillin
Mezlocillin
for biliary tract infections 268
during dialysis 55
in hepatic disease 57
for meningitis 236
for otitis 243
for pneumonia 254
in renal failure 48
for sepsis 204
MHATP See Microhemagglutinin for antibody test
Miconazole
adverse reactions 67
cost of 10
dosing regimens for 10
drug interactions 87
for fungal infections 148 161 220
in renal failure 48
for vulvovaginal candidiasis 304
Microhemagglutinin for antibody test (MHATP), for syphilis 289
Microsporidiosis 180
Minocin See Minocycline
Minocycline
for abscesses 30
adverse reactions 72
for brain abscess 30
cost of 10
during dialysis 55
dosing regimens for 10 15
for endocarditis 259
for liver abscess 30
for nocardiosis 30
for pneumonia 35 255
for pulmonary infection 30
in renal failure 48
for septicemia 35
for skin abscess 30
for soft tissue infections 29
for sporotrichosis 222
for urinary tract infections 35
Mintezol See Thiabendazole
Mites See Scabies
MMR vaccine See also Measles vaccine; Mumps vaccine; Rubella vaccine
for homeless 99
for immigrants and refugees 100
P.338
route of administration of 95
Moniliformis infection 180
Monistat See Miconazole
Monocid See Cefonicid
Monosodium glutamate 282
Monurol See Fosfomycin
Moraxella 28 229
Moraxella catarrhalis 28 243 246 254
Moraxella osloenia 225
Morganella morganii 28
Moxalactam, during dialysis 55
Moxifloxacin
for abscesses 18
adverse reactions 70
for anaerobic infections 213
for bacteremia 18
cost of 10
for dental infection 31
during dialysis 55
dosing regimens for 10
drug interactions 93
for female genital tract infections 19
for gynecologic infection 31
for Legionnaires' disease 27
for oral infections 31
for pneumonia 251
for pulmonary infection 31
in renal failure 49
for respiratory tract infections 249
for sepsis 18 31
for sinusitis 244
for tuberculosis 29 164
for ulcers 222
Mucopurulent cervicitis 293 301
Mumps vaccine See also MMR vaccine
for health care workers 100
for homeless 99
for immigrants and refugees 100
during pregnancy 98
recommendation by age 97
route of administration of 95
Mupirocin
cost of 10
dosing regimens for 10
for impetigo 220
Murine typhus 32
Mushroom toxins 282
Myambutol See Ethambutol
Mycelex See Clotrimazole
Mycifradin See Neomycin
Mycobacterial infections 162–173
Mycobacterium abscessus 28 171
Mycobacterium avium 170
Mycobacterium avium-intracellulare 28 228
Mycobacterium bovis 171 173
Mycobacterium chelonae 29 171
Mycobacterium fortuitum 29 170 228
Mycobacterium genavense 29 171 173
Mycobacterium gordonae 171 173
Mycobacterium haemophilum 29 171 173
Mycobacterium kansasii 29 170 228
Mycobacterium leprae 29
Mycobacterium malmoense 171 173
Mycobacterium marinum 29 171 228
Mycobacterium scrofulaceum 171
Mycobacterium simiae 171 173
Mycobacterium smegmatis 171 173
Mycobacterium szulgae 171 173
Mycobacterium tuberculosis 29 228 239 See also Tuberculosis
Mycobacterium ulcerans 29 171
Mycobacterium xenopi 171 173
Mycobutin See Rifabutin
Mycoplasma hominis 303
Mycoplasma pneumoniae 29 239 255
Mycostatin See Nystatin
MyE See Erythromycin
Myositis 17
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > N
N
Nabi-HB 8
Naegleria 174
Nafcil See Nafcillin
Nafcillin
for brain abscess 240
for burns 221
cost of 11
during dialysis 55
dosing regimens for 11
for endocarditis 259 261
in hepatic disease 57
for infected prosthetic devices 34
for meningitis 236 237
for osteomyelitis 224
for pneumonia 254
for prosthetic joint 227
in renal failure 49
for septicemia 34
in surgery 130
Naftifine, for fungal infections 161 220
Nail fungus 161
Nalidixic acid
adverse reactions 68 70
cost of 11
dosing regimens for 11
drug interactions 87
for infectious diarrhea 274
in renal failure 49
Nallpen See Nafcillin
Nanophyetus salmincola 177
P.339
Natamycin, for ocular infections 230
Nebcin See Tobramycin
NebuPent See Pentamidine
Necator americanus 177
Neck surgery, antibiotic prophylaxis for 129
Necrotizing fasciitis 223
NegGram See Nalidixic acid
Neisseria gonorrhoeae 30 288–289
in arthritis 226
polyarticular 228
septic 226
in conjunctivitis 229
in endocarditis 261
in mucopurulent cervicitis 301
in pelvic inflammatory disease 301–302
in pharyngitis 245
in urethritis 299–300
Neisseria meningitidis 30
in endophthalmitis 230
in meningitis 234 237
in polyarticular arthritis 228
Neo-Fradin See Neomycin
Neomycin
cost of 11
dosing regimens for 11
for infectious diarrhea 273
for ocular infections 229
for otitis 243
in surgery 127
Neonatal herpes 296
Neo-Tabs See Neomycin
Neotrizine See Trisulfapyrimidines
Netilmicin
adverse reactions 58
during dialysis 55
in renal failure 39 49
Netromycin See Netilmicin
Neurosurgery, antibiotic prophylaxis for 130
Neurosyphilis
diagnosis of 289
treatment of 291–292
Neutrexin See Trimetrexate
Neutropenia 206 (includes Sepsis and Sepsis Syndrome and Compromised
Host) 207–211
Niclocide See Niclosamide
Niclosamide 68
Nifurtimox
adverse reactions 68
for parasitic infections 182
Nilstat See Nystatin
Nitazoxanide
adverse reactions 68
dosing regimens 11
drug interactions 87
for infectious diarrhea 275
Nitrite poisoning 282
Nitrofurantoin
adverse reactions 68
cost of 11
for cystitis 286
dosing regimens for 11
drug interactions 87
in renal failure 49
for urinary tract infection 24 135 286
Nitrofurazone
adverse reactions 68
dosing regimens for 11
Nitroimidazoles, for tuberculosis 29
Nix See Permethrin
Nizoral See Ketoconazole
Nocardia asteroides
antibiotic treatment for 307
description of 30 228
Nocardiosis 30
Nodules 222
Norfloxacin
adverse reactions 70
cost of 11
for diarrhea
infectious 271 272 273 274 278
traveler's 142
dosing regimens for 11
for gonococcal infections 288
in renal failure 49
for traveler's diarrhea 142 278
for urinary tract infection 135 286
Noroxin See Norfloxacin
Nor-Tet See Tetracycline(s)
North American liver fluke 176
Nosocomial infections
pneumonia 251
sinusitis 245
Novobiocin 11
Nydrazid See Isoniazid
Nystatin
adverse reactions 68
cost of 11
dosing regimens for 11
for fungal infections 148
in renal failure 49
for stomatitis 247
for vulvovaginal candidiasis 304
Nystex See Nystatin
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > N
N
Obstetric surgery, antibiotic prophylaxis for 127–128
Ocular infections
description of 229–232
treatment of 28 35
Ocular surgery, antibiotic prophylaxis for 131
P.340
Ocular syphilis 291 292
Oesophagostomum bifurcum 180
Ofloxacin
adverse reactions 68 70
for chlamydia 294
cost of 11
during dialysis 55
for diarrhea
infectious 271 272 273 274
traveler's 142 278
dosing regimens for 11
for endocervicitis 21
for epididymitis 21 300
for gonococcal infections 288
for Mycobacterium avium 170
for pelvic inflammatory disease 21 302
for pulmonary infection 28
in renal failure 49
for traveler's diarrhea prevention 142 278
for tuberculosis 29
for urethral syndrome 21
for urethritis 21
for urinary tract infections 286
Omeprazole 26 270
Omnicef See Cefdinir
Omnipen See Ampicillin
Omnipen-N See Ampicillin sodium
Onchocerca volvulus 176
Ophthalmia neonatorum 294
Opisthorchis viverrini 177
OPV vaccine 95
Oral infections 19 23 26 28 31 See also Dental infections
Ornidazole 68
Ornidyl See Eflornithine
Orthopedic surgery, antibiotic prophylaxis for 129–130
Oseltamivir
adverse reactions 68 197
antiviral activity of 203
for bronchitis 251
for common cold 248
cost of 11
dosing regimens for 11
drug interactions 87
for influenza 195–196
for pneumonia 255
in renal failure 49
Osteomyelitis
description of 224–225
treatment of 17 19 221
Otitis externa, malignant 243
Otitis media
acute 243
acute diffuse 243
chronic suppurative 243
treatment of 26 28 240 306 (includes Sexually transmitted diseases
and Duration of Antibiotic Treatment)
Otomycosis 243
Oxacillin
cost of 11
during dialysis 55
dosing regimens for 11
for endocarditis 259 261
for infected prosthetic devices 34
for meningitis 236 238
for osteomyelitis 224
for pneumonia 254
for prosthetic joint 227
in renal failure 49
for septic arthritis 226
for septicemia 34
Oxamniquine
adverse reactions 68
for parasitic infections 181
Oxiconazole, for fungal infections 161
Oxytetracycline 15
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > P
P
Pacemaker insertion, antibiotic prophylaxis for 124
Panmycin See Tetracycline(s)
Pap smears 305
Paracoccidioides sp. 156
Paragonimus westermani 177
Parasitic infections
diarrhea 275–276 280–281
treatment of 174–190
Paromomycin
adverse reactions 68
cost of 11
dosing regimens for 11
for infectious diarrhea 275 276
for liver abscess 268
for parasitic infections 174 175 177
Paronychia 220
Parotitis 246
PAS 164 See also Aminosalicylic acid
Paser granules See Aminosalicylic acid
Pasteurella multocida 30 226
Pathocil See Dicloxacillin
Pediazole See Erythromycin-sulfisoxazole
Pediculosis pubis 297
Pediculus capitis See Lice
Pegasys See Interferon alfa; Peginterferon alfa-2b
Peg-interferon 8 49 55 66
Peg-interferon alfa-2b 8
PegIntron See Interferon alfa; Peg-interferon alfa-2b
P.341
Peliosis hepatitis 19
Pelvic inflammatory disease
chlamydia and 293
treatment of 21 301–302 307
Pen V See Penicillin V
Penciclovir
antiviral activity of 203
cost of 11
dosing regimens for 11
for herpes simplex 191
Penetrating trauma abdomen surgery, antibiotic prophylaxis for 127
Penetrex See Enoxacin
Penicillin See also Penicillin G; Penicillin V
for abscesses 18 240
for actinomycosis 17
for adenitis 246
adverse reactions 69
allergy to 75–78
alternatives for 290–291
for arthritis, septic 27 226
for bacteremia 18 28 35
Benzathine See Benzathine penicillin
for botulism 22
for burns 221
for cat bites 21
for cellulitis 35 219
for dental infection 247
desensitization 77–78
for dog bites 21
dosing regimens for 11–12
drug interactions 87
for endocarditis 17 21 25 27 35
for erysipelas 219
for female genital tract infections 18
for furunculosis 220
hypersensitivity reactions 75
for meningitis 17 28 35 236 237 238
for ocular infections 28 230 231
for parotitis 246
for pharyngitis 245 246
for pneumonia 17 24 28 32 33 35
Procaine, dosing regimens for 12
for rat bites 221
for sepsis 17 18 24 25 31 32
for septic arthritis 27 226
for septicemia 17 25 28 31 32 33
for sinusitis 244 245
for stomatitis 247
for systemic infection 31
for tetanus 22
for urinary tract infections 24 25 28 31 32 33
for whitlow 220
for wound infection 24 25 28 31 34
Penicillin G See also Penicillin; Penicillin V
for abscesses 25 246
for actinomycosis 17 222 246
for anaerobic infections 213
for anthrax 18
for arthritis, septic 30
for bacteremia 30
for bite wounds 23 30
cost of 11
for dental infection 25 28 31
during dialysis 55
for diphtheria 22
for endocarditis 24 25 258 259
for gas gangrene 22
for gynecologic infection 31
for Haverhill fever 35
in hepatic disease 57
for leptospirosis 27
for liver abscess 25
for Lyme disease 19 217
for meningitis 30 236
for oral infections 23 25 28 31
for pericarditis 30
for peritonsillar abscess 246
for pneumococcal infection prevention 134
for pneumonia 30 253 254
for pulmonary infection 25 31
for rat-bite fever 34 35
for relapsing fever 19
in renal failure 50
for sepsis 22 25 31 205
for septic arthritis 30
for septicemia 22 31
in surgery 128
for syphilis 36 290
for tonsillar abscess 246
Penicillin V See also Penicillin; Penicillin G
for actinomycosis 246
cost of 11
during dialysis 55
dosing regimens for 11–12
for endocarditis prophylaxis 139
for pneumococcal infection prevention 134
for pneumonia 254
in renal failure 50
for respiratory tract infections 249
for Whipple's disease 37
Penicillium marneffei 156
Pentam 300 See Pentamidine
Pentamidine
adverse reactions 69
P.342
cost of 12
during dialysis 55
dosing regimens for 12
drug interactions 88
guidelines for 50
Pentostam See Sodium stibogluconate
Pen-Vee K See Penicillin V
PEP See Postexposure prophylaxis
Peptic ulcer disease 26 270
Pepto-Bismol See Bismuth subsalicylate
Peptostreptococcus 31 213
Periapical abscess 247
Pericarditis 30 155
Periocular infections 229–232
Periodontal disease 21 See also Dental infections
Peripheral vascular surgery, antibiotic prophylaxis for 125
Peritonsillar abscess 246
Permapen See Benzathine penicillin
Permethrin
dosing regimens for 12
for parasitic infections 178 181
for pubic lice 297
for scabies 297
Pertussis
antimicrobial prophylaxis for 135
treatment of 19
vaccine 95
Pesticides 282
Pfizerpen See Penicillin; Procaine
pH test, for vaginitis/vaginosis 302
Pharyngitis 241 245–246
gonococcal infections and 288
membranous 246
treatment of 23 245–246 307
Phenoxymethyl penicillin (V) See Penicillin V
Phycomycetes sp. 156
Phycomycosis 232
PID See Pelvic inflammatory disease
Pinworm See Enterobius
Piperacillin
for anaerobic infections 213
for biliary tract infections 268
cost of 12
during dialysis 55
dosing regimens for 12
for mastoiditis 244
for meningitis 236
for osteomyelitis 225
for otitis 243
for pneumonia 22 254
in renal failure 50
for sepsis 205
for urinary tract infections 22
Piperacillin-tazobactam
cost of 12
during dialysis 55
dosing regimens for 12
for melioidosis 20
for pneumonia 32 251
in renal failure 50
for sepsis 32 204
for septicemia 20 32
Piperazine 88
Piperonyl butoxide 297
Pipracil See Piperacillin
Plague
description of 37
vaccine 95
Plaquenil See Chloroquine; Hydroxychloroquine
Plasmodium falciparum 178
Plasmodium malariae 178
Plasmodium ovale 178
Plasmodium vivax 178
Plesiomonas shigelloides 31 273
Pneumococcal infection, antimicrobial prophylaxis for 133–134
Pneumococcal vaccine 110–111
adverse reactions 111
for alcoholics 101 110 123
in asplenia 101 111 123
cost of 110
in diabetes 101 110 123
for HIV patients 101 123
for homeless 99 110
in nursing homes 99
recommendation by age 97
in renal failure 101 110 123
route of administration of 95
Pneumonectomy 125
Pneumonia 251
Pneumonitis 27
Pneumovax See Pneumococcal vaccine
Podofilox 298
Polio vaccine See eIPV vaccine
Polyarticular arthritis 228
Polycillin-N See Ampicillin sodium
Polymerase chain reaction 293
Polymyxin B
adverse reactions 69
dosing regimens for 12
drug interactions 88
for otitis 243
in renal failure 50
P.343
Postexposure prophylaxis 118–119
Praziquantel
adverse reactions 69
cost of 12
dosing regimens for 12
for parasitic infections 177 181 182
in renal failure 50
Precef See Ceforanide
Pregnancy
antimicrobial agents during 39
bacterial vaginosis and 303
Chlamydia trachomatis and 294
genital herpes simplex and 296
gonococcal infections and 288
hepatitis B vaccine during 117
immunization in 97–98 106 112 117
influenza vaccine during 106
management of 296
sexually transmitted diseases and 305
smallpox vaccination during 120
syphilis and 290 291
tuberculosis during 167
varicella-zoster vaccine during 112
Prevnar 95
Prevotella intermedius 19
Prevotella melanogenicus 19
Priftin See Rifapentine
Primaquine
adverse reactions 69
cost of 12
dosing regimens for 12
for parasitic infections 180
Primaquine-chloroquine 12
Primaxin See Imipenem/cilastatin
Procaine 12
Proctitis
chlamydia and 293
description of 300–301
Proctocolitis 300–301
Proguanil
for malaria prevention 143
for parasitic infections 178 180
Proloprim See Trimethoprim
Pronto See Permethrin
Propionibacterium acnes 31 230
Prostaphlin See Oxacillin
Prostatectomy, antibiotic prophylaxis for 131
Prosthetic devices, infected 34
Prosthetic joint 227 307
Proteus mirabilis 31
Proteus vulgaris 31
Protostat See Metronidazole
Providencia 31
Pseudoallescheria boydii 156 228
Pseudomonas aeruginosa 32
in brain abscess 240
in joint infections 225
in keratitis 229
in meningitis 238
in otitis 243
in pneumonia 254
Pseudomonas cepacia 20
Pseudomonas pseudomallei 20
Psittacosis 21
Pubic lice 297
Pulmonary infections 19 25 28 29 30 31 250–255
Pyelonephritis 286 308
Pyogenic meningitis 234
Pyorrhea 247
Pyrantel 13
Pyrazinamide
adverse reactions 70
cost of 13
during dialysis 55
for disseminated infection 28
dosing regimens for 13
drug interactions 88
for Mycobacterium genavense 171
in renal failure 50
for tuberculosis 29 162 163
Pyrethrin 297
Pyrimethamine
adverse reactions 70
cost of 13
dosing regimens for 13
drug interactions 88
for infectious diarrhea 276
for ocular infections 231
for parasitic infections 181
in renal failure 50
Pyrimethamine-sulfadoxine
cost of 13
dosing regimens for 13
for malaria prevention 145
for parasitic infections 178 180 182
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > Q
Q
Q fever 23 32 255
Quinacrine hydrochloride
adverse reactions 70
for infectious diarrhea 276
in renal failure 50
Quin-amino See Quinine sulfate
Quinamm See Quinine sulfate
Quindan See Quinine sulfate
Quinine
adverse reactions 70
for babesiosis 18
P.344
for parasitic infections 174
in renal failure 50
Quinine dihydrochloride
dosing regimens for 13
for parasitic infections 179
Quinine sulfate
cost of 13
dosing regimens for 13
for parasitic infections 178 179
Quinolones See Fluoroquinolones
Quinupristin/dalfopristin
adverse reactions 71
cost of 13
during dialysis 55
dosing regimens for 13
drug interactions 88
for infected prosthetic devices 35
for meningitis 237
for pneumonia 34 253
in renal failure 50
for septicemia 34
for wound infection 34
Quiphile See Quinine sulfate
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > R
R
RabAvert See Rabies vaccine
Rabies 8
Rabies vaccine 107–109
cost of 8
route of administration of 96
for travelers 103
Ranitidine 26 270
Rat bites 221 See also Bite wounds
Rat-bite fever 34 35
Raxar See Grepafloxacin
Rebetol See Ribavirin
Rebetron See Ribavirin
Recombivax See Hepatitis B vaccine
Rectocele repair, antibiotic prophylaxis for 128
Reese's Pinworm Medicine See Pyrantel
Refugees 100
Relapsing fever 19
Relenza See Zanamivir
Renal failure
antimicrobial dosing regimens in 39–57
immunization in 101 123
Respiratory tract infections
antimicrobials for 249
lower 250–255
overview of 241–255
upper 243–248
Rheumatic fever, antimicrobial prophylaxis for 133
Rhinoplasty, antibiotic prophylaxis for 129
Rhodococcus equi 32
Ribavirin
adverse reactions 71
antiviral activity of 203
cost of 13
during dialysis 55
dosing regimens for 13
drug interactions 88
for hantavirus pulmonary syndrome 200
in hepatic disease 57
for hepatitis C 198
in renal failure 50
Rickettsia spp. 32
RID See Permethrin
Rifabutin
adverse reactions 71
cost of 13
for disseminated infection 28
dosing regimens for 13
drug interactions 88
for Mycobacterium avium 170
for Mycobacterium haemophilum 171
for Mycobacterium malmoense 171
for Mycobacterium xenopi 171
for pulmonary infection 28
Rifadin See Rifampin
Rifadin-IV See Rifampin
Rifamate See Isoniazid-rifampin
Rifampin
for adenitis 247
adverse reactions 71
for brucellosis 20
cost of 13
during dialysis 55
for diarrhea, infectious 274
for disseminated infection 28
dosing regimens for 13
drug interactions 88–89
for endocarditis 19 259 261
for fungal infections 148
in hepatic disease 57
for infected prosthetic devices 35
for Legionnaires' disease 27
for meningitis 236 237 238
for Mycobacterium avium 170
for Mycobacterium genavense 171
for Mycobacterium gordonae 171
for Mycobacterium kansasii 170
for Mycobacterium marinum 171
for Mycobacterium scrofulaceum 171
for Mycobacterium ulcerans 171
for Mycobacterium xenopi 171
for osteomyelitis 19
P.345
for peliosis hepatitis 19
for pneumonia 34 254
for pulmonary infection 28 29
for Q fever 23
in renal failure 51
for septicemia 34
for skin infections 28
for soft tissue infections 28
for sporotrichosis 222
for tuberculosis 29 162 163
for wound infection 34
Rifapentine 13 51 55
Rifater see Isoniazid-rifampin-pyrazinamide
Rimactane See Rifampin
Rimantadine
adverse reactions 72 197
antiviral activity of 203
for bronchitis 251
for common cold 248
cost of 14
dosing regimens for 14
in hepatic disease 57
for influenza 196
for pneumonia 255
in renal failure 51
Ringworm 161
River blindness 176
Robicillin VK See Penicillin V
Robimycin See Erythromycin
Robitet See Tetracycline(s)
Rocephin See Ceftriaxone
Rochalimaea henselae See Bartonella henselae
Rochalimaea quintana See Bartonella quintana
Rocky Mountain spotted fever 32 239 308
Roferon-A See Interferon alfa; Interferon alfa-2a
Roundworm See Ascariasis
Rubella vaccine See also MMR vaccine
age-based recommendations 97
for health care workers 100
for homeless 99
for immigrants and refugees 100
during pregnancy 98
route of administration 96
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > S
S
Salmonella
in infectious diarrhea 273–274 278 279 (includes Infectious Diarrhea
and Foodborne Outbreaks) 280
in sickle cell disease 225
treatment for 33
Salmonella typhi
in infectious diarrhea 273 274 280
treatment for 33
Salpingitis 289
Sandoglobin see IVIG
Saquinavir, during dialysis 56
Sarcoptes scabiei 181 297
Scabies 181 297
Schistosomiasis 181
Scrub typhus 32
Selenium sulfide, for fungal infections 161 220
Sepsis 204–206
intra-abdominal 267–268
treatment of 18 25 27 31 32 204 267–268 307
treatment of 17 18 22 25 26
Septic arthritis
antibiotics for 307
description of 226–228
treatment of 27 30
Septic shock 204
Septicemia 17 18 20 22 25 27 28 30–31 31 32 33–34 34 37 150
Septra See Trimethoprim-sulfamethoxazole
Seromycin See Cycloserine
Serratia marcescens 33
Severe acute respiratory syndrome 200–202
Sex partners, syphilis and 291
Sexual assault 305–306
Sexually transmitted diseases 288–308
antibiotic treatment for 307
pregnancy and 305
Sheep liver fluke 176
Shellfish toxins 282
Shigella sp. 33 274 278 279 (includes Infectious Diarrhea and Foodborne
Outbreaks) 280
Silvadene See Silver sulfadiazine
Silver sulfadiazine 14
Sinusitis 241 244–245
acute 244
in brain abscess 240
chronic 244
fungal 156
nosocomial 245
treatment of 26 27 308
Skin abscess 30
Skin infections
streptococcal 212
treatment of 28
Skin test
for penicillin allergy 75–76
for syphilis 291
Sleeping sickness See Trypanosomiasis
Smallpox vaccination 119–121
Sodium fluoride 282
P.346
Sodium stibogluconate
adverse reactions 72
for parasitic infections 177
Soft tissue infections
deep serious 223
streptococcal 212
treatment of 28–29
Southeast Asian liver fluke 177
Soxa Gulfasin See Sulfisoxazole
Sparfloxacin 251
Spectinomycin
adverse reactions 72
for arthritis, septic 226
cost of 14
dosing regimens for 14
for gonococcal infections 288
in renal failure 51
for septic arthritis 226
Spectracef see Cefditoren
Spectrobid See Bacampicillin
Spinal surgery, antibiotic prophylaxis for 130
Spirillum minus 34
Sporanox See Itraconazole
Sporothrix schenckii 228
Sporotrichosis 157 222
Staphcillin See Methicillin
Staphylococcus aureus
in blepharitis 231
in bone/joint infection 225–226
in cervical adenitis 246
in dacryocystitis 232
in endocarditis 259–260
in endophthalmitis 230
in infectious diarrhea 273 278 280
in keratitis 229
in mastoiditis 244
in meningitis 234 238 240
in otitis 243
in parotitis 246
in pneumonia 254
in septic arthritis 226
in sinusitis 244
treatment for 34
Staphylococcus epidermidis
in bone/joint infection 226
in brain abscess 240
in endocarditis 257 259–260
in endophthalmitis 230
in meningitis 238
in sinusitis 244
treatment for 34
Staphylococcus saprophyticus 34–35
Stenotrophomonas maltophilia 35
Stomatitis 247
Streptobacillus moniliformis 35 225
Streptococcal infections 212 223
Streptococcal myonecrosis 223
Streptococcus anaerobic 213–214
Streptococcus bovis 35 258–259
Streptococcus iniae 35
Streptococcus milleri 35
Streptococcus pneumoniae
in dacryocystitis 232
in endophthalmitis 230
in keratitis 229
in mastoiditis 244
in meningitis 234 237
in otitis 243
in pneumonia 253
treatment for 35
Streptococcus pyogenes 212 232
in cervical adenitis 246
in epiglottitis 246
in mastoiditis 243
in pharyngitis 245
in tonsillar abscess 246
treatment for 36
Streptococcus viridans 35
Streptomycin
for anthrax 18
for bartonellosis 19
for brucellosis 20
cost of 14
during dialysis 56
dosing regimens for 14
for endocarditis 24 35 259
for Haverhill fever 35
for Mycobacterium avium 170
for Mycobacterium gordonae 171
for Mycobacterium malmoense 171
for Mycobacterium scrofulaceum 171
for Mycobacterium xenopi 171
for plague 37
for pulmonary infection 28 29
for rat-bite fever 34 35
in renal failure 40 51
for tuberculosis 29 162 164 167
for tularemia 25
Stromectol See Ivermectin
Strongyloides stercoralis 181
Strongyloidiasis 181
Subcutaneous tissue infections 219–222
Sulbactam, for pelvic inflammatory disease 302
Sulconazole, for fungal infections 161
Sulfadiazine
for abscesses 30
P.347
for brain abscess 30
cost of 14
dosing regimens for 14
for fungal infections 156
for liver abscess 30
for nocardiosis 30
for pulmonary infection 30
in renal failure 51
for skin abscess 30
Sulfamar See Trimethoprim-sulfamethoxazole
Sulfamethizole 14
Sulfamethoprim See Trimethoprim-sulfamethoxazole
Sulfamethoxazole
cost of 14
dosing regimens for 14
for Mycobacterium fortuitum 170
Sulfamethoxazole phenazopyridine 14
Sulfamycin See Erythromycin-sulfisoxazole
Sulfamycin Pediazole see Erythromycin-sulfisoxazole
Sulfamylon See Mafenide
Sulfapyridine 14
Sulfasalazine 14
Sulfatrim See Trimethoprim-sulfamethoxazole
Sulfa-trimethoprim
for abscesses 30
for bacteremia 17 28 30
for brain abscess 30
for bronchitis 26
for brucellosis 20
for cat scratch disease 19 221
for cellulitis 17
for colitis 33
for diarrhea 17 30
infectious 271 273 274 275
for donovanosis 20
for extra-intestinal infection 31
for granuloma inguinale 20
for infectious diarrhea 271 273 274 275
for Legionnaires' disease 27
for liver abscess 30
for melioidosis 20
for meningitis 17 28 30
for mesenteric adenitis 37
for myositis 17
for nocardiosis 30
for osteomyelitis 17
for otitis 26 28
for pericarditis 30
for pertussis 19
for pneumonia 20 22 24 27 28 30 34 35
for pneumonitis 28
for pulmonary infection 29 30
for Q fever 23
for sepsis 24 25 27 31
for septicemia 17 20 22 25 27 28 31 34 35 37
for sinusitis 26 28
for skin abscess 30
for soft tissue infections 29
for typhoid fever 33
for urinary tract infections 22 24 25 27 28 31 34 35
for Whipple's disease 37
for wound infection 22 24 25 28 31 34
Sulfisoxazole
for abscesses 30
for brain abscess 30
cost of 14
dosing regimens for 14
for endocervitis 21
for epididymitis 21
for liver abscess 30
for lymphogranuloma venereum 21
for melioidosis 20
for nocardiosis 30
for otitis 243
for pelvic inflammatory disease 21
for pulmonary infection 30
in renal failure 51
for septicemia 20
for skin abscess 30
for trachoma 21
for urethral syndrome 21
for urethritis 21
Sulfisoxazole-phenazopyridine 14
Sulfonamides See also specific agent
for abscesses 30
adverse reactions 72
for brain abscess 30
dosing regimens for 14
drug interactions 90
for fungal infections 156
for inclusion conjunctivitis 21
for liver abscess 30
for lymphogranuloma venereum 21
for Mycobacterium smegmatis 171
for nocardiosis 30
for pulmonary infection 29 30
silver sulfadiazine 14
for skin abscess 30
for skin infections 29
for soft tissue infections 29
sulfadiazine See Sulfadiazine
sulfamethizole, dosing regimens for 14
P.348
sulfamethoxazole See Sulfamethoxazole
sulfamethoxazole phenazopyridine 14
sulfasalazine 14
sulfisoxazole See Sulfisoxazole
for trachoma 21
trisulfapyrimidines See Trisulfapyrimidines
for urinary tract infections 25
for wound infection 29
Sulfur, for scabies 297
Sumycin See Tetracycline(s)
Suprax See Cefixime
Suramin
adverse reactions 72
for parasitic infections 182
Suspen See Penicillin V
Swimmer's ear 243
Symadine See Amantadine
Symmetrel See Amantadine
Synercid See Quinupristin/dalfopristin
Synergistic necrotizing cellulitis 223
Syphilis
aseptic meningitis and 239
classification of 289
diagnosis of 289
genital ulcers and 299
gonococcal infections and 288
late 291 292
latent 290–291 292
management of 292
neurosyphilis 291 292
ocular 291 292
pregnancy and 291
primary 289–290 292
secondary 289–290 292
sex partners and 291
skin test for 291
treatment of 36 289–291 307
Systemic infection 31
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > T
T
Taenia saginata 181
Taenia solium 181
Tamiflu See Oseltamivir
Tapeworm infection 181
Targocid See Teicoplanin
Tazicef See Ceftazidime
Tazidime See Ceftazidime
Tazobactam, for sepsis 205
3TC See Lamivudine
Td vaccine 109–110
age-based recommendations 97
for alcoholics 123
in asplenia 123
cost of 109
in diabetes 123
for HIV patients 123
for homeless 99
for immigrants and refugees 100
during pregnancy 98
in renal failure 123
route of administration of 96
Tegopen See Cloxacillin
Teicoplanin, in renal failure 51
Teline See Tetracycline(s)
Telithromycin
adverse reactions 72
cost of 15
dose 15
drug interactions 90
in hepatic disease 57
pneumonia 251 253
renal failure 51
respiratory tract infections 249 251 253–255
spectrum 21 26 27 34 36
Tenofovir 199
Tequin See Gatifloxacin
Terbinafine
adverse reactions 72
cost of 14
dosing regimens for 14
for fungal infections 149 161
Terconazole, for vulvovaginal candidiasis 304
Terramycin See Oxytetracycline
Tetanus
immunoglobulins for 8 122
treatment of 8 22 122
Tetanus/diphtheria toxoid vaccine See Td vaccine
Tetracap See Tetracycline(s)
Tetracon See Tetracycline(s)
Tetracycline(s) See also specific agent
for acne 31 219
for actinomycosis 17 222 246
adverse reactions 72
for anaerobic infections 213
for bartonellosis 19
for bite wounds 23 30 221
for bronchitis 26
for brucellosis 20
for cholera 37
for colitis 33
cost of 14
demeclocycline See Demeclocycline
for dental infection 28
during dialysis 56
for diarrhea 17 20 37
infectious 271 273 274 275
for donovanosis 20
dosing regimens for 14–15
doxycycline See Doxycycline
P.349
drug interactions 90
for endocarditis 17
for endocervicitis 21
for epididymitis 21
for granuloma inguinale 20
for Haverhill fever 35
for infected prosthetic devices 35
intolerance to 290
for Lyme disease 19
for lymphogranuloma venereum 21
for melioidosis 20
minocycline See Minocycline
for oral infections 23 28
for otitis 26
oxytetracycline 15
for parasitic infections 175
for pelvic inflammatory disease 21
for peptic ulcer disease 26 270
for periodontal disease 21
for pharyngitis 245
for plague 37
for pneumonia 17 21 22 30 35 255
for psittacosis 21
for Q fever 23
for rat bites 221
for rat-bite fever 34 35
for relapsing fever 19
in renal failure 51
for sepsis 17 31
for septicemia 20 22 31 35 37
for sinusitis 26
for syphilis 36
for systemic infection 31
for tonsillitis 21
for trachoma 21
for tularemia 25
for urethral syndrome 21
for urethritis 21
for urinary tract infections 22 25 31 35
for Whipple's disease 37
for wound infection 22 23 31 35 37
Tetralan See Tetracycline(s)
Tetram See Tetracycline(s)
Thiabendazole
adverse reactions 73
cost of 15
dosing regimens for 15
drug interactions 90
for fungal infections 151
for parasitic infections 174 175 181
Thiosulfil See Sulfamethizole
Thoracic surgery, antibiotic prophylaxis for 125
Thrush 247
Ticar See Ticarcillin
Ticarcillin
cost of 15
during dialysis 56
dosing regimens for 15
in hepatic disease 57
for mastoiditis 244
for meningitis 236
for otitis 243
for pneumonia 254
in renal failure 51
Ticarcillin-clavulanate
adverse reactions 73
for biliary tract infections 268
for burns 221
cost of 15
during dialysis 56
dosing regimens for 15
in hepatic disease 57
for intra-abdominal sepsis 32 204 268
for meningitis 17
for pneumonia 32 34 251
in renal failure 51
for sepsis 204
intra-abdominal 32 204 268
for septicemia 17 31 32 34
in surgery 127
for urinary tract infections 31 34
Tickbite fever 32
Ticonazole, for vulvovaginal candidiasis 304
Timentin See Ticarcillin-clavulanate
Tinactin See Tolnaftate
Tinea capitis 161
Tinea corporis 161
Tinea cruris 161
Tinea pedis 161
Tinea unguium 161
Tinea versicolor 161 220
Tinidazole, for infectious diarrhea 276
TMP-SMX See Trimethoprim-sulfamethoxazole
Tobramycin
adverse reactions 58
for biliary tract infections 268
cost of 15
during dialysis 56
dosing regimens for 15
for endocarditis 259
for mastoiditis 244
for Mycobacterium chelonae 171
for otitis 243
for pneumonia 32
in renal failure 39 40 51
for sepsis 32 204 267
for septicemia 32
for skin infections 28
P.350
for soft tissue infections 28
in surgery 131
Tobrex See Tobramycin
Tolnaftate 15
Tonsillar abscess 246
Tonsillectomy 129
Tonsillitis 21
Totacillin See Ampicillin
Totacillin-N See Ampicillin sodium
Toxic shock syndrome 211
streptococcal 212
Toxocariasis 182
Toxoplasma gondii 181 239
Toxoplasmosis 181 231
Trachoma 21
Travel
disease associated with, prevention 141–146
immunization for 101–104 113
Traveler's diarrhea 141–142 278
Trecator-SC See Ethionamide
Trench fever 19 32
Treponema pallidum 36 239
Tretinoin, for acne 219
Triazole See Trimethoprim-sulfamethoxazole
Trichinella spiralis 182 281
Trichinosis 182
Trichomonas vaginalis 182 299–300
Trichomoniasis 182 302–303 308
Trichostrongylus infection 182
Trichuriasis 182
Trichuris trichiura 182
Trifluridine
adverse reactions 73
cost of 15
dosing regimens for 15
for herpes simplex 192
for ocular infections 230
Trimethoprim
for abscesses 30
adverse reactions 73
for brain abscess 30
cost of 15
dosing regimens for 15
drug interactions 91
for infectious diarrhea 272
for liver abscess 30
for nocardiosis 30
for pertussis prevention 135
for pulmonary infection 30
in renal failure 51
for skin abscess 30
for urinary tract infection 135 284 286
Trimethoprim-sulfamethoxazole
adverse reactions 73
for anaerobic infections 213
for bronchitis 252
for cirrhosis prevention 136
cost of 15
for cystitis 285
during dialysis 56
for diverticulitis 269
dosing regimens for 15
drug interactions 91
for endocarditis 259
for infectious diarrhea 272 276 278
for meningitis 236 237 238
for parasitic infections 175 177 181
for Pneumocystis carinii prevention 135
for pneumonia 253 254 255
for pyelonephritis 286
in renal failure 51
for respiratory tract infections 249
for urinary tract infections 284 286
Trimetrexate
adverse reactions 73
cost of 15
dosing regimens for 15
drug interactions 91
for parasitic infections 181
in renal failure 51
Trimox See Amoxicillin
Trimpex See Trimethoprim
Trisulfam See Trimethoprim-sulfamethoxazole
Trisulfapyrimidines 14
Trisultam See Trimethoprim-sulfamethoxazole
Trobicin See Spectinomycin
Tropheryma whippelii 37
Tropical pulmonary eosinophilia 176
Trovafloxacin
adverse reactions 70
for anaerobic infections 213
cost of 15
during dialysis 56
dosing regimens for 15
in hepatic disease 57
in renal failure 52
Trovan See Trovafloxacin
Trypanosomiasis 182
Tryparsamide
adverse reactions 74
for parasitic infections 182
Tubal ligation, antibiotic prophylaxis for 128
Tuberculosis
in HIV patients 162
during pregnancy 167
prevention of 168–170 170
P.351
treatment of 30 162–168 308
Tubizid See Isoniazid
Tularemia 25 308
Twinrix See Hepatitis B vaccine
Typhoid fever 33
Typhoid vaccine 96 102
Typhus
murine 32
scrub 32
treatment of 32
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > U
U
Ulcers 222
Ultracep See Cefadroxil
Unasyn See Ampicillin-sulbactam
Unipen See Nafcillin
Upper respiratory tract infections 243–248
Ureaplasma urealyticum 37
Urethral syndrome 21
Urethritis 299–300
chlamydia and 293
treatment of 21 307
Urex See Methenamine hippurate
Urinary tract infections
antimicrobial prophylaxis for 135
description of 284–287
treatment of 22 24 25 27 28 31 32 33–34 34 308
Urobak See Sulfamethoxazole
Urologic surgery, antibiotic prophylaxis for 131–132
Uroplus See Trimethoprim-sulfamethoxazole
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > V
V
Vaccines 93–123 See also specific vaccine
age-based recommendations 97
for alcoholics 101
in asplenia 101
in bone marrow recipients 101
in diabetes 101
for drug abusers 100
for family members 98–99
for health care workers 99–100
for HIV patients 100–101
for homeless 99
for homosexual men 100
for immigrants and refugees 100
in immunodeficiency 100–101
in institutions for mentally retarded 99
in nursing homes 99
during pregnancy 97–98 106 112
for prison inmates 99
in renal failure 101
routes of administration 93–96
for travelers 101–103 101–104
Vaginal hysterectomy, antibiotic prophylaxis for 127
Vaginitis 302–304
antibiotics for 308
treatment of 25
Vaginosis 302–304
bacterial 303–304 308
Valacyclovir
adverse reactions 74
antiviral activity of 203
cost of 16
for cytomegalovirus 194
during dialysis 56
dosing regimens for 16
drug interactions 91
for genital herpes simplex 295
for herpes simplex 191
in renal failure 52
for stomatitis 247
for varicella-zoster 192
Valganciclovir
adverse reactions 74
antiviral activity of 203
during dialysis 56
dosing regimens 16 52
drug interactions 91
Valtrex See Valacyclovir
Valve surgery, antibiotic prophylaxis for 124
Vancocin See Vancomycin
Vancoled See Vancomycin
Vancomycin
adverse reactions 74
for anaerobic infections 213
for arthritis, septic 226
for brain abscess 240
for burns 221
for cellulitis 219
for colitis 22
cost of 16
for dental infection 31
during dialysis 56
for diarrhea 22
infectious 271 272
dosing regimens for 16
drug interactions 92
for endocarditis 24 35 259–260 261
prophylaxis 140
for furunculosis 220
for gynecologic infection 31
for infected prosthetic devices 34
for invasive disease 18
for meningitis 35 236 237 238
for ocular infections 35 230
for oral infections 31
for osteomyelitis 224 225
for parotitis 246
for pneumonia 34 253 254
P.352
for prosthetic joint 227
for pulmonary infection 31
in renal failure 52
for sepsis 24 31 204
for septic arthritis 226
for septicemia 18 22 34
in surgery 124 125 129 130
for urinary tract infections 24
for wound infection 24 34
Vancor See Vancomycin
Vansil See Oxamniquine
Vantin See Cefpodoxime
Varicella-zoster See also Herpes zoster
antimicrobial prophylaxis for 136–138
aseptic meningitis and 239
immune globulins for 8 122 193
treatment of 192–193
Varicella-zoster vaccine 111–113
adverse reactions 113
contraindications 112–113
cost of 8 112
for family members 99 112
for health care workers 100 112
pregnancy and 98 112
route of administration of 96
Vascular infections 20
V-Cillin K See Penicillin V
(VDRL), for syphilis 289
Veetids See Penicillin V
Velosef See Cephradine
Venereal Disease Research Laboratory, for syphilis 289
Vermox See Mebendazole
Vibramycin See Doxycycline
Vibra-tabs See Doxycycline
Vibrio cholerae 37 274 278 280
Vibrio fluvialis 275
Vibrio furnissii 275
Vibrio hollisae 275
Vibrio mimicus 275
Vibrio parahaemolyticus 37 275 278 280
Vibrio vulnificus 37 275
Vidarabine 56
Vincent's angina 247
Viral infections
diarrhea 281
hepatitis 264–266
treatment of 191–203
Viroptic See Trifluridine
Visceral larva migrans 182 239
Vistide See Cidofovir
Voriconazole
adverse reactions 74
antifungal uses 160
cost of 16
during dialysis 56
dosing regimens for 16
drug interactions 92
for fungal infections 147
guidelines for 52
in hepatic disease 57
Vulvovaginal candidiasis 304
VZIG see Varicella
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > W
W
Warts 298–299
Weight, and antimicrobial dosing regimens in 39
West Nile virus 202–203
Whiff test, for vaginitis/vaginosis 303
Whipple's disease 37
Whipworm See Trichuriasis
Whitlow 220
Wincillin See Penicillin V
Wintrocin See Erythromycin
Wound infection 22 23 24 25 28 31 34 37
Wuchereria bancrofti 176
Wyamycin S See Erythromycin stearate
Wycillin See Procaine
Wyamycin S see Erythromycin stearate
Wymox See Amoxicillin
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > X
X
Xanthomonas maltophilia 35
Xigris see Drotrecogin
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > Y
Y
Yersinia enterocolitica 39–47 271 275–276 280
Yersinia pestis 37
Yersinia pseudotuberculosis 38
Yodoxin See Iodoquinol
Editors: Bartlett, John G.
Title: 2004 Pocket Book of Infectious Disease Therapy, 12th
Edition
Copyright ©2004 Lippincott Williams & Wilkins
> Back of Book > INDEX > Z
Z
Zagam See Sparfloxacin
Zanamivir
adverse reactions 74 197
antiviral activity of 203
for bronchitis 251
for common cold 248
cost of 16
dosing regimens for 16
for influenza 196
for pneumonia 255
in renal failure 52
Zefazone See Cefmetazole
Zinacef See Cefuroxime
Zithromax See Azithromycin
Zolicef See Cefazolin
Zosyn See Piperacillin-tazobactam
Zovirax See Acyclovir
Zyvox See Linezolid